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Progress in pharmacokinetics and pharmacodynamics - I
P1022 Pharmacokinetics of telithromycin in plasma and
soft tissue after single-dose administration in healthy volunteers
R. Gattringer, F. Traunmueller, E. Urbauer, M. Zeitlinger,
M. Mueller, C. Joukhadar
Vienna, A
Objectives: Telithromycin was described to reach high concentra-
tions levels in inﬂammatory ﬂuid, in bronchopulmonary tissues
and in tonsillar tissue. Because of these data telithromycin is spe-
culated to be a new option in the therapy of skin and soft tissue
infections. To determine the concentration of telithromycin in the
interstitial space ﬂuid, the pharmacokinetics of this new antibiotic
were assessed after single dose administration in young healthy
volunteers by the use of microdialysis.
Methods: Plasma- and extracellular samples (subcutaneous adi-
pose tissue a. skeletal muscle) were taken from 10 healthy male
volunteers by a venous catheter (plasma) and by microdialysis
(soft tissue) every 20 min over a period of 8 h after administration
of 800 mg telithromycin. Telithromycin was analysed by a HPLC
method.
Results: The mean telithromycin AUC for plasma was
247.8 mg h/L. For muscle tissue and subcutis a mean AUC of
34.97 and 52.35 mg h/L, respectively, could be found. The mean
Cmax of plasma, subcutis and muscle was 1.23, 0.18 and
0.16 mg/L, respectively.
Conclusion: A once daily dose of 800 mg telithromycin achieves
concentrations in the interstitial space ﬂuid which are sufﬁcient to
eradicate highly sensible pathogens like S. pyogenes but the dosage
may lead to a therapeutic failure in treating infections caused by
bacteria exceeding a MIC of 0.18 mg/L.
P1023 Pharmacokinetics of tigecycline in healthy adult
volunteers and in subjects with renal impairment
A. Meagher, B. Cirincione, M. Piedmonte, S. Troy, P.G. Ambrose
Buffalo, Phildelphia, USA
Background: TG is a novel glycylcycline antibiotic with an expan-
ded spectrum of activity, including Gram-positive, Gram-negative,
atypical and anaerobic pathogens. TG has also shown activity
against pathogens resistant to other antibiotics. The goal of this
analysis is to summarise the PK of TG in healthy volunteers and
subjects with renal impairment.
Methods: PK data have been collected and analysed using non-
compartmental methods for 144 subjects in four Phase 1 studies:
three single IV dose (SD) and one multiple IV dose (MD) studies.
This included six subjects with severe renal impairment
(CrCl < 30 mL/min) and eight subjects with end stage renal dis-
ease (ESRD) receiving haemodialysis (HD). Doses ranged from
12.5 to 300 mg in SD and from 25 to 100 mg q12h in the MD
study. TG was given under both fasting and fed conditions.
Plasma and urine samples were collected and analysed using vali-
dated HPLC or LC/MS/MS methods. PK parameters, including
maximum plasma concentration (Cmax), half-life (t1=2), area under
the concentration-time curve (AUC), total clearance (CLt), renal
clearance (CLr), and volume of distribution (Vss), were calculated.
Results: The plasma concentration-time proﬁle was characterised
by a steep decline in the distribution phase during the ﬁrst 2 h,
followed by a slower terminal phase. Steady state was reached in
3 days. Healthy volunteer PK values listed in the table below
are mean  SD. With multiple doses, both Cmax and AUC
increased roughly in proportion with dose. CLr accounted for
20% of CLt and less than 13% of TG was excreted unchanged
in urine. CLt was reduced by 20% in subjects with severe renal
impairment or ESRD. TG was not removed by HD. Results of an
SD age and gender study concluded Cmax was lowest in young
men and highest in elderly women (26% difference) and AUC
was higher in young women than in young men (21% difference),
with only a 4% difference between elderly women and men. At
the target clinical dose of 100 mg load infused over 30–60 min fol-
lowed by 50 mg q12h, Cmax and AUCss (mean  SD) were
621  93 ng/mL and 3069  381 ng h/mL, respectively.
Conclusions: TG exhibited approximate linear PK across all dose
ranges evaluated in multiple-dose studies. TG has a long t1=2 with
a high Vss, indicating extensive tissue distribution. PK parameters
were not signiﬁcantly affected by food, age, or gender. TG is cur-
rently being developed for the treatment of complicated skin/soft
tissue and intra-abdominal infections.
P1024 Comparative pharmacodynamics of ABT492 and
ciproﬂoxacin (CIP) with Escherichia coli and Pseudomonas
aeruginosa in an in vitro dynamic model
I. Lubenko, A. Firsov, S. Vostrov, I. Alferova, Y. Portnoy,
S. Zinner
Moscow, RUS; Cambridge, USA
Objective: To compare the pharmacodynamics of ABT492 relative
to CIP, the kinetics of killing of Gram-negative organisms were
studied using a dynamic model that simulates human pharmaco-
kinetics of the ﬂuoroquinolones.
Methods: Clinical isolates of E. coli and P. aeruginosa (MICABTs
0.01 and 0.12; MICCIPs 0.01 and 0.19 mg/L, respectively) were
exposed to bi-exponentially decreasing concentrations of ABT492
(T1/2, alpha 2.1 h, T1/2, beta 23 h) and mono-exponentially
decreasing concentrations of CIP (T1/2 4 h). Single dose simula-
tions were performed with ABT492 vs. two 12-h doses CIP at dif-
ferent ratios of the area under the curve (AUC) to MIC, which
varied from 60 to 480 h. Both E. coli and P. aeruginosa were also
exposed to the clinically achievable AUC/MIC ratios of ABT492
(1740 and 140 h, respectively) and CIP (2200 and 120 h, respect-
ively) that correspond to a 400-mg dose of ABT492 and two
500-mg doses of CIP. In addition, an 800-mg dose of ABT492 was
simulated against P. aeruginosa as a single dose (AUC/MIC 280 h)
and as two 400-mg doses given with a 12-h interval (AUC/MIC
2  140 h).
Results: The maximal reductions in the starting inoculum of anti-
biotic-exposed E. coli and P. aeruginosa were greater with ABT492
than with CIP at most of the simulated AUC/MICs, but the times
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to regrowth were shorter with ABT492. Species-independent
AUC/MIC relationships of the intensity of the antimicrobial effect
(IE – area between the control growth and the time-kill/regrowth
curves) were speciﬁc for ABT492 and CIP. Despite greater IEs
produced by CIP at a given AUC/MIC ratio (from 120 to 480 h),
the effect of the clinically achievable AUC/MIC of ABT492
(1740 h) on E. coli was more pronounced than the respective
AUC/MIC of CIP (2200 h). With P. aeruginosa, a 140-h AUC/MIC
of ABT492 (400 mg as a single dose) provided an 1.8-fold smaller
IE than a 120-h AUC/MIC of CIP. However, two 12-h doses of
ABT492 (AUC/MIC 2  140 h) were even more efﬁcient than
CIP.
Conclusion: These ﬁndings predict comparable efﬁcacies of clinic-
ally achievable AUC/MICs of ABT492 and CIP against E. coli
(q.d. vs. b.i.d. quinolone dosing) and P. aeruginosa (b.i.d. dosing)
but suggest lower efﬁcacy of q.d. ABT492 against P. aeruginosa.
P1025 ABT492 vs. levoﬂoxacin in an in vitro dynamic
model: comparative pharmacodynamics with differentially
susceptible Staphylococcus aureus and the relative ability to
prevent the selection of resistant mutants
A. Firsov, I. Lubenko, S. Vostrov, Y. Portnoy, S. Zinner
Moscow, RUS; Cambridge, USA
Objective: To compare the kinetics of killing/regrowth of differen-
tially susceptible clinical isolates of Staphylococcus aureus exposed
to ABT492 and levoﬂoxacin and to explore their relative abilities
to prevent the selection of resistant mutants.
Methods: Three clinical isolates of S. aureus including two ciproﬂ-
oxacin-susceptible S. aureus 201 and 480 and a ciproﬂoxacin-resist-
ant S. aureus 866 were exposed to clinically achievable ratios of
area under the curve (AUC) to MIC in a dynamic model that
simulated human pharmacokinetics of ABT492 (400 mg) and levo-
ﬂoxacin (500 mg) as a single dose. In addition, S. aureus 201 was
exposed to single and multiple doses of ABT492 and levoﬂoxacin
(both q.d. for 3 days) over wide ranges of the 24-h AUC/MIC
(AUC24/MIC) including clinically achievable AUC24/MIC ratios.
Results: With each isolate, ABT492 at the clinically achievable
AUC/MICs produced greater anti-staphylococcal effects than lev-
oﬂoxacin. Areas between the control growth and the time-kill
curves (ABBC in single dose simulations and the sum of ABBCs
determined after the ﬁrst, second and third dosing in multiple
dose simulations – ABBC1 + 2 + 3) were larger with ABT492 than
levoﬂoxacin. Moreover, at comparable AUC/MICs and AUC24/
MICs maximal reductions in the starting inoculum of ABT492-
exposed S. aureus were more pronounced than with levoﬂoxacin.
Loss in the susceptibility of S. aureus 201 exposed to both ABT492
and levoﬂoxacin depended on the simulated AUC24/MIC.
Although the maximal increase in MIC (MICﬁnal) related to its
initial value (MICinitial) was seen at the higher AUC24/MIC ratio
of ABT492 (120 h) than levoﬂoxacin (50 h), similar AUC24/MICs
(240 and 200 h, respectively) were protective against the selection
of resistant S. aureus. These threshold values are readily achiev-
able with 400 mg ABT492 (AUC24/MIC 870 h) but not with
500 mg levoﬂoxacin (AUC24/MIC 70 h).
Conclusion: Overall, these ﬁndings predict greater efﬁcacy of clin-
ically achievable AUC/MIC (or AUC24/MIC) of ABT492 both in
terms of the anti-staphylococcal effect and prevention of the selec-
tion of resistant mutants.
P1026 Pharmacodynamic activity of iclaprim vs. resistant
Streptococcus pneumoniae using an in vitro model
G.G. Zhanel, M. Goolia, J. Rusen, N.M. Laing, A.M. Noreddin,
K. Nichol, S. Hawser, K. Islam, D.J. Hoban
Winnipeg, CAN; Munchenstein, CH
Objectives: Iclaprim (formerly AR-100) is a novel investigational
diaminopyrimidine currently completing Phase II clinical trials for
the treatment of ‘difﬁcult-to-treat‘ nosocomial infections. The pur-
pose of this study was to assess the pharmacodynamic activity of
Iclaprim using an in vitro pharmacodynamic model (IVPM)
against S. pneumoniae collected from across Canada.
Methods: Six S. pneumoniae isolates with varying susceptibilities to
penicillin, erythromycin, levoﬂoxacin, trimethoprim/sulfameth-
oxazole and Iclaprim. The IVPM was inoculated with
1  106 CFU/ml and Iclaprim was dosed at 0 and 12 h to simu-
late a Cpmax of 3.5 lg/mL and t1=2 of 3 h. Sampling was per-
formed over 24 h to assess viable growth.
Results: Of the six S. pneumoniae studied, three demonstrated Icla-
prim MIC of 0.03 lg/mL and three were 1 lg/mL. Resistant phe-
notypes included penicillin (MIC 2 lg/mL), erythromycin (MIC
1 lg/mL), levoﬂoxacin (MIC 8 lg/mL) and trimethoprim/sulfa-
methoxazole (MIC 4 lg/mL). At 6, 12 and 24 h, Iclaprim demon-
strated the following bacterial reduction (range of log 10 killing)
1–2.8, 1.3–2.6 and 1.8–2.9, respectively. No difference in bacterial
reduction was noted irrespective of antibiotic resistant phenotypes
including the trimethoprim–sulphamethoxaxole resistant strains.
No bacterial re-growth was observed during the study period.
Conclusion: Iclaprim demonstrated activity against S. pneumoniae
including penicillin, erythromycin, levoﬂoxacin and trimetho-
prim/sulphamethoxazole resistant strains. Iclaprim demonstrates
promising activity against S. pneumoniae resistant to other antibi-
otic classes.
P1027 Single dose pharmacokinetics (PK) of telavancin
(TLV) in healthy elderly subjects
K. Duchin, J. Shaw, E. Spencer, J. Seroogy, S. Barriere,
D. Wilbraham
South San Francisco, USA; London, UK
Background: TLV is a novel antibiotic that exerts rapid concentra-
tion dependent bactericidal activity against clinically important
gram-positive bacteria, including methicillin-resistant S. aureus
and penicillin-resistant pneumococci.
Objective: To determine single dose PK of TLV in healthy male
and female elderly subjects and compare the ﬁndings to those
from a group of young healthy male and female volunteers from
another study.
Methods: 16 healthy elderly subjects (average age 71 years, range
66–83) received TLV (10 mg/kg) intravenously over 60 min. Toler-
ability was assessed by collecting adverse events. Blood samples
were obtained at speciﬁed intervals and analysed for TLV concen-
tration with a validated LC/MS/MS assay. PK parameters were
determined using non-compartmental methods.
Results: Mean (SD) PK parameters for TLV in male and female
elderly subjects are shown below. The PKs of TLV were not dif-
ferent between genders. Compared with young subjects given
7.5 mg/kg TLV over 1 h, the average CL value of TLV from
plasma was similar in young and elderly subjects (12 mL/h/kg),
whereas Vdss was higher in elderly than young subjects (167 vs.
100 mL/kg) and t1=2 was longer in the elderly (11 vs. 7 h).
Adverse events included altered taste (n ¼ 2), ﬂushing with pos-
tural hypotension (n ¼ 1), headache (n ¼ 2), dizziness (n ¼ 1)
and paresthesia of the throat (n ¼ 1). All of these events were
transient and of mild intensity. Subjects with adverse events did
not have different PK parameters than those who did not report
them.
Gender
Cmax
(lg/mL)
AUC
(lghr/mL)
CL
(mL/hr/kg)
Vdss
(mL/kg) T1/2 (hr)
Male
(n ¼ 8)
84.7 (8.3) 820 (94) 12 (2) 173 (12) 11.0 (1.7)
Female
(n ¼ 8)
90.8 (10.7) 858 (92) 12 (1) 161 (13) 10.6 (1.1)
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Conclusions: Age does not affect the CL of TLV, but was associ-
ated with more extensive distribution and longer elimination t1=2.
In addition, gender did not inﬂuence the PK of TLV. No dose
adjustments of TLV are needed in elderly patients with normal
renal function.
P1028 Single dose pharmacokinetics (PK) of telavancin
(TLV) in subjects with renal dysfunction
K. Duchin, J. Shaw, E. Spencer, J. Seroogy, S. Barriere,
D. Wilbraham
South San Francisco, USA; London, UK
Background: TLV is a novel antibiotic with multiple mechanisms
of action that exerts rapid and concentration-dependent bacteri-
cidal activity against clinically important Gram-positive bacteria,
including methicillin-resistant S. aureus and penicillin-resistant
pneumococci. Previous studies in man have determined that the
primary route of elimination of TLV is the kidney.
Objective: To determine the single dose PK of TLV in subjects
with renal dysfunction (creatinine clearance CLcr <80 mL/min)
and compare the ﬁndings to a group of healthy volunteers from
another study (7.5 mg/kg over 1 h).
Methods: 10 (eight males, two females) subjects with renal impair-
ment received a single 7.5-mg/kg dose of TLV intravenously over
60 min. Five subjects had mild impairment (CLcr 51–80 mL/min),
three had moderate impairment (30–50 mL/min) and two had
severe renal impairment (<30 mL/min). Blood samples were
obtained at speciﬁed intervals and assayed for TLV with a vali-
dated LC/MS/MS assay. PK parameters were determined using
non-compartmental methods.
Results: The average preliminary values for PK parameters for
TLV in subjects with renal dysfunction are shown below. Mean
PK values for TLV in healthy subjects were: Cmax (89 lg/mL),
AUC (606 lg h/mL), CL (11 mL/h/kg), Vdss (101 mL/kg), and
t1=2 (7.2 h). Severe renal dysfunction was associated with slightly
higher AUC values, longer CL and t1=2 values compared with
subjects with mild to moderate renal impairment and healthy vol-
unteers. In subjects with renal impairment there was a signiﬁcant
correlation (r ¼ 0.88) between CL of TLV and CLcr. One subject
(mild) developed ‘red man syndrome’ and received only two-
thirds of the intended dose and was excluded from the PK analy-
sis. The other subjects tolerated TLV well.
Conclusions: Dose reductions of TLV may be needed in patients
with moderate to severe renal impairment who have serious infec-
tions.
P1029 Efﬁcacy of telavancin (TD-6424), a rapidly
bactericidal agent with multiple mechanisms of action, in a
murine model of MRSA pneumonia
S. Hegde, N. Reyes, R. Skinner, K. Kaniga
South San Francisco, USA
Objectives: Telavancin (TD-6424) is a novel lipidated glycopeptide
currently in Phase 2 trials, which possesses rapid and concentra-
tion-dependent bactericidal activity against clinically relevant
gram-positive organisms including methicillin-resistant Staphylo-
coccus aureus (MRSA). In the present study, the efﬁcacy of telavan-
cin (TLV) was compared with vancomycin (VAN) and linezolid
(LIN), against MRSA 33591 in a murine pneumonia model.
Methods: Immunocompromised mice (Balb/c, eight per group)
were inoculated intranasally with log 7 of MRSA 33591. At 24-h
after inoculation, mice were dosed intravenously with either no
drug (control) or two doses (q 12-h) of TLV (40 mg/kg), VAN
(80 mg/kg) or LIN (110 mg/kg). The doses of the three test drugs
were chosen to equate to human exposure (24-h AUC) at their
respective clinical doses. At 24-h after treatment initiation, lungs
were harvested and processed to quantify bacterial titres
(log CFU/g).
Results: At 1-h post-inoculation, the lung bacterial titre was
5.9  0.2 log CFU/g. The pre-treatment titre (24-h post-inocula-
tion) was 7.2  0.6 log CFU/g. The table below shows the lung
bacterial titre and % survival at 24-h after either no treatment
(control) or treatment with TLV, VAN or LIN.
Conclusions: Telavancin is efﬁcacious and produces signiﬁcantly
greater reduction in lung titre than vancomycin and linezolid in
the MRSA murine pneumonia model. Telavancin appears to be a
promising new antibacterial for the treatment of MRSA-induced
pneumonia.
P1030 Inﬂuence of gender on the pharmacokinetics of
BAL9141 after intravenous infusion of Pro-drug BAL5788
A.H. Schmitt-Hoffmann, B. Roos, M. Heep, M. Schleimer,
E. Weidekamm, A. Man, N. Abdou
Basle, CH; Lenexa, USA
Objectives: BAL5788 is the water-soluble pro-drug of BAL9141, a
novel cephalosporin with broad-spectrum bactericidal activity
against Gram-positive and Gram-negative pathogens, including
MRSA, VRSA, and penicillin-resistant Streptococcus pneumoniae.
The present study was speciﬁcally designed to characterise the
pharmacokinetic properties of the active drug BAL9141 in male
and female subjects.
Methods: The pharmacokinetics of active drug BAL9141 were
investigated in 12 male and 12 female subjects. Each subject
received a single 30-min constant-rate intravenous infusion of
BAL5788 (equivalent to 750 mg of BAL9141). Blood and urine
samples were collected at appropriate intervals up to 24 h after
start of infusion. Pharmacokinetic parameters were derived from
plasma concentrations of BAL9141 by non-compartmental
analysis.
Results: At the end of the 30-min infusion, plasma Cmax-values of
BAL9141 reached 65.6 lg/mL in males and 79.3 lg/mL in females.
The corresponding AUCinf-values were 137 and 157 lg h/mL,
respectively. Elimination half-lives (t1=2 (b)) of BAL9141 amounted
to 3.4 h in males and 2.8 h in females. Total systemic clearance
(CLS) was 5.5 L/h in males and 4.9 L/h in females. The largest
gender difference was in the volume of distribution (VSS), which
amounted to 17 L in males and 12 L in females. All of these gender
differences were statistically signiﬁcant (P < 0.05). However, if VSS
and CLS were corrected for body weight, and if AUC and Cmax
were normalised to doses of ‘1 mg/kg body weight’, no signiﬁcant
gender differences were found for VSS (P ¼ 0.13) or Cmax
(P ¼ 0.27). Urinary recovery of BAL9141 amounted to 92% of the
dose in males and to 96% in females.
Conclusion: Systemic exposure to BAL9141 was approximately
15% higher in female subjects compared with male subjects and
was primarily related to the lower body weight/size and hence
Degree of
dysfunction
CLcr
(mL/min)
Cmax
(lg/mL)
AUC
(lg/h/mL)
CL
(mL/h/kg)
Vdcc
(mL/kg)
t1=2
(h)
Mild (n ¼ 4) 71 68.1 537 11 165 11.8
Moderate (n ¼ 3) 39 74.1 628 9 149 13.2
Severe (n ¼ 2) 24 73.5 773 6 148 17.9
Control TLV VAN LIN
Lung titre
(log10CFU/g  SD)
8.4  0.2 4.4  0.7 # 7.0  1.8 7.6  1.6
% Survival 38% 100% 88% 88%
*P<0.05 vs Control
#P<0.05 vs VAN and LIN
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smaller volume of distribution (VSS) in females. These small dif-
ferences are clinically not relevant, and therefore, no dose adjust-
ment is required in females.
P1031 BAL5788 in patients with complicated skin and skin
structure infections caused by Gram-positive pathogens
including methicillin-resistant Staphylococcus species. Interim
pharmacokinetic results from 20 patients
A.H. Schmitt-Hoffmann, M. Harsch, M. Heep, M. Schleimer,
T. Brown, A. Man, W. O’Riordan
Basle, CH; Chula Vista, USA
Objectives: BAL5788 (pro-drug) is a new cephalosporin with
broad-spectrum bactericidal activity against Gram-positive and
Gram-negative pathogens, including methicillin-resistant Staphylo-
cocci and penicillin-resistant Streptococcus pneumonia. Studies in ani-
mals demonstrated that time above MIC (T > MIC) for BAL9141
(active drug) is predictive for antibacterial efﬁcacy. Based on
multiple dose pharmacokinetic studies in healthy volunteers (HV),
as well as Monte Carlo simulations, a dose of 750 mg bid resulted
in a T > MIC largely greater than 60% for a MIC90 of 2 lg/mL in
MRSS. BAL5788 is currently under evaluation in Complicated Skin
and Skin Structure Infections (cSSSI) at a dose of 750 mg bid.
Interim pharmacokinetic data from 20 patients (P) are available
with the objective to conﬁrm the dose selected.
Method: Patients were treated with 750 mg equivalent BAL9141
(given as BAL5788 as a 30-min infusion) bid for at least 7 days.
Serial blood samples were collected during the second administra-
tion (Study days 1 or 2) and on Study day 7 during the ﬁrst daily
administration. Plasma concentrations of BAL9141 were deter-
mined using a speciﬁc LC/MS assay.
Results: The plasma concentration-time proﬁles of BAL9141 were
similar on Study Days 2 and 7 indicating in P the lack of accumu-
lation after repeated administrations. At steady state (SS) on Study
Day 7, mean (SD) Cmax-values (close to the end of the infusion)
of 64.4 lg/mL (31.9, n ¼ 20) were obtained, similar to the repor-
ted mean Cmax of 60.6 lg/mL (9.99, n ¼ 6) in HV at SS. The
mean (SD) AUClast in P was 136 lg h/mL (34.0), also compar-
able to HV. At 10 h after start of the infusion (i.e. 80% of a 12-h
dose interval) the mean (SD) plasma concentrations of BAL9141
were 2.31 lg/mL (1.31) .The inter- and intra-subject variability
in P was low (<30%) and similar to HV.
Conclusion: The interim pharmacokinetics of BAL9141 conﬁrmed
that bid doses of 750 mg in patients resulted in plasma concentra-
tions above a MIC90 of 2 lg/mL for >80% of the dosing interval
and are therefore predicted to be efﬁcacious in cSSSI with MRSS.
P1032 Dose adjustment in subjects with normal and
impaired renal function based on the pharmacokinetics of
BAL5788
A.H. Schmitt-Hoffmann, B. Roos, M. Schleimer, E. Weidekamm,
T. Brown, M. Heep, A. Man, L.G. Nilsson
Basle, CH; Uppsala, S
Objectives: BAL5788 is the pro-drug of BAL9141, a novel cepha-
losporin with broad-spectrum bactericidal activity including meth-
icillin-resistant Staphylococci and penicillin-resistant Streptococcus
pneumonia. After intravenous infusion, cleavage of the prodrug to
BAL9141 occurred rapidly and quantitatively. BAL9141 was pre-
dominantly excreted in urine. Therefore the present study was
designed to assess the pharmacokinetics of BAL9141, to suggest
dose-adjustment and to evaluate methods to optimally classify the
subjects.
Methods: Pharmacokinetics of BAL9141 were investigated in 20
healthy male subjects (n ¼ 5/group) with normal renal function
and mild, moderate, or severe renal impairment (respectively, cre-
atinine clearance CLCR >80, 51–80, 31–50, and <30 mL/min). Each
subject received a single intravenous dose of BAL5788 (equivalent
to 250 mg BAL9141) infused over 30 min. CLCR was measured
by 24-h urinary excretion and was calculated using the Cockroft
& Gault and Levey equations.
Results: Renal function affected clearance, elimination half-life,
and urinary excretion of BAL9141. Based on the linear correlation
between measured creatinine clearance and systemic drug clear-
ance and taking as target systemic exposure a MIC value of 4 lg/
mL BAL9141 exceeded for at least 6 h (corresponding to 50% of a
12-h dose interval) the following dose adjustments were sugges-
ted: subjects with a CLCR of >80 mL/min: 750 mg twice daily;
subjects with a CLCR of 30–80 mL/min: 500 mg twice daily; and
subjects with a CLCR of <30 mL/min: 250 mg once daily. The
classiﬁcation of renal function was reliable when done using the
Cockroft equation down to CLCR of 30 mL/min. For more severe
renal impairment the Levey equation was more accurate.
Conclusions: In subjects with normal and impaired renal function,
systemic clearance of BAL9141 correlated well with creatinine clear-
ance. Therefore, dose adjustments for treatment of target pathogens
can be proposed based on creatinine clearance. Classiﬁcation of
renal function and appropriate dose adjustments can be reliably
based on the equation of Cockroft & Gault for CLCR >30 mL/min
using serum creatinine concentrations, body weight and age.
P1033 Pharmacokinetics of BAL4815, a new azole
antifungal, after administration of single ascending intravenous
doses of its pro-drug BAL8557
A.H. Schmitt-Hoffmann, B. Roos, M. Heep, M. Schleimer,
E. Weidekamm, A. Man, M. Roehrle
Basle, CH; Neu-Ulm, D
Objective: BAL8557 is a water-soluble pro-drug, rapidly converted
in plasma to the active azole BAL4815. In vitro, BAL4815 showed
broad-spectrum antifungal activity against all major opportunistic
fungi and the true pathogenic fungi, including ﬂuconazole-resist-
ant strains. The pro-drug BAL8557 is speciﬁcally suited for intra-
venous and oral administration. The objective of the present
study was the ﬁrst assessment of the intravenous pharmacokinet-
ics of BAL8557/BAL4815 in human, after single ascending doses.
Methods: In this double-blind, placebo-controlled study, 18 male
subjects were randomly assigned to receive single ascending
1h-constant rate intravenous infusions of 50, 100, or 200 mg of
BAL4815 equivalents in the form of BAL8557. Blood samples were
collected up to 960 h after infusion and pharmacokinetic parame-
ters were estimated from plasma concentrations of BAL4815 by
non-compartmental analysis.
Results: At the end of the 1-h infusion of 50, 100, and 200 mg,
Cmax-values of BAL4815 reached 0.446, 1.03, and 2.47 lg/mL. The
corresponding AUCinf-values were 11.3, 26.6, and 73.2 lg h/mL.
Concentrations of BAL4815 seemed to increase slightly more than
dose-proportionally. Mean elimination half-lives reached 77, 105,
and 79 h and appeared to be independent of the dose. The vol-
ume of distribution (VSS) amounted to 305–496 L and systemic
clearance was low and reached only 2.8–5.0 L/h. Urinary recovery
of BAL4815 was low (<0.4% of the dose).
Conclusion: BAL8557 was rapidly converted in plasma to
BAL4815. High systemic concentrations of BAL4815 were reached
for prolonged times. Non-renal excretion seems to be the predom-
inant elimination pathway of BAL4815. Comparison of the sys-
temic exposure to BAL4815 after intravenous administration with
that after oral administration points to an excellent absolute bio-
availability of the oral formulation.
P1034 Anidulafungin (ANID) pharmacokinetics are not
affected by concomitant voriconazole (VORI)
J. Dowell, J. Schranz, J. Wilson, A. Baruch, G. Foster
King of Prussia, New York, USA
Objectives: Currently there is a great deal of interest in the
combination of triazole and echinocandin antifungals for invasive
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aspergillosis. However, little information exists on the pharmaco-
kinetics when these agents are coadministered. ANID (Vicuron
Pharmaceuticals) is a novel semi-synthetic echinocandin in late-
stage development for the treatment of serious fungal infections.
VORI (Pﬁzer; VFEND) is an extended-spectrum triazole antifun-
gal agent with demonstrated efﬁcacy against invasive aspergillosis
and candidiasis. A study was done to assess a possible pharmaco-
kinetic interaction following co-administration of VORI and
ANID.
Methods: A blinded, randomised, multiple-dose, cross-over, two-
way pharmacokinetic interaction study was conducted in healthy
subjects. Subjects received treatments in a random sequence: IV
ANID with an oral placebo, IV placebo with oral VORI, and IV
ANID with oral VORI. Treatments were separated by a greater
than 10-day washout. ANID was given as 200 mg IV on Day 1,
then 100 mg IV/day (Days 2–4). VORI was given PO as 400 mg
q 12 h on Day 1, then 200 mg PO q 12 h (Days 2–4). Pharmacoki-
netic parameters for ANID and VORI were determined at steady-
state from samples collected after the Day 4 dose of each
treatment. Maximum plasma concentration (Cmax) and area under
the plasma concentration vs. time curve (AUC) were determined
for ANID and VORI administered alone and in combination.
Results: Eighteen healthy males were enrolled in the study. Sev-
enteen of these subjects, 20–40 years of age, completed all treat-
ments. Steady-state ANID and VORI pharmacokinetic parameters
were calculated and summarised in this analysis; ANID pharma-
cokinetic parameters are shown below (mean  SD). No dose-
limiting toxicities or serious adverse events occurred in the
study.
Conclusions: The pharmacokinetic parameters are not affected
when ANID and VORI are administered concomitantly.
P1035 Population pharmacokinetics conﬁrms absence of
anidulafungin drug–drug interactions
M. Stogniew, J. Dowell, D. Krause, T.J. Henkel
King of Prussia, USA
Objectives: Anidulafungin (ANID) is an echinocandin in develop-
ment for the treatment of serious fungal infections. It is chemically
degraded, not metabolised, and not excreted renally; therefore
ANID has low potential to interfere with the elimination of other
drugs. A population pharmacokinetics (PK) analysis was per-
formed to screen for potential drug interactions that may affect
ANID PK.
Methods: Population PK analysis included 600 steady state drug
concentrations from 225 patients with esophageal or invasive can-
didiasis, or aspergillosis. Patients received 50, 75, or 100 mg
ANID/day. Mixed-effects models were evaluated in the NON-
MEM program. Concomitant medications were categorised meta-
bolically as substrates, inducers, or inhibitors of cytochrome P450
and evaluated in the model. Rifampin, a known potent inducer,
was included as a separate variable. Only those categories present
in at least 10% of the sampled population were evaluated during
the modelling process.
Results: A two-compartment model with ﬁrst order elimination
best ﬁt the data. Interpatient variability (%CV) in clearance (CL)
was estimated at 28%. Weight, gender, and study differences
together accounted for variability <20% and were not clinically
relevant in that dosage adjustments were not warranted. The
steady state parameters for a typical 60-kg male patient with oeso-
phageal candidiasis taking 50 mg/day were Cmax ¼ 3.5 mg/L,
AUCss ¼ 53 mg h/L, Vss ¼ 33.4 L, t1=2 ¼ 25.6 h, and CL ¼
0.934 L/h. No other covariates had any statistically signiﬁcant
effects on the model. Patients receiving no concomitant interacting
medications, known inhibitors, and known inducers had CL
(mean  SD) values of 0.93 (0.29), 1.03 (0.34), and 0.95 (0.25) L/h,
respectively. Co-administration of rifampin also showed no
change in the PK (CL ¼ 0.94 (0.27) L/h). Based on the mechanism
of ANID elimination, mainly via chemical degradation, the lack of
an effect due to concomitant medication usage was expected. For
most of the concomitant medication categories (rifampin, inducer,
inhibitor), there were adequate numbers of patients (>10% per
category) to have detected any consistent, clinically meaningful
changes.
Conclusions: ANID PK parameters in patients with serious fungal
infections were predictable with low intersubject variability. No
dosage adjustments of ANID are required for concomitant use
with metabolic substrates, inducers, and inhibitors.
P1036 Assessment of the pharmacokinetics of
anidulafungin in patients with invasive aspergillosis receiving
concomitant liposomal amphotericin
J. Dowell, J. Schranz, M. Stogniew, D. Krause, T.J. Henkel
King of Prussia, USA
Objective: There is a great deal of interest in combination antifun-
gal therapy for the treatment of aspergillosis. There are, however,
little clinical PK data on the concomitant use of echinocandins
and amphotericin. ANID is an echinocandin being studied for
serious fungal infections. It is chemically degraded, not metabo-
lised, and not excreted renally, therefore ANID has low potential
to interfere with the elimination of other drugs. An investigation
of potential clinical PK interactions was performed by comparing
the PK of ANID in patients with IA receiving concomitant LAmB
to other patient populations.
Methods: Patients with IA were enrolled in an open label
non-comparative study of ANID and received a combination of
intravenous ANID (100 mg/day) and LAmB (AmBisome(R),
Gilead; 3–5 mg/kg/day). Patients were treated until the resolution
of signs and symptoms for a maximum of 90 days. Plasma sam-
ples obtained at steady-state on separate days, at various sampling
intervals post-dose, were assayed for ANID. Data were combined
with data from patients with invasive and oesophageal candidiasis
(CA), analysed using a population PK analysis (nonlinear mixed
effects modelling), and PK parameters were compared.
Results: A two-compartment population PK model was estab-
lished that described the steady-state PK of ANID. The model
was developed using 600 ANID plasma concentrations collected
from 225 patients from four recent patient studies. Seven
patients with IA, receiving concomitant LAmB, were included in
the analysis. Overall, the population PK model showed little
impact due to any intrinsic or extrinsic factors, such as patient
demography, concomitant medications, or disease. Patient weight
and gender were found to be covariates on the model, but had
little clinical importance, accounting for less than 20% of the
intersubject variability. Patients with IA receiving concomitant
LAmB had similar PK parameters as patients with CA who did
not receive concomitant LAmB, as shown in the table (parameter
means  SD).
Conclusions: Patients with IA receiving concomitant LAmB had
no observable differences in ANID PK compared with other
patients. This is consistent with other screened factors, and consis-
tent with the elimination mechanism of the drug.
Treatment Cmax (mg/L) AUC (mg.h/L)
Anidulafungin 7.87 (1.64) 120 (24)
Anidulafungin+Voriconazole 7.89 (1.35) 117 (22)
CL (L/h) Vss (L) t1/2 (h)
Patients w/IA 0.84 (0.23) 34.4 (1.7) 30.6 (7.2)
Patients w/CA 1.01 (0.35) 33.4 (4.8) 25.5 (7.4)
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P1037 Rifampicin and ritonavir do not affect the
pharmacokinetics of micafungin (FK463), an echinocandin
antifungal
N.A. Undre, P. Stevenson, D.D. Amakye
Munich, D; Leeds, UK
Objectives: Pharmacokinetic (PK) interactions between caspofun-
gin, a recently marketed echinocandin, and rifampicin were repor-
ted. Two PK studies were performed to determine the effect of
rifampicin or ritonavir on the single IV dose pharmacokinetics of
micafungin.
Methods: The potential for drug interactions between micafungin
and rifampicin or ritonavir was investigated in two phase I open-
label studies in healthy male subjects. All subjects (rifampicin:
n ¼ 24; ritonavir: n ¼ 24) received a single IV dose of 200 mg
micafungin on Day 1, followed by a washout period of 4 days
(ritonavir: 5 days). Subjects received oral doses of 600 mg rifampi-
cin once-daily on Days 5–15 or 300 mg ritonavir twice-daily
on Days 6–17. A second IV dose of 200 mg micafungin was
co-administered on Day 12 (ritonavir: Day 10).
Results: The geometric mean ratio (90% CI) for micafungin
plasma AUC(0–inf) on the day of co-administration relative to
administration alone was 1.02 (0.977, 1.06) for rifampicin and 1.02
(0.993, 1.05) for ritonavir. The corresponding ratio of Cmax were
0.974 (0.946, 1.00) and 1.04 (0.999, 1.07), respectively.
Conclusions: Multiple oral doses of rifampicin, a potent inducer of
CYP3A4, or ritonavir, a potent inhibitor of CYP3A4, had no effect
on the pharmacokinetics of micafungin. Co-administration of rif-
ampicin or ritonavir with micafungin did not change the systemic
exposure of micafungin compared with single IV doses given alone.
P1038 Pharmacokinetics of itraconazole and
OH-itraconazole as a nanocrystal formulation in healthy
volunteers after single and multiple doses
J.W. Mouton, J.P. Donnelly, R. Crabbe
Nijmegen, NL; Beerse, B
Background: Until recently, itraconazole was available as an oral
agent only. Because of the water insolubility of itraconazole, formu-
lations for intravenous use have met with great difﬁculties. So far,
the only formulation used for intravenous administration is a 40%
hydroxypropyl-beta-cyclodextrin solution (HBC). An alternative
method to administer itraconazole (IT) could be the use of a nano-
crystal formulation (NCF). However, studies using this approach in
several animal species revealed that the nanocrystals are speciﬁcally
trapped in Kupffer cells in the liver and the spleen. This could
result in signiﬁcant changes in the pharmacokinetics of IT.
Methods: Two pharmacokinetic studies in volunteers were per-
formed. Study 1 was a single ascending dose study (SAD) with
doses planned to range from 50 to 500 mg (n ¼ 9); Study 2 was a
single and multiple dose ascending study (MAD 100, 200 and
300 mg, n ¼ 4) of IT as the NCF and one dose level as HBC (200 mg,
n ¼ 4). Samples were collected immediately before starting the infu-
sion, at 0.5 and 1 and 2 h during infusion when applicable, at 0, 0.08,
0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8 h after the end of infusion and at 24, 32,
72, 96 and 168 h after the start of infusion and analysed by HPLC.
Results: The results of both the SAD as well as the MAD study indi-
cated that there was a dose dependency in half-life of the NCF. The
half-life of IT increased from 44 h (100 mg dose) to more than 150 h
(300 mg) once steady state was achieved. Similar dose dependent
effects were observed for the metabolite; the AUC was also dose
dependent. Comparing the 200 mg treatments of the two formula-
tions, mean peak plasma concentrations during infusion of NFI
were substantially higher compared with itraconazole HCI. How-
ever, during the ﬁrst 30 min after infusion of NFI there was a more
rapid concentration and, as a consequence, the difference between
the two 200 mg formulations for other pharmacokinetic parameters
was less pronounced or not signiﬁcant at all. Both formulations
were comparable with respect to the terminal half-life, both after
single dose as well as during steady state.
Conclusion: There is signiﬁcant a dose dependent increase in half
life for the nanocrystal formulation. This might be due to trapping
of the crystals in liver and spleen cells acting as a deep compart-
ment. High dose nanocrystal formulation may especially advanta-
geous for long term therapy and profylaxis.
P1039 Pharmacokinetics and tissue penetration of linezolid
in patients with diabetic foot infection
G. Haase, M. Sass, J. Majcher-Peszynska, S.C. Mu¨ller,
R.G. Mundkowski, W. Schareck, B. Drewelow
Rostock, D
Objectives: DFI continues to be a major problem in diabetic
patients. Linezolid (L) has microbiological activity against the pre-
dominant pathogens causing DFI. For clinical efﬁcacy sufﬁcient
penetration of antimicrobial agents into perinecrotic tissue is
necessary. Data on plasma pharmacokinetic of L in diabetic
patients are not available.
Methods: 14 patients with a mean age of 65 years (range 53–77)
with DFI (Wagner grade III) were included into the study and
received at least ﬁve oral doses 600 mg L, given every 12 h. At
steady state blood and tissue-samples from the perinecrotic area
were taken. Tissue penetration and plasma pharmacokinetic
parameters were determined. Concentrations of L were measured
by high-pressure liquid chromatography (HPLC).
Results: Mean pharmacokinetic parameters of L were: plasma
peak concentration (Cmax) 13.7  3.8 lg/mL attained at a time of
2.8  1.8 h (Tmax); AUC 0–12 112.3  32 lg h/mL; plasma elimin-
ation half-life (t1=2) 7.8  4 h. Based on MIC of 4 mg/L calculated
PK/PD-values were: AUC24/MIC ratio 56  16; time above MIC
100% in 11 patients and in remaining three patients 67–83%. The
mean concentration of L in the inﬂamed perinecrotic tissue after
3 h was 10.6  4 lg/mL (11 patients); after 6 h, 6.8 lg/mL (three
patients); after 7 h 5.0 lg/mL (one patient), this corresponds to
90, 70 and 93% of plasma levels.
Conclusion: L exhibits good penetration into inﬂamed perinecrotic
tissue, with concentrations 3–7 h after dosing exceeding the MIC
of susceptible pathogens. Compared with pharmacokinetic data of
L in healthy volunteers with similar dosage, Cmax and AUC tend
to be decreased whereas Tmax and t1=2 tend to be increased in dia-
betic patients. The data presented conﬁrm that L could be success-
fully used in the treatment of DFI.
P1040 Evaluation of tigecycline, linezolid, quinupristin-
dalfopristin, arbekacin and daptomycin alone and in
combination with various antimicrobials against two clinical
strains of vancomycin-resistant Staphylococcus aureus in an
in vitro pharmacodynamic model
V. Huang, W. Brown, M. Rybak
Detroit, USA
Objectives: Increase in vancomycin usage has led to the develop-
ment of resistance to this drug due to selective pressure. This was
ﬁrst observed with the emergence of Glycopeptide-Intermediate
Staphylococcus aureus (GISA) in 1996 and with Vancomycin-Resistant
Staphylococcus aureus (VRSA) reported in 2002. Treatment options
for glycopeptide resistant strains limited and efforts to investigate
various combination therapies against VRSA are warranted.
Methods: Two clinical strains of VRSA-MI (Michigan) and VRSA-
PA (Pennsylvania) and one presumptive parent-MRSA from
Michigan (pMRSA) were evaluated, and were obtained from the
Detroit Medical Center, Detroit, MI, and the Network on Antimi-
crobial Resistance in Staphylococcus aureus (NARSA) program.
MIC and MBC were performed by NCCLS. An in vitro Pharmaco-
dynamic Model (IVPM) with a starting inoculum of 106 CFU/mL
was used for all experiments. Human pharmacokinetic regimen
simulations were: tigecycline (T) 100 mg q24h, linezolid (L)
600 mg q12h, arbekacin (A) 100 mg q12h, daptomycin (D)
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6 mg/kg q24h, and vancomycin (V) 1 g q12h. Quinupristin–dal-
fopristin (QD) was simulated as separate components at 7.5 mg/
kg q8h. Bacterial density was measured over 48 h.
Results: MICs for T, L, QD, A, D, and V for both VRSA-MI/
pMRSA are 0.5/0.5, 1/1, 0.5/0.25, 0.5/0.5, 0.25/0.25, and 1024/
0.5 mg/L, respectively. MICs for VRSA-PA strain are 2, 0.25, and
32 mg/L. T alone demonstrated bacteriostatic activity against
VRSA. L, QD, A, and D alone exhibited bactericidal activity
(99.9% kill) by 48 h against VRSA. However, no combination
exhibited signiﬁcant activity vs. VRSA.
Conclusions: L, QD, A, and D were highly active against VRSA.
Further investigations with combination therapies are warranted.
P1041 Evaluation of cefepime, arbekacin, daptomycin,
gentamicin, tobramycin, and tigecycline alone and in
combination against methicillin-resistant Staphylococcus aureus
in an in vitro pharmacodynamic infection model
V. Huang, M. Rybak
Detroit, USA
Objectives: Over the last two decades, antimicrobial resistance
among Gram-positive bacteria has become widespread in the
intensive care unit. Treatment options are limited; therefore,
efforts to develop new treatment regimens in the critical care pop-
ulation are warranted. We investigated various regimens of cefep-
ime alone and in combination therapies against two clinical
Methicillin-Resistant Staphylococcus aureus (MRSA) isolates (R2481
and R2484) in an in vitro pharmacodynamic model in vitro Phar-
macodynamic Infection Model (IVPM).
Methods: Two clinical MRSA isolates (Beaumont Hospital, Royal
Oak, MI) were evaluated. An IVPM was used for all experiments.
Human pharmacokinetic regimen simulations were: cefepime (C)
2 g q8 and 12 h, cefepime continuous infusion (CCI) 2 g loading
dose followed by 4 g alone or in combination with gentamicin (G)
1.5 mg/kg q12h (3 and 6 mg/L), arbekacin (A) 100 mg q12h,
tobramycin (TB) 3 mg/kg q12h (3 and 6 mg/L), linezolid (L)
600 mg q12h, tigecycline (T) 100 mg q24h, and daptomycin (D)
6 mg/kg q24h. Bacterial density was measured over 48 h. MIC
and MBC were performed by NCCLS.
Results: MICs for C, G, A, TB, L, T, and D for the two clinical MRSA
isolates (R2481 and R2484) were 4/4, 0.25/0.5, 0.5/0.125, 128/0.5,
2/4, 0.25/0.25, and 0.0625/0.125 lg/mL, respectively. There was a
trend for more activity with CCI vs. q8h vs. q12h. At 48 h, combina-
tions of C q12h + A demonstrated enhanced kill (2.90 log 0
decrease) against R2484 (P < 0.05). C q12h + G3 mg/L demon-
strated enhanced kill (3.21 and 4.32 log 10 decrease) against
R2481 and R2484, respectively (P < 0.05). C q8h + G3 mg/L
demonstrated enhanced kill (3.06 and 2.05 log 10 decrease)
against R2481 and R2484, respectively. T alone demonstrated bac-
teriostatic activity against these isolates. However, T + CCI demon-
strated improved kill against R2481 but no difference with R2484.
Conclusions: Overall, the most potent combinations noted were C
q8 and 12 h + G3 mg/L and C q12h + A against both clinical iso-
lates. An improved kill were noted with these combinations:
CCI + G3, CCI + A, and CCI + T. D alone was highly active
against both clinical MRSA isolates. Further investigations with
combination therapies are warranted.
P1042 Simultaneous methicillin-resistant Staphylococcus
aureus and vancomycin-resistant Enterococcus faecalis infections
in an in vitro pharmacodynamic model: a comparison of
daptomycin, arbekacin, linezolid and tigecycline activities
K. Tedesco, M. Rybak
Detroit, USA
Objective: Mixed pathogen infections represent a serious thera-
peutic challenge and choosing appropriate therapy, especially if
the pathogens are multi-drug resistant (MDR) are difﬁcult. We
inoculated an In vitro pharmacodynamic model (IVPD) simulta-
neously with two pathogens to determine activity.
Methods: daptomycin (D), arbekacin (A), linezolid (L), tigecycline
(T), and vancomycin (V) MICs were determined according to
NCCLS guidelines. A clinical isolate of methicillin resistant Sta-
phylococcus aureus (MRSA-494) and vancomycin resistant Enterococ-
cus faecalis (VREFc-R2526) was used in an IVPD model at
7 log 10 CFU/g to mimic a mixed infection (MI). Simulated regi-
mens were D 6 mg/kg/day, A 100 mg q12h, T 100 mg q24, and L
600 mg q12h . Each sample was plated on an ampicillin (Am),
and vancomycin (V) TSA plate at 8 the MIC to isolate the
respective isolate. Simulations were performed in duplicate, bac-
terial quantiﬁcation occurred over 48 h and potential for resist-
ance was evaluated.
Results: MICs for MRSA vs. D, Am, A, L, T, and V were 0.25,
512, 0.25, 2, 0.125, and 0.25 mg/L; for VREFc vs. D, Am, A, L, T,
and V were 1, 1, 64, 2, 0.125, and >256, respectively. In the MI
model, stunting of MRSAs growth was noted (1.5 log CFU/mL
difference) as compared with growth controls run individually. D
and D/A demonstrated early and signiﬁcant bactercidal activity
(BC) (99.9% kill) at 2 h against both isolates and A demonstrated
BC activity at 32 h vs. MRSA. D/A vs. MRSA was synergistic
(>3 log kill) at 48 h and additivity (1–2 log kill) was noted against
VREFc. T demonstrated BC activity kill with both isolates at 48 h.
L/A demonstrated additivity (1.86 log drop) against MRSA. T/A
demonstrated an antagonistic effect against VREFc at 48 h.
Conclusions: MRSA growth is stunted when combined with VREFc
in an IVPD model. D and D/A demonstrate early signiﬁcant BC
kill. D/A demonstrate synergy against MRSA and additivity
against VREFc at 48 h. L/A demonstrated additivity against MRSA.
T demonstrate BC activity vs. both isolates at 48 h, however the
addition of A demonstrated antagonistic activity against VREF.
P1043 Pharmacodynamics of amoxicillin/clavulanic acid
against Haemophilus inﬂuenzae in an in vitro kinetic model:
a comparison of different dosage regimens including a
pharmacokinetically enhanced formulation
E. Lo¨wdin, O. Cars, I. Odenholt
Uppsala, S
Objectives: To compare the pharmacodynamic effects of a new
pharmacokinetically enhanced formulation of amoxicillin/clavula-
nate (A/C) 2000/125 mg (Augmentin XR) twice daily, with A/C
875/125 mg twice daily, 875/125 mg three times daily and 500/
125 mg three times daily against Haemophilus inﬂuenzae with dif-
ferent susceptibility to A/C in an in vitro kinetic model.
Methods: b-lactamase producing strains of H. inﬂuenzae with MICs
of 0.5, 1, 2, and 4 mg/L at an initial inoculum of approximately
106 CFU/mL, was exposed to A/C in an in vitro kinetic model with
a concentration time-proﬁle simulating human serum levels of the
new pharmacokinetically enhanced formulation (with a Cmax of
15 mg/L) twice daily. All isolates were also exposed to A/C with
concentration time-proﬁles correlating to the human dosage of 875/
125 mg twice daily (Cmax 15 mg/L after 1 h), 875/125 mg three
times daily and 500/125 mg (Cmax 8 mg/L after 1 h) three times
daily with a simulated half-life of 1 h. Repeated samples were taken
regularly during 24 h and viable counts were performed.
Results: A decrease of approximately 2–4 log CFU/mL of all
strains was seen after the ﬁrst exposure of A/C with all four
regimens. The initial killing was more pronounced when the ini-
tial dose was higher than 500/125 mg. With all regimens against
all strains there was a signiﬁcant reduction in bacterial counts
after 24 h as compared with a control. The dosing regimens of
875/125 mg three times daily and the 2000/125 mg XR-formula-
tion given twice daily were able to eradicate the strain with the
lowest MIC (0.5 mg/L). For all the other experiments a static
effect was achieved at 24 h and there was no signiﬁcant differ-
ence in efﬁcacy between the dosing regimens for the strains with
a MIC >0.5 mg/L.
Conclusions: In our experiments T > MIC of 80% was needed to
achieve a bactericidal effect (strain with MIC 0.5 mg/L). T > MIC
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between 23 and 73% yielded a static effect (strains with MIC
1–4 mg/L) irrespective of the dosing regimen. Our in vitro system,
like others does not include the potential synergistic effects
between the antibiotic and the immune defence factors and may
thus reﬂect the situation in immunocompromised hosts rather
than in normal patients.
P1044 The comparative antibacterial effect of ertapenem
and ceftriaxone on E. coli studied in an in vitro
pharmacokinetic model of infection
K. Bowker, A. Noel, A. MacGowan
Bristol, UK
Objectives: Ertapenem (erta) and ceftriaxone (ceftriax) are once-
a-day injectable beta-lactams commonly used to treat Gram-negat-
ive infection. There are, as yet, no comparative studies of their
antibacterial effects (ABE). We used a pharmacokinetic (pK)
model to simulate the serum free drug concentrations of both
agents over three doses (72 h) and assess the ABE and emergence
of resistance (EoR) for E. coli.
Methods: A recent human isolate of E. coli, ampicillin susceptible,
ceftriax MIC 0.14, erta MIC 0.018 mg/L was used at an inoculum
of 106 and 108 CFU/mL. A dilutional, open, single compartment
in vitro pK model was used to simulate the dosing regimens over
72 h. The pK parameters modelled were: ceftriax 1 g iv 24 hly
Cmax 11 mg/L, t1=2 8 h; ceftriax 2 g iv 24 hly Cmax 22.0 mg/L; erta
1 g iv 24 hly; Cmax 13 mg/L, t1=2 4 h. Antibacterial effect was des-
cribed by reduction in viable count at 24h (delta 24), 48 h
(delta 48), 72 h (delta 72), time to clear 99.9% initial inoculum
(T99.9) and area-under-bacterial-kill-curve (AUBKC) 0–24 h
(AUBKC24), 0–4 8h (AUBKC48), 0–72 h (AUBKC72). EoR was
measured by population analysis proﬁles (PAP).
Results: The ABE (means) were: Ceftriax 1 g was less effective
than ceftriax 2 g. Inoculum had an impact on ABE of both erta
and ceftriax; for ceftriax regrowth occurred to a greater degree
with the high inoculum; for erta regrowth only occurred at the
high inoculum. Erta was more effective in the clearance of E. coli
in the ﬁrst 24 h compared with ceftriax. No EoR was detected for
erta or ceftriax despite the regrowth.
Conclusion: Erta produces more rapid clearance of E. coli from the
model than ceftriax irrespective of inoculum and is less subject to
regrowth at an inoculum of 106 CFU/mL. Regrowth is associated
with a high initial inoculum for both agents and neither showed
any EoR.
P1045 Comparison of ertapenem, ampicillin, and
meropenem against the intracellular forms of Listeria
monocytogenes in human THP-1 macrophages
S. Lemaire, S. Van de Velde, S. Carryn, F. Van Bambeke,
M.P. Mingeot-Leclercq, P. Tulkens
Brussels, B
Objectives: Ertapenem (ETP) is a new carbapenem with prolonged
half-life (approximately 4 h), which could make it more suitable
than meropenem (MEM) or ampicillin (AMP) for the treatment of
listeriosis. However, L. monocytogenes is largely intracellular, and
the activity of ETP against these forms has not been investigated.
We, therefore, compared ETP to AMP and MPN in a model of
human macrophages where AMP and MEM are cidal over a 24 h
incubation (approximately 2 log CFU decrease; Carryn et al.,
J Antimicrob Chemother 2003; 51:1051–1052).
Methods: MIC (arithmetic dilutions) and MBC (geometric dilu-
tions) were determined in TSB by standard methods. Activity
against extracellular and intracellular forms of L. monocytogenes
was examined in THP-1 macrophages incubated with extracellular
concentrations (ETP, 155 mg/L; AMP and MEM, 50 mg/L) equiv-
alent to the Cmax achievable in human serum after conventional
dosing. The stability of the drugs in the culture medium under
our experimental conditions was checked by HPLC.
Results: Activities in broth and in the cellular model are shown in
the Table.
Thus, whereas AMP and ETP have similar activities against
L. monocytogenes in broth, AMP was cidal but ETP unable to control
the growth of intracellular L. monocytogenes. Yet, assay of cell-asso-
ciated ETP showed that its apparent cellular concentration excee-
ded the MIC. Decreasing the serum concentration in the culture
medium (from 10 to 2%) did not change the results. Stability stud-
ies failed to reveal signiﬁcant degradation of extracellular ETP.
Conclusions: In this model, ETP did not eradicate intraphagocytic
L. monocytogenes. Based on the results obtained MEM, ETP lack of
activity is unlikely to be due to its penem structure. It is possible
that intracellular conditions (e.g. binding to cytoplasmic proteins)
hinder ETP intracellular activity in comparison with AMP or MEM.
P1046 Pharmacokinetic–pharmacodynamic modelling of
activities of cefpodoxime and ceﬁxime based on in vivo tissue
concentrations and in vitro kill curves
H. Derendorf, P. Liu, K. Rand, B. Obermann
Gainesville, USA; Munich, D
The bacterial time-kill curves of cefpodoxime and ceﬁxime against
four bacterial strains (Haemophilus inﬂuenzae, Moraxella catarrhalis,
Streptococcus pneumoniae/penicillin sensitive, and Streptococcus
pneumoniae/penicillin intermediate) were compared in
in vitro infection models in which various human pharmacokinetic
proﬁles of unbound antibiotic were simulated. This approach
offers more detailed information than the minimum inhibitory
concentration (MIC) does about the time course of antibacterial
activity of an antibiotic. A pharmacokinetic–pharmacodynamic
(PK–PD) model based on unbound antibiotic concentrations at the
site of infection and a sigmoid Emax-relationship with EC50 as
the antibiotic concentration necessary to produce 50% of the
maximum effect effectively described the antimicrobial activity of
both cefpodoxime and ceﬁxime. The EC50 values of cefpodoxime
and ceﬁxime were consistent with their respective MIC values.
Both antibiotics had similar high potency against H. inﬂuenzae
(EC50: 0.04 mg/L) and M. catarrhalis (EC50: 0.12 mg/L), while the
potency of cefpodoxime against S. pneumoniae strains was about
10-fold higher than that of ceﬁxime (EC50s/sensitive strain: 0.02
vs. 0.27 mg/L; EC50s/intermediate strain: 0.09 vs. 0.69 mg/L).
erta
Ceftriax
1 g
Ceftriax
2 g erta
Ceftriax
1 g
Ceftriax
2 g
D24 4:3 4:4 4:3 6:03 2:5 4:4
D48 4:3 4:1 3:2 2:4 2:1 3:6
D72 4:3 4:4 3:2 2:1 2:0 3:1
T99.9 3 12 7 4 26 6
AUBKC24 7.3 25.7 20.1 26.1 99.8 60.3
AUBKC48 7.3 27.8 27.0 78.6 182.0 104.2
AUBKC72 7.3 37.6 53.0 165.0 274.1 173.5
Broth
THP-1 model (change log
CFU over 24 h)
MIC
(mg/L)
MBC
(mg/L)
Extracellular
(broth) Intracellular
ETP 0.48  0.03 >64 0:57 0.05 0.96  0.23
AMP 0.37  0.23 >64 0:46 0.03 1:81 0.01
MEM 0.05  0.00 >64 0:38 0.05 1:82 0.01
means  SEM (n ¼ 3 independent experiments).
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Applications of this model to unbound tissue proﬁles obtained by
microdialysis in a clinical study performed in our group showed
that cefpodoxime has higher bacteriological potency against
S. pneumoniae than ceﬁxime. The developed mathematical PK–PD
model (sigmoid Emax model combined with a PK model using
free tissue levels) allows for rational antibiotic dosing decisions by
predicting the antibacterial effect of various dosing regimens, tak-
ing into account the clinically effective free concentrations at the
target site. This PK–PD approach is a major improvement over
the currently used PK–PD approaches that are usually based on
the comparisons of pharmacokinetics of total plasma concentra-
tions and in vitro MIC.
P1047 Single-dose pharmacokinetics of cefodizime
in acutely ill elderly patients
B. Meyer, F. Traunmueller, T. Staudinger, G. Locker, R. Schmid,
F. Thalhammer
Vienna, A
Objectives: Cefodizime is an extended-spectrum third-generation
cephalosporin antibiotic with good in vivo and in vitro activity
against Gram-positive and Gram-negative pathogens including
most beta-lactamase-producing species.
Methods: Pharmacokinetic characteristics of cefodizime were
assessed in 21 acutely ill elderly patients (age >65 years). Thirteen
patients received a single-dose of 2 g cefodizime intravenously,
eight patients received a single-dose of 4 g cefodizime intraven-
ously. Serum concentrations of cefodizime were assessed by high-
performance liquid chromatography.
Results: After a single dose of 2 g cefodizime the mean cefodizime
serum concentration peak was 222  55 lg/mL, the elimination
half-life was 6.19  2.45 h. The total clearance, area under the
curve and volume of distribution were 35.8  13.2 mL/min,
1089.4  505.3 lg/mL h and 18.1  6.3 L, respectively. After a sin-
gle-dose of 4 g cefodizime the mean serum concentration peak was
319  79 lg/mL, the elimination half-life time was 6.81  4.30 h.
The total clearance, area under the curve and volume of distribu-
tion were 42.35  14.67 mL/min, 1763.2  630 lg/mL h and
21.87  8.08 L, respectively. Cefodizime was tolerated well in all
patients, no major side effects occurred.
Conclusion: Our results indicate that acutely ill elderly patients
can be treated safely and effectively with a standard dose of 2–4 g
cefodizime. No age-related dose-modiﬁcation is necessary.
P1048 Comparative effects of ertapenem and ceftriaxone
on the normal intestinal microﬂora
M.W.R. Pletz, M. Rau, A. de Roux, O. Burkhardt, M. Kurowski,
H. Lode, C.E. Nord
Berlin, D; Stockholm, S
Objectives: Ertapenem is a novel, long-acting parenteral 1-beta-
methyl-carbapenem, which is used for treatment of serious infec-
tions. Administration of antimicrobial agents causes disturbances
in the ecological balance between host and microorganisms. To
what extent disturbances occur depends on the spectrum of the
agent, the dose, the route of administration, pharmacokinetic and
pharmacodynamic properties, and in vivo inactivation of the
agent. The aim of the study was to investigate the ecological
effects of ertapenem compared with those of ceftriaxone on the
intestinal human microﬂora in healthy volunteers.
Methods: Ten healthy volunteers (ﬁve females and ﬁve males),
age range 18–40 years, participated in the investigation. The trial
was divided into two 35-day periods. The two treatment regimens
were (i) 1 g ertapenem intravenously o.d. for 7 days, and (ii) 2 g
ceftriaxone intravenously o.d. for 7 days. Each volunteer received
ﬁrstly one treatment regimen and secondly the other treatment
regimen. The wash-out period was 4 weeks between the two regi-
mens. Faecal samples were collected for microbiological analysis
before, during and after treatment.
Results: The number of enterococci increased signiﬁcantly during
the administration of ertapenem, while E. coli decreased. There
was an overgrowth of low levels of yeasts on day 8. The aerobic
microﬂora was normalised on day 35. Biﬁdobacteria and bactero-
ides were markedly reduced while there were minor alterations in
the number of lactobacilli and clostridia. On day 35 the anaerobic
microﬂora had returned to normal levels. The faecal concentrations
of ertapenem (mean value) were 37.2 and 32.7 mg/kg on days 4
and 8, respectively. C. difﬁcile was isolated from four volunteers.
Enterococci increased markedly while the number of E. coli
decreased during the administration of ceftriaxone. No signiﬁcant
overgrowth of yeasts was noticed on day 8. The aerobic microﬂora
had returned to pre-treatment levels on day 35. Lactobacilli, biﬁdo-
bacteria, clostridia and bacteroides were reduced in signiﬁcant
numbers during the ceftriaxone administration. C. difﬁcile was iso-
lated from three volunteers. On day 35 the anaerobic microﬂora
was normalised. The faecal concentrations of ceftriaxone (mean
value) were 153 and 258 mg/kg on days 4 and 8, respectively.
Conclusions: Ceftriaxone caused signiﬁcant ecological changes in
the intestinal microﬂora while ertapenem caused moderate altera-
tions.
P1049 Multiple dose and steady-state pharmacokinetics of
ertapenem compared with ceftriaxone in healthy young male
and female volunteers
M. Rau, M.W.R. Pletz, J. Bulitta, A. de Roux, G. Schreiber,
C.E. Nord, M. Kurowski, G. Kruse, H. Lode
Berlin, Nuremburg, D; Stockholm, S
Background: Ertapenem (ERT) is a new long-acting carbapenem
antibiotic with antibacterial activities similar to ceftriaxone. Both
drugs have to be administered i.v. once daily.
Methods: ERT (1 g, 30 min i.v.) and CFT (2 g, 30 min i.v.) both once
daily for 7 days were compared in a two-way randomised crosso-
ver study with 10 (ﬁve males and ﬁve females) healthy volunteers
(age: 35  5 years, weight: 70  13 kg, height: 173  9 cm, crea.
clear. 105.4  9.8 mL/min/1.73 m2, mean  SD). ERT and ceftriax-
one (CFT) were determined via validated bioassay and ERT was
additionally determined by chromatography (LCMS). Single dose
(SD) and steady-state (SS) pharmacokinetics (PK) were determined
by non-compartmental analysis. Statistical comparisons for day 1
vs. day 7 and gender-effects were performed by ANOVA and
equivalence statistics.
Results: Values are means  SD (PE: Point Estimate for ratio SS/
SD, CI: 90% conﬁdence interval).
Urinary recovery was 48  17% (SD) and 44  18% (SS) for
ERT. Females (f) and males (m) differed signiﬁcantly in AUC for
ERT (P < 0.004; SD: f 711  45, m 950  151; SS: f 770  88, m
901  192 lg h/mL), but not for CFT. The most frequently repor-
ted side effect for both drugs was diarrhoea (CFT and ERT: 6/10).
No severe adverse events were recorded.
Conclusions: No accumulation in SS was detected for ERT or CFT.
Females exhibited a decreased AUC for ERT. However this gen-
der-effect is not considered to be of clinical importance.
AUC
(lg  h/mL)
Cmax
(lg/mL)
t1=2
(h)
CLtot
(mL/min)
ERT SD,day 1 830  164 256  38 4.6  1.1 20.7  3.7
ERT SS, day 7 836  157 280  52 4.3  0.5 20.5  3.3
ERT PE(CI) 1.01
(0.88–1.16)
1.09
(0.95–1.24)
0.94
(0.83–1.08)
0.99
(0.86–1.14)
CFT SD, day 1 1576  240 315  82 7.6  1.3 21.7  3.9
CFT SS, day 7 1487  227 303  47 7.1  0.9 23.1  4.2
CFT PE, (CI) 0.94
(0.83–1.07)
0.98
(0.83–1.15)
0.95
(0.84–1.06)
1.06
(0.94–1.21)
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P1050 Bacterial inhibition of phosphatidylcholine
synthesis induces apoptosis in brain cells
J. Zweigner, S. Jackowski, S. Smith, M. van der Merwe, J. Weber,
E. Tuomanen
Berlin, D; Memphis, USA
Objectives: Streptococcus pneumoniae is the most common cause of
bacterial meningitis of high mortality and morbidity. In humans,
neurons of the hippocampus undergo apoptosis as a result of
meningitis. Phosphatidylcholine (PtdCho) is an essential compo-
nent of mammalian cell membranes and phosphatidylcholine deﬁ-
ciency, either due to chemicals or altered nutrition, leads to
apoptosis, especially in hippocampal neurons.
Methods: Microglia, neurons, and brain endothelial cells were
infected with 107/mL pneumococcal strain D39 capsular type 2,
its unencapsulated derivate R6, the pneumolysin-negative mutant
plan, the pyruvate oxidase mutant spxB, or the plan/spxB
double mutant for 4 h. Translocation of phosphatidylserine and
decrease of mitochondrial transmembrane potential as measure-
ments of apoptosis were detected by FACS analysis. Synthesis of
PtdCho was measured by incorporation of [methyl-3H]choline.
Inhibition of apoptosis in vivo was demonstrated by pretreatment
of infected C57BL/6 mice with citicoline. Damage in the hippo-
campus was quanitiﬁed by Tunel staining.
Results: D39 and R6 signiﬁcantly inhibited phosphatidylcholine
biosynthesis (41.2  6 and 67.4  8%, respectively) causing apop-
tosis of several different types brain cells. Loss of H2O2 or/and
pneumolysin signiﬁcantly reduced the ability of pneumocci to
cause cell death and caused less inhibition of PtdCho synthesis,
with [methyl-3H]choline incorporation into PtdCho increasing to
57.8, 77.9, 92.4%, respectively, compared with uninfected control
cells. Supplementation with exogenous lysophosphatidylcholine
prevented cell death in vitro and treatment of mice with CDP-cho-
line attenuated hippocampal damage during meningitis. Apopto-
sis inhibitors ZVAD, ALLN, fumonisin B1 or BAPTA-AM did not
prevent the bacterial-dependent inhibition of phosphatidylcholine
biosynthesis.
Conclusions: We conclude that bacterial inhibition of phosphat-
idylcholine biosynthesis activates an apoptotic cascade that is a
causative event in pathogenesis and is amenable to therapeutic
intervention.
P1051 Bacterial cell-wall derived products induce a
pro-inﬂammatory and pro-ﬁbrogenetic phenotype in murine
hepatic stellate cells
P. Brun, D. Martines, M. Pinzani, G. Palu`, I. Castagliuolo
Padua, I
Although activation of hepatic stellate cells (HSC) is recognised as
the initiating event leading to ﬁbrosis, the factor(s) responsible for
HSC activation in non-alcoholic steatohepatitis (NASH) are not
completely known. Since patients with NASH have a high preval-
ence of small intestinal bacterial overgrowth we tested the hypo-
thesis that gut-derived bacterial products may activate HSC. We
found by LAL test that endotoxin level (LPS) in portal blood of
obese C57lep= mice was signiﬁcantly increased as compared
with lean controls (8.74 + 1.08 vs. 6.11 + 0.8 EU/mL). Since we
also observed that murine HSC express speciﬁc mRNA transcripts
encoding mCD14, TLR4, MD2, TLR2 (endotoxin receptors) and
peptidoglycan recognition proteins (PGRP), we next studied the
effects of LPS, lipoteichoic acid (LTA) or muramic acid (NAM)
(10–0.01 lg/mL) on TGF-beta1, IL-6, PDGF-bb, MCP-1 and ﬁbro-
nectin (mRNA transcripts and peptides). Incubation of HSC for
24 h with LPS (1 lg/mL) increased TGF-beta1 (by 1.8-fold) and
IL-6 (by 12.5-fold) mRNA transcripts levels over controls, but had
no effect on ﬁbronectin mRNA levels. LTA (10 lg/mL) increased
only IL-6 (by 4.9-fold) mRNA transcripts, whereas NAM had no
signiﬁcant effects. Similar results were obtained also by cytokine
measurements in the conditioned media. Six days exposure of
HSC to 10 ng/mL of LPS alone increased TGF-beta1 and IL-6
mRNA transcripts by 2- and 3.9-fold over controls, respectively,
but still had no effect on ﬁbronectin mRNA levels. Similarly, LTA
and NAM by themselves signiﬁcantly increased only IL-6 mRNA
transcripts by 2.1- and 1.9-fold, respectively. However, simulta-
neous exposure of HSC to LPS and LTA (10 ng/mL/6 days)
induced a ﬁbrogenic phenotype signiﬁcantly increasing ﬁbronectin
mRNA levels by 1.95-fold over controls. In summary, we report
that LPS levels are increased in the portal blood of obese mice
and that short-term exposure of HSC to bacterial derived cell wall
products can induce a pro-inﬂammatory phenotype whereas a
long-term exposure induces a pro-ﬁbrogenic phenotype. We spe-
culate that in obese patients the intestinal barrier function is com-
promised causing a rise in LPS levels in the portal blood that in
turn may contribute to the activation of HSC thus leading to the
development of ﬁbrosis in NASH patients.
P1052 Lipopolysaccharide-induced vascular endothelial
growth factor expression
A.J. Huh, Y.A. Kim, Y.W. Kim, J.S. Yeom, Y.G. Song, K.H. Chang,
J.M. Kim
Go-yang, Seoul, KOR
Objectives: VEGF is a potent angiogenic and vascular permeabil-
ity factor. Recent studies have shown that the VEGF levels are
higher in various cells such as macrophages and smooth muscle
cells by LPS stimulation, suggesting its importance in the initi-
ation and development of sepsis. LPS-regulated contractility in
lung pericytes may play an important role in mediating pulmon-
ary microvascular ﬂuid haemodynamics during sepsis. We have
studies the production of VEGF by rat lung pericyte in response
to LPS.
Methods: Using rat lung pericytes as a cellular model, we dem-
onstrated that VEGF mRNA and protein expression stimulated
by LPS were changed. Pericytes were stimulated with 0.0001–
100 lg/mL LPS for up to 12 h to analyse the levels of VEGF
mRNA or secretion of VEGF protein. The quantitation of the
mRNA levels such as VEGF, iNOS, or 28S ribosomal RNA was
veriﬁed by RT-PCR. The concentrations of VEGF protein in the
conditioned medium or cell lysates were measured with ELISA.
To clarify the mechanism of VEGF expression, VEGF expression
was examined using the inhibitors of transcription factors such
as NF-kB or p38 MAP kinase. Western blot analysis was per-
formed to identify both active and inactive forms of p38MAP
kinase in pericytes.
Results: LPS enhanced VEGF mRNA expression in pericytes in a
concentration-dependent manner with the maximal levels after
2 h of stimulation. VEGF protein levels, both in the conditioned
medium and cell lysate, increased with the increasing concentra-
tion of LPS and reached the maximum at 24–48 h after LPS sti-
mulation. LPS also augmented iNOS expression in lung pericytes
signiﬁcantly within 6 h. However, the induction of iNOS mRNA
took place later than the LPS-induced increases in the levels of
VEGF mRNA. Inhibition of NF-aB or tyrosine kinase did not
suppress the LPS-induced augmentation of VEGF mRNA expres-
sion in the lung pericytes, although both of inhibitors markedly
inhibited the LPS-induced expression of iNOS mRNA. SB203580,
p38 MAP kinase inhibitor repressed the LPS-induced VEGF
mRNA expression. LPS stimulated a rapid and sustained phos-
phorylation of p38 MAP kinase. These results indicate that LPS
induce the VEGF expression in lung pericytes through p38 MAP
kinase.
Conclusion: We conclude that pericytes produce VEGF in
response to the stimulation with LPS, which may be partly medi-
ated by the p38 MAP kinase pathway.
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P1053 Antistaphylococcal effect of recombinant human
erythropoietin
H. Baskin, Y. Baskin, Y. Dogan, I.H. Bahar
Izmir, TR
Objective: Erythropoietin (EPO) was originally identiﬁed as a hor-
mone for adjustment of the circulating erythrocyte mass. Follow-
ing molecular biologic studies today it is known that EPO is a
member of the cytokine superfamily with signiﬁcant homology to
mediators of growth and inﬂammation. In this study, we ques-
tioned the antibacterial effect of EPO against an intracellular
pathogen.
Methods: A human isolated, non-mutant, non-37C resistant Sal-
monella typhimurium strain was used in experiments. Resting
mouse peritoneal macrophages were incubated for 24–48 h with
EPO (10 U/mL), EPO/2 (5 U/mL), EPO/4 (2.5 U/mL), L-NAME
(nitric oxide inhibitor), EPO/L-NAME, EPO/2/L-NAME in 10:1,
5:1, 1:1 m.o.i. Following incubations extracellular nitric oxide
(NO) levels (Griess) were determined; apoptosis (Hoechst 33342)/
necrosis (propidium iodide) determinations were made. In simul-
taneous groups, cells were lysed with sterile distilled water and
colony counts were performed.
Results: Following 24–48 h colony counts were signiﬁcantly lower
in EPO groups compared with EPO/2, EPO/4, Salmonella,
L-NAME, EPO/L-NAME groups in 10:1, 5:1, 1:1 m.o.i. Interest-
ingly, NO responses were higher in EPO groups compared with
EPO/2, EPO/4, and Salmonella groups. In apoptosis/necrosis
balance, apoptosis was dominant in EPO groups compared with
EPO/2, EPO/4, Salmonella, EPO/L-NAME, L-NAME groups.
Conclusion: It is known that EPO is a multifactorial tissue protect-
ive cytokine. S. typhimurium shows its pathogenicity by entering
the cell, and when enters the cell NO response and apoptosis
starts. This study showed that EPO inhibited the entry of
S. typhimurium into the macrophages, and simultaneously stimula-
ted NO response which triggered apoptosis more than the
bacteria expected.
P1054 Ex vivo release of pro-inﬂammatory cytokines of
blood monocytes of patients with sepsis: correlation to the
initiation of symptoms and to monocyte apoptosis
M. Kyriakopoulou, M. Raftogiannis, F. Baziaka, I. Skiadas,
H. Giamarellou, E.J. Giamarellos-Bourboulis
Athens, GR
Objectives: Failure of immunomodulation in sepsis is partly
attributed to lack of knowledge for the appropriate time necessary
for administration of therapy. This study was designed to corre-
late the time of the presentation of symptoms to the excretory
effect of patients’ monocytes in an attempt to identify the appro-
priate time period for immunomodulatory intervention.
Methods: Heparinised venous blood was sampled from 37
patients with sepsis according to the ASCP/SCCM 1992 criteria.
Blood was centrifuged over Ficoll and mononuclears were incuba-
ted in RPMI with 10% FCS. After removal of non-adherent cells,
monocytes were harvested and half of them were re-suspended in
wells with medium without/with the addition of 4% of the serum
of the patient and incubated for 18 h. The remaining half of cells
was lysed and caspase-3 activity was estimated in the cytosolic
extract by a chromogenic assay. Tumour necrosis factor-alpha
(TNF) and interleukin-6 (IL-6) were estimated in culture superna-
tants by EIA; malondialdehyde (MDA) was assessed by the thio-
barbiturate assay. Results were correlated to the time lapsed since
advent of fever.
Results: Median TNF excreted from monocytes of patients with
fever within 12 h, 13–24 h and more than 24 h post-admission
were 43.8, 21.9 and 29.6 pg/10 000 cells, respectively, and became
23.4, 21.1, 10.5 pg/10 000 cells, respectively, after incubation with
the patients’ serum. Median IL-6 excreted from monocytes of
patients at the above time intervals were 118.1, 58.1 and 32.8 pg/
10 000 cells, respectively, and became 163.2, 48.7, 52.6 pg/10 000
cells, respectively, after incubation with the patients’ serum. Med-
ian MDA excreted from monocytes of patients at the above time
intervals were 1.52, 0.67 and 2.43 mmol/10 000 cells, respectively,
and became 2.11, 1.06, 2.02 mmol/10 000 cells, respectively, after
incubation with the patients’ serum. Median monocyte caspase-3
activities at the above time intervals were 53.4, 200.0 and
99.7 pmol/min/10 000 cells.
Conclusions: Elevated biosynthetic activity of human monocytes is
found over the ﬁrst 12 h of symptoms of sepsis. Latter advent of
symptoms is accompanied by lower cytokine release and higher
apoptotic activity leading to the assumption that immunomodula-
tory intervention in sepsis should be kept only for patients with
early occurrence of symptoms.
P1055 Adherence factors of ocular isolates of nontypeable
Haemophilus inﬂuenzae from Saudi Arabia
A. Adlan, J.N. Fletcher, A.A. Al-Rajhi, A. Al-Theeb, A.M. Snelling
Riyadh, SA; Bradford, UK
Objectives: Nontypeable Haemophilus inﬂuenzae is a common cause
of otitis media, sinusitis and respiratory infections. In some coun-
tries it is also a signiﬁcant cause of conjunctivitis. The adherence
of H. inﬂuenzae to epithelial cells is an initial step in its pathogene-
sis. Such adhesion is not thought to be mediated by ﬁmbriae, but
several non-ﬁmbrial adhesins have been identiﬁed. HMW1 and
HMW2 are related high molecular weight adhesins, present in
many strains. Some strains express an alternative adhesin, Hia,
instead. Most of the studies examining the types and distribution
of these factors have looked at respiratory and otitis media iso-
lates collected in Western countries. This study investigated the
type and prevalence of adherence factors in ocular isolates from
Saudi Arabia.
Methods: Isolates were collected from patients in Riyadh present-
ing with ocular infections (OI, 100 isolates) or respiratory infection
(RI, 19). Commensal isolates were obtained from the eyes of
healthy volunteers (CE, 18 isolates). Strains were identiﬁed by
standard methods and biotyped by API NH strips. PCR was used
for serotyping and detection of the genes encoding HMW1,
HMW2, and Hia.
Results: All 137 isolates were conﬁrmed as nontypeable, and none
produced a PCR amplimer with primers designed against the
published sequence of hmw1. The prevalence of the hmw2 gene
amongst the different groups was: OI 47% +ve, RI 37% +ve, and
CE 39% +ve. The proportion of strains with hia was OI 46%, RI
21%, and CE 0%. Strains carrying hmw2 and hia together were
identiﬁed amongst the ocular infection and respiratory infection
groups (20 and 16% of isolates, respectively). Such strains were
spread across biotypes 2, 3, and 4. The percentage of strains with
neither adhesin was lower in the ocular infection group (27%)
than in the RI (58%) and CE (61%) groups.
Conclusion: Previous studies based on non-ocular isolates have
suggested the HMW and Hia adhesins are not found together in
strains. In this study, a signiﬁcant proportion of nontypeable
H. inﬂuenzae isolates from ocular and respiratory infections were
positive for both. The mixture of biotypes suggests such strains
were not members of a clonal group. The gene encoding HMW1
was not detected amongst the 137 isolates. The distribution of
HMW and Hia adhesins amongst isolates causing disease in Saudi
Arabia appears to differ from those isolated in Western countries.
P1056 Genetic relationships among nontypable
Haemophilus inﬂuenzae (NTHI) isolates presenting different
adhesins proﬁles
B. Rybak, E. Augustynowicz, A. Gzyl, G. Gniadek, J. Slusarczyk,
A. Samet
Gdansk, Warsaw, PL
Objective: Nontypable H. inﬂuenzae (NTHI) commonly colonising
human nasopharynx and causing the localised respiratory tract
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infections are known to demonstrate substantial strain heterogen-
eity. Within NTHI group, strains of different combinations of par-
ticular adherence factors (e.g. HMW1/HMW2 family like
proteins, Hia, Hap and pili) might be capable to different extent
colonise the host and induce infection. Comparison of the adher-
ence patterns seen in NTHI isolated from carriers and from local-
ised respiratory tract infections and their ﬁngerprinting proﬁles
might help to determine some relationships among epidemiologi-
cally unrelated strains/clades. Those relationships might suggest
different level of invasive potential.
Methods: We studied 55 NTHI isolates obtained from patients with
localised respiratory tract infections. Randomly ampliﬁed polymor-
phic DNA (RAPD) and automated ampliﬁed-fragment length poly-
morphism (AFLP) techniques with ﬂuorescently labelled primers
were used to ﬁngerprint NTHI isolates. PCR has been used to
evaluate gene organisation both of the pilus (hif) (detection of
insert within the purE-pepN region) and hmw clusters.
Results: Among 55 NTHI strains isolated from patients with bron-
chitis, pneumonia, pharyngitis and otitis, three different arrange-
ments of hif locus were found. For 14 strains 0.3 kb fragments
indicating lack of insert hif were found. The remaining 41 strains
harboured fragments of intermediate length, ranging from 0.9 to
1.1 kb. Locus of 3.4 kb, commonly seen in strains isolated from
healthy carriers, was not identiﬁed in any strain tested. Genes
encoding HMW1/HMW2 like proteins were found to predomin-
ate among isolates associated with pneumonia and pharyngitis
diseases. Most of the strains harboured hmw+ locus and genotype
of 0.9–1.1 kb hif locus. Only three hmw+ strains were found not
to contain insert hif. Genotypes of the purE-pepN region were
grouped into relationship classes by AFLP and RAPD and hmw
patterns. All genotypes grouped within a single AFLP set had
identical or near identical hmw patterns.
Conclusions: Relationships among strains classiﬁed according to
perE-pepN and hmw genotype, and AFLP and RAPD dendro-
grams clusters were found.
P1057 Bac protein based recombinant peptides as possible
means for vaccine development against GBS infection
L. Meringova, I. Ustinovitch, K. Grabovskaya, G. Leontieva,
A. Suvorov
St.Petersburg, RUS
Objectives: Group B streptococci (GBS) being the main cause of
infection pathology of the newborns can also cause serious infec-
tions in adults. Construction of the recombinant vaccine against
GBS infection might be important for the several risk groups
including pregnant women. Several recombinant peptides based
on the GBS IgA binding protein Bac were used for vaccination of
mice in order to evaluate their immunogenicity and possible pro-
tection against GBS infection.
Materials and methods: GBS strain 219, type IIbc was used as
source of DNA for cloning. Bac gene fragments corresponding to
the 3¢ portion of the gene were obtained by PCR and cloned in
E. coli expression vectors. Recombinant proteins P1, P5, P6 (26,
24, 35 kD) were puriﬁed by afﬁnity chromatography and used
for subcutaneous immunisation of mice. Immunisation was
accomplished in three doses of the antigens (5, 10 and 20 lg)
two times each dose with interval of 4 weeks. ELISA monitored
antibody titres starting from the 21st day until the 150th day
from the beginning of immunisation. Constant of association (Ka)
of the antibodies was estimated employing computer software
package ‘Polyconst’. Protection studies were accomplished in
mice infected intraperitoneum by GBS with doses 106 and 107
cells per mice.
Results: Three Bac based recombinant peptides were used for
immunisation of mice. Largest peptide P6 generated the highest
titres of antibodies (1  106) on the 69th day of experiment. That
titre was not changed till the end of the study. Ka of the antibod-
ies to the P6 peptide varied from 108 to 1013 M-1 with the 50%
share of high afﬁnity IgG. Immunisation with peptides P1 and P5
reached maximum on the 41st or 48th day of the experiment with
titres 1:50 000 or 1:12 000, respectively, with gradual decrease till
the end of the study. Afﬁnity of IgG to those peptides also varied
between 106 and 1012 M-1. Share of high afﬁnity IgG was
10–30%. Cross-absorbtion of the antibodies to the peptides dem-
onstrated the homology between anti-P6 and anti-P1 and differ-
ences with anti-P5. The most immunogenic peptide P6 was used
for mice protection study. It was shown that mice with IgG titre
against P6 equal to 1:100 000 were protected against GBS infection
and GBS was eliminated from blood and peritoneum.
Conclusion: Bac based peptides P6 and P1 can be considered as
possible vaccine components against GBS infection. Perspectives
of GBS vaccine development and epitop organisation of Bac pro-
teins are discussed.
P1058
Abstract withdrawn.
P1059
Abstract withdrawn.
P1060 Bacterial adherence ability and adherence factors of
quinolone sensitive and resistant E. coli strains isolated from
cirrhotic patients
I. Gasco´n, P. Ma´s, R. France´s, S. Pascual, V. Merino, J. Such,
J. Plazas
Alicante, Valencia, E
Objectives: Prolonged use of norﬂoxacin as secondary prophylaxis
of spontaneous bacterial peritonitis entails an appearance of 40%
of E. coli quinolone-resistant (QR) in stools. However, the devel-
opment of infections caused by these QR bacteria is not so fre-
quent as expected. Our aim was to assess bacterial adherence
(BA) of either quinolone-sensitive (QS) or QR strains to oral epi-
thelial cells in presence/absence of sub-MIC concentrations of
norﬂoxacin and to evaluate the inﬂuence of some relevant adher-
ence factors presence on adherence to cells.
Methods: 59 strains of E. coli obtained from rectal swabs of cir-
rhotic patients were studied and their MIC was determined by
E-test. Twenty strains from healthy volunteers were also tested as
controls. Strains were incubated with oral epithelial cells in pres-
ence/absence of sub-MIC of norﬂoxacin. BA was measured by the
percentage of epithelial cells with attached bacteria (marked with
ﬂuorescein). Adherence factors were determined by PCR of speci-
ﬁc sequences for type I ﬁmbriae, intimin and aﬁmbrial adhesin.
Type I ﬁmbriae expression was also measured by agglutination
inhibition with manose. Statistical analysis was performed with
the SPSS package. Student’s t-test or U-Mann–Whitney test was
applied for quantitative variables, and Ji-Square test or Exact
Fisher test were applied for qualitative ones.
Results: 22 QR and 37 QS strains were isolated. BA was similar in
both series (78.2 vs. 80.6%, P ¼ NS), and these percentages were
similarly and signiﬁcantly reduced when norﬂoxacin was added
(48.5 vs. 45.0%, P ¼ NS) (P < 0.001). The most frequent factor was
type I ﬁmbriae (71%), whose expression was shown in 52.3%.
Eighteen per cent of the strains lacked the adherence factors stu-
died. Adherence factors presence was less frequent in QR strains
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than in QS. Adherence observed is independent of the presence/
absence of the adherence factor studied. The joint presence of var-
ious adherence factors is correlated with a slightly increase in BA,
independently of the sensitivity to quinolones. No differences
were found respect to the control strains results.
Conclusion: BA capacity of E. coli is independent of its sensitivity
to quinolones, although QR strains seemed to be less infective.
Subminimal concentrations of norﬂoxacin decreases BA in both
bacterial phenotypes in the same degree. This result would
support the continuous use of norﬂoxacin in this patients, in spite
of the selection of QR strains in stools.
P1061 Effect of quinolones on the induction of the loss of
pathogenicity islands (PAIs) in uropathogenic Escherichia coli
S.M. Soto, J.P. Horcajada, J. Mensa, M.T. Jime´nez de Anta, J. Vila
Barcelona, E
Objective: In previous studies, a decrease in the virulence factors
was observed in quinolone-resistant vs. quinolone-susceptible uro-
pathogenic E. coli strains. The aim of this study was to analyse
the possible role of quinolones in the induction of the loss of PAI
which contains the hlyA (haemolysin) and cnf1 (cytotoxic necro-
tising factor) genes in uropathogenic E. coli.
Methods: Ten quinolone-susceptible uropathogenic E. coli strains
containing some PAIs were subjected to subinhibitory concentra-
tions of quinolones: nalidixic acid, ciproﬂoxacin, moxiﬂoxacin,
and levoﬂoxacin; and other antimicrobial agents such as ampicil-
lin and trimethoprim. In each step, the strains were spread on
blood agar plates to test the loss of haemolysin capacity. Non-
haemolytic colonies were tested by PCR to test the presence of
hlyA and cnf1 genes, as well as other virulence factors such as
sat, iha, focG, pap genes; and by PFGE, Southern blot and
hybridisation with hlyA, cnf1 and sat probes. In parallel, the
wild-type strains were subjected to the same procedure with
antimicrobial-free culture media, to detect a possible spontaneous
loss of PAI. The phylotype was analysed by PCR with speciﬁc
primers. Hypermutation assays were carried out by spreading of
an overnight culture onto MH plates containing rifampicin
50 mg/mL to determine the number of colonies able to grow on
these plates.
Results: Non-haemolytic colonies were found in nine strains
selected for analysis. These colonies were found in ﬁve isolates
with nalidixic acid; ﬁve with ciproﬂoxacin, three with levoﬂoxa-
cin; and only in one isolate with moxiﬂoxacin. In most of these
isolates, no mutations in the gyrA gene were observed. However,
non-haemolytic colonies were not observed when the strain was
subcultured in antimicrobial-free culture media. It is noted that
only one strain lost the PAI when the strain was submitted to
subinhibitory concentrations of ampicillin or trimethoprim. All
these colonies were hlyA and cnf1 negative by PCR and by
hybridisation of PFGE proﬁles. The colonies derived for wild-
type submitted to subinhibitory concentrations of nalidixic acid,
which contain the iha gene, lost this gene. No relationship was
found between hypermutation phenotype or phylotype and capa-
city to lose the PAI.
Conclusions: Subinhibitory concentrations of quinolones may
induce the loss of PAIs in some uropathogenic E. coli strains. This
fact could be due to the activation of the SOS system.
P1062 Use of deletion mutations to explore structure-
function relationships in Clostridium tetani neurotoxin
I. Belyi
Moscow, RUS
Objectives: Clostridium tetani neurotoxin represents one of the
most toxic substances known to date. The most effective way to
prevent intoxication caused by this molecule includes immunisa-
tion of humans with a toxoid. Such vaccines, used currently
throughout the world, represent partially puriﬁed from C. tetani
cultures and detoxiﬁed by formalin treatment protein. Consider-
able efforts are being carrying out in order to improve anti-tet-
anus vaccine using gene-engineering approach. The aim of such
studies is to obtain fully immunogenic yet void of toxic activities
molecule. However, this goal requires detailed knowledge in tox-
in’s domains, necessary for its lethal activity. One such domain is
known to include critical glutamic acid residue-234 (Li et al.,
2001). In our study, using deletion mutagenesis approach, we
investigate another critical part of tetanus neurotoxin-junction
region between light and heavy chains.
Methods and results: Initially, we cloned the gene and produced
full-size C. tetani neurotoxin, which was lethal for mice by yield-
ing clinical picture of typical tetanus. Then, using PCR strategy,
we deleted nucleotide sequences, coding for either amino acid res-
idues (aa) 429–457, 419–428 or 408–418. By studying biological
activities of the expressed protein product, we found out that
deletion of the last 29 amino acid residues of L chain (aa 429–457)
resulted in the non-toxic molecule. According to proteolysis pro-
ﬁle, mutated protein preserved overall structure of the active
recombinant neurotoxin and thus was speculated to retain its anti-
genic properties.
Conclusions: In our previous investigations we produced and
studied different individual fragments of tetanus toxin (L-chain,
H-chain, Hc domain) and two hybrid proteins, one composed of
tetanus toxin fragment Hc and C-terminal domain of C. difﬁcile
toxin B and another made of fragment Hc and S3 domain of
C. histolyticum collagenase (Varfolomeeva et al., 2003). During the
current study we continue this work by constructing a new set of
molecules, which could be considered as candidates for testing in
vaccine development. On the other hand, data obtained shed
some light onto the mechanisms of C. tetani neurotoxicity,
conﬁrming absolute necessity of intact interchain region for
neurotoxin activity.
P1063 The contribution of a subspecies-speciﬁc type IV
secretion system to pathogenicity in Campylobacter fetus
venerealis
G. Gorkiewicz, C. Schober, S. Scheicher, S. Kienesberger,
R. Zechner, E. Zechner
Graz, A
Objective: The pathogenicity mechanisms employed by Campylo-
bacter species remain poorly understood. Striking host speciﬁcity
is exempliﬁed by the highly related taxa C. fetus fetus (Cff) and
C. fetus venerealis (Cfv). Cff is transmitted orally and usually colo-
nises the intestinal mucosa of humans and sheep, causing gastro-
enteritis and septicaemia, whereas Cfv is transmitted venereally
and induces epidemic abortion in cattle. The genetic basis for the
difference in host and tissue speciﬁcity of C. fetus subspecies is
studied.
Methods: Subtractive hybridisation of the entire genomes of Cff
vs. Cfv identiﬁed genes unique to Cfv. The DNA was se-
quenced and speciﬁc genes were mutagenised. Phenotypic vari-
ation for DNA transfer, adherence and infection were assessed
in vitro.
Results: A type IV secretion system (T4SS) is exclusively present
on the chromosome of Cfv. T4SSs are complex multi-protein sys-
tems assembled by pathogenic bacteria to span the cell envelope
and to deliver virulence factors to target cells. The unique Cfv
DNA spans 30 kb and encodes homologues to mobility genes
(phage integrase, IS transposase) and virulence determinants.
Moreover, homologues with similar genetic organisation as the
A. tumefaciens VirB operon including all components from virB3 to
virB11 and virD4 were identiﬁed. Selected Cfv homologues
to genes essential to function in the highly related T4SSs of
A. tumefaciens, Helicobacter, Brucella, and Bartonella were inacti-
vated through recombination.
286 Abstracts
Conclusions: The genomes of C. fetus subspecies Cff vs. Cfv differ
at least by the additional presence of a 30 kb element resembling
a pathogenicity island in Cfv. This inserted sequence encodes
homologues of genes associated with lateral transmission as well
as virulence. Most importantly, it encodes genes phylogenetically
related to the VirB-VirD4 operon conserved in a variety of Gram-
negative pathogens. Genetic analysis combined with functional
in vitro assays will determine the relevance of this newly discov-
ered T4SS in Campylobacter virulence and its contribution to tissue
speciﬁcity and host adaptation.
P1064 The role of the SabA adhesin and other Helicobacter
pylori virulence factors in activation of human neutrophils
M. Unemo, D. Ilver, D. Danielsson, M. Hurtig, T. Bore´n,
S. Teneberg
O¨rebro, S
Objectives: A prominent feature of Helicobacter pylori (Hp)
induced gastritis is an inﬁltration of neutrophils into the epithe-
lium surface. Some Hp strains (40–60%) have the capacity to non-
opsonised activate neutrophils to release reactive oxygen and
nitrogen species and proteases, and such strains were more often
isolated from patients with peptic ulcer disease. Several soluble
factors were described to be involved including urease, HPNAP,
a low molecular weight factor in water extract of the bacteria and
the cecropin-like bactericidal peptide, but none have stood the
test. In the present study we used isogenic knock-out strains to
study the role of various Hp virulence factors for the nonopsonic
activation of neutrophils.
Materials and methods: Human neutrophils were challenged with
wild type (wt) Hp strains and isogenic knock-out mutants deleted
of HPNAP, BabA adhesin, SabA adhesin, VacA cytotoxin or the
37 kDa fragment of VacA, followed by chemiluminescence (CL)
measurements of the superoxide anions produced by the
neutrophils. The effects of signal transduction inhibitors on
Hp-induced neutrophil activation were also studied to identify
intracellular signalling pathways.
Results: The wt Hp strains induced in neutrophils a strong CL
response. The absence of HPNAP or the Leb-binding BabA adhesin
had no effect. However, no response was obtained after the dele-
tion of the sialyl Lex-binding adhesin, SabA. Deletion of the whole
VacA cytotoxin resulted in a delayed and reduced CL response,
and the same effect was observed when the 37 kDa fragment was
deleted. Effect of pertussis toxin indicated that the induction is
transduced by a member of the G protein receptor family.
Conclusions: The study shows that SabA adhesin plays a pivotal
role in the nonopsonic activation of neutrophils and might there-
fore be an important Hp virulence factor.
P1065 Characterisation of the penetration ability and
cytotoxicity of Serratia marcescens
L.-H. Su, C.-H. Chiu, C. Chu, T.-L. Wu, J.T. Ou, T.V. Riley,
B.J. Chang
Taoyuan, TW; Perth, AUS
Objectives: To characterise the penetration ability and cytotoxicity
of clinical isolates of Serratia marcescens that caused either invasive
or noninvasive infections.
Methods: Nineteen each of blood and urinary isolates of S. marces-
cens were examined in vitro for their ability to penetrate a Madin-
Darby canine kidney (MDCK) epithelial cell monolayer by using a
membrane ﬁlter system. The cytotoxicity against MDCK cells was
assessed by measuring the concentration of lactose dehydrogenase
(LDH) released from the cells into the medium. The Chi-square
test was used for statistical analysis.
Results: Signiﬁcantly more blood than urinary isolates were detec-
ted in the basolateral medium after 6 h (18 vs. 10, P < 0.01) incu-
bation. Nine blood isolates compared with only two urinary
isolates were high penetrators (>10 000 000 CFU/mL, P < 0.05). A
similar signiﬁcant difference in cytotoxicity between the two
groups was also found (17 blood vs. 9 urinary, P < 0.05). The
average LDH level of all blood isolates at 6 h after inoculation
was 157  74 U/L (median, 168 U/L) and that of all urinary iso-
lates was 92  63 U/L (median, 58 U/L). LDH level increased
proportionally as the number of bacteria that penetrated
increased, indicating a close association of the penetrative ability
of bacteria to their cytotoxicity. By using a ﬂuorescent acridine
orange-crystal violet staining method, viable bacteria were
observed intracellularly at 2 h, and the amount increased at 3 h,
indicating the invasive ability of S. marcescens and a possible
mechanism of transcytosis penetration. No apparent correlation
between genotypes and the ability to express penetration and/or
cytotoxicity. Neither plasmid proﬁles nor antimicrobial resistance
patterns were correlated with the ability to penetrate or to cause
cytotoxic effect, indicating that the genes encoding the associated
factors are not located on the plasmids. Further characterisation of
the cytotoxicity indicated that viable whole bacteria were required
to induce cytotoxicity in vitro, and neither toxic exoproducts pro-
duced during growth nor intracellular materials were responsible
for the cytotoxic effect. Inhibition of RNA and protein synthesis
abolished the cytotoxicity as well as the penetration.
Conclusions: Although other mechanisms may be involved, the
abilities to penetrate epithelial barriers and the associated cytotox-
icity are important virulence factors contributing to invasive infec-
tions associated with S. marcescens.
P1066 Modulation of Listeria monocytogenes interaction
with cellular substrate by b-lactam antibiotics and human
serum transferrin
G. Mihaescu, B. Manolescu, L. Petrache
Bucharest, RO
Background: Interactions between L. monocytogenes and cellular
substrate represents a very important model for the study of
molecular mechanisms in intracellular parasitism. L. monocytogenes
harbours many virulence factors which expression is regulated by
iron(III) concentration. This bacterium owns three different iron
uptake systems, one of them involving probably a bacterial cell
surface-located transferrin-binding protein.
Purpose: we have investigated how interaction between L. monocy-
togenes and cellular substrate is modulated by b-lactams and
human serum transferrin (HST) and the effect of HST on the
expression of listerial virulence factors.
Material and methods: The in vitro study of adherence and invasion
capacity of six L. monocytogenes strains to cellular substrate repre-
sented by Hep-2 cells was investigated by gentamycin-protection
assay. The ability to adhere to an inert substrate was evaluated by
the slime test. The phenotypic detection of virulence factors repre-
sented by Kanagawa haemolysin, sheep erythrocytes haemolysins,
DN-ase, lipase, lecitinase, amylase, gelatinase and caseinase was
performed on speciﬁc media. The inﬂuence of transferrin on bac-
terial growth was evaluated by determining the number of CFU.
Results: b-lactam antibiotics and vancomycin in subinhibitory
concentrations modulate the adherence pattern from a normally
diffused-one to a localised-one. Transferrin has a general stimula-
tory effect on L. monocytogenes growth rate and cell surface mole-
cules expression demonstrated by: (1) greater adherence capacity
to the inert surfaces; (2) a higher number of CFU/mL and (3) an
increased production of all tested virulence factors with the excep-
tion of Kanagawa toxin and DN-ase in the presence of transferrin.
Conclusions: We conclude that beta-lactams probably have affected
the bacterial adherence pattern to the cellular substrate by inducing
changes in the negative charges on bacterial surface. The increase
in cell surface hydrophobicity decreases the electrostatic repulsion
between cells, stimulating the clustered-adherence pattern. These
aspects were also correlated with the results of slime test. We also
have demonstrated that transferrin has stimulated the bacterial
growth rate and the production of virulence factors probably by
inducing the expression of genes coding for these virulence factors.
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P1067 Treponema pallidum pallidum (strain Nichols), but
not Treponema phagedenis (biotype Reiter), has an apical
structure that may be a pathogenic factor
A. Magalha˜es-Sant’Ana, C. Nogueira, G. Marra˜o, G. Rocha
Coimbra, P
Objectives: The re-emergence of syphilis in AIDS time justiﬁes the
return to the investigation about Treponema pallidum underestima-
ted by the successive failures on trying the culture of this bacter-
ium in continuous cell line.
Methods: Morphological studies on T. pallidum pallidum (strain
Nichols) maintained in rabbit testis and T. phagedenis, biotype
Reiter, growing in Spirolate Broth supplement with chicken serum,
were visualised by Transmission Electron Microscopy in ultra-ﬁne
sections with negative staining techniques with ammonium molyb-
dato, with and without chemical dissection by non-ionic (Triton
x100) and anionic (SDS) detergents in different concentrations.
Results: Beyond conﬁrming the close relation between the pepti-
doglican (P) and the cytoplasmic membrane (CM), the fragility of
the outer membrane (OM) that surrounds the periplasmic ﬂagella
(PF) which possess Gram-positive basal plates, and also the exist-
ence of cytoplasmic ﬁlaments (CF), it allowed: (i) to observe ultra-
ﬁne sections of the cytoplasmic insertion of the basal plates of PF
doing what Hovind and Hougen predicted 30 years ago with neg-
ative stain technique; (ii) to see that the basal apparatus is com-
plex, involved by the ‘mot proteins’ that give them the shape of a
sphere inserted in the cytoplasm, after the ﬂagellum hook has
passed the P and CM; (iii) from this motor apparatus have their
origin the CF, which extend along the cytoplasm, accompanying
the PF that are present in a greater number; (iv) in some pictures
from cells of T. pallidum treated with SDS, a membrane is noted
inside these ﬁlaments, suggesting a close relation between them
and the ﬂagella; (v) in T. pallidum, but not in T. phagedenis, is
observed, in the extremity, an apical structure that may be related
to the ﬁxation of these pathogenic treponema to the host cells.
Conclusions: The assumption that this apical structure is an
important factor of pathogenicity is reinforced by being exclusive
of T. pallidum, the observation of adherence by one of the extrem-
ities to testicular cells, when we extract these from rabbit testis;
and in the cases were the culture in cotton-tail testicular cells
show some success the Treponemas were adhere to the cells.
These observations emphasise the importance to proceed the
investigation about these fascinating bacteria, trying to properly
elucidate this apical structure.
P1068 Route of natural exposure in animal model of
brucellosis
Z. Yumuk, S. Caliskan, D. Dundar, V. Dundar
Kocaeli, TR
Objectives: The aim of this study is experiencing the route of nat-
ural exposure instead inoculation of the bacteria intraperitoneally
as in the existent animal model of brucellosis. Consequently,
improve the model’s reliability and extension to the new areas
may provide new insights into the understanding of human bru-
cellosis.
Methods: In this study, adult Wistar rats weighing 150–180 g were
used. The rats were matched by weight and paired so that one rat
of the pair was assigned as vector (n: 9) while the second rat was
target (n: 9). Target rats were marked with nail polish. Paired rats
were then caged individually. All vector rats in each cage were
inoculated with B. melitensis intraperitoneally. Cells of B. melitensis
strain 16 M were suspended in a saline and suspensions were
adjusted to yield 2  104 to 4  104 CFU. Inoculation was per-
formed by injecting one dose of 0.5 mL saline containing 2  105
to 4  105 intraperitoneally to vector rats. Seven days after chal-
lenge to B. melitensis, all rats were weighted and assessed for the
number of B. melitensis isolated from spleens. Spleens were asepti-
cally removed, weighted and a piece of each organ was homoge-
nised in 1.0 mL of sterile saline. Aliquots of 0.1 mL of the
homogenates were diluted tenfold in saline plated on to Brucella
agar plates to obtain a viable count. Comparative analysis
between groups, of mean CFU/organ weight, rat body weight,
spleen weight and their ratio were carried out by using the
Mann–Whitney test. A P value of <0.05 was considered to be sta-
tistically signiﬁcant.
Results: The number of B. melitensis isolated (CFU) from spleen in
vector rats was 1048.0  52.80, 869.0, 1367.0 (Mean  SEM, min,
max). All the target rats (100%) were found to be infected with
B. melitensis. The target rats received the infection from the vector
rats and the number of B. melitensis isolated (CFU) from their
spleen was 148.1  24.81, 62.67, 255.7 (Mean  SEM, min, max).
The number of B. melitensis isolated from spleen in the vector rats
(P < 0.05) was signiﬁcantly greater than the number in the target
rats.
Conclusion: In this study, the model of B. melitensis infection in
the setting of inoculation via route of natural exposure was modi-
ﬁed and it was observed that the natural route of inoculation is as
affective as the route of intraperitoneal inoculation. Further use of
this model may provide new insights into the therapy of humans
who may be threatened with this organism through zoonotic
infections and potentially bio-terrorism.
Insights into Hepatitis
P1069 Efﬁcacy of lamivudine in treatment of precore
mutant chronic hepatitis B
M.R. Hasanjani Roushan, M.A. Shafai, S.A. Asgharzadeh Ahmadi
Babol, IR
Objectives: Precore mutant chronic hepatitis B is very common
in Mediterranean countries, and these patients are at risk for
developing of cirrhosis. This study was conducted to evalu-
ate the efﬁcacy of one year of lamivudine therapy in these
patients.
Methods: From April 2000 to January 2003, 41 consecutive patients
with chronic anti-HBe positive, HBV DNA positive hepatitis B
were treated with 100 mg lamivudine daily for 1 year, in Babol,
Iran. Alanine aminotransferase (ALT) levels, HBV DNA, histologi-
cal activity index (HAI) score and ﬁbrosis score at the baseline
and the end of treatment were compared by chi-square and Fish-
er’s exact tests.
Results: 41 cases (38 males, 3 females) with the mean age of
32.4  11 years were treated. At the baseline, mean ALT levels
were 91  35 IU/L and mean HAI score was 5.5  3. After treat-
ment, HBV DNA became negative in 20 (48.8%) of cases. Histo-
logical activity index score was improved by two points or more
in 10 (24.4%) and increased in 13 (31.7%) of the cases. ALT
returned to normal values in 30 (73.2%) cases. HBV DNA became
negative in 12 (60%) cases with ALT levels of more than 80 IU/L,
but eight (40%) in cases with ALT levels of less than 80 IU/L
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(P ¼ 0.57). Reduction of ﬁbrosis score was seen in one (6.3%) case
with ALT levels more than 80 IU/L, compared with three (12%)
in cases with ALT levels less than 80 IU/L. Reduction of HAI
score was seen in four (25%) cases with ALT levels more than
80 IU/L, but in six (24%) cases with ALT levels less than 80 IU/L
(P ¼ 0.93). No patients lost HBsAg.
Conclusion: The results show that 1 year of lamivudine therapy is
not effective in most patients with precore mutant chronic hepati-
tis B. Longer duration of therapy is necessary for these group of
patients.
P1070 Molecular epidemiology of hepatitis B in Denmark
N. Fisker, C. Pedersen, M. Lange, N.T.T. Nguyen, K.T.T. Nguyen,
J. Georgsen, P.B. Christensen
Odense, DK
Objectives: Denmark has a low incidence of acute hepatitis B
(HBV) infections but the impact of an increasing number of immi-
grants with chronic HBV infection on HBV transmission is
unknown. The aim of this study was to characterise individuals
with chronic and acute HBV infection in a deﬁned region and to
examine relations between them.
Methods: During 2000–2001 all consecutive HBV infected individ-
uals in the County of Funen, Denmark, were classiﬁed according
to ethnicity, presumed route of transmission and stage of infec-
tion. HBV DNA was sequenced and subjected to phylogenetic
analysis.
Results: Of 309 identiﬁed HBV infected individuals, 218 (71%)
were classiﬁed as having chronic infection and 91 (29%) as having
acute infection. HBV DNA sequencing was possible in 125 cases.
Phylogenetic analysis showed that HBV isolated from injecting
drug users (IDUs) were identical or closely related. In other chro-
nic cases, the viral geno- and subtype mainly reﬂected the indi-
vidual’s ethnic origin. Among acute cases acquired in Denmark,
89% (74/83) were related to IDU (65 cases in IDUs and nine cases
in individuals presumably exposed to IDUs). Among 83 ethnic
Danes who acquired their HBV infection in Denmark, no new
cases of transmission from immigrants to ethnic Danes were
detected.
Conclusion: Injecting drug use was the single most important
factor for hepatitis B transmission in Denmark. The current Dan-
ish vaccination strategy is unable to protect IDUs from HBV
infection and IDUs pose a greater risk of HBV transmission to
the general population than immigrants. With few exceptions
chronic infection reﬂects a history of IDU or foreign ethnic back-
ground.
P1071 Much gained by integrating contact tracing and
vaccination in the hepatitis B antenatal screening programme in
Amsterdam, 1992–1999
J.E. van Steenbergen, D. Baayen, P.G.H. Peerbooms,
R.A. Coutinho, J.A.R. van den Hoek
Utrecht, Amsterdam, Netherlands, NL
Objectives: Hepatitis B control in Europe concentrates on antena-
tal screening to reduce vertical transmission. To reduce horizontal
transmission and the pool of infectious individuals, the Municipal
Health Service of Amsterdam integrated tracing and immunising
of contacts in the antenatal screening programme.
Methods: An 8-year (1992–1999) descriptive study of this public
health programme, where contacts are tested for serological mark-
ers of previous infection, and vaccination is offered to susceptible
contacts. Chronically infected contacts are counselled and referred
for treatment if justiﬁed.
Results: For 738 newly identiﬁed women testing positive for the
hepatitis B surface antigen, 1219 contacts were reported; 1100
(90.4%) contacts participated, 476 (43%) had serological markers
of previous infection, of whom 119 (25%) were infectious. Of the
603 eligible contacts, 568 (94%) completed the vaccination series.
Country of origin was an independent predictor of contact partici-
pation and compliance with completion of the vaccination series.
Postvaccination titres for antibodies against the surface antigen
were below 10 IU/L in 4.5% of contacts under 30, in 12.2% of
those over 30.
Conclusions: Tracing and immunising susceptible contacts of
women screened as HBsAg-positive should be an integral compo-
nent of any nations HBV control programme.
P1072 Different B2-microglobulin (b2m) curves in chronic
hepatitis B (CHB) patients, under long-term lamivudine (LAM)
monotherapy or interferon plus lamivudine (IFN/LAM)
combination treatment. Relationship with virological
breakthrough (VB)
I.S. Elefsiniotis, K.D. Pantazis, I. Glynou, N.V. Fotos,
C. Mavrogiannis, H. Kada
Athens, GR
Objective: To evaluate the predictive value of serum b2m levels
for VB, in CHB patients under long-term LAM monotherapy or
initial combination (IFN/LAM) treatment.
Methods: Serum b2m levels were calculated at baseline and every
3 months during treatment, in 25 HbeAg-negative CHB patients
under long-term (36 months) LAM monotherapy (group A) and
12 patients under IFN/LAM treatment for the ﬁrst 6 months fol-
lowed by LAM monotherapy thereafter (group B), using the
microparticle enzyme immunoassay technology. We used Cox
proportional hazard models in order to investigate the association
between serum b2m levels and VB.
Results: Seven of 25 patients (28%), 9/25 (36%) and 14/25 (56%)
from group A and 0/12, 2/12 (16.6%) and 3/12 (25%) from
group B exhibited VB at months 12, 24 and 36 of treatment,
respectively. All CHB patients, from both groups, who did not
show VB, exhibited b2m elevation in the third month of treat-
ment. In comparison to patients from group A whose b2m levels
were increased at 3 months, patients whose b2m levels were
decreased, had 4.6 times higher risk of experiencing VB
(RR ¼ 4.6, 95% CI, 1.22–17.36). When the pre-treatment variables
were evaluated, decreased b2m status was still associated with
increased risk of VB (RR ¼ 12.2; 95% CI, 1.28–116.8).
Conclusions: In CHB patients under long-term LAM monotherapy
or initial combination treatment, serum b2m levels at 3 months of
treatment, compared with baseline ones, are a good predictor of
risk for VB. The initial combination treatment seems to delay or
prevent the emergence of YMDD variants, irrespective of baseline
parameters.
P1073 Psychiatric adverse effects of interferon alpha 2a
treatment in chronic hepatitis patients
N. Kaya, E. Turk Aribas, A.C. Inkaya, M. Bitirgen
Konya, TR
Objectives: To investigate the adverse effects of interferon alpha
2a treatment in chronic hepatitis patients.
Method: Patients diagnosed to have either chronic hepatitis B or
chronic hepatitis C were admitted to this study. Patients with
chronic hepatitis B received interferon alpha 2a 9MU while chro-
nic hepatitis C patients received interferon alpha 2a 3MU three
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times a week. We planned to apply Hamilton Depression Rating
Scale (HDRS), Hamilton Anxiety Rating Scale (HAM-A), Mont-
gomery–Asberg Depression Rating Scale (MADRS) and Beck
Depression Inventory (BDI) to the patients before the onset of
treatment and at the second, fourth and sixth months of treatment
period. Depression was diagnosed with scores 7 or higher in
HDRS, 14 or higher in MADRS and 13 or higher in BDI. Wilcoxon
test was used in statistical analyses.
Results: Here we present the results of ﬁrst 2 months of the study
period. Totally 31 patients 67.7% (n ¼ 21) men and 32.2% women
(n ¼ 10) were involved in the study. Mean age was 40.80
(12.92). Statistically signiﬁcant increase in HDRS, HAM-A,
MADRS and BDI scores was noted at the second month of ther-
apy (P < 0.05). Depression was diagnosed at the beginning of the
treatment with HDRS scores in 22.7% (n ¼ 7), with MADRS in
12% (n ¼ 4), with BDI in 29% (n ¼ 9), whereas this was increased
at the second month of therapy to 41.9% (n ¼ 13), 19% (n ¼ 6),
48% (n ¼ 15), respectively.
Conclusions: Psychiatric ﬁndings are common in chronic hepatitis
patients. Interferon treatment also contributes to the psychiatric
ﬁndings, which is why psychiatric evaluation of patients undergo-
ing treatment is fundamental.
P1074 The prevalence of hepatitis B virus precore mutant
in patients with chronic hepatitis B virus infection
F. Yarkin, Z. Altun, O. Bayramoglu, N. Saltoglu, F. Koksal
Adana, TR
Objectives: The aim of this study was to determine the prevalence
of hepatitis B virus (HBV) precore mutant in chronic hepatitis B
patients. HBV with a mutation G to A point mutation at nucleo-
tide 1896 in the precore region is reported to be associated with
chronic progressive hepatitis B.
Methods: The presence of precore mutant was examined by
ampliﬁcation refractory mutation detection system (ARMS) in 63
chronic hepatitis B patients and 45 asymptomatic HBV carriers.
The precore stop codon mutant and wild type HBV were ampli-
ﬁed using two different upstream primers which were different
only at the 3¢ end at nucleotide 1896.
Results: HBV precore mutant was found in seven of 35 (20%)
HBe antigen (HBeAg) positive patients with chronic hepatitis
and 22 of 28 (78.5%) antiHBe positive patients. Among 45
asymptomatic HBV carriers, 24 were HBeAg positive and 21
were antiHBe positive. Precore mutant was detected in two of
24 (8.3%) HBeAg positive carriers and nine of 21 (42.8%) anti-
HBe positive carriers.
Conclusion: This study suggest that the patients with chronic
HBV infection in our area were frequently infected with precore
mutant and the overall prevalence of precore HBV mutant with
46% (29/63) in chronic hepatitis B patients was higher than the
prevalence of 24.4% (11/45) in asymptomatic carriers.
P1075 Antigenic property of different sequence variants of
the hepatitis B surface antigen wild types and vaccine escape
mutants
T. Ulanova, J. Yokosawa, A. Burkov, V. Puzyrev, A. Obriadina
Nizhniy Novgorod, RUS; Atlanta, USA
Objectives: The purpose of this study was to determinate and
evaluate of sequence heterogeneity on antigenic properties of
hepatitis B surface antigen (HBsAg).
Methods: A number of recombinant HBsAg wild subtypes adw2,
adw4, ayw1, ayw2, adr as well as ‘vaccine escape mutants’ adw2
T126S, Q129R, Q129L, T143K, Q145R and ayw1 Q145A were syn-
thesised, puriﬁed and tested by enzyme immunoassay with a
panel of 43 commercial available monoclonal antibodies speciﬁc
for different determinants of HBsAg.
Results: Recombinant proteins were tested at the same concentra-
tion 1 ng/lL. All recombinant HBsAg proteins were immunoreac-
tive and demonstrated very different level of reactivity. Among
wild subtypes mostly immunoreactive with this panel was recom-
binant HBsAg subtype adw2. This protein has been detected by
90.6% of used MABs. Average S/Co was 43.7. Recombinant
HBsAg subtype adw4 was least immunoreactive (55.8% MABs
and average S/Co 3.7). Point mutations affected very different on
HBsAg antigenic properties. The immunoreactivity of ‘vaccine
escape mutants’ strains with MABs panel varied from 88.4 to
34.8%.
Conclusion: These data suggest that HBsAg sequence heterogen-
eity has a signiﬁcant effect on the antigenic properties of this anti-
gen. Diagnostic test development requires careful selection of
MABs as diagnostic reagents. Recombinant HBsAg point mutants,
especially ‘vaccine escape mutants’, may be used efﬁciently for
evaluation of sensitivity commercial and ‘in house’ EIA for
HBsAg detection.
P1076 Performance of hepatitis B surface antigen (HBsAg)
assays for the detection of recombinant and native HBsAg
mutants and screening for HBsAg mutants in isolated anti-HBc
positive sera
B. Weber, N. Van Der Taelem-Brule´
Junglinster, LUX
Objectives: The genetic variability of hepatitis B virus (HBV) rep-
resents a challenge for the sensitivity of immunodiagnosis, especi-
ally for the detection of surface antigen (HBsAg). Mutant viruses
may escape detection by commercial HBsAg kits. The aim of the
present study was to evaluate the sensitivity of commercial immu-
noassays for the detection of HBsAg mutants and to screen for
mutants in samples with isolated reactivity to core antigen (anti-
HBc).
Methods: Four commercially available assays VIDAS HBsAg Ultra
(bioMe´rieux); Liaison HbsAg (Diasorin), Immulite HbsAg (DPC)
and Elecsys HbsAg (Roche Diagnostics), HbsAg (V2) (Axsym,
Abbott) were tested with different types of HBsAg mutants: (i)
HBsAg subtype ayw3 mutants that were obtained by site directed
mutagenesis, each mutant contained single amino acid (aa) substi-
tutions or insertions in the ‘a’ determinant from aa 122 to 147
(n ¼ 12). (ii) COS cell supernatants from cloned mutants with s
single or multiple aa substitutions (n ¼ 6). (iii) Native mutants
from patients with chronic hepatitis B or liver transplant recipi-
ents with antiviral or hepatitis B immune globulin therapy
(n ¼ 5). A total of 190 isolated anti-HBc positive samples were
screened with the ﬁve assays in order to detect any HBsAg
mutant or low-level surface antigen carrier.
Results: The sensitivity of the HBsAg assays for mutant virus
detection was highly variable, ranging from 17 (73.9%) (Elecsys
HBsAg) to 22 (95.7%) mutants detected (VIDAS HBsAg Ultra).
VIDAS HBsAg Ultra failed to detect one of ﬁve native mutants.
Two alternative assays detected all the ﬁve native mutants, but
they showed a lower performance for recombinant mutants than
VIDAS HBsAg Ultra. No positive result was obtained among the
190 isolated anti-HBc positive sera. Eight (4.2%) samples tested
positive with real-time PCR showed low viral loads ranging from
20 to 400 IU/mL.
Conclusion: Recombinant mutant Ag could be a useful tool as an
indicator of the ability of the kits to detect mutated Ag. Neverthe-
less, no correlation could be established between the performances
observed with recombinant toward native mutant Ag. Since only
a limited number of mutants were tested, the data obtained in the
present study do not exactly reﬂect the performance of the assays
in large ﬁeld trials. There was no evidence for the presence of S
gene mutants in isolated anti-HBc positive samples.
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P1077 Hepatitis B virus genotypes in the Czech Republic
O. Strunecky´, V. Nemecek
Prague, CZ
Objectives: The knowledge of genetic heterogeneity of hepatitis B
virus (HBV) is important for epidemiology of this virus also.
Sequence analysis of S gene PCR products enables to study phylo-
geny and to determine genotypes of HBV. The aim of study was
to ﬁnd out the heterogeneity of S gene of HBV from hepatitis B
patients in the Czech Republic and to determine the prevalence of
HBV genotypes, basic epidemiologic features and geographic dis-
tribution.
Methods: HBV S gene DNA ampliﬁed by PCR from sera of 176
hepatitis B patients was sequenced. Consensus nucleotide
sequences were obtained using CLUSTAL W (European Bioinfor-
matics Institute, GB) followed by manual editing using Bioedit
5.09. Phylogenetic trees were constructed with MEGA 2.1 using
UPGMA Kimura two-parameter model.
Results: HBV DNA sequences from 176 patients and 39 Gene-
Bank HBV DNA sequences of known genotype (A–H) were used
to construct a phylogenetic tree. Genotype A was determined in
118 (67.1%), genotype D in 50 (28.4%), genotype B in 6 (3.4%),
genotype C in 2 (1.1%) of 176 patient HBV. There was no signi-
ﬁcant difference in prevalence of genotypes A and D in males
and females, Prevalence ratio of genotype A/D is different in
the age group 10–29 years (56.7%/43.3%), age group 30–59 years
(80.4%/19.6%) and age group 50+ years (75.4%/24.6%). There
are no geographical differences in the prevalence of genotypes
between Bohemian, Moravian and Prague regions. In the cluster
of genotype A in the phylogenetic tree 31% of sequences were
identical. Out of six patients with genotype B four were Viet-
namese, two were native Czechs, one patient with genotype C
was Chinese.
Conclusions: There are two predominant HBV genotypes A and
D in the Czech Republic without signiﬁcant differences in their
geographic distribution. Genotypes B and C were found with
low prevalence. Genotypes B and C were found within Asian
immigrants, and rarely in patients native to the Czech Republic
also.
Acknowledgement: Supported by grant IGA MZCR No. NI 6796-3.
P1078 High prevalence of HFE gene mutations in patients
with hepatitis B and other liver diseases in the Czech Republic
I. Putova, M. Cimburova, B. Cieslarova, J. Stransky, J. Horak
Prague, CZ
Aim of study: To establish the prevalence of HFE gene mutations
in population of Czech Republic and among patients with com-
mon liver diseases.
Patients and methods: Altogether, 339 patients including 35
patients with haemochromatosis, 76 with alcoholic liver cirrhosis,
45 with chronic hepatitis C, 13 with chronic hepatitis B, 43 with
steatohepatitis, 41 with cryptogenic liver disease, 42 with Dupuyt-
ren’s contracture, 44 with diabetes and 257 randomly selected 13-
year-old Guthrie cards were examined. The HFE gene mutations
(C282Y and H63D) were screened for by restriction enzyme analy-
sis performed on PCR ampliﬁed products.
Results: In the control group we found 7.8% of C282Y heterozy-
gotes and 26.8% of H63D heterozygotes. In patients with haemo-
chromatosis we found 57% of C282Y (P < 0.0001) and 14% of
H63D homozygotes (P < 0.01). We detected an increased preva-
lence of heterozygotes for H63D mutation in comparison with the
control group in patients with hepatitis B (56.5%, P < 0.001), in
Dupuytren’s contracture patients (35.7%) and in diabetics
(27.3%). An increased percentage of both C282Y and H63D homo-
zygotes was found in patients with aetiologically unclear liver dis-
ease (9.8%, P < 0.001; 4.9%, P < 0.05) and of H63D homozygotes
in patients with alcoholic cirrhosis (7.9%, P < 0.001) and steatohe-
patitis (7%, P < 0.05).
Conclusions: HFE gene mutations are frequent in patients with
common liver diseases and hepatitis B. Therefore, we recommend
that patients with these diseases be genetically examined for
haemochromatosis.
Acknowledgement: Supported by the research goal 002 of the
Third Faculty of Medicine, Charles University.
P1079 Performance of AxSYM HBsAg in a Danish patient
population
I. Sleimann Petersen, A. Svendsen, G. Momsen, P. McNair,
H. Westh
Hvidovre, DK
Objectives: Patients with very varying pre-test probability for
hepatitis B virus (HBV) infection are often examined by the
same assay for detection of hepatitis B surface antigen (HBsAg).
An important subset is patients recently exposed to needle acci-
dents, who receive the ﬁrst HBV vaccination before blood
sampling for the test. We examined if conﬁrmation of the pri-
mary test result always is needed, in which situations other
tests than detection for HBsAg is preferred, and whether the
recommended cut-off level on 2.0 S/N is optimal in our Danish
patient population.
Methods: 3229 blood samples from a period of 15 month were
analysed for HBsAg ﬁrst by AxSYM HBsAg Abbott immunoassay
principle, second were samples with S/N value on at least 1.85 in
the AxSYM HBsAg assay reanalysed by the VIDAS HBsAg immu-
noassay, and lastly conﬁrmed by the VIDAS HgsAg conﬁrmatory
assay. This revealed 3084 negative tests and 145 positive tests.
The ﬁnal results of these tests were characterised by plotting into
a Probit-curve. Further, all variables indicating seroconversion
were registered for 20 patients with positive test results just above
the applied cut-off level on 1.85 S/N and 30 patients with results
just below this limit.
Results: The Probit-curve showed a sigmoid curve with 50 sam-
ples surrounding the cut-off point, situated in the horizontal mid-
dle part of the curve. Nine of these patients had positive results
in both AxSYM and VIDAS even though none were infected.
Instead, seven of them were persons exposed to needle accidents,
and therefore vaccinated against HBV. The present test had in our
patient population a positive predictive value of 93.8% and a neg-
ative predictive value of 99.9%.
Conclusions: By excluding patients, who had just received HBV
vaccination, from HBsAg tests, and by adjusting the cut-off point
of AxSYM immunoassay from 1.85 S/N to the recommended 2.00
S/N, we had a gain in the positive predictive value of 99.3% with
the same high negative predictive value of 99.9%. In our patient
population, we found no beneﬁt by conﬁrming samples with
AxSYM values higher than 40 S/N. Due to this study, our laborat-
ory is now able to perform HBsAg analyses with a much higher
positive predictive value and to a lower cost.
P1080 Cytomegalovirus acute viral hepatitis – results of a
6-year study (1998–2003) after introducing CDC case deﬁnitions
and hepatitis B vaccination
A. Radulescu, D. Tatulescu, V. Zanc, M. Turdean
Cluj-Napca, RO
Objectives: To establish the diagnostic hints and clinical picture
for cytomegalovirus acute viral hepatitis in the Cluj-Napoca
Teaching Hospital of Infectious Diseases after introducing the
hepatitis B vaccination in the National Vaccination Programme
(1995) and the conﬁrmatory serological testing for acute viral
hepatitis A, B, C (1998).
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Methods: We retrospectively studied all acute viral hepatitis (2842
cases) admitted in the Cluj-Napoca Hospital of Infectious Diseases
between 1998 and 2003. We designed a database using the med-
ical records comprising of: demographic data, premorbid condi-
tions, questionnaire about possible nosocomial and other
exposures, bilirubin, ALT, other biochemical tests, the main sero-
logical markers for AVH (IgM anti-HAV, IgM anti-HBc, third gen-
eration HCV EIA). In cases of unknown type serology for
Epstein–Barr virus, cytomegalovirus, Toxoplasma gondii were per-
formed as other examinations if considered (2001–2003). EPI6 soft-
ware was used for statistical analysis.
Results: The incidence rates of acute viral hepatitis type B were
signiﬁcantly decreasing representing 408 cases, 14% of all cases,
while type C and non-A–C acute viral hepatitis demonstrated an
increasing trend with 370 cases, 13% of all cases. We found 19
cases of cytomegalovirus acute hepatitis based on exclusion cri-
teria for presumable aetiology, on positive serology (IgM positivi-
ty, seroconversion). The majority of cases were found in
immunocompetent teenagers and adults (16 cases), three cases
occurred in renal transplant recipients coincident with positive
serological markers for types B and C hepatitis probably repre-
senting viral reactivation. In all teenagers the presence of radio-
graphic interstitial pneumonitis (with no or mild clinical signs),
enlargement of lymph nodes and spleen were found. The onset
duration was quite long (range between 14 and 30 days) and the
evolution in all cases was moderate but prolonged (moderate
increase in ALT levels). In striking contrast with the literature
prolonged jaundice and hiperbilirubinaemia were described in im-
munocompetent cases (even in teenagers). Immediate prognosis
was good but cases occurring in adults showed a clinical and bio-
chemical unsatisfactory evolution.
Conclusion: The WHO eradication project of hepatitis B demon-
strates very good results with almost no cases in children,
under a good notiﬁcation of cases. Hepatitis C and other aetiol-
ogies are increasingly found affecting immunocompetent sub-
jects.
P1081 Results of vaccination against VHB and VHA in
HIV-positive patients
V. Aster, M. Stankova´, H. Rozsypal
Prague, CZ
Objectives: In connection with quality of life improvement and
long-term survival of HIV-positive patients in HAART era there
has been relative morbidity and mortality increase on liver dis-
eases within this particular population. Therefore we started a
vaccination programme against VHB and VHA in selected
patients in AIDS Center of the University Hospital Na Bulovce
Prague.
Methods: Patients with CD4 lymphocytes over 200/ll and with
negative markers of current or past infection (anti-HAV IgG-,
anti-HBc IgG- and HBsAg-) have been included in the vaccination
programme. The vaccines of the Engerix, Havrix and Twinrix
types were used based on regular vaccination schemes. Serocon-
version of anti-HAV IgG or anti-HBs with continuing antibody
titres over 10 IU/L in anti-HAV IgG and over 10 IU/L in anti-
HBs in the period of 6 months after the completion of vaccination
has been considered as a positive response.
Results: 25 patients have been vaccinated against VHA. We recor-
ded positive response in 21 of them (84.0%). Twenty-six patients
have been vaccinated against VHB. Positive response was recor-
ded in 18 patients (69.2%).
Conclusions: HIV-positive patients in our cohort responded signi-
ﬁcantly better to vaccination against VHA than to vaccination
against VHB. Although serologic response to vaccination is worse
than in general population, we support generally accepted recom-
mendation of vaccination in HIV-positive patients against VHA
and VHB.
P1082 Evaluation of the Artus HBV LightCycler kit for
quantitative detection of hepatitis B virus in serum samples
K. Levi
Nottingham, UK
Objectives: To evaluate the Artus HBV LightCycler kit for the
quantitative detection of hepatitis B virus (HBV) in serum samples
in comparison with the Roche COBAS system.
Methods: The Artus HBV LightCycler kit is designed to amplify
a 290-bp sequence of the HBV genome. An internal control,
included in the kit, was added to serum samples (n ¼ 50) to
monitor extraction as well as ampliﬁcation inhibition. Quantita-
tive data were compared with that generated by the Roche
COBAS system.
Results: Thirty-three (67%) samples were positive by both meth-
ods (one sample was insufﬁcient for COBAS analysis). Two sam-
ples that were positive by COBAS but negative by Artus were both
low copy number samples (2  102 and <2  102 copies/mL). One
additional low copy number sample (3  102 copies/mL by
COBAS assay) could not be quantiﬁed with the Artus kit. Ampliﬁ-
cation of the internal control was demonstrated for all of the negat-
ive samples. One-third of the positive samples (12/36) exceeded
the dynamic range of the COBAS assay. Removing these samples
from analysis, there was <1 log variation between the two assays
for 16/24 (67%) of the comparable samples. Five samples were
retested to assess intra-assay and batch-to-batch reproducibility.
Variation for samples containing 103 –107 copies/mL was <0.5 log,
whilst the low copy number sample (102 copies/mL) displayed
<1 log variation over the three runs.
Conclusions: Overall, results obtained with the Artus kit on the
LightCycler were in agreement with the COBAS data. Although
the Artus kit appeared to be slightly less sensitive, a greater
dynamic range was demonstrated.
P1083 Correlation of circulating endothelin-1 and nitrates/
nitrites with the liver histopathological staging and grading in
patients with chronic viral hepatitis B
Y. Ersoy, N.M. Bayraktar, S. Gunal, B. Mizrak, G. Bilisik,
I.H. Ozerol
Malatya, TR
Objectives: To estimate the endotheline-1 (ET-1) and nitric oxide
(NO) metabolism products (nitrite and nitrate) and correlate them
with the liver histopathological grading and staging in patients
with chronic hepatitis B.
Methods: From September 2000 to September 2002, 32 patients (21
men and 11 women) with chronic hepatitis B and 30 healthy vol-
unteer control persons (14 men and 16 women) included in this
study. Mean age was 33.3 (18–59) in the study group and 31.6
(18–46) in the control group. Clinical diagnostic criteria for chronic
hepatitis B were positive test result of HBsAg for minimum
6 months and concomitant elevated serum alanine transaminase
(ALT) levels. Liver biopsies have been performed for all patients.
Histopathological activity were scored as minimal (1–4), mild
(5–8), moderate (9–12), severe (13–18) and 0–6 according the activ-
ity and ﬁbrotic index, respectively, using classiﬁcation of chronic
viral hepatitis described by Knodell et al. ET-1 serum concentra-
tion was determined with a commercially available ELISA assay
kit according to the instructions of manufacturer. Nitrite was
measured by using Griess reaction. Nitrate concentration of the
serum was calculated by subtracting nitrite measured from total
nitrite.
Results: There were no signiﬁcant differences in age and sex
distributions between chronic hepatitis B patients and control
groups (P > 0.05). Serum ET-1 levels were higher in patients
with chronic hepatitis B (9.43  3.45 pg/mL) than the healthy
voluntary people (2.9  0.86 pg/mL) (P < 0.0001). ET-1 levels
correlated well with the severity of the viral hepatitis using the
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Knodell’s liver histological activity index (r ¼ 0.440, P ¼ 0.046).
There was a signiﬁcant increase of serum nitrite and nitrate lev-
els in patients with chronic hepatitis B compared with the con-
trol group (P < 0.001 and P < 0.01). In addition there was a
positive correlation between serum nitrite/ET-1 (r ¼ 0.719,
P ¼ 0.001) and nitrate/ET-1 (r ¼ 0.651, P ¼ 0.005) levels in chro-
nic hepatitis B patients but the same correlation was not found
in the control group.
Conclusions: It was found that there was a positive correlation
between serum nitrite, nitrate and ET-1 levels with liver histo-
pathological grading and staging in patients with chronic hepatitis
B. Serum ET-1 levels may be useful clinical indicator for use in
the follow-up of patients with chronic hepatitis B.
P1084 Hepatitis D super infection that developed due to
endoscopy
F. Yildiz Zeyrek, H. Ozbilge, O. Sirmatel, F. Sirmatel
Sanliurfa, TR
Objectives: Hepatitis D (HDV) is a defective virus. It uses hepati-
tis B surface antigen (HBs) for being an infectious agent. In chro-
nic HBV cases if super infection develops it leads to chronic HDV
in 90% of the cases. In a follow-up study of three sustained
responded chronic HBV patients to therapy with interferon plus
lamivudin were analysed and HDV superinfection was observed
after endoscopic instrumentations.
Methods: Anti HDV positivity and elevations in liver enzymes
were observed in three patients aged between 38 and 53. They
had been analysed with endoscopy. One case had been analysed
with maxillary sinus endoscopy and two cases with gastroendos-
copy.
Results: After 8–18 weeks anti-HDV IgG–IgM positivity was
observed by EIA (Sorin Italy). There was no way of transmis-
sion of HDV. Three cases were diagnosed as chronic HDV
through clinical, virological (anti-HBs IgM and HBV-DNA neg-
ative) and histological (liver biopsy) techniques. Ten million
units interferon has been used for 1 year three times a week.
At the and of treatment in both these cases anti-HDV markers
were negative and liver enzymes of patients were normal and
only one patient had positive anti-HBs:25 IU/mL. Other two
cases have been followed for HBs, anti-HBe, anti-HBc IgG
which were positive, but HBV-DNA negative and live normal
level.
Conclusions: Endoscopic trials in chronic HBV patients can be a
transmission way of HDV superinfection.
P1085 The epidemiology and phylogeny of TT virus in the
Czech Republic
M. Salakova, V. Nemecek, J. Konig, R. Tachezy
Prague, CZ
Objective: TT virus (TTV) is prevalent worldwide with the highest
rate in African and South American countries. The prevalence of
this virus is higher in people with a risk of parenteral acquisition
of infection but other routes of transmission are being investi-
gated. This virus is suspected to be an aetiological factor of non-
A-E hepatitis but so far most studies have failed to support this
hypothesis. In our study we investigated the epidemiology of
TTV in the Czech Republic.
Methods: The following groups of subjects were enrolled: a con-
trol group consisting of 196 blood donors, 20 patients with hae-
mophilia, 49 drug users, 100 prostitutes, 50 prisoners, 208 healthy
children aged 1–14 years, 54 cord blood samples, 52 patients with
non-A-E hepatitis, 74 patients with hepatitis C and 51 blood
donors with increased ALT level. Two sets of primers, speciﬁc for
the open reading frame 1 (ORF1) and non-coding region (NCR)
region, were used.
Results and conclusions: In the control group the prevalence was
7.1 and 52.6%, respectively. Patients with haemophilia, intraven-
ous drug users (IVDUs), prisoners and patients with hepatitis C
had a signiﬁcantly higher prevalence of TTV DNA regardless of
the set of primers used. Additionally, using the primer set for
NCR, patients with non-A-E hepatitis had also a signiﬁcantly
higher prevalence of TTV. We did not detect any TTV DNA in
the cord blood specimens but we observed an increase of TTV
DNA prevalence with age both in children and adults. Phylo-
genetic analysis of 70 isolates revealed that the most prevalent
genotypes in the Czech population are G2 and G1, followed by
G8 and G3. Our study subjects infected with HBV and/or HCV
were signiﬁcantly more often TTV DNA positive, suggesting a
common route of transmission of these viruses.
P1086 Absence of occult HCV and HBV infections in
haemodialysis patients
M.L. Mateos, J. Chaco´n, P. Ruiz, G. Tabernero,
M. Fernandez-Lucas, J.L. Teruel
Madrid, E
Objectives: Haemodialysis patients are a risk group for HBV and
HCV infections. Occult HBV infection is deﬁned by detection of
HBV-DNA in absence of HbsAg. Occult HCV infection is deﬁned
by presence of HCV-RNA in absence of anti-HCV. The aim of this
study is to determine the prevalence of occult HBV and HCV
infections and the diagnostic utility of anti-HCV and HBsAg as
markers of HCV and HBV infections in haemodialysis patients
since it has important implications in the dissemination of these
diseases.
Methods: We have studied prospectively 61 patients (33 males, 28
females, mean time in haemodialysis 41 months, range 1–256,
mean age 65 years, range 28–83). Blood samples were drawn
before dialysis treatment. HBsAg, anti-HBc, anti-HBsAg and anti-
HCV were studied by an automated EIA (Asxym, Abbott Diag-
nostics). Detection of HBV-DNA and HCV-RNA was performed
by an automated PCR system (Ampliprep and Amplicor, Roche
Diagnostics). The limit of detection is 200 c/mL and 50 IU/mL,
respectively.
Results: HBsAg was detected in none of the patients (0%). Anti-
HBc and anti-HBs were detected in seven patients (11.5%) and
anti-HBc alone in two patients (3.3%). Anti-HBsAg was present in
35 patients (57.4%). HBV-DNA testing was performed on all the
samples and none resulted positive. Anti-HCV was detected in
seven patients (11%). HCV-RNA testing was performed on all the
samples (anti-HCV positive and anti-HCV negative) with six
being positive. These six positive HCV-RNA samples were also
anti-HCV positive. None of the anti-HCV negative patients has
HCV-RNA in serum.
Conclusion: Prevalences of HBV-DNA in absence of HBsAg as
variable as 19, 36 and even 58% have been reported in haemodi-
alysis patients. The authors have studied the presence of HBV-
DNA by in-house assays. Prevalence may vary depending on the
assays used to detect HBV-DNA. Regarding HCV infection, some
investigators have found prevalence rates of 9% of HCV-RNA
positivity without anti-HCV in the serum of haemodialysis
patients. Other authors have not conﬁrmed these data. In our
study, the prevalence of occult HBV and HCV infection is null.
HBsAg and anti-HCV are very useful markers for identiﬁcation of
potentially infectious cases of HBV and HCV hepatitis in the hae-
modialysis setting.
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P1087 Streptococcus pyogenes resistance to erythromycin
and selection pressure of macrolides
M. Kolar, K. Urbanek, L. Cekanova, D. Koukalova, P. Hejnar
Olomouc, CZ
Objectives: The aim of the study was the evaluation of the Strepto-
coccus pyogenes resistance to erythromycin in Olomouc region
(population 300 000), Czech Republic, in association with selection
pressure of macrolides.
Methods: During the period of 1997–2002, S. pyogenes strains
were isolated from oropharyngeal smears of community patients
suffering from bacterial tonsillitis. The susceptibility to antibiot-
ics was assessed by disk diffusion method in accordance with
the NCCLS guideline. Utilisation of macrolides was obtained
from the data of regional General Health Insurance Com-
pany and expressed in deﬁned daily doses per 1000 patients
per day.
Results: There was a signiﬁcant increase (P ¼ 0.05) in the occur-
rence of erythromycin-resistant S. pyogenes strains from 2% in
1997 up to 33% in 2001, whilst in 2002 they dropped remarkably
(P ¼ 0.05) to 17%. Utilisation of macrolides increased by 13% in
the period of 1997–2001 (from 2.69 to 3.05 DDD/1000/day), their
utilisation represented 11.40% of total antibiotic prescription in
1997 and 15.48% in 2001. In 2002, macrolides consumption
decreased to 1.89 DDD/1000/day, which represents 10.41% of
total antibiotic utilisation.
Conclusion: The study documented a probable association
between macrolide utilisation and the frequency of erythromycin-
resistant S. pyogenes strains. Absolute susceptibility of S. pyogenes,
which is the most important bacterial pathogen in community-
acquired bacterial tonsillitis, to penicillin contrasts with macrolide
resistance. It seems reasonable that penicillin should be an antibi-
otic of ﬁrst choice in bacterial tonsillitis, macrolides should be
reserved for patients allergic to penicillins only.
Acknowledgement: Supported by the MSM 151100002.
P1088 Susceptibility of Streptococcus pyogenes to
telithromycin and erythromycin: results from PROTEKT
(years 1–3)
R. Reinert, D. Felmingham – The PROTEKT Study Group
Objectives: The increasing prevalence of resistance among
S. pyogenes to macrolide antibacterials is a cause for concern,
particularly as macrolides are considered the main treatment
alternative for penicillin-intolerant patients with tonsillitis/
pharyngitis caused by S. pyogenes. Data from the PROTEKT
study – a global, longitudinal study to assess the antimicrobial
susceptibility of common bacterial pathogens associated with
community-acquired respiratory tract infections (RTIs) – have
been analysed to assess the prevalence of macrolide resistance
among clinical isolates of S. pyogenes collected over 3 years and
to assess the activity of the ketolide antibacterial telithromycin
(TEL) against such isolates.
Methods: The MICs of clinical isolates of S. pyogenes collected
worldwide as part of the PROTEKT programme over three con-
secutive respiratory seasons (1999–2002) were determined cen-
trally by NCCLS broth microdilution methods. Isolates were
tested for the presence of macrolide resistance genes erm(B),
mef(A) and erm(A) subclass erm(TR) using PCR.
Results: A total of 5034 isolates of S. pyogenes were collected
between 1999 and 2002 from 34 countries. Over the 3 years, the
prevalence of resistance to erythromycin (MIC 	1 mg/L) was
12.1% (10.4, 9.8 and 14.9% in years 1, 2 and 3, respectively).
Rates of resistance varied considerably between countries,
ranging from 0% (Ecuador and The Netherlands) to 90.9%
(40/44) in China [data from years 1 and 3 (one centre only)]. Of
the 622 isolates analysed by PCR, 48.9% (304) tested positive for
the mef(A) gene, 23.8% (148) were positive for erm(B), 26.2%
(163) were positive for erm(A) subclass erm(TR) and 1.1% (7)
were negative for the mechanisms tested. TEL retained potent in
vitro activity against S. pyogenes, with 97.5% (4907/5034) of iso-
lates susceptible at concentrations 
0.5 mg/L. Over the 3 years,
no major changes in susceptibility to TEL were observed: TEL
mode MIC against S. pyogenes was 0.015 mg/L for all 3 years,
with an MIC90 of 0.03 mg/L in year 1, 0.015 mg/L in year 2
and 0.25 mg/L in year 3.
Conclusion: Approximately 12% of S. pyogenes isolates collected
worldwide were resistant to macrolides, with mef(A)-mediated
resistance the most prevalent mechanism. In contrast, TEL dis-
played high activity against S. pyogenes (>97% of isolates suscept-
ible), including strains resistant to erythromycin.
P1089 Antibiotic susceptibilities of invasive group A
streptococci in England, Wales and Northern Ireland:
a comparison of results between hospital laboratories and the
national reference laboratories
S. Neal, M. Warner, T. Lamagni, M. Emery, C. Dhami, T. Parsons,
A. Efstratiou
London, UK
Objectives: To compare antimicrobial susceptibilities of invasive
GAS isolates reported from hospital laboratories with data gener-
ated from the Streptococcus and Diphtheria Reference Unit
(SDRU) and the Antibiotic Resistance Monitoring and Reference
Laboratory (ARMRL). The distribution of antibiotic resistance will
also be determined against denominator and typing data (M or
emm types).
Methods: Laboratories in England, Wales and Northern Ireland
report cases of invasive GAS disease weekly to the Communicable
Disease Surveillance Centre. This includes demographic, clinical
and microbiological data. Isolates are also submitted to the
national reference laboratories and subjected to M typing and
antimicrobial testing. Datasets from both sources during the per-
iod January to July 2003 were reconciled and analysed. Data used
in this analysis included age (in 10 year bands), sex, laboratory,
region, site of isolation and GAS type.
Results: A total of 812 invasive GAS isolates were reported by
hospital laboratories and received by SDRU between January and
July 2003; 723 of these had antimicrobial results. A total of 98.3%
(711/723) had been tested by both hospital laboratories and ARM-
RL; the susceptibilities correlated exactly for all four antibiotics.
No penicillin resistance was reported, but 0.7% (5/723) were
resistant to clindamycin, 4.0% (29/723) to erythromycin and
13.6% (98/723) to tetracycline. Furthermore, six erythromycin and
tetracycline resistant strains were reported, three erythromycin
and clindamycin resistant, and two were erythromycin, tetracyc-
line and clindamycin resistant strains. Tetracycline resistance was
higher in the younger age groups, peaking at 22.0% (29/132) in
30–39 years olds (P ¼ 0.09). Tetracycline resistance was observed
in 16.8% (59/351) males compared with 9.3% (29/311) females
(P ¼ 0.018). GAS M types emm43 (10/11), M77 (4/5), M83 (28/31)
and emm91 (3/3) appeared to be associated with tetracycline
resistance (P < 0.000).
Conclusions: An improvement was noted in the number of inva-
sive GAS cases reported from laboratories, which included antibi-
otic susceptibility data; from 81% in 2002 to 87.6% during
January to July 2003. There was also excellent correlation between
these data and the ARMRL results. Erythromycin and tetracycline
resistance rates were similar to previous years.
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P1090 Macrolide resistance rates and resistance
phenotypes of invasive Streptococcus pyogenes isolates in
Greece
A. Stathi, J. Papaparaskevas, P.T. Tassios, L. Zachariadou,
N.J. Legakis, A. Pangalis – The Hellenic Strep-EURO Study Group
Introduction: The importance of invasive infections caused by
Streptococcus pyogenes is due to their severe clinical features and
signiﬁcant increase in occurrence in recent years. The goal of this
presentation was the phenotypic and genotypic study of invasive
disease isolates, collected in Greek Hospitals, during the period
January to October 2003.
Materials and methods: A total of 30 isolates obtained from six
Greek Hospitals were studied. Susceptibility to penicillin, eryth-
romycin, clindamycin, vancomycin, cefotaxime, cloramphenicol
and tetracycline was tested by a disk diffusion method and
interpreted according to NCCLS criteria. Macrolide-lincosamide-
streptogramin (MLS) resistance phenotypes were determined by
the double-diffusion test using adjacent erythromycin and clin-
damycin disks. Detection of resistance genes mefA, ermTR and
ermB was carried out using the polymerase chain reaction
(PCR).
Results: Of the 30 isolates from 14 male and 16 female patients,
13 had been isolated from blood, nine from deep abscesses, three
from synovial ﬂuid, two from cutaneous wounds, two from pleu-
ral ﬂuid and one from cerebrospinal ﬂuid. The patients‘ mean age
was 19.6 years (range 1–76 years). No resistance to penicillin,
vancomycin, cefotaxime and chloramphenicol was detected. Five
isolates (17%) were resistant to erythromycin (EryR), whereas
eight (27%) were intermediately or fully resistant to tetracycline.
Clindamycin resistance was detected only in two EryR isolates,
both displaying the IR-MLSB phenotype. The remaining three
EryR isolates belonged to the M phenotype. The mefA and ermTR
genes were detected in all isolates with M and IR-MLSB pheno-
types, respectively.
Conclusion: Invasive S. pyogenes strains in Greece remain suscept-
ible to penicillin. Erythromycin resistance was detected among
17% of the isolates, lower than the average resistance rate (27%)
recorded previously on 2002.
Acknowledgements: The members of the Hellenic Strep-EURO
Study Group are: Drs A. Avlamis, G. Koupari, A. Pangalis,
T. Papadopoulos, E. Papafragas and M. Foustoukou. This work
was done as part of the multicentre Strep-EURO project ﬁnanced
by the European Commission.
P1091 Large differences in resistance to erythromycin in
Streptococcus pyogenes isolates of pharyngitis among regions in
Spain
E. Perez-Trallero, C. Garcia-Rey, E.J. Perea, D. Romero, L. Calbo,
M. Casal, J. Garcia-de-Lomas, L. Aguilar – The Spanish Surveil-
lance Group for Respiratory Pathogens
Objectives: Resistance to erythromycin in S. pyogenes must be
monitored in order to ensure the adequacy of the empiric use of
macrolides in the treatment of acute bacterial pharyngitis. Vari-
able rates of resistance have been reported around the world and
in Europe they are higher in the West Mediterranean region. In
our last surveillance (1998–1999) we described a decrease in resist-
ance up to 20%. We wanted to check whether this decrease is
conﬁrmed in 2001–2002 similarly to what happens with resistance
to penicillin in pneumococci.
Methods: A prospective, multicentre (25 hospitals) antimicrobial
survey was carried out between November 2001 and October
2002. A total of 3374 consecutive S. pyogenes isolates from adult
and paediatric patients with acute bacterial pharyngitis were col-
lected and sent to a central laboratory for further processing. Sus-
ceptibility testing was then performed by a semiautomated
microdilution method following NCCLS M100-S12 guidelines and
breakpoints against antibiotics commonly used.
Results: 70% of the strains were paediatric and 30% from adults.
All strains had a penicillin MIC of less than or equal to
0.015 mg/L and therefore considered as susceptible to betalac-
tams. However, the activity displayed by either erythromycin,
clarithromycin and azithromycin, which were equivalent to each
other, was not optimal. We documented large variations in the
prevalence of resistance among regions (Autonomous Communi-
ties), with a mean erythromycin resistance rate (and therefore of
clarithromycin and azithromycin) of 33.2% (95%CI: 24.7–41.8%).
Only Northern regions (Cantabria: 18.9%, Basque Country: 20.8%,
Galicia: 25.4%) and Madrid (25%) had a rate below the national
mean. Aragon, Andalucia and Catalun˜a had resistance rates
between 30 and 35%, Castilla-Leo´n had 40%, Murcia 46.3% and
Castilla-La-Mancha 63.8%.
Conclusions: (1) We have not conﬁrmed the decrease in erythro-
mycin (clarithromycin and azithromycin) resistance that seemed
to have happened during the late 1990s. (2) On the contrary, what
we have seen is an alarming mean increase in resistance (33.2%)
with very concerning hot spots in some regions (above 40%).
Only a few northern regions remain around 20%. (3) In view of
these results, erythromycin, clarithromycin and azithromycin
should not be prescribed empirically but given only once a
susceptibility testing has been done.
P1092 Erythromycin-resistant Streptococcus pyogenes
G. Lazarevic, S. Laban, M. Jovanovic, B. Potkonjak
Belgrade, CS
Streptococcus pyogenes is the most prevalent cause of tonsylophar-
yngitis in children. The drug of choice for infections caused by
this organism is penicillin. The problem with treating such infec-
tions arises when erythromycin-resistant strains occur.
Objectives: The aim of the study was to determine the incidence
of S. pyogenes resistant to penicillin. The organism was recovered
from the pharynx of children hospitalised or ambulatory treated
at the University Children’s Hospital in Belgrade.
Methods: S. pyogenes was identiﬁed on blood agar, using bacitra-
cin disc, and conﬁrmed by latex agglutination test (Slidex Bio Me-
rieux). Disc diffusion test was carried out to estimate the
penicillin sensitivity. Erythromycin disc was used as a screening
method to detect erythromycin-resistant S. pyogenes. MIC for
erythromycin was performed by broth dilution method.
Results: In the study period from January 2001 to December 2003
all 1100 isolates of S. pyogenes showed usual level of penicillin
sensitivity. In 2001 only 0.45% of isolates were erythromycin-
resistant. In 2002 erythromycin resistance was 0.63%, while in
2003 it was 1.09%. MIC for erythromycin was from 1 to 128mg/L.
Three strains expressed constitutive and one strain expressed
inducible resistance to clindamycin.
Conclusion: According to the results we can conclude that, despite
sensitivity to penicillin, resistance to macrolides is the emerging
phenomenon. The reasonable use of macrolide antibiotics is neces-
sary to maintain the resistance at the low level.
P1093 Phenotypic and genotypic characterisation of
macrolide-resistant Streptococcus pyogenes strains isolated in the
Czech Republic during two years (2001–2002)
V. Jakubu, P. Urbaskova, L. Strakova, O. Melter
Prague, CZ
Objectives: To determine prevalence of MLSB resistance mecha-
nisms among erythromycin-resistant S. pyogenes strains by pheno-
typic and genotypic methods.
Methods: A total of 916 clinical isolates of S. pyogenes resistant to
erythromycin were collected in 39 microbiology laboratories.
Erythromycin susceptibility was tested by the disk diffusion
method and strains which formed an inhibition zone <21 mm
around the erythromycin disk (15 lg) were sent to the National
Reference Laboratory for Antibiotics (NRL). The resistance pheno-
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types of all isolates were characterised in NRL by the double-disk
test with erythromycin (ERY, 15 lg) and clindamycin (CLI, 2 lg).
Antibiotic susceptibility by disk diffusion method was also deter-
mined to azithromycin (AZI, 15 lg) and spiramycin (SPI, 100 lg).
Presences of MLSB resistance genes (ermTR, ermB and mefA) were
tested by PCR and T serotypes were determined in random repre-
sentatives of each phenotype (n ¼ 252).
Results: The prevalence rate of the strains resistant to MLSB anti-
biotics (constitutive resistance) was 63% and 51% in 2001 and
2002, respectively. The prevalence rate of the strains resistant to
ERY, AZI and inducible resistant to SPI and to CLI (inducible
resistance) was 28 and 23%. The prevalence rate of the strains
resistant to ERY, AZI but susceptible to SPI, CLI (M phenotype)
was 9 and 26%. The major prevalent T types among the strains
analysed were serotype T 28 (58%), T 12 (10%), T 4 (8%) and
T B3264 (8%).
Conclusion: M phenotype, constitutive and inducible resistance to
MLSB antibiotics was detected and genes ermTR, ermB and mefA
were found among the strains analysed. The major mechanism of
MLSB resistance was constitutive with twofold higher prevalence
than the inducible mechanism. M phenotype which was the less
frequent mechanism in the ﬁrst year increased three times in sec-
ond year of the study. T serotype 28 was proved the most fre-
quent serotype associated with constitutive and inducible
resistance to MLSB antibiotics. The study showed the dynamic
change in prevalence of phenotypes, which are in relation with
T serotypes.
P1094 Increasing rate of tetracycline resistance in
Streptococcus pyogenes in Sweden
E. Bloom, J. Darenberg, F. Norrberg, B. Henriques-Normark,
C. Schalen, A. Jasir – Strep-EURO
Objectives: Streptococcus pyogenes, a major human pathogen, is still
considered susceptible to betalactams, but for other relevant anti-
biotics highly variable resistance rates have been reported. Since
the EC funded Strep-EURO project started in September 2002, a
total number of 301 invasive and 500 non-invasive control strains
were collected from different region of Sweden. One main objec-
tive was to study antibiotic susceptibility and type distribution of
resistant strains.
Methods: The strains used in this study were clinical isolates
from different diagnostic laboratories in Sweden. The invasive
strains were mainly blood isolates, but also from other sterile
sites, whereas control strains were throat or skin isolates.
Strains were maintained frozen at 80 C in calf serum. The in
vitro susceptibility to antibiotics was tested by disk diffusion on
PDM agar following the instruction provided by the Swedish
Reference Group for Antibiotics (homepage: www.srga.org).
MICs of resistant strains were determined by the E-test (Bio-
disk AB) following the recommendations of the manufacturer.
T typing was performed by slide agglutination according to
previously documented methods using sera from Sevapharma,
Prague.
Results: Erythromycin resistance was uncommon (0.6%), whereas
an overall high rate of tetracycline resistance was found (25–30%).
MIC for tetracycline resistant strains varied between 8 and
64 mg/L with a clustering at 24 mg/L. The tetracycline resistant
strains belonged to more than 10 different T types, the majority
being types 3/3264, 13, 28 and B3264. Among Invasive strains
T-types 3/3264, 3/13/3264 and 28 predominated.
Conclusion: Since in Sweden tetracycline is used in the treatment
of chlamydial and mycoplasmal rather than streptococcal infec-
tions the level of tetracycline resistance among GAS clinical iso-
lates, 25–30%, appeared comparatively high. However, in certain
countries much higher rates were recently reported. To account
for resistance development, horizontal gene transfer from chlamy-
dia or mycoplasma seems more unlikely than from other strepto-
cocci (groups B, C, D, G) especially with regard to increasing
veterinary usage of tetracycline.
Acknowledgments: The Strep-EURO project is funded by the Euro-
pean Commission. We are grateful to diagnostic laboratories pro-
viding strains and patient data to Strep-EURO.
P1095 Multicentre evaluation of macrolide and ketolide
activities and different genotypes of erythromycin resistance in
Italian streptococci
A. Mazzariol, R. Koncan, G. Bahar, L. Ricci, P. Nicoletti, P. Pecile,
F. Luzzaro, R. Fontana, G. Cornaglia
Verona, I; Ankara, TR; Reggio Emilia, Florence, Varese, I
Objectives: To investigate the actual incidence and nature of
macrolide and ketolide susceptibilities among Streptococcus pyo-
genes and Streptococcus pneumoniae isolated in Italy.
Methods: The activities of erythromycin and telithromycin, as well
as of other reference antibiotics, were assayed on 200 S. pyogenes
and 188 S. pneumoniae isolated in different Italian centres through-
out 2003. The presence of known resistance genes – both erm and
mef – was investigated by PCR on all resistant strains.
Results: 11.5% of the S. pyogenes isolates proved resistant to eryth-
romycin. The genotypic analysis revealed the presence of an erm
gene in 78.3%, and of a mef gene in 21.7% of the erythromycin-
resistant isolates, respectively. About 27.7% of the S. pneumoniae
isolates proved erythromycin-resistant, whilst 8% were not sus-
ceptible (intermediate) to penicillin. The genotypic analysis
showed an erm gene in 86.5% and a mef gene in 13.5% of the
erythromycin-resistant isolates, respectively. All the S. pyogenes
and S. pneumoniae erythromycin-resistant strains proved also
resistant to azithromycin and clarithromycin. A total of 94% of
the S. pyogenes isolates and 95.2% of the S. pneumoniae isolates
were susceptible to telithromycin.
Conclusions: Erythromycin resistance could be attributed to the
presence of either an erm or a mef gene in both S. pyogenes and S.
pneumoniae isolates, and the erm gene accounted for the vast
majority of resistant isolates in both streptococcal species. As
opposed to recent reports, erm and mef genes did not coexist in
any strain. Telithromycin resistance was present in both species,
though still limited to a few individual strains.
P1096 Incidence of ﬂuoroquinolone-resistant
beta-haemolytic Streptococci in North America (NA) and Europe
(EU): report from the SENTRY Antimicrobial Surveillance
Program, 1997–2002
D.J. Biedenbach, M. Toleman, T. Walsh, R. Jones
North Liberty, USA; Bristol, UK
Background: Recent publications have reported rare cases of beta-
haemolytic streptococci (BHS) with resistance (R) to ﬂuoroquino-
lones (FQ). These pathogens can cause invasive disease and have
generally remained susceptible (S) to the FQ class. This multi-cen-
tre investigation was initiated to determine the rate of FQ-R and
the responsible quinolone resistance-determining region (QRDR)
mutations among BHS.
Methods: The SENTRY Program has tested FQ against BHS in
NA and EU since 1997. This study used NCCLS broth microdi-
lution and Etest methods to determine S to ciproﬂoxacin (CIP),
gatiﬂoxacin (GAT), levoﬂoxacin (LEV), garenoxacin (GAR), gemi-
ﬂoxacin (GEM) and moxiﬂoxacin (MOX). Nineteen BHS isolates
from NA and EU had CIP MIC results >2 mg/L. Vitek and API
20 strep as well as conventional methods and colony morphol-
ogy were used to conﬁrm identiﬁcation. Eleven strains were
available for molecular analysis using PCR to determine muta-
tions in the QRDR. Primers were designed to amplify the QRDR
of gyrase and topoisomerase genes (gyrA, gyrB, parC, parE)
from S. pyogenes (BSA) and S. agalactiae (BSB) against respective
genes found in the GenBank database. PCR products were
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sequenced on both strands by the dideoxy-chain termination
method and analysis performed using laser gene DNA Star soft-
ware.
Results: The rate of FQ-R BHS was 0.36% (EU) and 0.46%
(NA) during the study period with the highest rate in 2002
(1.7%). These isolates included BSA (8), BSB (8) and S. dysgalac-
tiae (BSC/G; 3). The MIC90 for the FQs (mg/L) showed highest
potency for: GEM (2) > GAR (4) > MOX (8) > GAT (16) > LEV
(>4) > CIP (>32). All strains had signiﬁcant mutations in either
parC (position 79 or 83) and/or gyrA (position 81 or 85). Two
BSA strains with lower level R to CIP (4 mg/L) had only parC
mutations (Ser79 to Phe). All isolates of BHS with high-level R
(>32 mg/L) to CIP had gyrA mutations and often parC muta-
tions. Numerous other mutations in the QRDR region were
found including gyrB and parE, although their signiﬁcance
remains unknown.
Conclusions: The increasing rate of FQ-R streptococci including
S. pneumoniae, viridans group streptococci and more recently
reported, BHS, is becoming a clinical concern due to the morbid-
ity and mortality caused by these pathogens. Strains of BHS with
high-level R to FQ have point mutations common to other strepto-
cocci in gyrA and parC.
P1097 In vitro activity of telithromycin against
erythromycin-resistant and susceptible viridans group
streptococci isolated from blood
I. Rodrı´guez-Avial, C. Rodrı´guez-Avial, E. Culebras, J.J. Picazo
Madrid, E
Objectives: Emergence of erythromycin resistance in viridans
group streptococci (VGS) has been observed in many parts of the
world. We studied the activity of telithromycin against VGS isola-
ted from blood and determined the macrolide mechanism of
resistance.
Methods: 155 SGV unique and consecutive strains isolated from
blood were included in the study. Isolates were identiﬁed at the
species level by ID 32-Strep system (Biome´rieux, Marcy L’Etoile,
France) and then classiﬁed according to the review of Coykendall.
The antibiotic susceptibility to erythromycin (E), clindamycin (C)
and telithromycin (T) was performed by the agar dilution method.
The erythromycin resistance phenotypes were determined by the
double disc diffusion test and detection of mef(A) erm(B) and
erm(A) genes was performed by PCR.
Results: The VGS were identiﬁed as: S. mitis (68), S. anginosus
(44), S. sanguis (25), S. bovis (10), S. salivarius (7) and S. mutans
(1). Overall, the E and C resistance percentages were 52.2 and
32.2%, respectively. Among the 81 E-resistant strains, 62%
belonged to the cMLSB phenotype and 38% to the M pheno-
type. The MIC90 (mg/L) for E, C, and T in the different
groups of VGS was: S. mits (128/128/0.25), S. anginosus (256/
256/0.25), S. sanguis (128/128/0.12), S. bovis (256/256/64) and S.
salivarius (2/0.06/0.12). Among the 50 cMLSB phenotype strains
all were erm(B)+ and ﬁve were erm(B)+ and mef(A)+. All M
phenotype strains harboured the mef(A) gene. None of the
erythromycin-resistant isolates exhibited the erm(A) gene. The
most E-resistant group was S. bovis (90%) and the less resistant
group was S. salivarius (14%). All VGS groups showed T MICs
<4 mg/L independently of the erythromycin resistance geno-
type. The exception was the S. bovis group with ﬁve strains
showing telithromycin MIC 	4 mg/L.
Conclusions: We have found a high rate of erythromycin resist-
ance among our VGS and the main macrolide resistance mechan-
ism is mediated by erm(B) gene. Telithromycin was active against
all VGS groups, but S. bovis, with MIC90 
0.25 mg/L. The S. bovis
group was the most resistant to erythromycin and the only that
showed telithromycin MIC 	4 mg/L.
P1098 Resistance rates of viridans group Streptococci in
children attending day-care centres
G. Melica, H. Carsenti Dellamonica, B. Dunais, C. Pradier,
P. Dellamonica
Nice, F
Background: Viridans Group Streptococci (VGS) form the major
part of the commensal ﬂora of the human upper respiratory tract
and antibiotic resistance is of currently concern among this bacter-
ial population in several settings.
Objectives: To determine colonisation and resistance rates to bet-
alactams, macrolides and ﬂuoroquinolones antibiotics of VGS iso-
lated from 600 healthy children 3 months to 3 years old attending
to familial and collective day care centres in Nice (France).
Methods: A total of 63 positive cultures were obtained by naso-
pharyngeal aspiration. Antibiotic susceptibility was determined
by disk diffusion method and E-test on Mueller Hinton agar
plates supplemented with 5% sheep blood.
Results: Streptococci were identiﬁed by species: 28 S. mitis, 19 G.
morbillorum, 7 S. oralis, 3 S. sanguis, 1 A. viridans, 1 S. bovis, 2 S. ad-
jacens and 2 G. haemolysans. The carriage of penicillin resistant and
intermediate strains was in order 36.5 and 25%, according to E-
test values and NCCLS recommendations; erythromycin resistance
rate was 50%, while no strains telithromycin resistant were found.
Among the erythromycin resistant isolates the erm phenotype of
macrolide resistance predominated (95%). The new generation
ﬂuoroquinolones studied (levoﬂoxacin and sparﬂoxacin) showed
good activity against VGS, while a ciproﬂoxacin resistance rate of
4.7%was observed.
Conclusions: Penicillin resistance of VGS (61.5%) is equivalent to
penicillin resistance of S. pneumoniae (58.5%) in this children pop-
ulation, while the comparison of erythromycin resistance in the
VGS and S. pneumoniae isolates showed a higher level of erithro-
mycin resistance in the pneumococcal isolates (74%) than in the
VGS isolates (50%). Newer ﬂuoroquinolones showed good activity
towards the bacterial isolates tested, apart from a 4.7% ciproﬂoxa-
cin resistance rate observed, not easily explicable in this children
population and which requires further evaluations.
P1099 The eagle effect revisited. Penicillin resistance in
group G beta haemolytic streptococcal infection
A. Pillai, S. Thomas, C. Williams
Dumfries, UK
Background: Severe invasive beta haemolytic streptococcal celluli-
tis requires prompt diagnosis and rapid administration of appro-
priate antibiotic therapy. Because group A streptococcal infection
continues to be exquisitely sensitive to betalactam antibiotics, clin-
ical studies recommend the intravenous administration of Penicil-
lin G. Despite known antibiotic sensitivity to penicillin however,
there have been some treatment failures reported. Known as the
‘Eagle Effect’, penicillin appears effective against group A strepto-
coccus if given early in the infective process or where streptococ-
cal titres are low, however shows a marked reduction in efﬁcacy
if the infective process is allowed to progress or the inoculum size
is high (Inoculum effect).
Case report: Although well documented in group A streptococcal
infection, the Eagle Effect has been less well reported with infec-
tions due to other streptococcal serogroups. This report examines
a case of cellulitis in an otherwise healthy 47-year-old male where
the sole bacterial isolate was a beta haemolytic group G strepto-
coccus. Treatment failure with penicillin was observed despite
known culture sensitivity and the addition of clindamycin, gave
dramatic clinical improvement.
Conclusion: This ﬁnding may implicate an Eagle-Like Effect in
poorly responding group G beta haemolytic infections. This has
not been previously reported and may have important implica-
tions for clinical management.
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Resistance in pseudomonas and other Gram-negative bacilli
P1100 Suitability of current routinely generated data for
surveillance of antimicrobial resistance of Escherichia coli and
Pseudomonas aeruginosa in the UK and Ireland
R. Reynolds, N. Potz – BSAC Working Party on Bacteraemia
Resistance Surveillance
Objective: To assess whether clinical laboratories’ routine data can
be used for surveillance of antimicrobial resistance. Do routine
tests detect resistance reliably, and is there selection bias in the
isolates tested with particular antibiotics?
Methods: In 2001 and 2002, 29 local laboratories in the UK and
Ireland collected 495 isolates of E. coli (EC) and 367 P. aeruginosa
(PA) for the BSAC Bacteraemia Resistance Surveillance Pro-
gramme and supplied routine data on them, generated by local
methods. Isolates were re-tested centrally with the BSAC agar
dilution MIC method and breakpoints. Local test with ampicillin
was accepted as an alternative to amoxicillin with E. coli.
Results: There were no signiﬁcant differences in percentage sus-
ceptibility by reference tests between isolates tested and not tested
locally, implying no selection bias in local testing. Local laborator-
ies’ detection rates for susceptibility were high (	86% for EC and
	94% for PA, for all antibiotics), but detection rates for resistance
varied from 29% (PA/TZP) to 89% (EC/CIP) and averaged only
70% for the organism–agent combinations reported here. Of 183
undetected resistances, local laboratories reported 25 as intermedi-
ate and 158 as susceptible. Not all MICs in cases of undetected
resistance were near their breakpoints.
Conclusion: Routine susceptibility data on E. coli and P. aeruginosa
can be useful for surveillance, but cautious interpretation is nee-
ded for some antimicrobials. Further efforts to increase reliability
and standardisation are warranted.
P1101 Diversity among 2481 Escherichia coli from women
with community-acquired lower urinary tract infections in 17
countries (ECOSENS project)
M. Landgren, H. Ode´n, I. Ku¨hn, A. O¨sterlund, G. Kahlmeter
Va¨xjo¨, Stockholm, S
Objectives: In the ECO.SENS project the prevalence and suscepti-
bility of pathogens causing community-acquired acute uncompli-
cated urinary tract infections in women in 16 European countries
and Canada was investigated (JAC 2003; 51: 69–76). It revealed
vast differences in resistance between countries. We used the
PhenePlateTM (PhP) System to determine the clonal diversity of
the 2481 E. coli of the ECO.SENS survey.
Methods: The E. coli were typed using the PhP system. This is a
biochemical typing method which measures not only positive and
negative reactions but also the kinetics of each reaction. PhP-RE
plates, speciﬁcally intended for use with E. coli, include 11 rea-
gents. The speed and result of the reactions (measured at 8, 24
and 48 h of incubation) are expressed in a numerical code. Data
were analysed with the PhPWIN Software.
Results: The PhP system divided the 2481 E. coli strains into 74
Common PhP Types (CT), each containing two or more isolates
(n ¼ 2067), and 414 Single PhP Types. The diversity index was
0.94 among all isolates. The antimicrobial susceptibility patterns
identiﬁed 46 types and yielded a diversity of 0.55 among all iso-
lates. Type CT-48 was the most frequent type in 13 countries and
the second most frequent in four countries. It contained 400 iso-
lates and exhibited 11 different antimicrobial resistance patterns.
Sixty-four per cent of the E. coli isolates did not exhibit resistance
to any of the investigated drugs. Frequent susceptibility patterns
were isolated resistance to ampicillin, combined resistance to
ampicillin and trimethoprim, single resistance to trimethoprim fol-
lowed by single resistance to nalidixic acid.
Conclusion: Although some types exhibited distinct differences in
their susceptibility patterns there was no obvious correlation
between the phenotypes identiﬁed with the PhP system and the
susceptibility pattern. Thus, our data did not suggest a dissemin-
ation of resistant clones within or between countries as an explan-
ation for differences in antimicrobial resistance rates.
P1102 Characterisation of clinical isolates of
Enterobacteriaceae resistant to third generation cephalosporins
from a university hospital in Bratislava, Slovakia
M. Zarnayova-Skopkova, E. Siebor, H. Bujda´kova´, C. Neuwirth
Bratislava, SK; Dijon, F
Objectives: A total of 101 clinical isolates of Klebsiella pneumoniae
(67), Escherichia coli (14), Enterobacter cloacae (10) and Citrobacter
freundii (10) resistant to third-generation cephalosporins (TGC)
were isolated in Ruzinov University Hospital in Bratislava (Slova-
kia) during a discontinuous survey performed during a few
months of 1998, 1999, 2001 and 2002. The aim of this study was to
determine the mechanism(s) of resistance to TGC and to investi-
gate the epidemiology of ESBL producers.
Methods: Susceptibility testing was performed by disk diffusion on
Mueller–Hinton agar, and the double-disk synergy test (on medium
with and without oxacillin) was used for detection of ESBL produc-
tion. The determination of the pI of the b-lactamases was performed
by isoelectric focusing. The relatedness of the isolates was investi-
gated by pulsed-ﬁeld gel electrophoresis (PFGE). One isolate of
each pulsotype was used for analysis of the bla gene by PCR using
primers speciﬁc for TEM, SHV and CTX-M enzymes.
Results: The double-disk synergy test was positive for all isolates
of K. pneumoniae, 12 isolates of E. coli and only for two isolates of
E. cloacae and two isolates of C. freundii. The isolates with negative
double-disk synergy test were assumed to be mutants that over-
produced their chromosomally encoded cephalosporinase. PFGE
revealed respectively 10, 8, 7 and 5 pulsotypes among the isolates
of K. pneumoniae, E. coli, E. cloacae and C. freundii. SHV-type ESBLs
with pI 7.6 were found in all species, SHV-type ESBLs with pI 8.2
were present in isolates of K. pneumoniae and E. cloacae. TEM-type
ESBLs with pI 5.2 and 6.0, as well as a CTX-M-type ESBL with pI
8.4 were produced by isolates of K. pneumoniae. Two strains of
K. pneumoniae produced two different ESBLs simultaneously (one
with a TEM-type of pI 6.0 plus SHV-type of pI 7.6, and one with
a SHV-type of pI 8.2 plus a CTX-M-type of pI 8.4).
Conclusion: The production of ESBL was the major mechanism of
resistance to TGC in Ruzinov University Hospital in Bratislava. At
least ﬁve different ESBLs were encountered and a few clonal
strains disseminated in different wards.
Species
and
drug
n of isolates
tested,
not tested
locally
% S for
isolates
tested, not
tested locally
Local
detection
of S
Local
detection
of R
EC AMX 475,20 41,40 167/194 ¼ 86% 249/281 ¼ 87%
EC AMC 362,133 76,77 255/274 ¼ 93% 41/88 ¼ 47%
EC CAZ 403,92 97,98 385/392 ¼ 98% 5/11 ¼ 45%
EC CIP 480,15 93,100 442/444 ¼ 100% 32/36 ¼ 89%
EC CXM 401,94 90,91 331/360 ¼ 92% 19/41 ¼ 46%
EC GEN 490,5 89,80 429/436 ¼ 98% 19/54 ¼ 35%
EC IPM 246,249 100,100 246/246 ¼ 100% n < 10
EC TZP 263,232 95,98 247/250 ¼ 99% 6/13 ¼ 46%
PA CAZ 342,25 96,92 310/330 ¼ 94% 8/12 ¼ 67%
PA CIP 361,6 87,83 308/313 ¼ 98% 23/26 ¼ 88%
PA GEN 362,5 56,60 201/203 ¼ 99% 15/23 ¼ 65%
PA IPM 171,196 91,94 151/156 ¼ 97% 10/15 ¼ 67%
PA TZP 250,117 94,96 224/236 ¼ 95% 4/14 ¼ 29%
AMX amoxicillin, AMC amoxicillin–clavulanate, CAZ ceftazidime, CIP
ciproﬂoxacin, CXM cefuroxime, GEN gentamicin, IPM imipenem, TZP
piperacillin–tazobactam.
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P1103 Role of clonal occurrences of multi-drug-resistance
(MDR) in the MYSTIC Programme (USA; 1999–2003)
R. Jones, G. Deshpande, P. Rhomberg, H. Sader, T. Fritsche
North Liberty, USA
Background: The Meropenem (MEM) Yearly Susceptibility Test
Information Collection (MYSTIC) Programme was initiated in
1997, but in 1999 for the USA. This programme monitors resist-
ance (R) in participant centres where carbapenems are prescribed
and drug use data are obtained. An earlier report found antimi-
crobial use was not a clear cause of local or aggregate changes in
R rates (Mutnick et al., JAC 2004). This study addresses the role
of dissemination of R clones on R rates for non-fermentors Acine-
tobacter spp. (ACB) and P. aeruginosa (PSA).
Methods: Carbapenem (CARB)-multi-drug R strains (MDR) from
among 226 ACB and 1112 PSA were tested by reference broth
microdilution methods, automated ribotyping and PFGE to deter-
mine possible clonal dissemination. Each strain was also tested
for metallo-beta-lactamases (MBL) and then analysed by CARB-R
rate (phenotypic and PCR) and DDD/100 days use groupings
(high, moderate, low).
Results: For the aggregate 15 sites in the MYSTIC Programme each
year, the PSA CARB-R rate decreased over 5 years (16.1 vs. 7.3%);
but other drug-R rates generally escalated. ESBL-R rates were sta-
ble in E. coli and Klebsiella (1–7%). Changes were not related to use
calculations. Discovered clonally spread strains were elevated in
high-R (1.8 clones/site) and moderate-R (0.6 clones/site) rate cen-
tres (22–30% of CARB-R strains were clonal), compared with
unique MDR-PSA in low-R hospitals. ACB clonality was extreme
in one geographic area with dissemination of ﬁve clones (931.7/B,
C or D; 1090.2/A; 167.5/A) in four centres (02, 04, 06, 18). R-rates
in ACB and PSA were clearly related to clonal occurrence and
spread, and one MBL (VIM-7; Toleman et al., AAC 2004) was
detected, representing its persistence in a Texas site. Decreased
CARB-R rates from 1999 to 2002 were directly attributable to the
disappearance of R clones in some locations.
Conclusions: ACB and PSA CARB-R and MDR-R rates in MYSTIC
Programme institutions have been greatly inﬂuenced by clonal
dissemination, less by antimicrobial use patterns. Most severe
examples of clonality were observed among ACB in New York
City and the documented endemic nature of VIM-7 PSA (0.9% of
all PSA isolates). MEM remained the most active agent tested in
the programme and surveillance networks must implement epi-
demiologic typing to assess the role of clonal spread on the R
rates.
P1104 Optimising pharmacodynamic target attainment
using the MYSTIC antibiogram (OPTAMA) – Acinetobacter spp.
and P. aeruginosa in Europe, 2002
R. Masterton, J. Kuti, C. Nightingale, D. Nicolau
Crosshouse, UK; Hartford, USA
Objectives: The goal of OPTAMA is to provide insight into the
most appropriate antibiotic options for empiric therapy of
common nosocomial pathogens. This is accomplished by consider-
ing the variability in pharmacokinetic (PK) parameter estimates,
dosage regimens and MIC distributions from varying regions of
the world to calculate the probability of attaining critical pharmac-
odynamic (PD) targets. For the 2002 data analysis Europe was
divided into North (NE), South (SE) and East (EE) regions.
Methods: A 5000 subject Monte Carlo simulation was conducted
to estimate PD target attainment (TA) for meropenem, imipenem,
ceftazidime (CF), cefepime, piperacillin/tazobactam (PT), and ci-
proﬂoxacin (CP) against Acinetobacter spp. (AS) and P. aeruginosa
(PSA). PD targets were free drug of 40%T > MIC for M and I,
50%T > MIC for CZ, CM and PT, and a total AUC/MIC ratio of
125 for CP. Standard dosing regimens for Europe were used. PK
variability was derived from existing healthy subject data. MIC
data were obtained from the MYSTIC Program.
Results: Probabilities of TA are listed in Table 1.
Conclusions: NE shows the highest TAs and EE the lowest. Carb-
apenems show the best TAs achieved. Other b-Lactams, partic-
ularly PT and CF, do not possess good TAs. Desirable TAs are
not readily attainable against either pathogen, even when doses
are high. CP achieved the lowest TAs for both pathogens.
P1105 Optimising pharmacodynamic target attainment
using the MYSTIC antibiogram (OPTAMA) – Escherichia coli
and Klebsiella pneumoniae in Europe, 2002
R. Masterton, J. Kuti, C. Nightingale, D. Nicolau
Crosshouse, UK; Hartford, USA
Objectives: The goal of OPTAMA is to provide insight into the
most appropriate antibiotic options for empiric therapy of com-
mon nosocomial pathogens. This is accomplished by considering
the variability in pharmacokinetic (PK) parameter estimates, dos-
age regimens and MIC distributions from varying regions of the
world to calculate the probability of attaining critical pharmacody-
namic (PD) targets. For the 2002 data analysis Europe was divi-
ded into North (NE), South (SE) and East (EE) regions.
Methods: A 5000 subject Monte Carlo simulation was conducted
to estimate PD target attainment (TA) for meropenem, imipenem,
ceftazidime, cefepime, piperacillin/tazobactam (PT), and ciproﬂ-
oxacin (CP) against E. coli (EC) and K. pneumoniae (KP). PD targets
were free drug of 40%T > MIC for M and I, 50%T > MIC for CZ,
CM and PT, and a total AUC/MIC ratio of 125 for CP. Standard
dosing regimens for Europe were used. PK variability was
derived from existing healthy subject data. MIC data were
obtained from the MYSTIC Program.
Results: Probabilities of TA are listed in Table 1.
Table 1.
Drug regimen
Target attainment (%)
AS PSA
EE SE NE EE SE NE
Meropenem 500q8h 53.5 66.2 88.7 58.5 67.5 81.4
Meropenem 1000q8h 57.6 81.8 93.1 63.2 75.5 81.4
Imipenem 500q6h 54.2 73.0 94.6 56.9 64.9 80.5
Ceftazidime 1000q8h 22.1 22.4 70.7 53.7 69.8 78.5
Ceftazidime 2000q8h 29.2 37.7 79.1 59.6 79.5 84.3
Cefepime 2000q12h 34.7 53.9 72.9 55.0 62.7 81.0
Pip/Taz 4.5q8h 12.3 14.0 45.5 27.9 39.0 46.7
Pip/Taz 3.375q6h 16.1 19.6 – 37.3 55.9 –
Cipro 400q12h 14.1 10.7 40.2 28.1 22.8 39.1
Cipro 400q8h 17.9 15.7 52.3 37.8 31.0 47.7
Table 1.
Drug regimen
Target attainment (%)
EC KP
East South North East South North
Meropenem 500q8h 99.8 99.5 100 98.3 96.2 99.8
Meropenem 1000q8h 99.9 99.8 100 99.5 97.5 99.8
Imipenem 500q6h 99.2 99.7 99.9 99.3 97.1 99.8
Ceftazidime 1000q8h 80.5 95.1 96.5 52.0 83.1 88.3
Cefepime 1000q12h 78.5 98.8 99.7 67.4 96.0 98.7
Cefepime 2000q12h 84.0 100 99.8 77.0 96.0 99.4
Pip/Taz 4.5q8h 62.1 77.1 85.2 37.2 59.0 69.7
Pip/Taz 3.375q6h 70.4 87.4 92.1 45.1 72.9 81.2
Cipro 400q12h 57.7 62.7 80.9 60.8 69.1 72.4
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Conclusions: NE shows the highest TAs and EE the lowest. Carb-
apenems show the most sustained high TAs, though in EE there
is some reduction against KP. High TAs are more attainable
against EC. Apart from in NE other b-Lactams, particularly PT,
do not consistently possess high TA against EC and KP. CP
achieved the lowest TAs for both pathogens.
P1106 Sustained activity of the carbapenems against
Gram-negative pathogens: 6-year data from the UK MYSTIC
(Meropenem Yearly Susceptibility Test Information Collection)
programme
R. Masterton on behalf of the UK MYSTIC Group
Objectives: To monitor resistance trends to meropenem (MEM)
and other broad-spectrum antibiotics over six years in UK centres
through the MYSTIC Programme, a global, longitudinal antimicro-
bial surveillance study.
Methods: Isolates were tested using National Committee for
Clinical Laboratory Standards methodology to determine the
susceptibility breakpoints of MEM and several other antimicro-
bial agents including imipenem (IPM), ceftazidime (CAZ), pip-
eracillin–tazobactam (TAZ), ciproﬂoxacin (CIP) and gentamicin
(GM). 1136 Gram-negative isolates were collected from three
centres in the UK from 1997 to 2002. Data are grouped in 2-
year blocks.
Results: The study susceptibility results are shown in
Table 1. Overall the carbapenems were the most active antimi-
crobial agents. They were also the most active against non-fer-
menters, including Pseudomonas spp. and Acinetobacter spp. With
the exception of susceptibility to CIP, which decreased amongst
Enterobacteriaceae at the end of the 6-year period all antibiotics
tested retained their levels of activity. The proportion of exten-
ded-spectrum beta-lactamse (ESBL) and AmpC-producing
enterobacteriaceae increased during the study (4.8 and 11.3% in
1997–1998; 7.4 and 16.7% in 2001–2001, respectively). Both MEM
and IPM retained their potency against these ESBL and AmpC-
producing isolates (100% for all time periods). All the other
antimicrobial agents tested had much lower susceptibility
against these resistant isolates and this decreased further over
the 6-year period, with the exception of TAZ, which maintained
its low levels.
Conclusions: During this 6-year study, some minor but no major
susceptibility trends were observed. Although all antibiotics tested
retained acceptable activity the carbapenems remained the most
active antimicrobial agents against Gram-negative bacteria, inclu-
ding ESBL and AmpC-producing isolates. Continued surveillance
is needed to monitor future resistance trends.
P1107 P. aeruginosa clonal dissemination in Brazilian
intensive care units during 2002
C. Mendes, S. Sinto, J. Sampaio, S. Leao, C. Oplustil, P. Turner,
C. Kiffer on behalf of the MYSTIC Brazil Group
Objective: To investigate the clonal dissemination of multiresistant
P. aeruginosa causing nosocomial infections within and between
Brazilian intensive care units, which participated in the MYSTIC
Program Brazil 2002.
Methods: Thirty-six P. aeruginosa isolates with the same phenotyp-
ic characteristics were collected during 2002 at four centres in Sa˜o
Paulo (#1, 4, 6, 7) and at one centre in Brası´lia (#5). They were
analysed by pulsed ﬁeld gel electrophoresis (PFGE). Isolates
resistant to meropenem or imipenem plus at least two of the fol-
lowing drugs: ciproﬂoxacin, cefepime, ceftazidime or piperacillin/
tazobactam were studied. SpeI chromosomal restriction fragments
were separated with CHEF-DR III System. Electrophoretic pat-
terns were analysed with GelCompar II v. 2.5 (Applied Maths,
Kortrijik, Belgium). Interpretative criteria used were those des-
cribed by Tenover et al.
Results: Five major clones were identiﬁed (A, B, C, D, G).
Clone A was constituted by eight samples with indistinguish-
able PFGE pattern present in two centres (#1 and 6). Clone A
also had closely related strains (A1–3) present in three centres
(#1, 5 and 6). Clone B was constituted by four indistinguishable
samples predominant in centre 6. Clone C had three indistin-
guishable samples, with closely related clones (C1–3). Also,
Clone D had three indistinguishable samples, with closely rela-
ted (D1) and possibly related (D2/D3) clones. Clones C and D
were present in centre 1, as well as other related clones
(C1–3 and D1–3). Clone G was constituted by two indistin-
guishable samples and was present in centre 7. Finally, eight
samples were not related. Centre 4 did not present any cloned
isolates.
Conclusions: Clonal dissemination was detected within (Clones A,
B, C, D, and G) and between centres (Clone A). These ﬁndings
are important when analysing surveillance data, since susceptibil-
ity rates may be signiﬁcantly affected with elevated resistance
mainly due to clonality.
P1108 Resistance of Pseudomonas aeruginosa: 10-year
experience in a Portuguese hospital
C. Marcelo, A. Azevedo, M. Pessanha, E. Gonc¸alves, T. Cruz,
H. Silva, I. Alves, P. Bruno, N. Rosa, J. Santos, F. Martins,
J. Esperanc¸a-Pina
Lisbon, P
Objectives: The aim of this study was to evaluate the evolution of
antibiotic resistance pattern of Pseudomonas aeruginosa strains isola-
ted at a central hospital in Lisbon for a period of 10 years.
Methods: This was a retrospective study of 2219 pathogenic
strains isolated between 1993 and 2002. Bacterial identiﬁcation
was achieved using the APi system (BioMe´rieux) and the suscep-
tibility tests were performed by the disk diffusion method of Kir-
by-Bauer according to NCCLS. Since 1994, bacterial identiﬁcation
and susceptibility tests were performed by Vitek system (Bio-
Me´rieux). Gentamicin, tobramycin, amikacin, ceftazidime, ciproﬂ-
oxacin, imipenem, aztreonam and the association piperacillin/
tazobactam were tested.
Results: The 2219 pathogenic strains were distributed uniformly
during the 10 years of study. The resistance rate to aminoglyco-
sides reached its highest value in 1997 and its lowest in 2000.
The resistance rate to gentamicin ranged from 12 to 46%; to to-
bramycin ranged from 5 to 27% and to amikacin ranged from 2
to 17%. In 1993, it was introduced as a new surveillance pro-
gramme of pharmacokinetics control (Kinetidex) of the aminogly-
cosides starting with gentamicin and later with tobramycin and
amikacin. The resistance rate to ceftazidime ranged from 6%
(1995) to 35% (2001); to ciproﬂoxacin ranged from 10% (1995) to
42% (1998), both with progressive increase. The resistance rate to
imipenem ranged from 8% (1995; 2000) to 27% (1999). The
Table 1. Percentage susceptibility of isolates over the study period
MEM IMI CAZ TAZ CIP GM
Enterobacteriaceae
1997–1998 (n ¼ 186) 100 99 80 75 94 90
1999–2000 (n ¼ 280) 100 100 81 74 94 90
2001–2002 (n ¼ 270) 99 98 83 71 85 89
Non-fermenters
1997–1998 (n ¼ 94) 86 90 70 85 70 75
1999–2000 (n ¼ 142) 97 94 70 83 80 70
2001–2002 (n ¼ 128) 90 87 71 87 77 74
All Gram-negatives
1997–1998 (n ¼ 280) 95 96 77 81 86 85
1999–2000 (n ¼ 422) 99 98 77 83 89 83
2001–2002 (n ¼ 434) 97 94 80 80 84 85
300 Abstracts
resistance rate to aztreonam ranged from 18% in 1994–1995 to
about 35% in the last 5 years, although it is not used in our hos-
pital. The resistance rate to the association piperacillin/tazobac-
tam was progressively increased, from 9% in 1993 to 30% in
2001–2002.
Conclusions: The resistance rates of Pseudomonas aeruginosa to
ceftazidime, ciproﬂoxacin and piperacillin/tazobactam doubled
in 10 years. The resistance rate to imipenem, even thought is a
third-line choice antibiotic, has not increased. The resistance
rates to the aminoglycosides had the highest value in 1997 but,
with the implementation and the optimisation of the pharmaco-
kinetics control programme, we have seen a decreasing pattern
of resistance.
P1109 Convergent resistance development between two
carbapenems for Pseudomonas aeruginosa
F. Walsh, S. Bracher, P. Turner, S.G.B. Amyes
Edinburgh, Cheshire, UK
Objectives: The objectives of this study were to evaluate the activ-
ity of meropenem against isolates of P. aeruginosa and to investi-
gate the relationship between imipenem and meropenem in
selecting resistance in P. aeruginosa. P. aeruginosa isolates (n ¼ 104)
were collected from Edinburgh between January and May 2003.
Methods: The MICs of imipenem, meropenem, ceftazidime, pip-
eracillin/tazobactam and ciproﬂoxacin were determined by agar
dilution according to the BSAC guidelines.
Results: Meropenem had the lowest level of resistance at 1.9%,
followed by piperacillin/tazobactam with 4.8%, imipenem at
5.8%, ceftazidime with 13.5% and ciproﬂoxacin with 20% resist-
ance. In order to assess any relationship between meropenem and
imipenem in the selection of carbapenem resistance by P. aerugi-
nosa the ratio of imipenem MIC to meropenem MIC was com-
pared with the imipenem MIC for each strain. At low MICs,
meropenem was commonly more than 10-fold more active than
imipenem, but as the imipenem MIC increased, the ratio
decreased. A similar analysis was performed on a random set of
342 strains from European MYSTIC data from 1997 to 2000 in
which the same relationship occurred.
Conclusion: The results of both sets of analyses suggest that imi-
penem could be a more powerful selector of resistance than me-
ropenem. However, in the strains analysed, once resistance has
been selected, it conferred a similar degree of insusceptibility to
both imipenem and meropenem. Therefore, in order to minimise
the risk of multiple carbapenem resistance developing, the most
active group member should be selected to treat infection with
P. aeruginosa, this agent would be meropenem.
P1110 Lack of association between hypermutation and
antibiotic resistance development in Pseudomonas aeruginosa
from intensive care unit patients
O. Gutie´rrez, C. Juan, M.D. Macia´, J.L. Pe´rez, A. Oliver
Palma de Mallorca, E
Objectives: Antibiotic resistance in Pseudomonas aeruginosa from
cystic ﬁbrosis (CF) patients has been found to be linked to the
presence of hypermutable strains. The objective of this work was
to study the role of hypermutation in antibiotic resistance devel-
opment in patients from Intensive Care Units (ICU).
Methods: A total of 216 P. aeruginosa isolates recovered from clin-
ical samples of 103 patients admitted to the H. Son Dureta ICU
from September 2002 to November 2003 were analysed. Identiﬁca-
tion and initial susceptibility testing was performed with the
WIDER system. Additionally, MICs for ceftazidime (CAZ), cefepi-
me (FEP), imipenem (IMP), meropenem (MER), ciproﬂoxacin
(CIP) and tobramycin (TOB) were determined with Etest. The ﬁrst
P. aeruginosa isolate obtained from each of the patients and type
of clinical sample as well as any subsequent isolate that devel-
oped resistance to any of the antibiotics tested were further stud-
ied. Pulsed ﬁeld gel electrophoresis (PFGE) and mutation
frequencies (mf) estimations were performed in these isolates by
standard procedures.
Results: Following the deﬁned criteria 160 isolates from the 103
patients were included. With the exception of IMP primary resist-
ance was low or moderate for all antibiotics: 7.5, 6.5, 23.4, 11.2, 8.4
and 0% for CAZ, FEP, IMP, MER, CIP and TOB, respectively. On
the other hand, resistance development during antibiotic treat-
ment (secondary resistance) had a high impact in resistance.
P. aeruginosa strains from 20.4% of the patients developed resist-
ance to at least one of the antibiotics (15.5, 17.5, 8.7, 8.7, 8.7 and
1% for CAZ, FEP, IMP, MER, CIP and TOB, respectively). PFGE
revealed that most of the patients were infected with unique
P. aeruginosa clones (82 different clones for the 103 patients). Also,
when a subsequent resistant isolate was recovered from a given
patient it was, in most cases, consequence of resistance develop-
ment in the infecting strain and not of its replacement by a differ-
ent resistant clone. Mutation frequencies estimations revealed
that only one of the 160 isolates (<1%) was hypermutable
(mf 6.0  106 ) whereas the other 159 were non hypermutable
(mean mf 1.8  108 ).
Conclusions: Despite P. aeruginosa mutational antibiotic resistance
development has an important impact in the ICU setting, selection
of hypermutable strains is a very infrequent event, in contrast to
what happens in CF patients.
P1111 Detection and susceptibility testing of
hypermutable Pseudomonas aeruginosa strains with the Etest
M.D. Macia´, N. Borrell, O. Gutie´rrez, J.L. Pe´rez, A. Oliver
Palma de Mallorca, E
Objectives: Detection of hypermutable Pseudomonas aeruginosa
strains from cystic ﬁbrosis (CF) patients by microbiology labor-
atories might be useful for establishing adequate antimicrobial
therapies due to the link between the presence of these strains
and antibiotic resistance development. The objective of this
work was to study the reliability of the Etest method for the
detection and susceptibility testing of hypermutable P. aeruginosa
isolates.
Methods: Strains PAO1 and its hypermutable derivative PAOdelta-
mutS were used for the standardisation of the procedure, which
was tested with 35 P. aeruginosa isolates from 21 CF patients. Muta-
tion frequencies were estimated by standard methods. MICs were
determined using Etest strips for ceftazidime, imipenem, merope-
nem, ciproﬂoxacin and tobramycin. The presence (or absence)
within the inhibition zones of resistant mutant subpopulations
(RMS), as well as their relative numbers and their highest MICs
were recorded.
Results: Of the 35 isolates 10 (29%) were found to be hypermuta-
ble by mutation frequency estimations. Although the observation
of RMS within the inhibition zones of an individual antibiotic was
only suggestive of the presence of a hypermutable strain due to
the occasional documentation of RMS in non hypermutable
strains, the presence of RMS with three or more antibiotics
unequivocally identiﬁed the strains as hypermutable (10/10 vs. 0/
25 for hypermutable and non hypermutable strains, respectively).
Additionally, this method allowed us to differentiate a dual effect
of hypermutation in antibiotic resistance: (i) hypermutable isolates
were substantially more resistant than non hypermutable isolates,
and (ii) the resistance of hypermutable isolates was dramatically
increased due to the presence of RMS.
Conclusions: (1) the Etest can be used as a simple method for the
detection and susceptibility testing of hypermutable P. aeruginosa
strains. (2) This method allowed as to differentiate the dual effect
of hypermutation on antibiotic resistance. (3) This differentiation
might be relevant for the design of adequate treatments since, in
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contrast to what happens with the ﬁrst premise, the second can
be overcome by antibiotic combinations. A guideline for the detec-
tion, susceptibility testing and reporting of hypermutable P. aeru-
ginosa strains with the Etest is proposed.
P1112 Partial reduction of antimicrobial resistance of
Pseudomonas aeruginosa following new antibiotic strategies in
an intensive care unit in Italy
B. Allegranzi, A. Azzini, A. Luzzani, F. Rapagna, F. Favari,
E. Concia
Verona, I
Objective: To evaluate the impact of a strategy of rotating and
choosing antibiotics on the basis of local patterns of antimicrobial
resistance (AMR) and synergy assays, in patients with Pseudomonas
aeruginosa suspected or conﬁrmed infections.
Methods: During two consecutive periods we prospectively evalu-
ated AMR patterns of P. aeruginosa isolates in patients admitted
for more than 48 h to the intensive care unit (ICU) of Verona. Sus-
ceptibility tests were performed by Kirby Bauer method. Data
refer only to strains with different antibiotype in case of repeated
isolations in the same patient. We classiﬁed isolates as multidrug
resistant (MDR) when resistance to piperacillin, imipenem, ceftazi-
dime and gentamicin was detected and as PAN resistant (PAN-R)
when the isolate was resistant to all tested antibiotics. Following
the alarming observation of very high levels of AMR (Table) dur-
ing the ﬁrst year of study (Period A: April 2001 to March 2002),
we modiﬁed the local protocols of empiric therapy recommending
to possibly avoid the use of aminoglycosides and to use the
association of a cephalosporin of third- or fourth-generation plus
levoﬂoxacin in severe nosocomial sepsis. Furthermore in infec-
tions due to MDR P. aeruginosa, we chose the most effective anti-
biotic combination on the basis of synergy assays (Etest). One
year later (Period B: April 2002 to March 2003) we evaluated
again AMR patterns in P. aeruginosa isolates.
Results: During period A, among 183 isolates of P. aeruginosa, 27
(14.7%) were MDR, of which 14 PAN-R. During period B (174 iso-
lates), among 34 (19.5%) MDR strains, 11 were PAN-R. Compar-
ing periods A and B, we observed an overall decrease of AMR
levels of P. aeruginosa isolates against the principal antibiotics,
which in particular was statistically signiﬁcant for amikacin and
ciproﬂoxacin (Table).
Conclusions: AMR of P. aeruginosa isolates remains an alarming
issue in the studied ICU. In this setting the isolation of MDR and
PAN-R strains was conﬁrmed as a relatively frequent event dur-
ing the last 2 years. Nevertheless the application of a new antibi-
otic strategy contributed to determine a relevant decrease of
resistance levels against the principal antibiotics. Furthermore we
believe that it is worth planning a case control study to evaluate
the clinical efﬁcacy of the combination of beta-lactams plus ﬂuoro-
quinolones which demonstrated synergy in several vitro studies
against MDR strains of P. aeruginosa.
P1113 Polyphasic approach to the characterisation of
Pseudomonas aeruginosa isolates from a Portuguese central
hospital
A.P. Fonseca, P. Correia, A. Fonseca, R. Tenreiro, J.C. Sousa
Porto, Lisbon, P
Objectives: Bacteria can have population structures ranging from
fully panmictic to highly clonal. Despite many studies, the popu-
lation structure of Pseudomonas aeruginosa is still unclear. In this
work a polyphasic approach was used based on two DNA-based
ﬁngerprinting methods and an antimicrobial resistance ﬁnger-
printing, which are combined using biological data analysis soft-
ware in order to get an insight into the population structure of P.
aeruginosa clinical isolates in a Portuguese Central Hospital.
Methods: A representative sample of P. aeruginosa clinical isolates
(180/400) from different biological products/patients/wards was
collected at a Portuguese Hospital during the year 2002. The
strains were biochemically identiﬁed (Vitek auto microbic system).
Two genomic typing systems, namely the minisatellite-primed
PCR (MSP-PCR) and the enterobacterial repetitive consensus
sequence PCR (ERIC-PCR), were used to discriminate the strains.
The antibiotic susceptibility was analysed using the Vitek AMS
System. The data obtained from DNA-based ﬁngerprinting and
antiobiotyping were combined and analysed using BioNumerics
biological data analysis software.
Results: In the dendogram from the composite data set we identi-
ﬁed a reduced number of genomic groups or clonal complexes
(CCs) with >80% similarity. Most CCs contain strains from differ-
ent origins, suggesting high rates of nosocomial migration and an
outstanding versatility probably caused through recombination.
The variability within each ward of the hospital was as nearly as
within the whole population. Although some clusters showed
>90% similarity, we also observed unique isolates, some of which
diverged considerably from the rest of the population. The close
genomic relationship among the isolates of each clone was detec-
ted by MSP-PCR analysis, pointing to its potential use in clinical
settings to recognise epidemic P. aeruginosa clones over the short
term. It also permits the selection of a few representative strains
of each group for, as an example, antimicrobial chemotherapy
studies.
Conclusion: There is sufﬁcient justiﬁcation to suggest that P. aeru-
ginosa displays an epidemic population structure in this Hospital.
Acknowledgements: This study was supported by a research grant
from Fundac¸a˜o Calouste Gulbenkian.
P1114 Emergence of Pseudomonas aeruginosa (PA)
resistance to imipenem vs. meropenem
S. Navon-Venezia, Y. Mekuzas, O. Hammer-Muntz, D. Schwartz,
Y. Carmeli
Tel Aviv, IL
Background: Resistance of Pseudomonas aeruginosa (PA) to anti-
pseudomonal carbapenems is usually due to the combination of
low intracellular concentrations due to OprD loss and efﬂux
pumps and slow hydrolysis by beta-lactamases. For MER resist-
ance to arise, both OprD loss and efﬂux pump expression is
required, while IMP is affected only by OprD. Therefore it has
been hypothesised that the two mechanisms required for MER
resistance will result in lower likelihood of emergence of resist-
ance.
Methods: 10 PA clinical isolates and one ATCC strain were stud-
ied. About 5  104 CFU/well were inoculated onto 96 multi-well
plates containing Mueller–Hinton broth (MHB) serial dilutions of
IMP and MER. Isolates were serially transferred. Number of trans-
fers in sub-MIC concentration until emergence of resistance was
determined. MICs were determined according to NCCLS guide-
lines. OMPs mapped on SDS-PAGE.
Results: Each of the selected isolates had distinct PFGE pattern.
All had MIC <2 for ciproﬂoxacin, two were resistant to ceftazi-
dime (CTZ). The MIC50 for IMP was 2 (range 1–4) and for MER 1
Anitbiotic
Period A
(183 isolates) R %
Period B
(174 isoloates) R% P
Piperacillin/
tazobactam
(79) 43.2% (67) 38.5% NS
Gentamycin (95) 51.9% (85) 48.8% NS
Ciproﬂoxacin (103) 56.3% (74) 42.5% .013
Imipenem (105) 57.4% (87) 50.0% NS
Amikacin (61) 33.3% (32) 18.4% .002
Ceftazidime (72) 39.3% (68) 39.1% NS
Cefepime (68) 37.2% (51) 31.3% NS
Aztreonam (97) 53% (72) 46.4% NS
NS: not signiﬁcant
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(range 0.25–2). Emergence of resistance was detected after two to
eight passages and occurred at similar rate for both IMP and
MER (average 4.6 vs. 4.8 passages). In each isolate resistance to
both agents occurred at the same pace (up to one passage differ-
ence). At the time IMP resistance emerged, CTZ MICs did not
change in seven strains and increased two to ﬁve dilutions in
three strains. On emergence of MER resistance, CTZ MICs did not
change in ﬁve isolates and increased two to four dilutions for the
other ﬁve. Only one of these isolates became resistant to CTZ.
Over-2-dilution-increase in ciproﬂoxacin or tetracyclin MIC
occurred in one isolate at emergence of resistance to IMP and in
six at emergence to MER. OMPs and beta lactamases activity cor-
relates were determined.
Conclusions: We found similar pace of emergence of MER resist-
ance compared with IMP in PA, despite the lower MIC, and the
additional mechanism required for its development. The loss of
OprD by both agents and induction of efﬂux pumps by MER
were shown.
P1115 Risk factors for emergence of resistant Pseudomonas
aeruginosa to beta-lactams in intensive care units
B. Georges, M. Archambaud, E. Bonnet, S. Saivin, J. Conil,
P. Cougot, T. Seguin, C. Virenque
Toulouse, F
Objectives: Emergence of P. aeruginosa resistance to antimicrobial
agents is usual in intensive care units (ICU) and could be correla-
ted with the use of some speciﬁc agents. We attempted to ﬁnd a
correlation between the use of various beta-lactams and the emer-
gence of speciﬁc mechanisms of resistance.
Methods: We performed an open prospective study for a 3-year
period including all patients for which P. aeruginosa was isolated
from one or more specimens: bronchial aspiration, blood cultures,
catheters, urinary cultures. Antibiotics we focused on were: am-
oxiclav, ticarcillin, piperacillin–tazobactam, cefotaxime, ceftazi-
dime, cefepim and imipenem. Mechanisms of resistance we
studied were: production of penicillinase or cephalosporinase,
non-enzymatic mechanisms and loss of porine OprD2. Khi-2 test
was used with a level of signiﬁcance of 0.05.
Results: 132 patients were included in the study. Eighty-two
strains emerged with mechanisms of resistance during antibiotic
treatment. When using multivariate analysis no correlation was
found between the use of amoxiclav, piperacillin–tazobactam, ce-
fepim and any of the mechanisms. The use of cefotaxime was
associated to the appearance of a non-enzymatic mechanism
(P ¼ 0.005). No correlation was found with the use of ceftazidime
but if resistance appeared during ceftazidime treatment, it was
due to secretion of cephalosporinase ( P ¼ 0.001). There was a sig-
niﬁcant relation between the use of imipenem and emergence of
resistance by loss of porine OprD2 (P ¼ 0.00001). Thirty-six strains
from nine patients, analysed with pulsed-ﬁeld gel electrophoresis,
show that for a same patient all the strains were genetically linked
together.
Conclusion: Our results show a high risk of selection of non enzy-
matic resistance by cefotaxime and emergence of resistance during
treatment with imipenem.
P1116 Molecular genotyping of Pseudomonas aeruginosa
clinical isolates resistant to quinolones: detection of mutations
in the gyr genes
S. Ferreira, S. Mendo
Aveiro, P
Objectives: The aim of this study is to assess the diversity and ge-
nomic variability of quinolone resistant Pseudomonas aeruginosa
isolates from 35 patients from a ICU of a hospital from the central
part of Portugal. A second objective of the present study was to
examine the mutations in the quinolone resistance determining
regions (QRDR) of the gyrA, gyrB, parC and parE.
Methods: Bacterial isolates were identiﬁed using the VITEK Sys-
tem (Biomerieux). Their antibiotic resistance pattern was also ana-
lysed by MIC determination to several antimicrobial agents.
Quinolone resistant P. aeruginosa isolates were used for following
studies: The bacterial isolates were analysed by several molecular
typing methods namely, Rep, Box and ARDRA PCR, in order to
select those methods that will be reliable proof for epidemiologic
studies. Due to its discriminatory abilities pulsed ﬁeld electro-
phoresis (PFGE) and ribotyping techniques were also used. Single
cell conformation polymorphism technique (SSCP) complemented
with DNA sequencing (automated) were used in order to detect
the mutations in the gyr genes.
Results: The molecular techniques used for typing P. aeruginosa iso-
lates proved to be very useful. An attempt was made to compare
the patterns obtained by the different PCR based techniques as a
rapid tool with prognostic value for epidemic and nonepidemic
studies. PFGE proved to be the most powerful technique to achieve
this objective. Mutation detection SSCP analysis allowed us to sep-
arate the 35 isolates in various different groups that after DNA
sequencing proved to contain mutation in the QRDR region. In
codon 464 of the QRDR region a change of a Serine (TCC) to a tyro-
sine (TAC) was detected. Previously a mutation on the same codon
was described but instead of a tyrosine a phenylalanine (TTC) was
inserted. The mutation detected by us in our isolates was described
for Salmonella enterica, but not in P. aeruginosa. So far this seems to
be the ﬁrst time that this mutation is described in P. aeruginosa. Sev-
eral silent mutations were detected in the QRDR region that appar-
ently has no signiﬁcant value for quinolone resistance.
Discussion: PFGE, although a very tedious technique, proved to
be the most reliable and reproducible method to be used in epi-
demiologic studies. In the present study, by SSCP, some muta-
tions were detected in the gyrA and gyrB genes of Pseudomonas
strains. One of these mutations was not described so far and it
seems that it could be assigned as a mutation implied in the
quinolone resistance of the referred strain. WAVE DHPLC is a
ﬁner technique that is currently used for the detection of these
mutations, but this technique could not be used for the present
study. As the number of strains analysed was not excessive, we
decided to complement SSCP results with DNA sequencing of this
QRDR regions. Also, we are aware of the fact that quinolone
resistance can also be due to multidrug efﬂux pumps (MDR). Our
aim is to proceed with this study looking closer to other mecha-
nisms implied in quinolone resistance in P. aeruginosa.
P1117 In vitro effects of silicone oil on the growth and
adherence of Pseudomonas aeruginosa
S. Kirdar, M. Ucar, S. Ozden, Y. Dogan, H. Baskin, S. Kaynak,
I.H. Bahar
Izmir, TR
Objectives: Silicone oil has been used as an effective long term
tamponade in vitreoretinal surgery. Bacterial endophtalmitis may
occur in an eye after vitrectomy and silicone oil injection.
Although postsurgical endophtalmitis is rare; it is the most seri-
ous complication of vitreoretinal surgery. Pseudomonas aeruginosa
is one of the common causative agents of endophtalmitis. Bacter-
ial virulence reﬂects the ability of infecting microorganisms to
produce pathological effects in an invaded host. The aim of this
study is to investigate the in vitro effects of silicone oil on the
growth and adherence of P. aeruginosa.
Methods: P. aeruginosa ATCC 15442 strain was used in this study.
Cell suspensions of bacteria were prepared from overnight culture
on blood agar at 37 C. Following preparing the bacteria suspen-
sions, 1 mL of the bacteria suspensions (McFarland 1) were added
to 9 mL silicone oil. Distilled water (DW) was used as a negative
control and brain heart infusion broth (BHI) was used as a posit-
ive control. As examining that bacterial suspension formed a
vacuole in the silicone oil, inner and the outer parts of the vacuole
were investigated separately. The colony counts and number of
bacteria adhered to buccal epithelial cells (gram stained) were
determined daily, until no growth was seen in the sample taken
from silicone oil.
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Results: P. aeruginosa showed an apparent decrease in colony
counts following 1 day after inoculation in inner part of the vacu-
ole of silicone oil and were eliminated from the medium at the
14th day; in the outer part of the vacuole eliminated after the ﬁfth
day. Colony forming units of P. aeruginosa in the distilled water;
peaked at the third day and began to decrease at the 14th day,
but never eliminated through the 21st day like BHI broth. We
observed that silicone oil also inhibited the adherence to buccal
epithelial cells comparatively with BHI and DW.
Conclusion: Silicone oil, a retinal tamponading agent, has an anti-
microbial activity against P. aeruginosa; this effect may be correla-
ted with the exception of nutrients for the growth and the high
surface tension of silicone oil that destroys the cell wall character-
istics of microorganisms.
P1118 Susceptibilities of clinical Acinetobacter baumannii
and Stenotrophomonas maltophilia isolates to 14 antimicrobial
agents: results of the Antimicrobial Resistance Surveillance
Study of the Paul Ehrlich Society for Chemotherapy, 2001
M. Kresken, F. Allerberger, D. Hafner, H. Seifert on behalf of the
Working Group Antimicrobial Resistance of the Paul Ehrlich
Society for Chemotherapy
Objectives: S. maltophilia and A. baumannii are important pathogens
causing nosocomial infections, particularly in the compromised
host. Intrinsic resistance to many antibiotics coupled with acquired
resistance in both species represents a major clinical problem. The
objective of this study was to evaluate the in vitro susceptibilities of
contemporary clinical isolates to selected antibiotics.
Methods: In November 2001, a total of 158 isolates of A. baumannii
and 183 isolates of S. maltophilia were prospectively collected from
26 Clinical Microbiology Laboratories distributed throughout
three Central European countries (Austria, Germany, and Switzer-
land). Minimal inhibitory concentrations of antimicrobial agents
(belonging to seven different drug classes) were determined using
the broth microdilution procedure according to the standard of
the German DIN: piperacillin, piperacillin–tazobactam, cefepime,
ceftazidime, imipenem, meropenem, amikacin, gentamicin, tobra-
mycin, ciproﬂoxacin, levoﬂoxacin, moxiﬂoxacin, co-trimoxazole,
and doxycycline.
Results: One hundred and twenty-three and 173 isolates were col-
lected from patients in intensive care units (ICUs) and non-ICU
inpatient areas, respectively. The remainder were either from
outpatients or data were not available. Susceptibility patterns of
A. baumannii isolates showed the highest susceptibility to merope-
nem (97%) followed by imipenem (96%), doxycycline (91%), and
tobramycin (90%). Ciproﬂoxacin, cefepime, ceftazidime, piperacil-
lin and piperacillin–tazobactam were each active against <80% of
isolates. Eight (5.1%) strains were resistant towards antibiotics of
ﬁve or more drug classes. Levoﬂoxacin (87%), co-trimoxazole
(80%), and moxiﬂoxacin (79%) were the most active compounds
against S. maltophilia. The vast majority of isolates was resistant to
b-lactams and aminoglycosides. One-third of S. maltophilia isolates
displayed resistance towards ﬁve or more drug classes.
Conclusion: Carbapenems seem to be the most active antimicro-
bial agents against A. baumannii isolates recovered from patients
in hospitals located in Germany, Austria, and Switzerland.
S. maltophilia showed the highest susceptibility rates for levoﬂoxa-
cin and co-trimoxazole.
P1119 Resistance rates of Pseudomonas aeruginosa isolates
using The Surveillance Network (TSN) Database – Greece
G. Totos, C. Kleisiari, T. Konstantinidis, V. Gizaris, D. Soﬁanou
Athens, Thessalonica, Alexandroupolis, GR
Objectives: Pseudomonas aeruginosa (PA) isolates from nosocomial
infections are frequently resistant to many antimicrobial agents.
This study was designed to deﬁne the current incidence of antibi-
otic resistance of PA isolates to ceftazidime (CAZ) and ciproﬂoxa-
cin (CIP), two drugs used broadly as ﬁrst choice therapeutic
options in serious infections.
Methods: TSN was used to analyse the antimicrobial resistance
proﬁle of non-repeat PA isolated from patients of two tertiary care
Greek hospitals located at distinct areas during a period of 3 years
(January 2000 to December 2002). Susceptibility data from isolates
originating from patients on the intensive care unit (ICU) and
inpatients (non-ICU) were compared. All PA included in the
study were identiﬁed and tested for susceptibility using the
VITEK system (bioMerieux, France). Susceptibility data were
interpreted using NCCLS breakpoint criteria.
Results: During the 3-year time period data from 740 PA strains
from ICU patients and 949 strains from inpatients were reviewed.
Resistance rates for ICU to CAZ and CIP were 38.2 and 67.2%
respectively, while for inpatients 17.4 and 37.1%, respectively. For
both CAZ and CIP there was a statistically signiﬁcant difference
among ICU patients and inpatients (P < 0.001). For ICU patients
there was a signiﬁcant (P < 0.001) increasing annual trend of resis-
tance towards both CAZ (34.4–48.5%) and CIP (62.3–79.1%). For
inpatients a similar signiﬁcant (P < 0.01) annual trend of resis-
tance was observed for CAZ (13.5–23%), while for CIP there was
no signiﬁcant difference.
Conclusions: The high rates of antimicrobial resistance of PA to
CAZ and CIP indicate that the broad use of these drugs needs to
be revised and alternative therapies should be considered. Con-
tinuous surveillance studies in order to observe changes in resist-
ance which might effect therapeutic choices are necessary.
P1120 Integrons carried by Enterobacteria from avian
cloacal swabs harbour the same cassette arrays as isolates from
clinical human origin
F. Gionechetti, F. Gombac, C. Monti-Bragadin, C. Lagatolla,
E. Tonin, L. Dolzani
Trieste, I
Objectives: Gull populations have increased in many European
towns during the past years. The proximity of these birds, which
are able to nest on roofs and feed of urban waste, to human activit-
ies, together with their high power of dispersal, have risen the prob-
lem of their potential role in the dissemination of resistance genes.
As many resistance determinants are inserted into integrons, we
decided to investigate the frequency of integron carriage among En-
terobacteria isolated from gulls and to compare their cassette con-
tent with that of integrons from human clinical isolates.
Methods: Enterobacteria were isolated from Larus cachinnans
michahellis cloacal swabs and identiﬁed as E. coli (n ¼ 84), Proteus
sp. (n ¼ 89), Klebsiella sp. (n ¼ 18), Salmonella sp. (n ¼ 17), Citrob-
acter sp. (n ¼ 6) by conventional methods. Eighty epidemiological-
ly unrelated clinical isolates (46 Proteus sp. and 34 E. coli),
collected in the same period from the Trieste city hospital were
also analysed. All strains were screened for the presence of the
IntI1 gene by dot blot hybridisation of genomic DNAs. Positive
strains were further analysed by ampliﬁcation and characterisa-
tion of the integron variable regions. Selected E. coli strains of
human and avian origin were typed by PFGE analysis of XbaI
generated genomic DNA fragments.
Results: 25/214 (12%) avian enterobacterial isolates and 16/80
(20%) human clinical isolates carried the intI1 gene. Ampliﬁcation
and subsequent restriction analysis of the variable regions of class
1 integrons revealed the presence of 13 different integron types
among the avian isolates, some of which were carried by isolates
of different bacterial species and collected from different birds.
Three of these integron types were recovered also from human
clinical isolates. Nucleotide sequencing of the variable regions of
these integrons revealed the presence of the following cassette
arrays: InA: aadA1; InB: dhfrI, aadA; InC: dfr17, aadA5. Typing of
six E. coli strains carrying InC, four of which collected from human
blood specimens and two from birds, demonstrated no similarity
of PFGE patterns among human and avian strains.
Conclusion: Our study demonstrates that resistance determinants
carried by integrons are frequently present in avian strains. The
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same integrons are also associated to clinically relevant, genotypi-
cally distinguishable human strains, thus supporting the hypothe-
sis that integron carried resistance determinants are exchanged
between gulls and humans.
P1121 Study of an imipenem-resistant Klebsiella
pneumoniae cluster in a Greek hospital
S. Kanavaki, S. Karabela, H. Moraitou, P. Giakouppi,
G. Dimopoulos, M. Makarona, S. Avgeropoulou, A. Vatopoulos,
A. Rasidakis
Athens, GR
Objectives: Metallo-beta-lactamases (MBLs) producing bacteria
present a major nosocomial infection risk and increased cautious-
ness is required to limit their spread.
Methods: In ‘Sotiria’ Chest Diseases Hospital of Athens six
K. pneumoniae imipenem-resistant strains were isolated from
patients hospitalised in ICU, from June 2003 to August 2003. The
susceptibility phenotype was determined by the standard disk dif-
fusion method (Kirby-Bauer) and the MIC by the automated sys-
tem Vitek2 (Biomerieux, France). From the patients studied, four
of six originated from hospitals other than ours and all were hos-
pitalised in the ICU for separate reasons, but they all progres-
sively developed VAP. Regarding the site of isolation, four of six
strains were isolated from central venous catheters, two of six
from bronchial secretions and one of six from urine sample of a
patient who developed urine infection besides the VAP. The
patients were treated with wide range antimicrobial chemother-
apy, including third-generation cephalosporins, aminoglycosides
and quinolones, with a favourable outcome. The imipenem-resist-
ant K. pneumoniae strains were further investigated for MBL pro-
duction, by the imipenem + EDTA disk synergy test se well as
the MBL Etest with strips containing imipenem/imipe-
nem + EDTA (AB Biodisk, Sweden).
Results: Positive results were obtained for all six strains, by conven-
tional methods, indicating the MBL production. Molecular analysis
proved that all six imipenem-resistant K. pneumoniae strains carried
the blaVIM gene, while the ERIC-PCR revealed genotypic similarity
among them, as well as among imipenem-resistant K. pneumoniae
strains isolated in other hospitals in the capital of Athens.
Conclusion: The implementation of measures of increased caution
and care in our hospital resulted in no further isolation of
MBL-producing K. pneumoniae so far in the ICU.
P1122 Epidemiology of Enterobacter aerogenes in Belgium:
preliminary results of a multicentre survey
Y. De Gheldre, Y. Glupczynski, C. Berhin, M. Hallin, M. Struelens,
R. Boreux, P. De Mol, B. Jans on behalf of GDEPIH-GOSPIZ
Objectives: A national prospective study was conducted in 2003
to characterise the epidemiology of E. aerogenes (EA) clinical iso-
lates from patients in Belgian hospitals and to compare results
with data of a similar survey in 2000–2001.
Methods: Antimicrobial susceptibility [MICs of piperacillin-tazo-
bactam (PTZ), ceftazidime (CTZ), cefotaxime (CTX), cefepime
(FEP), imipenem (IMP), meropenem (MER), gentamicin (GEN),
amikacin (AMK) and ciproﬂoxacin (CIP) determined by the Etest
method] and ESBL production (detected using the ceftazidime/
clav and cefotaxime/clav Oxoid combination disks) were deter-
mined on strains collected from hospitalised patients (ﬁve con-
secutive non-duplicate EA strains for each centre) from January
to July 2003.
Results: 87 centres (regional distribution as follows: 42 from
Flanders, 30 from Wallonia and 15 from the Brussels area) sent
403 strains isolated from patients (mean age 69 years, range 1–98)
hospitalised mostly in medical (29%), intensive care (22%), long-
term care (16%) and surgical (13%) units. Strains mainly origin-
ated from urinary (39%) and respiratory (31%) tracts, wound
swabs (11%) and blood cultures (4%). Eighty-ﬁve per cent of the
strains were resistant to CIP, 78% to CTZ, 59% to PTZ, 18% to
CTX, less than 9% to aminoglycosides and 1% to FEP and carbap-
enems. ESBL production was detected in 58% of the strains; these
strains were more resistant to CTZ (100 vs. 47%; P < 0.001) and
CIP (99 vs. 66%; P < 0.001) than non-ESBL-producing strains. The
evolution of resistance rates between 2000–2001 and 2003 were
compared in the 42 hospitals which took part in both studies.
Strains were more frequently susceptible in 2003 to CTZ (23 vs.
14%; P ¼ 0.01), CTX (70 vs. 45%; P < 0.001), FEP (99 vs. 91%;
P < 0.001) and AMK (92 vs. 85%; P ¼ 0.04), probably because
strains showed a trend to be less frequently producers of ESBLs
than in 2000–2001 (54 vs. 61%, P ¼ 0.17).
Conclusions: These data conﬁrm that multi-resistant EA strains
are widespread in all care departments of Belgian hospitals but
that the increasing prevalence of ESBL-producing strains seen in
the past years appears to have more recently stabilised.
P1123 Antibiotic susceptibility in invasive E. coli isolates,
Belgium, 2002
E. Hendrickx, D. Pie´rard
Brussels, B
Objectives: To monitor reduced susceptibility (RS) in invasive
E. coli isolates in Belgium using validated antibiotic susceptibility
testing (AST) results from diagnostic laboratories.
Methods: In October 2001, 27 diagnostic laboratories started to
report AST results and extended spectrum beta-lactamase (ESBL)
production in each ﬁrst E. coli blood or cerebrospinal ﬂuid isolate
per patient per quarter, using their routine laboratory methods.
Suspected ESBL positive strains were sent to the National refer-
ence laboratory. Quality assessment (QA) of AST in 2002 was
done by sending two blinded E. coli strains of the European Anti-
microbial Resistance Surveillance System (EARSS) to 107 laborat-
ories. As deﬁned by EARSS, isolates lacking mandatory
information and duplicates within the same quarter were exclu-
ded. Statistical signiﬁcance was tested using chi-square.
Results: In 2002, 1185 E. coli strains from blood or cerebrospinal
ﬂuid were reported. The mean age of patients was 67 years
(range: 0–98) and 57% were female. RS was 48.5% for amoxicillin
or ampicillin, 6.0% for gentamicin or tobramycin, 3.1% for third
generation cephalosporins and 13.3% for ciproﬂoxacin or oﬂoxa-
cin. ESBL production was detected in 19 (1.9%) of 983 isolates tes-
ted. RS to three or four of antibiotic classes was observed in 5.7%
of the strains, while 47.7% were susceptible to all tested antibiot-
ics. Of the 93 Belgian laboratories returning results for both
blinded QA strains, 99% obtained correct identiﬁcation and 92%
correct AST results for all antibiotics included in the surveillance.
The national reference laboratory received 15 of the 19 isolates
suspected to be ESBL positive and conﬁrmed all 15 cases.
Conclusion: In comparison with EARSS results for neighbouring
countries, Belgium had a lower RS rate to aminopenicillins than
France (57%; P < 0.001), a higher RS rate to third-generation
cephalosporins than France, The Netherlands and Germany
(respectively, 2, 1 and 1%; P < 0.05) and a higher RS rate to ﬂuor-
oquinolones than France and The Netherlands (respectively, 9 and
6%; P < 0.05). Multiple drug resistance and ESBL production in
Belgium, although still relatively low, certainly warrant monitor-
ing because of a possible rapid increase through selection of
linked resistance and spread and evolution of ESBL genes.
P1124 Dynamics of ciproﬂoxacin-resistance for
Gram-negative bacilli isolated in urinary paediatric infections
R. Filip, E. Petraru, M. Cirlan, C. Dahorea, G. Coman
Iasi, RO
Objectives: To evaluate ciproﬂoxacin (CIP) resistance in urinary
paediatric pathogens for years 1999 and 2002; to compare the
results obtained.
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Methods: The study was conducted on 698 strains (1999: 349;
2002: 349) isolated from urine, in children hospitalised in the ‘Sf.
Maria’ paediatric hospital from Iasi, Romania, the largest paedi-
atric hospital in eastern Romania. Identiﬁcation was done by
classical methods, and susceptibility testing by disk diffusion
method (Bauer-Kirby) according to NCCLS criteria and con-
trols. Thirty-six strains were tested by Etest (AB Biodisk, Solna,
Sweden).
Results: In 1999, the resistance ratio was 9.16%, with Pseudomonas
aeruginosa (85.7%), Enterobacter cloacae (37.5%), Proteus mirabilis
(9.5%) and Escherichia coli (7.6%) on the ﬁrst places. For 2002, the
results were predictable, with an increase in resistance ratio to
14.8%, with the same pathogens as leaders: P. aeruginosa
(55.15%), E. cloacae (46.15%), K. pneumoniae (15.5%) and E. coli
(10.2%). Minimum inhibitory concentration determination proved
high level of resistance (>32 lg/mL) for 89.4% of strains.
Conclusion: This survey – performed on strains isolated from
urinary paediatric infections – shows an increase of resistance
ratio in 2002, 14.8% compared with 9.16% in 1999. This behaviour
is explained by the unrestricted use of CIP in therapy and some-
times in sequential schema for relapsing paediatric urinary tract
infections. The results are an advertisement for clinicians that
should reconsider the therapeutic option.
P1125 Antimicrobial resistance of Escherichia coli isolated
in bacteraemia during 2002: results from the Ile de France
Microbiologist Network
Y. Pe´an, M. Bingen, A. Boisivon, F. Faibis, M.-C. Demachy,
B. Ferre´, B. Hacquard, F. Richardin, A. Scanvic – Ile de France
Microbiologist Network
Objectives: To survey antimicrobial resistance in E. coli bacterae-
mia in order to review chemotherapy guidelines.
Methods: All bacteraemia from eight French non-teaching hospi-
tals around Paris were included. Community acquired (CA) or
hospital acquired (HA) bacteraemia was based on patient his-
tory; sources were investigated clinically and microbiologically:
urinary (U), gastrointestinal (GI), intravascular device (IVD), res-
piratory (R), surgical site (SS), foetomaternal (FM), others. Resist-
ance was deﬁned according to the recommendations of ‘Comite´
de l’antibiogramme de la Socie´te´ Franc¸aise de Microbiologie’ for
amoxicillin (AMX), AMX + clavulanate (AMC), cefotaxime (CTX),
gentamicin (GM), amikacin (AN), nalidixic acid (NAL), ciproﬂ-
oxacin (CIP). Resistance rates, deﬁned in accordance with ONER-
BA recommendations (www.onerba.org), were stratiﬁed by age,
wards, sources.
Results: 1731 bacteraemia occurred in 1661 patients, 615 (36%)
were E. coli bacteraemia (incidence: 0.75/1000 days of hospitalisa-
tion and 0.4/100 admissions) and 27% were HA bacteraemia.
More than 50% of E. coli was isolated in patients older than
60 years. Sources were: U ¼ 387 (63%), GI ¼ 97 (16%), R ¼ 15
(2.5%), FM ¼ 11 (1.8%), SS ¼ 10 (1.6%), IVD ¼ 5 (0.8%), oth-
ers ¼ 90. Resistance rates are presented in the following table:
Resistance of E. coli HA to betalactams or quinolones in surgery
was higher than in medecine (AMX: 64.9/55.1%, NAL:
25.8/17.4%, CIP:12.9/8.7%). A high rate of resistance to amino-
sides was observed among NAL R strains.
Conclusion: Yearly survey of severe infections like bacteraemia
allows to up date chemotherapy guidelines: third-generation
cephalosporins and gentamicin represent actually our basis of
ﬁrst-intention chemotherapy.
P1126 Colonisation of long-term-care facilities
residents with antimicrobial-resistant enterobacteriaceae
(EB) in Greece
K. Kanellakopoulou, V. Grammelis, A. Kapaskelis, D. Chalkiadaki,
I. Galani, K. Orlandou, M.K. Lazanas, H. Giamarellou
Athens, GR
Objectives: Interfacility transmission of antimicrobial-resistant (R)
pathogens has been well documented. Considering the increasing
frequency of isolation of EB-R in hospitals, a survey was per-
formed to determine the prevalence of LTCF residents colonised
with EB-R.
Methods: 18 LTCF were randomly selected from the public sani-
tation list of Attic province. Urine, nasopharyngeal and wound
samples were collected from 561 residents; from each LTCF, we
chose randomly 30% of the existing population (minimum sum
25 residents). MacConkey agar plates were inoculated and colon-
ies grown were identiﬁed by API strips (bio Mereux Vitek Inc)
and underwent antimicrobial disk susceptibility testing, follow-
ing the NCCLS guidelines. Conﬁrmation of ESBL-R was done by
MIC broth microdilution and double disk diffusion, as per
NCCLS.
Results: 295 EB were isolated from 1148 samples (34.8%). Resist-
ance to ampicillin (AMP), ampicillin–sulbactam (AM/SB), amino-
glycosides (AMS), ﬂuoroquinolones (FQ) and third-generation
cephalosporines (Chep3) was analysed. AMP and AM/SB resist-
ant rates were 67% (leading bacteria Proteus spp. 67% and Escheri-
chia coli 53%) and 39% (leading isolates Klebsiella spp. 59% and
Proteus spp. 46%), respectively. About 7.8% of the isolated EB
were Chep3-R (Proteus spp. 17.6%, Klebsiella spp. 7.3% and E. coli
4.8%). About 48% of them were producing ESBL (leading isolates
E. coli 50% and Klebsiella spp. 39%). About 62.5% of the ESBL
strains were FQ-resistant. From AMS-R isolates (R-rate 22%), we
distinguished the R-rates of Providencia stuartii (68%) and Proteus
spp. (24%). R to FQ estimated to be 16% (leading isolates Morga-
nella morganii 41% and E. coli 20%).
Conclusions: (1) Resistance among EB to Chep3, FQ and AMS in
Greek LTCF is worrisome. (2) The close relationship between
FQ-R and ESBL production is remarkable. (3) Resistance of E. coli
to FQ (20%) is relatively high and must be considered, especially
in case of urinary and respiratory infections.
P1127 Comparative evaluation of uropathogenic E. coli
resistance during a 5-year period
D. Gianneli, O. Zarkotou, P. Kanellopoulou, K. Tryﬁnopoulou,
C. Nikolopoulou, G. Chrysos
Piraeus, GR
Objectives: To study the antimicrobial resistance of uropathogen-
ic Escherichia coli strains (UPEC) among outpatients and inpa-
tients hospitalised in different departments, during a 5-year
period.
Methods: From 1998 to 2002 a total of 2983 E. coli strains were
studied. They were isolated from urine cultures obtained from
patients (adults and children) hospitalised or visited the outpa-
tients clinics with clinical manifestations of urinary tract infection.
The cultures were performed by conventional methods and the
identiﬁcation of E. coli was based on the API 20E system (Bio-
Merieux). The susceptibility testing was carried out by the disk
diffusion method (Kirby-Bauer) according to the current NCCLS
guidelines. The expression of ESBLs was detected by the double
disk synergy test in all strains isolated during 2002. The data ana-
lysis was based on WHONET software.
% E. coli resistance (R+I)
n AMX AMC CTX GM NAL CIP
CA 445 56.4 49.1 0.9 1.1 10.7 6.2
HA 170 62.9 53.3 1.8 4.2 19.8 10.8
U CA 310 61.6 50 0 0.3 8.4 4.8
U HA 77 68.6 59.7 0 7.8 22.1 14.3
GI CA 73 49.3 45.2 1.4 1.4 15.1 8.2
GI HA 24 62.5 54.2 4.2 4.2 25 8.3
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Results: The resistance rate (%) of 1998 and 2002 are presented in
the table below:
The incidence of resistance to gentamicin (GEN), cefotaxime
(CXT) and ceftazidime (CAZ) in 1998 and 2002 was as follows:
GEN 1.6%/3.3%, CXT 0%/5.2%, CAZ 0.4%/2.4%. The resist-
ance to imipenem and piperacillin/tazobactam was very limited
(<1 and <2%, respectively). No signiﬁcant increasing trends
were observed during the study period for all antibiotics tested
except from norﬂoxacin in hospitalised patients. During 2002,
3.8% of the strains isolated from hospitalised patients and 1.9%
of those recovered from paediatric patients were ESBL-
producing ones.
Conclusion: The resistance of UPEC is similar to those reported
by other hospitals in our country and seems to remain stable dur-
ing the last 5 years. The high incidence of resistant strains in pae-
diatric patients reﬂects the prescription habits. The updated local
surveillance data provide useful information for a successful
empiric therapy.
P1128 Prevalence and antibiotic resistance of the most
important urinary pathogens responsible for non-complicated
cystitis in women: the IceA 2 Study
A. Speciale, G. Nicoletti, R. Musumeci, G. Fadda, S. Caponera,
C. Archibusacci, A. Rossi, E.A. Debbia, A. Marchese, M. Tellarini,
G.C. Schito
Catania, Rome, Terni, Genoa, Milan, I
Objectives: This observational study has set the aim of providing
data both about the prevalence of the most important pathogens
responsible for non-complicated acute cystitis in women and
about resistance patterns to the most common antimicrobial
agents. A female population representative of the national distri-
bution with an evident pathology with related clinical and micro-
biological signs was evaluated.
Methods: Fifty researchers operating in Italy were chosen by the
European School of General Medicine and enrolled. A broth dilu-
tion method using sensititre plates was performed as susceptibil-
ity test.
Results: 522 outpatient women (age: 18–57; average age: 35.7)
with diagnosis of ﬁrst episode of non-complicated acute cystitis
were enlisted. Symptoms appeared between 24 and 48 h in
35.5%, 48–72 h in 27.1%, within 24 h in 26.7% of cases, in
10.7% symptoms duration was unknown. Bacteriuria was con-
sidered signiﬁcant when concentration of one isolate was
>105 CFU/mL. Two hundred and seventy-four specimens were
positive and were processed, according to standard bacterial
isolation and identiﬁcation methods and 247 microorganisms
were isolated. Escherichia coli (71.7%), Klebsiella pneumoniae
(8.9%), Proteus mirabilis (8.1%) were the most frequent isolated
uropathogens. The in vitro susceptibility of 169 E. coli, 22 K.
pneumoniae and 20 P. mirabilis was tested against ciproﬂoxacin,
levoﬂoxacin, norﬂoxacin, fosfomycin/trometamol (FOS), nitrofu-
rantoin (NIT), co-trimoxazole (SXT), amoxicillin/clavulanate
(AMC). Against all the ﬂuoroquinolones E. coli showed a sus-
ceptibility rate of 96.4%, P. mirabilis and K. pneumoniae of
100%. The susceptibility rates were 98.2, 70 and 77.3%, respect-
ively, for FOS and 92.3, 100 and 95.4%, respectively, for AMC.
SXT (82.4, 70 and 72.7%, respectively) and NIT (95.3% of sus-
ceptibility for E. coli and 59.1% for K. pneumoniae) showed good
activity only against E. coli.
Conclusion: This epidemiological study showed that in Italy the
aetiology of non-complicated acute cystitis (over of 50% of cases
showed signiﬁcant bacteriuria) is highly predictable and mostly
associated with E. coli, P. mirabilis and K. pneumoniae. Fluoroquino-
lones still represent a rational choice conﬁrmed by their microbio-
logical effectiveness against the predominant pathogens.
Ciproﬂoxacin retains excellent activity and is an appropriate
choice for empirical therapy of UTIs because of its low possibility
to create resistance, low rates of clinical failure and rapid symp-
tom relief.
P1129 The prevalence of antibiotic resistance of
Escherichia coli and Enterococci isolated from faeces of pigs in
communal farming areas of Maﬁkeng district (R.S.A.)
M.S. Moneoang, P.T. Mmolawa
Mmabatho, ZA
Aims and objectives: The aims of this study were to isolate Escheri-
chia coli and Enterococcus from faeces of pigs, to determine their
prevalence of antibiotic resistance and to check the presence or
absence of vancomycin resistant Enterococci.
Methods: A total of 100 faecal samples were collected using ster-
ile gloves directly from the rectum and put on sterile containers.
Bacterial isolation were achieved by culturing approximately 1 g
of faeces into 3 mL of nutrient broth and incubated for 24 h at
37 C. Subcultures were performed on Eosin methylene blue
agar and Enterococcus selective agar for E. coli and enterococci,
respectively, and incubated for 24 h at 37 C. Gram staining was
performed, then API 20E and API 20STREP employed for E. coli
and enterococci, respectively. Serological typing was performed
on all E. coli species. Antimicrobial susceptibility test was per-
formed on Mueller–Hinton Agar (Bauer et al., 1966) and blood
agar using different antibiotics for E. coli and Enterococcus,
respectively.
Results: Multiple antibiotic resistance was observed in most of the
E. coli isolates, with E. coli O26:B6 having the highest incidence at
53.1% as compared with E. coli O111:B4, E. coli O126:B16 strains
and other E. coli strains that did not react with any of the antisera
used at 50, 46.7 and 18.2%, respectively. Multiple antibiotic resist-
ance was also determined on Enterococcus species with E. faecium
having the highest incidence at 85.7% as compared with E. dur-
ans, E. avium and E. gallinarum at 69.2, 61.9 and 60.2%, respect-
ively. Despite the high incidence of antibiotic resistance, all
Enterococccus isolates were susceptible to amoxicillin and vanco-
mycin. The difference in the number and types of microorganisms
in the faeces among the treatment group were determined by
ANOVA and Duncan’s multiple range tests using Minitab Release
13.1 software. There were signiﬁcant differences among groups in
microorganism’s multiple antibiotic resistance, and resistance was
determined by Chi-square. A signiﬁcant value was determined at
P < 0.05.
Conclusion: This study showed that vancomycin resistant Entero-
cocci is not a problem in communally reared pigs, except for mul-
tiple antibiotic resistance.
Antibiotics
Ampicillin
Amox/
Clav
Cephalo-
thin
Cotrim-
oxazole
Norﬂoxa-
cin
Year 98 02 98 02 98 02 98 02 98 02
Internal Medicine
Dept. n ¼ 1431
39 39.6 8.4 4.5 9.9 14.9 25.8 4.5 11
Surgical Dept.
n ¼ 528
48.6 42.6 11.4 1.5 18.1 21.2 36.6 21.1 1.7 10.1
Out-patients
n ¼ 596
25.3 30.7 2 2.1 6.1 5.8 18.6 13 2.2 0
Children
n ¼ 428
43.8 44.6 3.7 2.9 6.1 5.8 25 14.3 1.5 1.1
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S. pneumoniae: resistance and epidemiology
P1130 Antimicrobial resistance with Streptococcus
pneumoniae in 2003 – results of the Multinational GRASP
Surveillance Program
K. Heilmann, S. Beekmann, S. Richter, J. Garcia-de Lovias,
G. Doern
Iowa City, USA; Valencia, E
Objectives: A multinational surveillance study, GRASP, was con-
ducted between November 2002 and April 2003 with the aim of
assessing rates of antimicrobial resistance among isolates of Strep-
tococcus pneumoniae (Spn) in 20 countries in Europe, Eastern Asia
and South Africa.
Methods: A total of 2487 isolates of Spn from patients with respir-
atory tract and systemic infections were characterised in a central
laboratory (UIHC). MICs were determined by broth microdilution
using methods described by the NCCLS. Specimen sources of iso-
lates were: sinus aspirates and middle ear ﬂuid, 27.6%; lower res-
piratory tract, 46.5%; blood cultures, 19.9%.
Results: Conspicuous differences were noted in the resistance
rates observed in various countries/regions for penicillin (2.4–
79.2%), erythromycin (4.0–66.1%), tetracycline (2.4–68.7%),
TMP–SMX (3.2–78.0%), chloramphenicol (0–22.2%) and ciproﬂ-
oxacin (0–7.0%). Countries/regions with consistently highest
resistance rates included France, Spain, Hungary, South Africa
and Hong Kong–Singapore; consistently lowest resistance rates
were noted in Sweden, the Netherlands, Germany, Switzerland
and the United Kingdom. The relative percentages of macrolide
resistant Spn expressing the efﬂux and MLSB phenotypes also
varied considerably by country/region. The efﬂux phenotype
was more common than the MLSB phenotype in Germany,
Switzerland and the United Kingdom; in Hong Kong and Sin-
gapore, the percentage of isolates with each phenotype was
essentially comparable; in all of the remaining countries/regions
surveyed, strains with the MLSB phenotype were conspicuously
more common than isolates with the efﬂux phenotype. Finally,
the prevalence of multiply drug resistant strains of Spn also
varied markedly by country/region. Generally, MDR Spn were
most common in areas characterised by highest overall resist-
ance rates.
Conclusion: Antibiotic resistance with Spn remains a signiﬁcant
problem worldwide, particularly in certain countries.
P1131 Detection of internationally spread multiresistant
Streptococcus pneumoniae clones in Germany using multi locus
sequence typing
B. Henrichfreise, S. Bagel, M. Kresken, K. Sherwood,
B. Wiedemann
Bonn, D
Objectives: Multiresistant S. pneumoniae (SP) strains have become
a global concern. In global spread of multiresistant SP only a few
clonal complexes are widely distributed. By international compar-
ison in Germany resistance in SP is low. The aim of our study
was to investigate whether in Germany, despite of low resistance
rates, internationally spread multiresistant SP clones occur in iso-
lates recovered from outpatients with RTIs.
Methods: We performed two multicentre studies in Germany in
the winter of 2000/2001. MICs were determined using the broth
microdilution procedure following NCCLS. Among others eryth-
romycin (ERY), penicillin (PEN), tetracycline (TET) and co-trim-
oxazole (SXT) were tested. Resistance to ERY and PEN was
examined by ermB and mefE duplex-PCR and pbp2b RFLP analy-
sis, respectively. Clonal identity was proven by PFGE. One isolate
per clone was analysed by MLST.
Results: Of the 595 SP included, 14.1, 27.6 and 8.1% were resist-
ant to ERY, TET and SXT, respectively. Eighteen per cent were
PEN intermediate. With 16 and 17 isolates two multiresistant
clones (I and II) dominated in ERY resistance. Clone I, resistant to
ERY, TET and SXT and intermediate to PEN, harboured ermB
and had unique pbp2b RFLP and PFGE patterns. At three centres
in Eastern Germany clone I was found. Clone II was resistant to
ERY, TET and SXT, susceptible to PEN, harboured ermB and had
a pbp2b RFLP pattern that was typical for PEN susceptible iso-
lates. Its PFGE pattern was unique and was found in two centres
in eastern Germany and one centre in southern Germany. The
MLST database proved that clones I and II were of international
importance. Clone I had sequence type (ST) 135 and was found
three times in Spain. Clone II, whose ST was 273, was detected
once in Greece, Iceland and Israel, three times in Portugal and
twice in Italy. Moreover, clone II, also designated Mediterranian
Clone, was related to the Spain-6B-2 clone.
Conclusion: Our results underline the strong impact of a few
widely spread multiresistant genetic complexes on resistance in
SP at local as well as at the global level. In consideration of this
phenomenon one should carefully choose options for the ther-
apy of pneumococcal infections to not select multiresistant SP
clones. In Germany, relatively low resistance may be due to the
eradication of – also internationally spread – multiresistant
clones by high dosed penicillins; however PEN susceptible but
ERY resistant strains may be selected by the increasing use of
macrolides.
P1132 Trend in antimicrobial susceptibility of
nasopharyngeal Streptococcus pneumoniae recovered from
Italian children: a 7-year study
R. Bandettini, L. Pescetto, C. Peri, A. Scaramuccia, M. Mentasti,
G. Manno
Genoa, I
Objective: Streptococcus pneumoniae (Sp) represents the major cause
of bacterial respiratory tract infections in children, with a world-
wide increase of its resistance to antimicrobial drugs. We retro-
spectively determined the trend of antibiotic susceptibility
patterns of SP strains recovered from children attending the Gas-
lini Children’s Hospital, Genoa, Italy, in a 7-year period.
Methods: Nasopharyngeal swabs were taken from a total of 2078
children (age 1 month to 14 years) from 1 January 1996 to 10
November 2003. Cultures and species identiﬁcations were carried
out by conventional methods. Antimicrobial susceptibility to peni-
cillin, ciproﬂoxacin, cotrimoxazole, chloramphenicol, tetracycline,
clindamycin and vancomycin were evaluated by NCCLS standard
methods. The erythromycin resistance phenotypes were deter-
mined by the double-disk test with erythromycin and clindamy-
cin. Rokitamycin susceptibility was also investigated in 2001–2002.
Results: A total of 469 paediatric patients (23%) were SP colo-
nised, isolation rate was higher in children aged between 2 and
5 years. Nasal swabs were signiﬁcantly (P < 0.001) more efﬁcient
than throat swabs in recovering SP (410 vs. 63 strains). The rate of
resistance to penicillin decreases, from 23% in 1996–1999 to 19%
in 2000–2003, the high level of resistance (MIC >2) decreases from
7.1 to 5.7%; on the contrary, the rate of macrolide-resistance rose
from 37% in 1996–1999 to 45% in 2000–2003, with 82% of isolates
showing the cMLSB phenotype. The rate of rokitamycin resistance
was 10.4% in 2001–2002. Particularly, 50% of penicillin resistance
strains had macrolide-resistance with cMLSB phenotype. The
resistance to cotrimoxazole was high in all the study periods
(14.8%).
Conclusions: Our data show: (i) stable rate of penicillin resistance
between 1996 and 2003 in our paediatric patients; (ii) worrisome
increase of macrolide resistance rate in our area with a prevalence
of cMLSB phenotype strains that could suggest a clonal spread of
Sp strains; *iii) a continuous surveillance of antibiotics resistance
in Sp in paediatric population is required.
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P1133 The International Circumpolar Surveillance System
for population-based surveillance of invasive pneumococcal
disease, 1999–2002
M. Bruce, T. Cottle, J. Butler, D. Parks, S. Deeks, T. Tam,
M. Lovgren, L. Jette, K. Kristinsson, G. Sigmundsdottir,
K. Brinklov Jensen, O. Lovoll, P. Nuorti, E. Herva, T. Hennessy,
A. Parkinson
Anchorage, USA; Ottawa, Edmonton, Quebec, CAN; Reykjavik, I
Background: The International Circumpolar Surveillance (ICS) Pro-
ject is a population-based surveillance network for invasive bac-
terial disease in the US Arctic (AK), Northern Canada (N Can),
Greenland (GN), Iceland (IC), Norway (Nor) and Finland (Fin).
Among circumpolar countries, the seven-valent conjugate vaccine
(pcv7) has been used for routine infant immunisation in AK since
2001 and in selected areas in N Can since 2002.
Methods: We deﬁned a case of invasive pneumococcal disease
(IPD) as illness in a surveillance area resident with isolation of
Streptococcus pneumoniae from a normally sterile site. We analysed
data on IPD from AK and N Can (January 1999 to December
2002), and from GN, IC, Nor, Fin (January 2000 to December
2002) to determine: (1) common clinical syndromes, (2) rates of
disease by country, (3) serotype distribution and (4) antimicrobial
susceptibility patterns.
Results: A total of 5283 cases of laboratory-conﬁrmed IPD were
reported from AK (449), N Can (165), GN (26), IC (142), Nor
(2643), and Fin (1858). Case–fatality ratios varied from 5.0 to
19.0%. Pneumonia (45%), septicaemia (27%), and meningitis (8%)
were the most common clinical presentations. Rates of IPD in abo-
riginals in AK and N Can were 43 and 45 cases per 100 000 per-
sons, respectively. Rates of IPD in children <2 years of age and
persons >2 years of age ranged from 39 to 154 and from 11 to 25
cases per 100 000 persons, respectively. Overall, 67% of isolates
from children <2 years of age were serotypes contained in pcv7.
In AK, the rate of IPD in children <2 with pcv7 serotypes declined
by 80% after routine vaccination; from 137 in 1999–2000 to 28.4 in
2001–2002 (P < 0.001); preliminary data from AK for 2003 indicate
a rate of 12.3. Rates of non-pcv7 serotypes in AK increased from
26.4 in 1999–2000 to 46.5 in 2001–2002 in children <2 years of age
(P ¼ 0.151). Overall, 89% of isolates from persons >2 years of age
were serotypes contained in the 23-valent polysaccharide vaccine.
The proportion of isolates fully resistant to penicillin varied by
country from <1% in Fin to 8% in AK.
Conclusions: Rates of IPD are high in aboriginals and children
<2 years of age residing in Arctic countries. After introduction of
pcv7 in AK, rates of disease in children <2 years of age with pcv7
serotypes rapidly declined; however, increasing rates of non-pcv7
serotypes are concerning and merit further surveillance. Contin-
ued surveillance is needed to determine the impact of pcv7 after
introduction into other circumpolar countries.
P1134 Trends in beta-lactam resistance in community-
acquired lower respiratory tract infection in the UK and Ireland
R. Reynolds, D. Felmingham – BSACWorking Party on Respiratory
Resistance Surveillance
Objective: To assess trends in beta-lactam resistance in pathogens
associated with community-acquired lower respiratory tract infec-
tion in the UK and Ireland.
Methods: 2799 Streptococcus pneumoniae and 3736 Haemophilus
inﬂuenzae from lower respiratory specimens were collected from a
total of 26 laboratories in the UK and Ireland over the four win-
ters from 1999–2000 to 2002–2003, excluding duplicates within
2 weeks, cystic ﬁbrosis and patients in hospital more than 48 h.
Isolates were centrally tested by BSAC agar dilution MIC method
and categorised by BSAC breakpoints. Linear trends in propor-
tions were assessed by a chi-squared test.
Results: Only two isolates (of S. pneumoniae) were resistant to
cefotaxime, both in Ireland, one in each of the ﬁrst 2 years. Rates
of resistance to amoxicillin (AMX), cefuroxime (CXM), ampicillin
(AMP) and amoxicillin/clavulanate (AMC), non-susceptibility to
penicillin (PEN), and beta-lactamase (B-LAC) production are
shown in the table. The only signiﬁcant trend in the UK was a
reduction in CXM resistance in H. inﬂuenzae. In Ireland, starting
from a higher baseline, there were signiﬁcant trends towards
reduced resistance in S. pneumoniae for PEN, AMX and CXM and
in H. inﬂuenzae for B-LAC and AMP. However, cautious interpret-
ation is required as the sample includes few centres in Ireland.
Conclusion: Beta-lactam resistance in community-acquired lower
respiratory S. pneumoniae and H. inﬂuenzae is no longer rising in
the UK and may be falling in Ireland.
P1135 Susceptibility of Streptococcus pneumoniae
respiratory isolates from adults in Spain (2001–2002)
M. Gobernado, C. Garcia-Rey, C. Garcia-de-la-Fuente, V. Ausina,
J. Ruiz, F. Marco, J. Garcia-de-Lomas, L. Aguilar for the Spanish
Surveillance Group for Respiratory Pathogens
Objectives: Surveillance of antibiotic resistance of S. pneumoniae is
a clear need mainly in countries with high resistance rates. Sus-
ceptibility results of pneumococci isolated from adults to com-
monly prescribed oral antibiotics in Spain are presented. The
impact of the new oral pharmacokinetically enhanced coamoxiclav
2000/125 mg formulation is also shown.
Methods: A prospective, multicentre (25 hospitals) antimicrobial
survey was carried out between November 2001 and October
2002. A total of 2348 consecutive S. pneumoniae isolates from
patients with community-acquired respiratory tract infections
were collected and sent to a central laboratory for further process-
ing. Susceptibility testing was performed by a semiautomated
microdilution method following NCCLS M100-S12 guidelines and
breakpoints against antibiotics commonly used, except for ciproﬂ-
oxacin (resistant if MIC greater than or equal to 4 mg/L). New
enhanced coamoxiclav 2000/125 mg allows for shifting to the
right one dilution the NCCLS breakpoints for coamoxiclav.
Results: MIC50/MIC90 (mg/L), and percentage of fully resistance
are given for each antibiotic: penicillin (less than or equal to 0.01/2;
1999–2000 2000–2001 2001–2002 2002–2003 P
S. pneumoniae,
UK, n
595 608 631 683
PEN %I+R 7.4 7.1 4.6 6.4 0.24
AMX %R 0.3 1.2 0.5 1.0 0.37
CXM %R 4.8 3.6 3.3 4.1 0.48
S. pneumoniae,
Ireland, n
66 59 68 89
PEN %I+R 41 42 37 25 0.02
AMX %R 9 3 4 0 0.01
CXM %R 38 34 25 21 0.01
H. Inﬂuenzae,
UK, n
863 861 822 830
B-LAC %
positive
14.0 15.4 16.1 16.4 0.16
AMP %R 14.5 15.6 16.7 16.1 0.27
AMC %R 7.6 3.8 5.2 5.2 0.08
CXM %R 18.8 16.7 17.4 13.4 0.01
H. Inﬂuenzae,
Ireland, n
73 97 94 96
B-LAC %
positive
22 19 12 7 <0.01
AMP %R 23 20 13 9 0.01
AMC %R 10 5 5 4 0.18
CXM %R 22 7 16 10 0.18
R resistant (MIC 	 2 mg/L). I intermediate (MIC 0.12–1 mg/L).
P value for test of linear trend.
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20.3%); coamoxiclav (0.03/2; 4.6%); cefaclor (1/greater than or
equal to 16; 35.5%); cefuroxime–axetil (less than or equal to 0.12/
8; 25.4%); erythromycin (0.06/greater than or equal to 64; 32.4%);
ciproﬂoxacin (1/2; 5.1%). Clarithromycin and azithromycin
behaved exactly like erythromycin. Augmentin Plus reduces the
high resistance to former coamoxiclav until only 0.4% (a 91.3%
reduction). By shifting the NCCLS breakpoints one dilution,
reduction of co-resistance with coamoxiclav 2000/125 is shown in
the Table.
Conclusions: (1) While erythromycin resistance remains above
30%, penicillin resistance seems to be decreasing (20.3%) with
respect to previous surveillances. (2) Erythromycin, clarithromy-
cin, azithromycin and cefaclor displayed the worst intrinsic activ-
ity and the highest resistance rates. (3) Coamoxiclav and penicillin
were the most active drug in terms of MIC50 and MIC90. Coam-
oxiclav presented the lowest prevalence of resistance. (4) The
potency of the new oral pharmacokinetically enhanced coamoxi-
clav 2000/125 mg formulation (with only a 0.4% of resistance)
means additionally the almost virtual disappearance of the prob-
lem of co-resistance in S. pneumoniae.
P1136 Serotypes and antimicrobial resistance of
Streptococcus pneumoniae: evolution (1989–2003) in Asturias,
Spain
A. Fleites, R. Trabazo, F. Pe´rez, L. Molinos, A. Moreno,
M. Hidalgo, J. Rodrı´guez and The Spanish Pneumococcal
Infection Study Network
Objectives: To assess the prevention and the treatment strategies
in pneumococcal disease, we have analysed the serogroups/seo-
types (SGTs) and the antibiotic resistance in our geographical area
during 1989–2003.
Methods: Invasive strains, from adult patients, were studied. The
serotyping was performed in the national reference centre. The
oxacillin disk and the broth microdilution method (NCCLS M100-
S13) were used. The distribution was determined during three
periods: I 1989–1993, II 1994–1999, III 2000–2003. The chi-square
test was used.
Results: 510 invasive isolates were identiﬁed (421 blood, 49 CSF,
40 others). The most frequent SGTs (%) were: 3 (19.6), 14 (10.5),
19 (7.8), 4 (7.8), 9 (7.6), 8 (6.6), 6 (6.4) and 23(4.5). The distribution
(%) in the periods I (n ¼ 192), II (n ¼ 139), III (n ¼ 179) was: SGT
3: 21.8, 18.7, 17.8; SGT 14: 8.8, 8.6, 13.9; SGT 19: 6.2, 7.1, 10.0; SGT
4: 5.2, 3.5, 13.9; SGT 9: 9.8, 10.7, 2.7; SGT 8: 4.6, 8.6, 7.2; SGT 6: 7.8,
6.4, 5.0 and SGT 23: 6.7, 4.3, 2.2. Relevant trends between periods
I, III were: SGT 4, 5.2 vs. 13.9% (P ¼ 0.003), SGT 9, 9.8 vs. 2.7%
(P ¼ 0.005) and SGT 23, 6.7 vs. 2.2% (P ¼ 0.036). The coverage of
the 23-valent vaccine for all SGTs was 96.2% and 95.6, 94.1, 98.3%
in periods I, II, III, respectively. The coverage for SGTs in the
elderly (more than 64 years) was 97.2%. The resistance to penicil-
lin was 30.3% (22.3% intermediate, 8.0% resistant); the evolution
was: 31.2, 33.8 and 26.8% (P ¼ 0.347). The trend in erythromycin
resistance was 5.7, 16.5 and 23.4%; the progressive increase was
very signiﬁcant among periods I and III (P < 0.0001). The preva-
lence of resistance (%) to tetracycline and chloramphenicol was
35.4, 25.1, 21.7 and 23.9, 16.5, 7.2, respectively.
Conclusions: There were no signiﬁcant changes in the SGTs’ dis-
tribution. The prevention with the 23-valent vaccine can be recom-
mended in this population. The resistance to penicillin remains
stable, by contrast the resistance to macrolide has increased dra-
matically. Continuous monitoring is mandatory.
P1137 Investigation of genetic relatedness among
penicillin-nonsusceptible pneumococci isolated in Turkey
M. Bicmen, Z. Gulay
Izmir, TR
Objective: To analyse the clonal relationship among penicillin-
nonsusceptible Streptococcus pneumoniae isolates recovered at dif-
ferent medical centres in Turkey by different methods.
Methods: The isolates consisted of 90 penicillin-nonsusceptible (10
high level resistant (PenR) and 80 low level resistant (PenI)) and
20 consecutive penicillin-susceptible S. pneumoniae which had
been isolated at seven different centres between November 1999
and January 2001. Clonal relationship between the isolates were
investigated by the analysis of restriction endonuclease patterns of
pbp (1a, 2b, 2x) genes (PBP-REA) and by BOX-PCR using the
BOX-A1R primer. Antibiotic susceptibility patterns and capsular
serotypes were also determined.
Results: 12, 8 and 15 different PBP-REA patterns were detected by
the analysis of pbp 1a, 2b and 2x, respectively. The combination of
these revealed a total of 55 REA patterns among the isolates. The
most common PBP-REA pattern (pattern 1/2/1) observed in peni-
cillin-nonsusceptible strains, was not detected among the suscept-
ible isolates. Likewise, the most common pattern of the susceptible
strains (pattern 2/4/5) was speciﬁc to only this group. When BOX-
PCR was used, 8, 62 and 18 different patterns were identiﬁed
among PenR, PenI and PenS isolates, respectively.
Conclusions: (i) PBP-REA patterns of the isolates were more lim-
ited when compared with BOX-PCR results which can be
explained by different speciﬁcities of the techniques, namely the
whole chromosome for BOX-PCR and speciﬁc pbp genes for REA.
(ii) Although discrepancies exist between different methods, a sig-
niﬁcant clonal relationship and spread was not detected among
penicillin-nonsusceptible pneumococci isolated in Turkey.
P1138 Selection of single step parC mutations among
levoﬂoxacin susceptible S. pneumoniae in Canada
R.J. Davidson, H. Musgrave, S. Campbell, C. Howley
Halifax, CAN
Objectives: The ﬂuoroquinolones were ﬁrst introduced into routine
clinical practice for the management of community acquired RTIs
in Canada during the late 1990s. Despite extensive penetration into
the community, ﬂuoroquinolone resistance in S. pneumoniae remains
low. However, in this study, we document the selection of ﬁrst step
parC mutations among levoﬂoxacin susceptible strains.
Methods: S. pneumoniae were collected from both respiratory tract
specimens and sterile sites from the Maritime region of Canada as
part of a regional surveillance programme. Isolates collected in 1999,
2002, and 2003 with MICs to levoﬂoxacin of 1 and 2 lg/mL were
analysed. MICs to levoﬂoxacin and moxiﬂoxacin were determined
using a microbroth dilution method. The QRDR regions of gyrA and
parC were ampliﬁed by PCR and their DNA sequence determined.
PFGEwas performed using SmaI and standardmethods.
Results: 50 isolates with an MIC to levoﬂoxacin of 1 lg/mL from
each year (150 strains), and 15, 28, and 34 isolates with an MIC to
levoﬂoxacin of 2 lg/mL, respectively, were selected for study.
The MIC90s to levoﬂoxacin and moxiﬂoxacin were 1 and 0.25 lg/
mL, respectively. In 1999, <2 and 6% of isolates with MICs of 1
and 2 lg/ml (levoﬂoxacin), respectively, harboured parC muta-
tions. In 2002, 6 and 14% of isolates with MICs of 1 and 2 lg/
mL, respectively, harboured parC mutations and in 2003, 6 and
48% of isolates with MICs of 1 and 2 lg/mL, respectively, har-
boured parC mutations. No evidence of clonal dissemination was
Among isolates
resistant to:
Full resistance (%) to:
Current coamoxiclav
NCCLS breakpoints
New PK/PD enhanced
coamoxiclav breakpoints
Penicillin 22.7% 1.9%
Cefaclor 13.0% 1.1%
Cefuroxime-axetil 17.8% 1.5%
Erythromycin 6.3% 0.9%
Ciproﬂoxacin 10.0% 0.8%
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observed among the isolates. Only one isolate was found to con-
tain a single step gyrA mutation.
Conclusions: Fluoroquinolone resistance among S. pneumoniae in
the Maritime region of Canada remains low, however, a signiﬁ-
cant increase in isolates containing a parC mutation has been
observed in the last 12 months. The selection of parC mutations is
may be related to the use of levoﬂoxacin to treat S. pneumoniae
infections. Conversely, use of the 8-methoxyﬂuoroquinolones such
as moxiﬂoxacin, that preferentially select for DNA gyrase muta-
tions, does not appear to be contributory as evidenced by the
isolation of only one strain with a single gyrA mutation.
P1139 Evolution of macrolide resistance in Streptococcus
pneumoniae in Italy
M. Monaco, R. Camilli, F. D’Ambrosio, M. Del Grosso, A. Pantosti
Rome, I
Objectives: In the past years, resistance of Streptococcus pneumoniae
to erythromycin and the other macrolides has increased in many
parts of the world, including Italy. The most important mecha-
nisms of macrolide resistance involve the erm(B) gene, conferring
resistance to macrolides, lincosamides and streptogramin B, and
the mef(A) gene, encoding a drug efﬂux pump. Our aim was the
study of the evolution of erythromycin resistance in S. pneumoniae
invasive isolates in Italy.
Methods: 934 isolates from blood or CSF collected from patients
in several Italian hospitals were studied: 503 from the period
1997/2000 and 431 from the period 2001/2003. Susceptibility tests
to antimicrobial agents were determined by Etest and Sensititre
panels. A PCR assay was performed to detect the presence of
erythromycin resistance determinants. By this assay the erm(B)
gene and the two subclasses of the mef(A) gene, mef(A) and
mef(E), could be recognised. Capsular serotyping was performed
in all strains using the Pneumotest panel.
Results: Out of 503 isolates from the period 1997/2000, 145 (29%)
were resistant to erythromycin; out of these, 106 (73%) carried
erm(B) and 39 (27%) carried mef(A); out of these, 6 (15%) carried
subclass mef(E). Out of 431 isolates from the period 2001/2003,
150 (35%) were resistant to erythromycin; out of these 89 (59%)
possessed erm(B), 57 (38%) possessed class mef(A), 3 isolates pos-
sessed both genes and one neither of these genes. Out of 57
mef(A) strains 9 (16%) carried subclass mef(E). In both periods
the most frequent serotypes of erythromycin resistant strains were
14, 19F and 6B. All subclass mef(A) strains, except two strains iso-
lated in 2001/2003, belonged to serotype 14, while subclass mef(E)
strains belonged to different serotypes (14, 9V, 11A, 6B).
Conclusions: In Italy, erythromycin resistance in S. pneumoniae has
been increasing steadily. The majority of the erythromycin resist-
ant isolates carry erm(B). However, the increase is mainly due to
the increase in the number of isolates carrying mef(A). Moreover,
in the more recent period we observed the appearance of strains
carrying both genes. The distribution of resistance genes and sero-
types suggest that the increase of macrolide resistance is due to a
combination of clonal expansion and horizontal transmission.
P1140 Evolution of levoﬂoxacin activity against
Streptococcus pneumoniae in France (1999–2002)
C.J. Soussy, H. Drugeon
Creteil, Nantes, F
Levoﬂoxacin (LVX) was the ﬁrst antipneumococcal ﬂuoroquino-
lone (FQ) available by parenteral and oral route introduced for
therapeutic use in France, at the end of 1999. Three follow-up sur-
veys of its in vitro activity against Streptococcus pneumoniae (SP)
have been initiated since this time, in France.
Methods: The ﬁrst survey (S1) was conducted during the respirat-
ory season 1999–2000 and was representative of the epidemiology
before the clinical use of LVX. The second (S2) was done during
the respiratory season 2000–2001, and the third (S3) during the
year 2002 corresponding to the status of LVX activity after 1 and
2 years of use, respectively. Thirty-ﬁve, 30 and 42 French metro-
politan hospital laboratories participated in the S1, S2 and S3 sur-
veys, respectively. In the three surveys, SP strains were isolated
from respiratory tract infections. LVX in vitro activity was deter-
mined by disc diffusion in S1 (with a good correlation with MICs
by agar dilution against a sample of strains) and by MIC deter-
mination in S2 and S3. All strains were isolated from adult
patients during S2 and S3 and 79% during S1. Quality control
was performed with SP ATCC 49619. Susceptibility rates were cal-
culated according to the recommendations of the Comite´ de l’An-
tibiogramme de la Socie´te´ Franc¸aise de Microbiologie.
Results: 477, 675 and 965 strains were, respectively, isolated dur-
ing the S1, S2 and S3 surveys. The rates of strains susceptible (S),
intermediate (I) and resistant (R) to LVX were the following: S1:
97.3% S, 1% I and 1.7% R; S2: 99% S, 0.1% I and 0.9% R; S3:
98.6% S, 0.1% I and 1.2% R.
Conclusions: LVX demonstrates a very good activity against SP with
less than 2% of resistant strains. LVX resistant strains were pre-
existing to the introduction of antipneumococcal FQs in France and
did not increased after introduction of LVX on the French market.
P1141 Trends of ceftriaxone resistance in Canadian strains
of Streptococcus pneumoniae
K. Wong, K. Green, S. Pong-Porter, T. Mazzulli, K. Weiss,
R.J. Davidson, D. Church, D.J. Hoban, P. Kibsey, M. Kuhn,
B. Toye, Y. Rzayev, A. Plevneshi, J. Powis, J. Fuller,
O. Vanderkooi, D.E. Low on behalf of the Canadian Bacterial
Surveillance Network
Objectives: In January 2002, NCCLS published new susceptibility
interpretive criteria for ceftriaxone for non-meningeal isolates of
S. pneumoniae (SP). Previous susceptibility interpretive breakpoints
were 
0.5/1/	2 lg/ml for S/I/R, respectively. The new interpret-
ive criteria for susceptibility in non-meningitis are 
1/2/	4 lg/ml
for S/I/R, respectively. The criteria for meningeal isolates remain
unchanged. We examine the trends of ceftriaxone resistance under
the new interpretive guideline for both groups of isolates.
Methods: In 1988 and from 1993 to present, 19 323 SP isolates
from 192 labs were submitted for susceptibility testing according
to NCCLS protocols. We analysed the activity of ceftriaxone
against 19109 strains of SP isolated from CSF and non-CSF speci-
mens applying the old interpretive breakpoint prior to January
2002 vs. the new breakpoint.
Results: Of the 19 109 isolates, 269 were from CSF, 18 840 were
from non-CSF specimens (6532 from respiratory specimens and
5218 from other sites). The percentage of resistance (R) and inter-
mediate (I) by year is shown in the following table.
Year
Penicillin Ceftriaxone
All Source CSF Non-CSF
Old
Guideline
New
Guideline
I R N I R N I R I R
2003 7.5 5.8 10 20.0 0 944 4.6 2.0 1.7 0.3
2002 8.5 6.7 32 6.3 0 2507 6.2 1.5 1.4 0.2
2001 7.7 6.8 28 10.7 3.6 2230 4.9 2.4 2.3 0.1
2000 6.7 5.9 44 6.8 2.3 2226 4.9 2.0 1.9 0.1
1999 7.6 5.9 20 10.0 5.0 2131 4.8 1.5 1.2 0.3
1998 9.2 5.6 17 11.8 0 1444 4.0 2.4 2.3 0.1
1997 6.9 6.5 19 5.3 0 1525 5.5 1.3 1.2 0.1
1996 8.0 4.1 32 0 3.1 1153 4.0 0.6 0.5 0.1
1995 6.6 2.2 30 0 0 1504 1.7 0.1 0.1 0
1994 6.8 1.3 29 0 0 2811 0.8 0.2 0.1 0
1993 4.7 0.9 2 0 0 210 0.5 0 0 0
1988 2.5 0 6 0 0 155 0 0 0 0
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Penicillin susceptibility is included for comparison.
Conclusions: Using the new interpretive criteria, we found that only
0.14% of all SP isolates were resistant to ceftriaxone. Resistance in
CSF isolates (1.5%) is higher than non-CSF isolates (0.12%). Because
the sample size of CSF isolates is very small, further study is
required to determine the signiﬁcance. Ceftriaxone resistance in
pneumococci rapidly increased until 1998 but has since remained
stable. This holds true for both groups of isolates interpreted under
both the old and the new criteria. Resistance to ceftriaxone is low
compared with other antibiotics including penicillin.
P1142 Isolation and resistance patterns of S. pneumoniae in
a 6-year period (1997–2003)
S. Kanavaki, S. Karabela, M. Makarona, H. Moraitou, S. Arbilia,
S. Triantaphyllou, A. Pefanis
Athens, GR
Objectives: The aim of the present study was to investigate the
resistance patterns of S. pneumoniae isolates consecutively collected
in the Microbiology Department of ‘Sotiria’ Chest Diseases Hospi-
tal of Athens, from 1993 to 2003.
Methods: In total, 282 clinical isolates were investigated. The sus-
ceptibility of S. pneumoniae was tested against penicillin, cefotaxi-
me, erythromycin, tetracyclin, trimethoprim/sulfamethoxazole
and ciproﬂoxacin. The standard disc diffusion method was per-
formed for all isolates, as described in the guidelines of the
National Committee for Clinical Laboratory Standards. The sus-
ceptibility for penicillin was detected with oxacillin 1 lg discs and
the MICs by the Etest method (AB Biodisk, Sweden). Concerning
the site of infection, 210/282 (74.5%) isolates were isolated from
sputum, while 72/282 (25.5%) from invasive infections, mostly
bacteraemia (>50%).
Results: From the total of 282 isolates, 52 (18.4%) were non-sus-
ceptible to penicillin. The MIC detection revealed that 37/52
(71.1%) were intermediate and 15/52 (28.9%) fully resistant to
penicillin (MICs 0.12–1.0 and >2, respectively), while 1/52 (1.9%)
was resistant to cefotaxime (MIC>2). Regarding the clinical
source, 41/52 (78.9%) of the PNSP strains were isolated from spu-
tum and 11/52 (21.2%) from invasive infections. From the total of
282 isolates, 86 (30.2%) were resistant to erythromycin. Regarding
the PNSP isolates, 34/52(65.3%) were erythromycin resistant,
while 52/230 (22.6%) of the penicillin sensitive isolates were
erythromycin resistant. In addition, 35/52 (67.3%) PNSP isolates
were multi-resistant, while 52/230 (22.6%) penicillin susceptible
isolates were multi-resistant.
Conclusion: Referring to a previous study of ours, for the period
1992–1993, it is demonstrated that both the PNSPs as well as the
erythromycin resistant isolates show an increasing incidence of
4.5 and 10.2%, respectively.
P1143 Macrolide and quinolone resistance mechanisms in
Streptococcus pneumoniae population from children in day-care
centres and orphanages in Asian Russia
K.M. Kosowska, R.S. Kozlov, L.S. Stratchounski, P.C. Appelbaum
Hershey, USA; Smolensk, RUS
Objective: Data on pneumococcal carrier rates in Asian Russia are
sparse. S. pneumoniae isolates (SPIs) were collected from children
<5 years in ﬁve cities of Asian Russia. The aim was to determine
distribution of macrolide and ﬂuoroquinolone resistance mechan-
isms and clonal relatedness in the S. pneumoniae population
among paediatric carriers.
Methods: A total of 866 SPIs isolated from nasopharyngeal swabs
of carriers in Asian Russia (Habarovsk, Vladivostok, Tyumen,
Novosibirsk and Yakutsk) were studied by microdilution MIC
(NCCLS). Macrolide resistance genes erm(B), and mef were tested
by PCR. Genes encoding L4, L22 and 23S rRNA in erm(B)/mef
negative strains and topoisomerase IV and DNA gyrase genes in
SPIs with raised ciproﬂoxacin MICs (all 4 lg/mL) were se-
quenced. PFGE analysis was done.
Results: Of 866 SPIs 55 (6.3%) had raised MICs: 40 to macrolides
and 15 to quinolones. Of 40 macrolide resistant SPIs four (10%)
were mef positive and 16 (40%) had erm(B). In 20 erm(B)/mef
negative SPIs seven had S20N change in L4 protein and three
strains possessed additional 69GTG71 to TPS substitution in L4;
16 (including four strains with alteration in L4) had a mutation in
L22 and 6 SPIs had additional nucleotide substitution in 23S
rRNA. The resistance mechanism for one strain is unknown. Of
15 SPIs with raised cipro MICs, 14 (93.3%) had changes in ParE:
I461V or A, V460A, A466D, A488D; three strains had additional
mutation in ParC (K137N) and 1 strain had a substitution in GyrA
(A149G). Macrolide resistant SPIs with erm(B) were associated
with three PFGE types (n ¼ 11) and ﬁve erm(B) strains as well as
all four mef strains, were unique. All strains with 69GTG71 to
TPS substitution in L4 shared one PFGE type (clones), but differ-
ent serotype (23 or 19). SPIs with raised cipro MICs were mostly
unique. Most common serotypes among resistant SPIs (n ¼ 72)
were 23 (n ¼ 26), 6 (n ¼ 20) and 19 (n ¼ 17). Remaining nine
strains had serotypes: 3, 9V, 12, 14 and 18.
Conclusions: Macrolide resistance mechanism in strains from
nasopharyngeal carriers in Asian Russia resulted mainly from
presence of erm(B) but also mef gene and mutations in ribosomal
proteins. Surprisingly 93.3% strains with raised cipro MICs had
one, double or triple change in ParE.
P1144 Serotype and antimicrobial susceptibility of
Streptococcus pneumoniae isolated in non-invasive disease in
Portugal
C. Pissarra, R. Dias, D. Louro, M. Canic¸a – GEMVSA
Lisbon, P
Objectives: Streptococcus pneumoniae is a leading cause of pneu-
monia and other respiratory tract infections. The aim of this study
was to evaluate the serotype-antimicrobial susceptibility of non-
invasive pneumococci isolated in Portugal.
Methods: We studied 445 non-invasive S. pneumoniae, with low or
high resistance to penicillin (MIC	0.1 mg/L), isolated from differ-
ent specimens in 16 Portuguese hospitals, and collected in the
Antibiotic Resistance Unit in National Institute of Health, between
1994 and 2000. MICs (mg/L) to eight antibiotics were determined
by agar dilution method (NCCLS). Serotype was performed by
Dot-Blot and Quellung reaction.
Results: 42% of penicillin resistant S. pneumoniae showed resist-
ance against cefotaxime (Ctx) and 35% against ceftriaxone (Ctr);
45, 23, 18, 31, and 2% were resistant against tetracycline (Tet),
erythromycin (Ery), chloramphenicol (Cm), clindamycin (Cli)
and oﬂoxacin, respectively. Serotypes 23F, 9V, 14, 15A, 19F, 6B,
6A (in descending order) represented 90% of the isolates caus-
ing non-invasive pneumococcal disease. Multidrug resistance
reached 43% of penicillin resistant strains. The prevalent multi-
drug resistant phenotype was Pen plus Ctx plus Ctr plus Tet
plus Cm (mainly from serotype 23F, 96%), followed by the phe-
notype Pen plus Ctx plus Ctr plus Ery plus Cli (mainly from
serotype 15A, 33%). Overall were detected 25 different multi-
drugresistant phenotypes. Penicillin resistant strains from sero-
type 23F diminished from 44 to 23% between 1994 and 2000, in
opposite to serotype 14 which increased from 6 to 33%, in the
same period.
Conclusions: In this study we showed that penicillin resistance
and multidrug resistance was mostly associated with non-invasive
S. pneumoniae strains of serotype 23F. Serotypes found among the
sample (15A, 5% and 6A, 3%) are not included in the pneumo-
coccal 7-valent conjugate vaccine. Our work highlights the import-
ance of monitoring the serotype and antimicrobial susceptibility
of isolates from patients with non-invasive pneumococcal disease
in Portugal.
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P1145 Antimicrobial susceptibility and serotype
distribution of invasive Streptococcus pneumoniae isolated in
Portuguese children under 5 years old (1999–2002)
R. Dias, D. Louro, M. Canic¸a – GEMVSA
Lisbon, P
Objectives: To establish a relationship between serotypes and anti-
microbial resistant patterns in Invasive Pneumococcal Disease
(IPD) in children under 5 years old in Portugal.
Methods: 151 consecutive isolates were collected in the Antibiotic
Resistance Unit in National Institute of Heath, from blood, CSF
and pleural liquid, between 1999 and 2002, in the scope of a mult-
icentre study with the participation of 16 hospitals; 55% of strains
were isolated in males and 45% in females. MICs to 10 antibiotics
were determined by agar dilution method (NCCLS). Serotype was
performed by Dot-Blot and Quellung reaction with antiserum
from Statens Serum Institute.
Results: MICs90 (mg/L) ranged as follows: 0.5–1.6 to penicillin,
0.25–1 to cefotaxime, 0.5–1 to ceftriaxone, 2–64 to tetracycline, 8–
32 to erythromycin, 32–64 to clindamycin, 4 to chloramphenicol, 2
to oﬂoxacin and 1–2 to ciproﬂoxacin. Serotypes 14, 1, 23F, 6B, 7F,
19F, 3, 9V (in descending order) represented 80% of the isolates
causing IPD in children. Serotype 14 was the most important in
children under 2 years old (34%) and serotype 19F was the most
important in the age group 3–5 years old (21%). Serotypes 14, 1,
6B and 7F were more frequent in blood then in CSF and serotypes
23F, 19F and 6A in CSF than in blood. The main serotypes of
penicillin resistant strains were: 14, 23F, 9V, 6B, 19A and 19F (in
descending order). Serotypes 14, 6B, 19F, 33F and 15C (in des-
cending order) were prevalent among erythromycin resistant
strains. Tetracycline resistant isolates were mainly from serotypes
6B, 19F, 14 and 33F (in descending order).
Conclusions: Our results suggest that the pneumococcal 7-valent
conjugate vaccine should protect against 95, 86, and 81% of peni-
cillin, tetracycline, erythromycin resistant strains, respectively, and
against 100% of cefotaxime and ceftriaxone resistant strains. This
vaccine cover 61% of IPD in the paediatric Portuguese population
under 5 years old and the vaccine serotypes plus vaccine-related
serotypes cover 69%. Monitoring of serotypes and antimicrobial
susceptibility is of high concern in Portugal in terms of Public
Health.
P1146 Results of multicentre study of antimicrobial
resistance of nasopharyngeal Streptococcus pneumoniae in
children from day-care centres and orphanages in Asian Russia
(SPARS-ASIA study)
R.S. Kozlov, P.C. Appelbaum, K. Kosowska, O.I. Kretchikova,
L.S. Stratchounski
Smolensk, RUS; Hershey, USA
Objectives: There are no prospective data on resistance to anti-
microbials amongst nasopharyngeal pneumococcal carriers in Asian
Russia. A single group of clinicians and microbiologists performed
sampling of children during 2001–2002, followed by isolation and
susceptibility testing of strains using a uniﬁed methodology.
Methods: Nasopharyngeal swabs were collected from 1669 chil-
dren <5 years from 40 day-care centres and orphanages in eight
cities of Asian Russia (Anadyr, Irkutsk, Khabarovsk, Khanty-Man-
siysk, Novosibirsk, Tyumen, Vladivostok, Yakutsk) with immedi-
ate plating on to 5% Columbia blood agar with 5 mg/L
gentamicin. Susceptibility testing to penicillin G (PEN), amoxicil-
lin (AMO), amoxicillin/clavulanate (AMC), cefotaxime (CTX), ery-
thromycin A (ERY), azithromycin (AZI), clarithromycin (CLA),
clindamycin (CLI), telithromycin (TEL), ciproﬂoxacin (CIP), levo-
ﬂoxacin (LEV), gemiﬂoxacin (GEM), tetracycline (TET) and co-tri-
moxazole (SXT) was performed by NCCLS microdilution.
Breakpoints were those of NCCLS except for TEL (equal or less
than 0.5; 1–2; >2 mg/L), CIP (equal or less than 2; 4; more or
equal to 8 mg/L), GEM (equal or less than 0.12; 0.25; more or
equal to 0.5 mg/L).
Results: A total of 912 S. pneumoniae were isolated, with carriage
rate varying from 11.1% to 86.7% between institutions. Suscepti-
bility testing results are presented in the Table.
Conclusions: (i) Pen I and Pen R were found in 15.4 and 1.0% of
strains, respectively. All but one strain were AMO-S and AMC-S;
(ii) Macrolide non-susceptibility occurred in 5.9–6.3% of strains
and all were S to TEL with low rates of increased quinolone
MICs; (iii) High rates of R to TET and SXT were detected.
P1147 Antimicrobial susceptibility of Streptococcus
pneumoniae isolated from adults with acute sinusitis in three
Russian centres
L. Stratchounski, A. Tarasov, R. Kozlov, I. Edelstein, A. Kryukov,
T. Alexanyan, A. Sedinkin, J. Yanov, D. Sergeev, O. Kretchikova,
M. Sukhorukova
Smolensk, Moscow, St. Petersburg, RUS
Objectives. The purpose of this study was to determine the
susceptibility of the S. pneumoniae causing acute sinusitis (AS) in
adults.
Methods. A total of 142 S. pneumoniae isolated from aspirates
obtained via maxillary sinus punctures in Smolensk (S), Moscow
(M) and St. Petersburg (SP) were studied. Susceptibility to penicil-
lin G, amoxicillin, amoxicillin/clavulanate, cefotaxime, cefepime,
erythromycin, azithromycin, clarithromycin, clindamycin, tetracyc-
line, levoﬂoxacin, moxiﬂoxacin, chloramphenicol and co-trimoxaz-
ole was determined by broth microdilution according to NCCLS
(2003) guidelines.
Results. The most active antimicrobials were amoxicillin, amoxi-
cillin/clavulanate, cefotaxime, cefepime, levoﬂoxacin and moxiﬂ-
oxacin to which no resistance was found. Intermediate resistance
to penicillin G was 4.2% (6.5, 4.3 and 1.8% in S, M and SP,
respectively). Proportion of non-susceptible strains to macrolides,
chloramphenicol and clindamycin was 1.4% (S, 0%; M, 4.3%; SP,
1.8%), 4.9% (S, 3.2%; M, 4.3%; SP, 7.0%) and 0.7% (S, 0%; M,
0%; SP, 1.8%), respectively. The highest percentage of non-sus-
ceptible isolates was found to tetracycline and co-trimoxazole –
28.2% (S, 30.6%; M, 30.4%; SP, 24.6%) and 41.6% (S, 35.4%; M,
30.4; SP, 52.7%), respectively.
Conclusion. S. pneumoniae retained their susceptibility to amino-
penicillins, III–IV generation cephalosporins and respiratory ﬂuor-
oquinolones. The highest non-susceptibility was found to
tetracycline and co-trimoxazole, substantially compromising possi-
bility of their usage for empiric therapy of AS.
Antimicrobial %I (n) %R (n)
MIC50
(mg/L)
MIC90
(mg/L)
MIC range
(mg/L)
PEN 15.4 (140) 1.0 (9) 0.06 0.25 0.008–4
AMO 0.1 (1) 0 0.03 0.125 0.03–4
AMC 0.1 (1) 0 0.03 0.125 0.03–4
CTX 0.3 (3) 0 0.016 0.125 0.008–2
ERY 0.2 (2) 5.7 (52) 0.03 0.06 0.016–128
AZI 0.6 (5) 5.6 (51) 0.06 0.125 0.03–128
CLA 0.6 (5) 5.7 (52) 0.03 0.06 0.016–128
CLI 0.2 (2) 2.5 (23) 0.03 0.06 0.016–128
TEL 0 0 0.016 0.03 0.002–0.5
CIP 2.1 (19) 0 1 2 0.125–4
LEV 0 0 0.5 1 0.125–2
GEM 0 0 0.016 0.06 0.016-0.125
TET 4.9 (45) 50.6 (461) 8 32 0.25–64
SXT 42.7 (389) 25.4 (232) 1 8 0.06–16
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P1148 Distribution of macrolide resistance mechanisms in
Streptococcus pneumoniae: 3-year update from the PROTEKT
study
D. Farrell, I. Morrissey – The PROTEKT Study Group
Objectives: PROTEKT — a global, longitudinal study of the anti-
microbial susceptibility of bacterial community-acquired respirat-
ory tract pathogens — has completed its third year (Year 1: 1999–
2000; Year 2: 2000–2001; Year 3: 2001–2002). This is an update on
the distribution pattern of macrolide resistance mechanisms
among S. pneumoniae.
Methods: Erythromycin nonsusceptible (intermediate and resist-
ant, MIC 	0.5 mg/L; ERY-I/R) S. pneumoniae isolates were tested
centrally for the presence of macrolide resistance genes [erm(B),
mef(A) and erm(A) subclass erm(TR)] using PCR.
Results: Genotyping data are available for 4818 ERY-I/R S. pneu-
moniae isolates (Year 1: 1084; Year 2: 1397; Year 3: 2337) collected
from 32 countries. As in previous years, erm(B) alone and mef(A)
alone were the most prevalent resistance mechanisms worldwide
in Year 3, accounting for 57.7 and 30.6% of ERY-I/R isolates tes-
ted, respectively. Over the 3 years, the erm(B) genotype predomin-
ated in many European countries, while mef(A) was particularly
prevalent in the UK, USA, Argentina, Peru and Austria. Overall,
10.1% of Year 3 ERY-I/R isolates contained both erm(B) and
mef(A), with the highest prevalence found in South Africa and
South Korea (occurring in 41.6% [131/315] and 37.0% [114/308] of
all ERY-I/R isolates, respectively). The overall proportion of iso-
lates with ribosomal mutations remained low worldwide (1.7, 1.5
and 1.4% in Years 1, 2 and 3, respectively), but accounted for 9.2%
(20/217) of all ERY-I/R isolates from Canada. Approximately half
of all ERY-I/R isolates were resistant to penicillin, with co-resist-
ance most common in isolates with dual macrolide resistance
mechanisms (89.7%). Susceptibility of macrolide-resistant isolates
to the ketolide antibacterial telithromycin remained unchanged
over the 3 years of investigation. Overall, telithromycin mode MIC
and MIC90 values were, respectively, 0.03 and 0.25 mg/L against
erm(B) strains, 0.06 and 0.25 mg/L against mef(A) strains and 0.5
and 0.5 mg/L against isolates with both erm(B) and mef(A).
Conclusions: Mechanisms of macrolide resistance continue to vary
worldwide; however, telithromycin retains high activity against
macrolide-resistant S. pneumoniae, irrespective of resistance mech-
anism.
P1149 Susceptibility of Streptococcus pneumoniae to
penicillin, azithromycin and telithromycin (PROTEKT
1999–2002)
G. Schito, D. Felmingham – The PROTEKT Study Group
Objectives: PROTEKT is a global, longitudinal surveillance
programme established in 1999 to study the antimicrobial suscep-
tibility of common bacterial pathogens associated with commu-
nity-acquired respiratory tract infections (RTIs). This analysis was
undertaken to determine the susceptibility of Streptococcus pneumo-
niae to penicillin, azithromycin and telithromycin and to assess
the prevalence of co-resistance between these antibiotics.
Methods: S. pneumoniae isolates have been collected from 32 coun-
tries as part of the PROTEKT programme over three consecutive
respiratory seasons (Year 1: 1999–2000; Year 2: 2000–2001; Year 3:
2001–2002). MICs for penicillin, azithromycin and telithromycin
were determined centrally by NCCLS broth microdilution meth-
ods and interpreted using NCCLS breakpoints.
Results: Data are available for a total of 14 011 isolates of S. pneumo-
niae collected between 1999 and 2002. Mode MIC, MIC90 and MIC
range were, respectively, 0.015, 2 and 
0.008 to >4 mg/L for peni-
cillin and 0.12, >64 and 
0.03 to >64 mg/L for azithromycin. In all,
13.6% of isolates were found to have intermediate susceptibility to
penicillin (PEN-I; MIC 0.12–1 mg/L) and 21.6% were penicillin
resistant (PEN-R; MIC 	2 mg/L). Similarly, 33.9% were resistant to
azithromycin (AZI-R; MIC 	2 mg/L), with 22.9% of isolates having
an azithromycin MIC of >64 mg/L. A total of 55.3% of PEN-I
isolates and 73.0% of PEN-R isolates were found to be co-resistant
to azithromycin, with 22.2% of AZI-R isolates having intermediate
susceptibility to penicillin and 46.5% being fully resistant. Telithro-
mycin was more potent than the other two antibacterials tested,
with a mode MIC of 0.008 mg/L, an MIC90 of 0.12 mg/L and an
MIC range of 
0.002–8 mg/L. Telithromycin retained high activity
against PEN-R and AZI-R isolates, with 99.7% of PEN-R isolates
and 99.8% of AZI-R isolates susceptible to telithromycin (MIC

1 mg/L) using tentative breakpoints as approved by the NCCLS
Antimicrobial Susceptibility Testing Subcommittee, January 2003.
Conclusions: Over one-third of all S. pneumoniae isolates collected
between 1999 and 2002 were found to have reduced susceptibility
to penicillin or azithromycin, with co-resistance to these antibacte-
rials apparent in the majority of cases. In contrast, telithromycin
was found to have potent antibacterial activity against this major
community-acquired RTI pathogen, with 	99.7% of PEN-R and
AZI-R strains retaining susceptibility to telithromycin.
P1150 Serotype distribution and antimicrobial resistance
of Streptococcus pneumoniae in Austria, 1996–2002: Implications
for vaccination strategies
A. Buxbaum, S. Forsthuber, W. Graninger, A. Georgopoulos –
Austrian Bacterial Surveillance Network
Streptococcus pneumoniae is a major cause of morbidity and mortal-
ity worldwide and the most common cause of severe diseases like
meningitis or community-acquired pneumonia. In this study a
total of 2367 strains of S. pneumoniae were collected in an Aus-
trian-wide surveillance system from 1996 to 2002. Isolates were
tested on their susceptibility to penicillin and clarithromycin and
serotyping was performed by the capsular swelling method. Over-
all, a rise in penicillin resistance from 4.9% in 1996 to 10.0% in
2002 (including both intermediate-resistant and resistant strains)
could be observed. Also, a distinct rise in macrolide resistance
was recorded in this period. The overall distribution of serotypes
remained relatively stable with serotypes 23, 19, 6 and 14 being
the most frequent ones. While in 1996 penicillin resistance was
predominantly associated with serotype 23F, in 1998 serotype 9
and in 2002 serotype 14, was most frequently found in these
resistant strains. Coverage rates for currently available vaccines
ranged from 57.4% (7-valent) to 72.4% (23-valent) of all serotyped
strains. This rise in pneumococcal resistance against penicillin and
the macrolides and the shift in serotype in these resistant strains
clearly warrant ongoing surveillance programmes in order to still
be able to formulate both effective vaccination strategies and opti-
mal antibiotic therapies in an era of ever-increasing resistance.
P1151 Tracking the activity of levoﬂoxacin and comparator
compounds against Streptococcus pneumoniae collected from
ﬁve European countries during 2001–2002 and 2003
R. Blosser, J. Karlowsky, D. Sahm, M. Jones
Herndon, USA
Background: Continued increases in the prevalence of antimicro-
bial resistance among S. pneumoniae that are observed in many
European countries demonstrate the importance of tracking resist-
ance on an ongoing basis. The GLOBAL Surveillance initiative
provides a unique perspective in the effort to track resistance
among respiratory pathogens, with particular focus on tracking
changes in the in vitro activity of levoﬂoxacin (LEV), the most
widely used respiratory ﬂuoroquinolone.
Methods: During 2001–2002 and 2003, 5835 (2001–2002: 3915;
2003: 1920) S. pneumoniae were isolated from patient specimens
collected at hospital laboratories in France (Fr), Germany (Ger),
Italy (It), Spain (Sp), and the United Kingdom (UK). Isolates were
centrally tested by broth microdilution against LEV, penicillin
(PEN), azithromycin (AZI), ceftriaxone (CTX), and trimethoprim-
sulfamethoxazole (TMP-SMX) (NCCLS, 2003). Susceptibility data
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were analysed according to different parameters, including patient
age and specimen source.
Results: During 2003, PEN R was 2.1% in Ger, 2.5% in the UK,
7.1% in It, 24.0% in Sp, and 31.9% in Fr. Fr showed the largest
increase (5.6%) in PEN R compared with 2001–2002 (26.3%).
AZI R was >20% in all countries except the UK (11.6%) with
the highest rates reported in Fr (58.0%). Overall, LEV R was rare
with an average of 0.98% and MIC90s ¼ 1 mg/L in all countries.
By age, LEV R was 
0.8% among isolates collected from
patients <18 years in all countries, 0–2.6% among isolates col-
lected from patients 18–64 years, and 0–3.1% among isolates col-
lection from patients 	65 years. No isolates collected from blood
specimens at laboratories in Fr, Ger, It, or the UK were LEV R;
2.2% of blood isolates in Sp were LEV R. Isolates collected from
upper and lower respiratory specimens showed similar rates of
LEV R with ranges of 0–1.1 and 0–2.6% in all countries, respect-
ively.
Conclusions: LEV continued to show potent activity against
S. pneumoniae despite increases in R to PEN and AZI. LEV was
the most potent oral agent tested against S. pneumoniae collected
from all age groups, including isolates collected from patients
	65 years. Continued monitoring of antimicrobial resistance pat-
terns is important to track changes in resistance, should they
occur.
P1152 Antibiotic sensitivity and serotypes of
S. pneumoniae isolates in blood culture during a 12-year period
in a community-based hospital in Madrid, Spain
M.D. Martı´n-Rodrigo, G. Sesen˜a, S.M. Quevedo-Soriano,
R. Jime´nez, Y. Gil, J.M. del A´lamo, A.C. Velasco, I. Wilhelmi
Legane´s, E
Objectives: To ﬁnd out the prevalence and seasonal distribution
of pneumococcal bacteraemia and the serotypes and antibiotic
sensitivity of isolates.
Material and methods: Retrospective study based on the records of
our Microbiology Department with a focus on serotypes and
MICs of pneumococcal strains isolated from adult and children
with bacteraemia. Serotyping was performed by a Quellung tech-
nique in the National Reference Center. Sensitivity tests were per-
formed by agar dilution following NCCLS criteria. Proportions
comparison was performed by squared chi test.
Results: The average number of pneumococcal isolates in blood
culture was 29/year which accounts for a 7% of all signiﬁcant
bacteraemias and a near 2/1000 admissions. A 62% of cases
occurred from December to May. A total of 70% of patients
were male. Age distribution was: 18.7% isolated from infants 0–
2 years; 10.3% from children 3–15 years; 45.7% from patients
16–65 years; and 25.3% from patients >66 years. Nine serotypes
(14, 19, 3, 6, 1, 8, 18, 9, and 4) account for near 75% of isolates.
A total of 82% of serotypes were isolated from children under
2 years. Similarly, 96% of serotypes from patients >65 years are
included in the polysacharide vaccine. The 33% of isolates
showed a reduced sensitivity to penicillin (22% intermediate
resistance and 11% resistant), 19% showed a reduced sensitivity
to cefotaxime (16% intermediate resistance and 3% resistant).
A 22% of isolates were resistant to erithromycin; 29% to tetra-
cycline; 17% to cloramfenicol. All isolates were susceptible to
vancomicine. Strains from children under 2 years were more
resistant to antimicrobials, being this difference os statistical
meaning (P < 0.05), standing out ﬁgures of 59% with reduced
sensitivity to penicillin, 38% with reduced sensitivity to cefotax-
ime, and 43% resistant to erithromicin. No statistical difference
was obtained between tetraciclina resistance proportion in the
different age groups (P ¼ 0.215).
Conclusions: In our environment, S. pneumoniae bacteraemia is
found mainly in adult males. We found a high prevalence of
strains with a certain degree of resistance to penicillin (33%),
highlighting a 59% of resistant isolates from infants. The majority
of serotypes from invasive infections are included in the current
available vaccines.
P1153 Antimicrobial resistance among community-
acquired respiratory tract infections in Brazil: PROTEKT 2002
C. Mendes, C. Kiffer, J. Sampaio, C. Oplustil, C. Zoccoli, C. Dias,
D. Farrell, D. Felmingham – PROTEKT Brazil Group
Objectives: Establish the susceptibility pattern of S. pneumoniae
and the beta-lactamase production of H. inﬂuenzae and M. catarrh-
alis isolated from patients with community-acquired respiratory
tract infections through an international surveillance study.
Methods: During 2002, six centres in Brazil collected bacterial iso-
lates from patients with one of the following infections: pneu-
monia, acute bacterial exacerbation of chronic bronchitis, acute
exacerbation of chronic obstructive airways disease, acute/chronic
sinusitis, pharyngitis, and acute otitis media. S. pneumoniae iso-
lates were tested against penicillin, amoxacillin, amoxacillin/cla-
vulanic acid, cefuroxime axetil, cefaclor, and azithromycin.
Minimal inhibitory concentrations (MIC) were determined by
broth microdilution in a central lab. Interpretative criteria used
were those described by NCCLS documents M100-S13. H. inﬂuen-
zae and M. catarrhalis isolates were tested for beta-lactamase pro-
duction by chromogenic cephalosporin method (Ceﬁnase[R]).
Results: There were 687 isolates as follows: S. pneumoniae (35%);
H. inﬂuenzae (31%); S. aureus (15%); S. pyogenes (12%); M. catarrh-
alis (7%). Among H. inﬂuenzae and M. catarrhalis 10 and 100%
were beta-lactamase producers, respectively. Among S. pneumoniae
67.6% were susceptible (S), 17.2% were intermediate resistant (I),
and 15.1% were fully resistant (R) to penicillin.
Conclusions: The production of beta-lactamase among M. cathar-
ralis and H. inﬂuenzae strains was similar to that found by other
local studies. The prevalence of penicillin resistant pneumococci
has increased dramatically compared with previous local data,
suggesting, among other factors, a possible methodological issues.
Empiric therapy with penicillins alone or in low dose should be
avoided in this population.
P1154 Study of invasive penicillin-resistant pneumococci
isolated in Romania between 2000 and 2003
M. Pana, M. Ghita, S. Iacob, O. Dorobat, R. Papagheorghe,
N. Popescu, G. Bancescu, M. Andrei, V. Ungureanu, I. Nistor,
S. Botea
Bucharest, RO
Objective: To study the antibiotic resistance in pneumococci isola-
ted in the past years in Romania.
Methods: 317 strains of Streptococcus pneumoniae coming from
blood (n ¼ 196) and CSF (n ¼ 121) were collected between Janu-
ary 2000 and March 2003 at the National reference Center for
Streptococcus. The isolates were tested for susceptibility (MICs) to
the following antibiotics: penicillin (Pc), erythromycin (Em), tetra-
cycline (Te), chloramphenicol (Cm), cephalothin (Kf), cefuroxim
(Cxm), cefotaxim (Ctx), amoxicillin (Amx), trimethoprim/sulfa-
methoxazole (Sxt), oﬂoxacin (Ofx), vancomycin (Va) by standard
dilution MIC testing.
Results: Breakpoints were used as proposed by NCCLS 2002.
During the study period penicillin-resistant strains of S. pneumoni-
ae were noted as follows: 40% in blood (25.9% low level and
14.1% high level) with MIC50 ¼ 0.12 mg/L, MIC90 ¼ 1 mg/L
and 12% in CSF (9% low level and 3% high level) with
MIC50 ¼ 0.06 mg/L and MIC90 ¼ 2 mg/L. The penicillin-resist-
ant strains coming from blood showed 100% susceptibility to
Amx and Ofx and resistance to the following antibiotics: Em
(27%), Kf (36%), Cxm (27%), Ctx (9) against penicillin-resistant
strains coming from CSF with following phenotypes: 100% sus-
ceptibility to Amx, Ofx, Ctx, Cxm, Cm and resistance to Em
(33%), Kf (33%). No resistant strain to Va was found.
Conclusions: The most efﬁcient drugs against penicillin-resistant
pneumococci were: Amx, Ofx and Ctx. These results from Roma-
nia also underline the previous observations regarding the higher
emerging rates of resistance in S. pneumoniae worldwide. In addi-
tion, the ﬁndings emphasise the importance of antimicrobial sur-
veillance programmes for guiding empirical therapy.
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P1155 Analysis of macrolide-resistant isolates of
Streptococcus pneumoniae gained from the Far East of Russia
A. Martynova, V. Turcutyuikov
Vladivostok, RUS
Background: Macrolide resistance has been reported to be high
among pneumococci in Asian countries, but the distribution of
these macrolide resistance determinants is not known. The inci-
dence of erythromycin-resistant strains among Streptococcus pneu-
moniae isolates in such a large territory as the Far East of Russia
was approximately 5% until the early 1990s, but nowadays eryth-
romycin-resistant strains have been greatly increasing.
Aims: To further deﬁne molecular mechanisms of macrolides
resistance in pneumococci strains at the territory of the Far East of
Russia.
Methods: MICs of penicillin, erythromycin, clarithromycin, and
clindamycin were determined by the agar dilution method. PCRs
were performed with appropriate primers.
Results: A total of 35.82% (48 of 134 strains) of the S. pneumoniae
strains were resistant to erythromycin with an MIC of 1.0 g/mL.
Of these, 31.25% (15 of 48) showed an MLSB phenotype with
erythromycin and clindamycin 50% MICs (MIC50s) and MIC90s
of 64 g/mL; 66.6% (32 of 48) showed resistance to erythromycin
alone (M phenotype), with a MIC50 and MIC90 of 8.0 g/mL. One
isolate was positive with both ermB and mefE primers. Of the iso-
lates expressing the MLSB phenotype, only the ermB gene was
detected in 86.63% (13 strains of 15) of the isolates by PCR. Two
isolates were repeatedly negative on testing for ermB but were
positive for ermA gene. All the isolates expressing the M pheno-
type were positive for the mefE gene by PCR. The majority of the
M-phenotype strains (84.37%, or 27 of 32) had constitutive resist-
ance (cML phenotype); only 15.625% of these strains had indu-
cible resistance (iML phenotype). Before 2000, it was recorded (5)
that among the erythromycin resistant S. pneumoniae isolates, the
majority (78%) had an ML phenotype and 22% had an M pheno-
type. All S. pneumoniae isolates exhibiting a cML or iML pheno-
type harboured the ermB gene.
Conclusion: This study indicated a high percentage of erythromy-
cin resistance among clinical isolates of S. pneumoniae in the Far
East of Russia. It requires a more careful approach to diagnostics
of macrolide resistance in pneumococci in the clinical microbio-
logy laboratory, particularly in areas with high rates of macrolide
resistance.
P1156 Impact of telithromycin vs. azithromycin on the
nasopharyngeal microﬂora of patients with respiratory tract
infections caused by pneumococci
J.P. Guggenbichler, G. Juhl, R.B. Nieman, E. Wahlund, C.E. Nord
Erlangen, Munich, D; Bridgewater, USA; Stockholm, S
Objectives: Telithromycin belongs to the family of ketolides repre-
senting a new class of antibiotics. Telithromycin possesses a tar-
geted spectrum of activity directed against pathogenic bacteria
involved in respiratory tract infections. The purpose of the present
study was to investigate the impact of telithromycin versus azith-
romycin on the nasopharyngeal microﬂora of patients with respir-
atory tract infections caused by pneumococci.
Methods: 227 patients from Germany with respiratory tract infec-
tions were enrolled in this prospective, assessor-blinded study
and were randomised to telithromycin 800 mg od (5 days for
upper respiratory tract infections, 7 days for pneumonia), or to
azithromycin 500 mg od for 3 days. Nasopharyngeal and oropha-
ryngeal cultures were taken from all patients before, during and
after antibiotic treatment, i.e. at weekly intervals up to 42 days.
The samples were cultured on different selective agar media and
the microorganisms identiﬁed. In 50 of the patients, the presence
of pneumococci was conﬁrmed. These pneumococci were sero-
typed and the sensitivity to telithromycin and azithromycin was
determined according to NCCLS. Additionally, clinical efﬁcacy
and safety was determined.
Results: Clinical cure was found in 95 of 113 patients treated with
telithromycin and in 77 of 114 patients treated with azithromycin.
Clinical failure occurred in eight patients (7%) in the telithromycin
group and in 15 patients (13%) in the azithromycin group. Pneumo-
cocci were re-isolated in 5 of 28 patients (18%) in the telithromycin
group and in 6 of 22 patients (27%) in the azithromycin group. The
following pneumococcal serotypes were found: 3, 4, 6, 9, 11, 14, 15,
19, 20 and 23. All (100%) pneumococci were sensitive to telithromy-
cin, MIC range 0.008–0.5 mg/L; 12% of the pneumococci were
resistant to azithromycin, MIC range 0.064–512 mg/L. A variety of
other microorganisms, i.e. staphylococci, streptococci, enterococci
and candida, were isolated. Both drugs were well tolerated.
Conclusions: The patients treated with telithromycin had a better
clinical response than the patients treated with azithromycin. The
isolated pneumococci were more susceptible to telithromycin than
to azithromycin. Furthermore, telithromycin appeared to have a
more favourable ecological and efﬁcacy proﬁle compared with
azithromycin in these patients with pneumococcal infections of
the respiratory tract.
Antibiotic therapy and public health issues
P1157 Process costs of intravenous antibiotic therapy for
community-acquired intra-abdominal infections
R. Andersson, G. Eckerwall, M. Nuijten, P. Engelfriet, S. Sen
Lund, S; Jisp, NL; Whitehouse Station, USA
Objective: A time and motion study was conducted in a large aca-
demic hospital in Lund, Sweden to assess the actual time and
supplies involved in the preparation, administration, and routine
monitoring of IV antibiotics to patients admitted to the hospital
with an IAI requiring IV antibiotic treatment and to estimate the
cost of the total process of preparing and intravenously adminis-
tering an antibiotic from the perspective of the hospital, separately
from the acquisition cost of the antibiotic.
Methods: Routine acts of preparing and administering cefuroxim
(Zinacef) by gravity-driven (piggyback) intermittent infusion, or
by bolus injection for treatment of community-acquired IAI were
observed and timed by a research nurse at the general surgical
ward of Lund University Hospital between September and
November of 2003. Also, materials consumed, other than the anti-
biotic, were recorded. Cost of administration was calculated based
on personnel time and materials consumed multiplied by respect-
ive salary and purchase price for different materials (expressed as
2003 SEK).
Results: A total of 60 observations were made, 31 for piggyback
administration while 29 for bolus IV administration. The average
overall time for each IV administration was 8.70 min (SD 2 min
29 s), which included review of chart/prescription (average
time  SD: 0.72  0.44 min), preparation of drug (3.27 
1.26 min), administration of drug (4.35  1.28 min) and disposal
of materials (0.36  0.17). The average overall time for prepar-
ation and administration of each piggyback IV administration was
8.99 min (SD ¼ 2.08) while that for bolus IV administration was
8.38 min (SD ¼ 2.13). The average overall cost of materials used
excluding cost of drugs in each administration was 23.57 SEK
(29.80 SEK for piggyback and 16.91 SEK for bolus), while average
overall labour cost was 35.25 SEK (36.44 SEK for piggyback and
33.97 SEK for bolus). Thus the average cost of each IV antibiotic
administration was estimated to be 58.82 SEK (SD ¼ 13.04) while
the acquisition cost of the study drug was SEK 74.80 for a 1.5 g
vial and SEK 34.40 for a 750 mg vial.
Conclusions: The cost of each intravenous antibiotic administra-
tion including personnel time and material cost involved in
administering and preparing the IV antibiotic approaches the cost
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of antibiotic. Simplifying drug regimens and methods of adminis-
tration may reduce these components and lead to considerable
cost savings.
P1158 Economic impact of S. pneumoniae macrolide
resistance in children with acute otitis media in ﬁve European
countries
M. Sikirica, R. Mera, M. Higashi, J. Davidson
Collegeville, USA; Greenford, UK
Objective: To estimate the economic impact of S. pneumoniae
(SPN) macrolide (MAC) resistance in children with AOM, in ﬁve
European countries using resistance rates (RR) from the Alexan-
der Network 2001 (AN); randomised clinical trial (RCT) data con-
taining: erythromycin-based RR, bacteriologic and clinical success
and failure rates; and published literature.
Methods: Medline and IPA were searched for country-speciﬁc
estimates of incidence and number of MAC prescriptions, for chil-
dren with AOM. Country-speciﬁc SPN MAC RR were obtained
using isolates from the AN. Data from the azithromycin arm of a
RCT was used to obtain the increased risk of bacteriologic failure
in SPN MAC-resistant strains by comparing patients with resist-
ant vs. susceptible isolates. Increased risk of clinical failure associ-
ated with bacteriologic failure was also obtained from the RCT.
Data 4.0 (TreeAge, Inc.) was used to create a decision tree, shown
below. Drug costs, based on average wholesale price, were
obtained from the Genesis and Europrice databases. Treatment
failure costs include new drug and one ofﬁce visit (MedTap Inter-
national Database of Unit Costs for Health Care 2001).
Results: In the RCT, children with SPN MAC resistant strains had
an increased risk of bacteriologic failure vs. MAC susceptible
strains, relative risk ¼ 4.11 (95% CI 1.76–9.63). France and Italy
had higher treatment failure costs per case, 16.35E and 9.56E,
respectively. Germany and the UK had lower RR and thus lower
treatment failure costs, 2.45E and 2.01E per case, respectively.
Remaining results are presented in the table below.
Conclusions: MAC resistance can lead to increased bacteriologic
and clinical failure rates. Countries with higher RR appear to have
higher failure costs if MACs are commonly prescribed. In terms
of economic costs, high failure rate may have signiﬁcant implica-
tions for health care payers.
P1159 Comparison of level of physician satisfaction with
ertapenem, piperacillin/tazobactam and ceftriaxone/
metronidazole for the treatment of community-acquired
intra-abdominal infections requiring surgery
A. De La Pena, N. Navarro, W. Asperger, P. Mavros, C. Chan,
M. Shivaprakash, S. Sen – OASIS Study Team
Objective: To compare the level of satisfaction with ertapenem
(ERT, a once-a-day parenteral group 1 carbapenem) to piperacil-
lin/tazobactam (P-T) and ceftriaxone/metronidazole (C-M) in the
treatment of IAI requiring surgical intervention.
Methods: In two open-label, multicentre trials (OASIS I and II), 802
adults with clinical and/or radiographic evidence of IAIwho required
surgery were randomised to ERT 1 g, P-T 13.5 g daily, or ceftriaxone
2 g daily (2 g IV/IM q24h or 1 g IV/IM q12h) and metronidazole
30 mg/kg daily (q6h, q8h or q12h, IV or oral) daily for 4–14 days. Phy-
sician’s satisfaction with over all therapy, number of times of adminis-
tration the study antibiotics, efﬁcacy of the study antibiotics, and
safety and tolerability proﬁle of the study antibiotics were rated at dis-
continuation of therapy visit on a seven-point scale where 1 indicates
very satisﬁed and 7 stands for very dissatisﬁed. One-way analysis of
variance between group designs was used to compare the mean satis-
faction with each of these three treatments. The null hypothesis was
that there were no differences between the three treatment groups
with respect to their mean scores of the satisfaction. When the null
was rejected, pair wise comparisons were made after adjusting for
multiple comparisons using Tukey’s HSD test.
Results: Baseline characteristics were comparable in all treatment
groups. The mean scores of physicians’ over all satisfaction with
therapy were 1.53, 2.04 and 1.76 for ERT, P-T and M-N, respect-
ively indicating signiﬁcantly higher level of overall satisfaction
with ERT (P < 0.05). Similarly mean scores of physicians’ satisfac-
tion with safety and tolerability, efﬁcacy proﬁle, and number of
times of administration of treatment were signiﬁcantly (P < 0.05)
lower for ERT as compared with P-T and C-M (see table) indicat-
ing higher level of satisfaction with ERT.
Conclusion: Physicians were signiﬁcantly more satisﬁed with
ertapenem as compared with piperacillin/tazobactam or ceftriax-
one/metronidazole in treating IAI patients requiring surgery. This
includes higher level of satisfaction with safety and tolerability,
efﬁcacy proﬁle, and number of times of administration of ertape-
nem and overall satisfaction with ertapenem.
P1160 Fixed-dose combination drugs for tuberculosis and
HIV/AIDS: what are the issues?
J. Primo-Carpenter
Rockville, USA
Objective: To determine issues of concern on the use of ﬁxed dose
combination (FDC) drugs for tuberculosis (TB) and human immu-
Country
AOM
Incidence
Rate
(106)
Percentage
of AOM Rx’s
for a MAC
Approximate
AOM Cases
using
MAC’s# (103)
AN RR
for
MACs
Total Estimated
Population Cost Cost of Resistance
(x106) 2003 Euros
Res. & Susc. No Resistance Difference
France 0.82 23.0%3 70.5 57.7% 3.45 2.30 1.15
Germany 1.22 48.1%2 220 11.4% 8.01 7.47 0.54
Italy 1.14 40.1%1 172 35.9% 5.11 3.47 1.64
Spain 0.57 10.1%4 21.5 26.4% 6.64 5.20 0.14
UK 1.11 12.9%5 53.5 11.1% 1.38 1.28 0.11
Miller et al. UK-based incidence rate
#Correction factor of 35% accounts for S.pneumono prevalence
1. Borgnolo G, et al.; 2. Schindler C, et al.; 3. Gulleimon D, et al.; 4. Solis G, et al.; 5. Molstad S, et al.
Satisfaction with
Mean satisfaction score
Ertapenem
(n ¼ 397)
Piperacillin/
Tazobactam
(n ¼ 188)
Ceftriaxone/
Metronidazole
(n ¼ 217)
Safety and tolerability 1.55 1.85 1.74
Efﬁcacy proﬁle 1.54 1.83 1.72
Number of times
of administration
1.32 2.82 2.23
Overall therapy 1.53 2.04 1.76
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nodeﬁciency virus/acquired immunodeﬁciency syndrome (HIV/
AIDS).
Methods: The United States Pharmacopeia (USP), a not-for-proﬁt,
non-governmental organisation, has been the standard setting
authority for pharmaceuticals in the US since 1820. Through its
Drug Quality and Information (DQI) program, USP conducted a
literature search and reviewed studies and reports published
between 2000 and 2003 on FDC drugs used in the treatment of TB
and HIV/AIDS.
Results: For anti-TB drugs, the bioavailability of rifampicin in sev-
eral marketed FDCs containing isoniazid and/or pyrazinamide
has been demonstrated to be inferior/variable, which could result
in therapy failure; it also contributes to the increasing resistance
to anti-TB drugs. FDCs available in strip-packed products were
more stable than blister-packed products which showed physical
and chemical changes; unpacked products showed a 60% decom-
position of rifampicin. Limited stocks of single-drug TB tablets
need to be kept for those experiencing adverse events with FDCs.
For HIV/AIDS drugs, some patients on FDCs may experience
side effects caused by one of the medicines in the combination
product; packaging the drugs in one tablet would limit the ﬂexi-
bility to switch patients to a different drug combination. The
International Federation of Pharmaceutical Manufacturers con-
tends that generic FDCs for HIV/AIDS have not been rigorously
tested which may encourage counterfeit drugs to enter the mar-
ket. Paediatric equivalents, especially crucial now that more pae-
diatric AIDS cases are being diagnosed due to increasing number
of mother-to-child transmission (MTCT) interventions being car-
ried out are seriously lacking.
Conclusions: There are a number of concerns with the use of
FDCs that need to be addressed. Quality assurance of FDCs for
TB is needed through bioavailability testing by manufacturers.
Packaging materials used for FDCs should be of the highest qual-
ity. Paediatric formulations, especially for FDCs used for HIV/
AIDS, should be developed. (Splitting FDC adult tablet is unac-
ceptable, but in the absence of alternatives, health care providers
in resource-limited settings are left with no choice.)
P1161 Association between inappropriate initial empiric
antibiotic therapy and outcomes among patients undergoing
surgery for community-acquired intra-abdominal infections in
Israel
A. Wertheimer, S. Sen
Philadelphia, Whitehouse Station, USA
Objective: To assess the association between inappropriate initial
empiric antibiotic therapy and the clinical outcome among
patients undergoing surgery for community-acquired intra-
abdominal infections (IAI) in Israel.
Methods: Records of patients who underwent surgery for commu-
nity-acquired IAI from January 2000 to June 2002 in hospitals in
Israel were reviewed. Initial empiric antibiotic therapy was classi-
ﬁed as inappropriate if at least one pathogen was resistant to all
antibiotics in initial regimen in case of positive culture or not
according to guidelines in case of negative/missing culture. Ther-
apy was classiﬁed as successful if IAI was resolved with initial
therapy or with decrease from initial therapy; as unsuccessful oth-
erwise. Logistic regression analyses were performed to assess
associations between inappropriate therapy and clinical outcome,
after adjusting for patients’ characteristics and site/type of infec-
tion.
Results: 279 patients were included. Mean (SD) age was
53.2 years (21.05) while 36.8% were female. Almost 87% of the
patients received appropriate initial empiric therapy, while 75.9%
of all patients’ initial empiric therapy was successful. Compared
with patients on appropriate therapy, patients on inappropriate
therapy were less likely to have IAI resolved with initial therapy
(45.9 vs. 80.2%, P < 0.0001). Multivariate logistic regression
showed that patient who received inappropriate initial empiric
therapy were almost four times less likely to have success in their
therapy (OR ¼ 3.6, 95%CI: 1.6–7.8).
Conclusion: Among patients undergoing surgery for community-
acquired IAI in Israel, inappropriate initial empiric antibiotic ther-
apy signiﬁcantly increases the likelihood of unsuccessful clinical
outcomes.
P1162 Social and ﬁnancial factors inﬂuencing rational use
of antibiotics in Peru
C. Kristiansson, M. Larsson, A. Thorson, E. Gotuzzo, L. Pachecco,
H. Rodriguez Ferrucci, M. Reilly, E. Carvallo, A. Bartoloni,
F. Bartalesi, M. Strohmeyer, A. Bechini, F. Paradisi, T. Falkenberg
Stockholm, S; Lima, Tarapoto, Iquitos, Yurimaguas, PE; Flor
Objective: To investigate social and ﬁnancial factors inﬂuencing
antibiotic use in households with children in an urban community
in the jungles of Peru.
Methods: Cross-sectional study including household interviews
and focus group discussions (FGD) in the urban community
Yurimaguas, Peru. Carers of 800 children aged 6–72 months
were interviewed on health seeking strategies (public/private
sectors; formal/informal providers) and antibiotic use (type,
number of days, cost, administration, expiry date, etc.) in rela-
tion to reported symptoms and socio-economic status. 15 FGDs
(6–8 participants/group) were performed with health workers
and caregivers, including mothers, fathers and grandmothers
(topics discussed include concepts and utilisation of pharmaceu-
ticals and traditional medicine, gender and opinions on antibiot-
ics and health services).
Results: 36% of the children with symptoms reported use of
antibiotics within 2 weeks, most frequently for acute respiratory
infections (ARI) and diarrhoea-like syndromes. Many children
obtain health care and medicines free of charge, due to the new
public health insurance. Self-medication with antibiotics for chil-
dren is low. Use of traditional medicine is frequent. Doubts
about quality of ‘insurance-antibiotics’ and lack of information
on proper use of antibiotics contribute to problems with compli-
ance. Health seeking behaviour and antibiotic use vary with
socio-economic status. Different types of irrational use of antibi-
otics are found to be linked with different socio-economic
groups of the society.
Conclusions: The new public health insurance has increased
access to health care for children. Interventions are recommended
to address health care providers and include providers–patient
dialogue addressing topics related to rational use of antibiotics.
Community interventions should promote antibiotic compliance
and home management of symptoms including appropriate use of
traditional medicine. Interventions acknowledging the different
types of irrational use of antibiotics among different societal
groups will be more prone to succeed.
Acknowledgements: EC-INCO DEV for RTD projects, 5th frame-
work programme of the European Community for research. Con-
tract number: ICA4-CT-2001-10014.
P1163 Antibiotic consumption trends in the case of fever
with unknown aetiology in the Turkish community
N. Yapar, H. Tarakci, A. Sener, B. Karaca, O. Eren, A. Yuce
Izmir, TR
Objectives: Appropriate antibiotic consumption deﬁned as right
diagnosis, clinically maximum impact for treatment, minimum
side effect, prevention of antibiotic resistance and cost-effective-
ness. Antibiotic consumption principles are same with other
drugs. Bacterial resistance develops because of inappropriate con-
sumption of antibiotics and affects not only the patients’ but also
the community’s health. Multi-drug resistance results in unsuc-
cessful treatment of bacterial infections and because of these
resistant species are widespread, selective resistance rates increa-
ses throughout the world. The community should be informed
about the appropriate antibiotic consumption.
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Methods: Dokuz Eylul University Hospital is a 720-bed tertiary
care hospital. From January 2000 to June 2003, 850 patients were
hospitalised in Infectious Disease Clinic. Of them, 79 had no
symptoms except fever. Patients who presented with only fever
were questioned for antibiotic use, antibiotic choice, dosage, dos-
ing interval, and duration of therapy.
Results: Out of 79 patients, 46 were male (58.2%) and 33 were
female (41.8%). Age interval was between 18 and 93. Of the
patients 38 (48.1%) have taken no antibiotics, 41(51.9%) have used
at least one antibiotic before hospitalisation. Of 41 patients, 22 of
them had one drug, 8 had 2 drugs, and 2 had 4 drugs. Amoxicil-
lin-clavulanate and levoﬂoxacin were the most common antibiot-
ics used. According to ﬁnal diagnosis of patients who used
antibiotics before the admission, 32 (78.1%) of them had no indi-
cation for antibiotic use while the others (9–21.9%) had bacterial
infections and necessity of antibiotic usage. Of the 9 patients who
had indication for antibiotic therapy, 4 patients have taken inap-
propriate therapy. Of 38 patients who came up to hospital with-
out having any therapy, 15 (39.5%) had antibiotherapy indication
and treated with appropriate drugs. Of 38 patients 23 (60.5%)had
no diagnosis of infectious aetiology. It was also observed that
most of the patients having antimicrobial therapy have not used
drugs appropriately according to dosage, dosing interval and
therapy period.
Conclusions: In our study we concluded that inappropriate and
unnecessarily usage of antibiotics is common in our community.
In order to prevent this problem, community and healthcare
workers have to be informed about antibiotics policy pro-
grammes.
P1164 Analysis of urgency and effectiveness of
post-graduate distance education on antimicrobial therapy
in Russia
I. Andreeva, V. Rafalski, O. Stetsiouk, B. Makushkin, A. Andreev,
V. Kostin, G. Reschedko, L. Stratchounski
Smolensk, RUS
Objectives: (1) To assess the urgency of development of post-
graduate distance education (DE) programme on antimicrobial
therapy (AT) in Russia. (2) To evaluate effectiveness of DE course
upon changes of ‘students’ level of knowledge after completion of
DE course in comparison with baseline.
Methods: First Internet centre of DE in Russia was founded under
the auspices of the Institute of Antimicrobial Chemotherapy, the
Department of Clinical Pharmacology of Smolensk State Medical
Academy with the support of the United States Pharmacopeia
and the United States Agency for International Development.
Web-site for medical professionals ‘Antibiotics and Antimicrobial
Therapy’ (http://www.antibiotic.ru) serves as the basis for this
DE Internet centre. To assess the urgency of DE for physicians the
on-line survey was performed on www.antibiotic.ru. To evaluate
the effectiveness of DE course the comparison of baseline level of
knowledge in AT and the ﬁnal test (after completion of the DE
course) results of ‘students’ was done.
Results: 491 of www.antibiotic.ru visitors took part in the on-line
survey ‘Urgency of DE (via Internet) for physicians’. 309 respond-
ents (63%) answered ‘Yes, deﬁnitely!’, 57 (11.6%) – ‘Yes, prob-
ably’, 48 (9.8%) – ‘Doubtfully, Internet access is not available for
everyone’, 67 (13.7%) – ‘No, physicians are not ready to learn via
Internet’ and 10 (2%) – ‘I don’t know, I am not a physician’. Since
the implementation of the project, 87 doctors from 12 Russian
regions have been trained using DE technology. Analysis of the
DE results revealed the obvious increase in the number of the cor-
rect answers given by physicians in their preliminary test (62.6%)
and the ﬁnal exam (88.7% of correct answers), conﬁrming the
effectiveness of the DE. After passing the ﬁnal examination all
physicians received the ofﬁcial state certiﬁcate conﬁrming the
improvement of knowledge in the ﬁeld of AT.
Conclusions: (1) DE via Internet is a demanded form of
post-graduate professional education among physicians in the
ﬁeld of AT in Russia. (2) DE is an effective form of professional
level increase in AT.
P1165 Impact of an antibiotic policy in a community
hospital
E. Espejo, A. Baste´, R. Busquets, M.A. Morera, E. Anoro, F. Bella
Terrassa, E
Objective: To evaluate the impact of an antibiotic policy on the
antibiotic usage and costs.
Methods: In March 1999 an antibiotic policy was implemented in
a 320-bed community hospital. The main strategies used were: (1)
Constitution of an antibiotic committee (two pharmacists, two
infectious diseases physicians [IDP], and a microbiologist). (2)
Elaboration of a guide to empiric antimicrobial therapy for the
prevalent community-acquired infections, after consensus meet-
ings with the concerned services. (3) Elaboration of a controlled
antibiotics list. (4) No prescribing restrictions. (5) Daily revision
by an IDP of the controlled antibiotics prescribed in the hospital,
and personal discussion with the prescribing doctor when
deemed appropriate. The average time devoted to the programme
by the IDP was 10 h weekly. During the 1998–2002 period, the
annual antibiotic consumption was recorded by the pharmacy.
The data are expressed as deﬁned daily doses (DDD) per 100 bed
days. The annual antibiotic costs were also calculated.
Results: From 1998 to 2002 there was an increase in the use of
amoxicillin (+3.03 DDD/100), amoxicillin/clavulanate (+31.24
DDD/100), 1st generation cephalosporins (+1.79 DDD/100), peni-
cillin (+0.52 DDD/100), carbapenems (+0.43 DDD/100), and
quinolones (+2,53 DDD/100), and a decrease in the use of 2nd
generation cephalosporins (11.62 DDD/100), macrolides (2.69
DDD/100), 3rd and 4th generation cephalosporins (2.25 DDD/
100), and aminoglycosides (0.55 DDD/100). There was no signi-
ﬁcant modiﬁcation in the use of glycopeptides (+0.07 DDD/100)
or piperacillin/tazobactam (0.17 DDD/100). From 1998 to 2002,
the overall expenditures for antibacterial agents decreased every
year, reaching a 26.5% reduction in 2002, in spite of a 13.5%
increase in the total bed days during the 5-year period.
Conclusions: The implementation of an antibiotic policy results in
a signiﬁcant change in the antibiotics usage. The overall expendi-
tures for antibacterial agents decreased by 26.5% in a 5-year per-
iod.
P1166 Costs of MRSA infection in a department of
physical medicine and rehabilitation
R. Boehmer, U. Wilhelm, A. Reiners, K. Perkuhn, H. Blaufuss
Munich, D
Objectives: To determine the additional costs involved in dealing
with MRSA infection or colonisation in a department of physical
medicine and rehabilitation.
Methods: At a Munich academic teaching hospital with 1000 beds
and with an MRSA incidence of 13% (expressed as the percentage
of the total number of penicillin resistant Staphylococcus aureus :
n ¼ 1228 for 2003), the actual costs relating to MRSA infection per
patient were prospectively studied in the department of physical
medicine and rehabilitation. After patients had been identiﬁed
with MRSA infection in the 38-bed unit, the recommended proce-
dures (as stipulated by national and local recommendations) to
deal with MRSA were put into place. The procedures were pro-
spectively documented on check-lists each time upon entry into
the patient’s single isolation room for the duration of the patient
stay. This included amongst others time to put on or discard
gloves, masks as well as gowns, once daily ﬂoor disinfection by
the cleaning staff, time to relate the MRSA issue to family mem-
bers and friends, time to perform therapeutic measures (intraven-
ous vancomycin, linezolid, intranasal mupirocin), time to perform
diagnostic measures (nose, axilla and groin swabbing), time to
perform logistical measures and disinfection of used materials.
The time required for performing each procedure was deﬁned by
the infection control sister as an average of 10 timed procedures.
These were then expressed in monetary values ( ) relating to staff
– equipment – and other costs. Costs of bed closure were also
included.
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Results: The procedures to deal with MRSA infection (single bed-
room, gowning, gloving and masks if required has led to consid-
erable extra monetary costs compared with the non-infected
patient in long-lying patients. On average, the staff have to gown
up 20 times per day per patient upon entry in to the room. To
move existing patients around to other rooms in the ward when a
new MRSA case is admitted to a single room necessitate logistics,
which are very time consuming.
Conclusion: MRSA infection causes signiﬁcant costs in terms of
time, increased need for staff and therapeutic costs. In Germany
reimbursement of patients with MRSA infection is not adequately
represented in the current diagnosis related group (DRG) reim-
bursement scheme, which is in operation since the beginning of
2004.
P1167 Evolution of the institutional antibiotic policies
between 1999 and 2002 in French hospitals
A.M. Rogues, C. Dumartin, P. Parneix, N. Marty, J.C. Labadie,
J.P. Gachie
Bordeaux, Toulouse, F
Objective: To determine the evolution of the institutional policies
to control use of antibiotics and to improve antimicrobial use.
Participants and method: Pharmacy and infection control staff at 37
hospitals participating in the survey conducted by the CCLIN SO.
We collected information about total antibiotics used and about
susceptibility of Staphylococcus aureus and Pseudomonas aeruginosa
isolates recovered from clinical specimen during 12 consecutive
months, as well as descriptions of the type of antibiotic manage-
ment policies and procedures being used by the individual hospi-
tals by means of a standardised questionnaire in 1999 and in
2002. Responses were analysed using chi-square MacNemar and
Wilcoxon matched-pairs signed-ranks test.
Results: 37 hospitals with a median of 205 beds (range 28–893)
and with a mean of 54 029 patients-days in 2002. Respectively, in
1999 and in 2002: a local committee supervised antibiotics use in
47 and 80% of the hospitals (P < 0.01), 80% had a validation pro-
cess before dispensing antibiotics. Local clinical practice guide-
lines were reported at 29.7 and 48.6% of the hospitals, feed-back
information existing in 51 and 83.7% (P < 0.01) for antibiotic con-
sumption and in 57 and 86.5% for antibiotic resistance (P < 0.01).
Fewer than 30% used computer for the management of dispen-
sing of antibiotics. Only 3% used an electronic network to share
information on antibiotics prescription and bacteriological results.
Fewer than 30% reported evaluation of antibiotic practices.
Decreasing in antibiotics consumption was not signiﬁcant: respec-
tively, 364 and 345 deﬁned daily doses per 1000 patients-days
(DDD/1000). In 2002, a lower antibiotic consumption was asso-
ciated signiﬁcantly with antibiotic order form obligatory for get-
ting the drug from pharmacy (441 vs. 305 DDD/1000). Variations
of bacterial resistance rates were not signiﬁcant for Staphylococcus
aureus and methicillin, Pseudomonas aeruginosa and imipenem or
ceftazidime or ciproﬂoxacin.
Conclusion: Our survey shows improvement in the reported anti-
microbial use programmes but hospitals also must focused on
appropriateness of use and on computer equipment.
P1168 The ﬁrst 3 years of an outpatient and home
parenteral antibiotic therapy (OHPAT) service in Glasgow
R.A. Seaton, E. Bell, L. Semple
Glasgow, UK
Objectives: To evaluate how patterns of referral and patient man-
agement strategies have evolved over the ﬁrst 3 years of the Glas-
gow OHPAT service.
Methods: Comparisons were made between years 2001, 2002 and
2003 (until December 8th) utilising patient data recorded prospec-
tively.
Results: Since January 2001, 588 patients have received OHPAT
(112, 236 and 240 per year). Growth reﬂects increasing referrals
from A&E (6, 70, 57 per year), GP (3, 18, 37 per year), medicine
(16, 61, 46 per year). Referrals from ID (55–63 per year) and ortho-
paedics (13–21 per year) were similar. Increasing numbers of
patients with skin and soft tissue infections (62 (55.4%), 174
(74%) and 154 (62%), bone and joint infections (BJI) (22 (19%), 34
(14%) and 37 (16%)), endocarditis/ bacteraemia (7 (6%), 10 (4%),
16 (7%)) and MRSA infections (10 (9%), 20 (9%), and 33 (14%)
were observed. Admission was avoided in 28 (26%), 116 (49%)
and 137 (57%). The number of days of OHPAT service for each
year was 1814, 2856 and 2913 days with a median length of ther-
apy per patient of 9, 5 and 5 days (range 1–107). A similar pro-
portion of patients self-administered therapy (10, 7, and 12%),
although a greater proportion with BJI self-administered in year 3
(30 vs. 4% in year 1 and 18% in year 2). Fewer patients with BJI
received home visits in year 3 (5 vs. 55% in year 1 and 19% in
year 2). Unplanned admissions attributed to the infection or the
therapy occurred in 5, 4 and 8% of patients. Cure or improvement
at end of treatment was observed in 95, 93 and 97%. Overall three
deaths occurred and none were directly attributable to the infec-
tion or therapy.
Conclusions: The service in Glasgow is expanding and providing
a safe alternative to hospital admission for a wide range of
patients with infection. Increasing numbers of patients with soft
tissue infection are referred directly from A&E or GP and are
managed without admission. More patients on longer-term ther-
apy are self-administering antibiotics at home.
P1169 Antibiotic prescribing knowledge among junior
doctors – how can we improve it?
H. Ziglam, S. Moitra, D. Morales, K. Webb, K. Gray, D. Nathwani
Dundee, UK
Background: Prescribing of antibiotics, often in the empiric setting,
frequently falls on training grade or junior doctors, who are often
the least experienced in this. Recognition of infection and sepsis
represents basic components of good antibiotic prescribing prac-
tice.
Methodology: We undertook two questionnaire and interview
based surveys (1999 and 2003) of prescribing training grade doc-
tors in a teaching hospital in North-East Scotland to determine
their knowledge level regarding (i) doctor’s knowledge of the
deﬁnitions of systemic inﬂammatory response syndrome (sirs),
sepsis, severe sepsis and septic shock; (ii) the source of local or
other information each doctor used when prescribing an antibi-
otic; (iii) the criteria each doctor used when choosing the route
of administration of antibiotic and to determine if each doctor
knew the likely cost differential between an intravenous and oral
antibiotic. Interventions: Between the two audits 4 years apart
several initiatives have been introduced to improve the educa-
tion and support related to antibiotic prescribing. These included
a pharmacy and ID led 6-monthly teaching programme for all
residents and ﬁnal year medical students in Dundee, introduct-
ion of sepsis protocols on all medical and surgical wards and
improving access to and awareness of the local antibiotic prescri-
bing formulary.
Result: (see attached table/ﬁgure).
Table 1. Results of the antibiotic prescribing knowledge among junior doctors
Audit
year % sirs % sepsis
% severe
sepsis
% septic
shock
IV route ⁄ source of
information
Cost
awareness
difference
between IV
and oral
Sepsis
protocol
Micro ⁄ ID
advice
BNF
1999 21% 38.2% 38.2% 20% 10.9% 47.2% 23.6% 36.3%
2003 65.4% 54% 48% 67.4% 40% 26.7% 2.7% 35.8%
% indicate positive or correct responses for the above deﬁnitions or criteria BNF ¼ British
National Formualry
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Fifty-ﬁve junior doctors in a large teaching hospital participated
in the survey in 1999 and 78 in 2003. There has been a signiﬁcant
improvement in doctor’s knowledge of regarding various sepsis
deﬁnitions and more (29%) used the desired locally derived sep-
sis protocol, which guided the prescriber through sepsis recogni-
tion, empiric choice and monitoring of antibiotics. Use of this
protocol appeared to be at the expense of telephone ID/micro
advice and the BNF, which we regard as not ideal as a local sepsis
management guideline. In term of awareness of the cost difference
between intravenous (IV) and oral antibiotic there was no signiﬁ-
cant improvement in the percentage of doctors that could acknow-
ledge that parenteral antimicrobials were more expensive than oral
antimicrobials (63.7% in 1999, 64.2% in 2003). Overall, there was
signiﬁcant improvement in doctor’s knowledge in understanding
sepsis and the source of information they utilised to select the anti-
biotic of choice although the majority did not acknowledge the
price difference between IV and oral forms of antibiotics.
P1170 Antibiotic prophylaxis in severe acute pancreatitis:
randomised multicentre prospective trial with meropenem
S. Hejtmankova, J. Spicak, P. Cech, D. Hoskovec, R. Kostka,
J. Lefﬂer, M. Kasalicky, P. Svoboda, J. Bartova
Prague, CZ
Background: Nowadays, most deaths in acute pancreatitis are
caused by infection, thus the role of prophylaxis of infectious
complications in severe acute pancreatitis (SAP) still remains a
debatable issue.
Aim: The aim of the study was to assess the efﬁcacy of prophy-
lactic antibiotic treatment comparing rates of local and infectious
complications, mean hospital stay, necessity of surgical treatment
and mortality in two groups of patients with SAP.
Methods: 41 patients with SAP were enrolled into the randomised
multicentre prospective study according to the clinical criteria
deﬁned at the Atlanta symposium, necrotising pancreatitis on CT
or CRP level exceeding 190 mg/L. The patients were randomised
either into the prophylactic (P) or into the therapeutic (T) group.
In the P-group, meropenem 500 mg was administrated every 8 h
for 10 days. In the T-group, the patients received the same antibi-
otics only in the case of conﬁrmed infectious complications (infec-
ted necrosis, abscess, urinary infection, pneumonia, etc.).
Results: The most important assessed criteria were: mean hospital
stay, local complications, infectious complications, surgical treat-
ment and mortality. No statistically signiﬁcant difference between
group P and group T was found regarding the examined criteria.
Conclusions: Prophylactic antibiotic treatment reduced neither the
rate of infectious complications nor mortality and other criteria in
patients with SAP.
P1171 Inventory and identiﬁcation of lactic acid bacteria
used as probiotics
V. Vankerckhoven, T. Van Autgaerden, G. Huys, M. Vancanneyt,
J. Swings, H. Goossens
Wilrijk, Ghent, B
Objectives: Within the framework of the European project PRO-
SAFE – Biosafety evaluation of lactic acid bacteria used for human
consumption – we made an inventory of commercial probiotic
strains, veriﬁed their identiﬁcation and collected relevant informa-
tion.
Methods: Fifty-four companies involved in the production and/or
distribution of probiotics were invited to submit their strains and
to complete a questionnaire. Species identiﬁcation of the strains
was veriﬁed using ampliﬁed fragment length polymorphism
(AFLP), repetitive DNA element (rep)-PCR ﬁngerprinting, and
protein proﬁling.
Results: Of the 54 companies contacted, 27 submitted their strains,
13 claimed not to manufacture probiotics and were therefore
excluded from the survey, 2 did not wish to participate, and 12
(mostly US companies) did not respond. All 27 participating com-
panies returned the questionnaire. In total, 202 strains were sub-
mitted and received as Lactobacillus (54.0%), Biﬁdobacterium
(26.7%), Enterococcus (5.9%), Propionibacterium (5.9%), Lactococ-
cus (2.5%), Pediococcus (2.0%), Streptococcus (2.0%), Bacillus
(0.5%) and Oenococcus (0.5%). The most frequently used identiﬁ-
cation techniques included biochemical characterisation (34.9%),
DNA ﬁngerprinting (21.8%) and 16S/23S rDNA sequencing
(20.8%). Comparison with our current identiﬁcation results for
174 strains, the identity of 17.2% of these strains did not corres-
pond to the identiﬁcation by the company. Out of 202 strains,
53.5% are of human origin, 44.5% of non-human origin, whereas
for 2.0% the source of isolation is unknown. Two strains were
submitted as genetically engineered. 46.5% of the strains are used
for human consumption, 5.4% for animal use, 7.0% for both
human and animal use, 7.4% were categorised as probiotic, 5.0%
are industrial starters and 28.7% are still under investigation.
Conclusions: A large number of strains received from the contac-
ted companies was correctly identiﬁed and the majority belonged
to the genera Lactobacillus and Biﬁdobacterium. More than half
of the strains are of human origin, and about the same number is
used for human consumption.
P1172 Implementation of quality assurance programme for
manually cleaned bronchoscopes following a pseudoepidemic
of Mycobacterium chelonae
M. John, J Vandierendonck, G. Peters, Z. Hussain, P. Chedore,
G. Broukhanski
London- Ontario, CAN
Objectives: To standardise cleaning and high-level disinfection
protocols for manually cleaned bronchoscopes in a tertiary care
institution. To develop a quality assurance program that tracks
the usage and reprocessing of bronchoscopes.
Methods: Six bronchial lavage samples yielding acid-fast bacilli in
a 3-week period from a critical care trauma unit lead to an inves-
tigation of manually cleaned bronchoscopes. Environmental sam-
ples and rinse water from bronchoscopes post-disinfection were
cultured for 7 days at 30C. The acid-fast rods were identiﬁed
using high performance liquid chromatography (HPLC) and
typed using an adaptation of the Enterobacterial Repetitive Inter-
genic Consensus Sequencing (ERIC) method. A quality assurance
method was implemented and correctional measures were made
in the processing of bronchoscopes.
Results: Percentage of the six patient isolates and three environ-
mental samples were identiﬁed as Mycobacterium chelonae. The
sixth was identiﬁed as M. fortuitum/peregrinum. The molecular
patterns for M. chelonae were identical. A contaminated hose ﬁlter
used to drain the bathes was identiﬁed as the point source.
Weekly cultures results of water rinsed bronchoscopes post-disin-
fection yielded reports ranging from sterile to mixture of bacteria
including acid-fast rods, and fungi.
Conclusions: Many hospitals are cleaning and disinfecting bronch-
oscopes manually in less than ideal conditions. Inadequately
trained personnel and poor quality control pratices may lead to
contaminated bronchoscopes. It is recommended that infection
control personnel review the cleaning and disinfection procedures
and that a quality assurance method include proper documenta-
tion and chemical and or biological testing to ensure the safe
reuse of bronchoscopes.
P1173 Occupational sharp injuries and exposure to body
ﬂuids among health care workers
A. Azap, O¨. Ergo¨nu¨l, K.-O. Memikoglu, A. Yesilkaya,
A. Altunsoy, G. Yilmaz Bozkurt, E. Tekeli
Ankara, TR
Objective: To determine the risk factors of sharp injuries and
exposure to body ﬂuids among health care workers (HCWs).
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Method: The study was conducted in the hospitals of Ankara Uni-
versity School of Medicine. The maximum number of HCWs was
targeted to be included in the study. The study was approved by
the Research Board of the hospital. All the HCWs were asked to
participate in the study, and the HCWs, who had accepted to par-
ticipate were included. A structured survey form was adminis-
tered by person to person interview. The survey included the
questions related to demographics, injury, attitude of HCW after
injury, and status of vaccination against Hepatitis B. The logistic
regression was modelled to determine the risk factors for the nee-
dlestick injury occurred in the last 6 months.
Results: The study included 988 HCWs. The mean age was 31,
and 70% were female. The study group included 500 nurses
(51%), 212 residents (21%), 152 nurse assistants (15%), 26 radiol-
ogy technicians (2.5%), 46 laboratory technicians (4.5%), 36 fel-
lows (3.5%), and 16 anaesthesiology technicians (2.5%). The
majority of HCWs (68%) had been vaccinated against hepatitis B
before. The rate of the exposed (sharp injuries and exposure to
body ﬂuids) HCWs was 64%. The most frequent causes of the
exposures were, recapping the needle (38%), operation (15%),
phlebotomy (10%), suturing (5.2%), and resuscitation (4.6%). Of
the injured HCWs 211 (33%) were not using protective equip-
ments (masks, gloves, etc). The most common (55%) reason for
not using protective equipment was being in a hurry. The number
of the injured HCWs who did not seek any medical advice for
injury was 381(61%). The age, gender, and duration of work had
no effect on the needlestick injuries. However, being a nurse
(odds ratio 2.3, conﬁdence interval, 1.2–4.5, P ¼ 0.015), and work-
ing overtime (OR, 1.3; CI, 1.1–1.6; P ¼ 0.015) affected the outcome.
Conclusion: Majority of HCWs had the history of sharp injuries.
Nurses working overtime had higher risk of needlestick injuries.
Systematic occupational exposure control programmes should be
implemented.
P1174 Multicentre microbiological trials based on
non-proﬁt membership framework
V.A. Kostin
Smolensk, RUS
Objectives: To determine optimal type of organisation structure
for multicentre microbiological trials.
Methods: Ofﬁcial reports of different scientiﬁc non-proﬁt organi-
sations and published data on management of similar organisa-
tion were analysed.
Results: Since 1997, Interregional Association for Clinical Micro-
biology and Antimicrobial Chemotherapy (IACMAC) with the act-
ive participation of 1,897 members (33 regions of Russia) has been
conducting the monitoring of antimicrobial resistance in Russia.
That monitoring has some advantages compared with similar
activity of proﬁt and state research organisations: (a) It is not
merely well-paid work, but great scientiﬁc interest that is a moti-
vation for member-researchers’ activity on antimicrobial resistance
monitoring. (b) Collection of data on antimicrobial resistance is a
result of close communication between members and leaders of
IACMAC, which is a result of joint scientiﬁc and educational
actions as well as functioning Internet portal http://www.antibi-
otic.ru. (c) Reliability and validity of data being obtained is due to
high authority of IACMAC, using social marketing concept and
principles of evidence-based medicine. Dependence of IACMAC
on sponsors (pharmaceutical companies) is minimal, whereas the
level of collaboration and mutual conﬁdence between IACMAC
and international societies, such as APUA, ISC, ESCMID, and
FESCI is very high. The IACMAC took part in 11 multicentre
microbiological studies on antimicrobial resistance of community-
acquired and nosocomial pathogens in Russia. With the
international support, 55 000 copies of ‘Practice guidelines on anti-
microbial chemotherapy’ were published and distributed free of
charge to the medical community.
Conclusions: As an example of successful scientiﬁc activity, IAC-
MAC is an association that forms necessary public awareness
about resistance among professionals and non-medical opinion
leaders, and develops national policies in the ﬁeld. Results of
IACMAC activities over the past 5 years demonstrate the
advantages of researchers collaboration within a non-proﬁt
organisation.
P1175 Comparison of the different disinfecting capacities
of contact lens solutions for rigid gas permeable (RGP) lenses
against ocular pathogens
S.Y. Lai, M.M. O’Donoghue, M.V. Boost, P. Cho
Kowloon, HK
Objectives: To evaluate the disinfectant capacity of three commer-
cially available disinfecting solutions and to determine if they are
able to meet the FDA criteria for contact lens disinfectant solu-
tions. To determine the effects of storage conditions on disinfect-
ant activity because although manufacturer’s recommend a
3-month period of use this does not take into account higher tem-
peratures experienced in tropical and sub-tropical areas.
Methods: Disinfectants were challenged with Escherichia coli, Pseu-
domonas aeruginosa, Staphylococcus aureus and Candida albicans
according to the FDA standalone criteria. Duplicate bottles of
those meeting the minimum criteria of a 3.0 log reduction in
viable count (for bacteria) and 1 log reduction (for Candida)
within the minimum recommended disinfection period were then
stored at a range of temperatures and conditions and challenged
at weekly intervals for 1 month.
Results: Boston Simplicity met the FDA acceptance criteria for the
standalone procedure for all organisms and for all conditions tes-
ted. Boston Advance though meeting the criteria for all organisms
when careful handling was employed, failed to adequately reduce
numbers of S. aureus when poor handling technique over a
1-month period was utilised. Poor handling reduced activity
against Ps aeruginosa for all solutions. Alcon Optisoak failed to
meet the FDA criteria against S. aureus and E. coli in initial testing.
Fridge storage resulted in reduced activity of Boston Simplicity
against two organisms. All solutions showed some loss of activity
after storage in a covered water bath at 30C (simulating bath-
room conditions in warm climates) for 1 month.
Conclusions: Microbial keratitis, which can lead to severe loss of
visual acuity, is associated with breeches in correct handling of
contact lenses. Poor handling techniques may result in loss of dis-
infectant activity, conﬁrming the need for reinforcement of educa-
tion of contact lens users. Storage at temperatures other than
room temperature adversely affects the activity of disinfectants
and clients should be advised not to store solutions in the fridge
and to dispose of solutions after a shorter period of time if the
ambient temperature exceeds 25C. Failure of one solution to meet
the FDA requirements may be a cause for concern.
P1176 National electronic Library of Infection in the
UK – can it change clinical practice?
P. Kostkova, G. Madle, J. Weinberg, J. Mani-Saada
London, UK
Motivations: Recent technical advances resulting in a boom in
medical digital libraries that have resulted in an overwhelming
amount of medical information available on the Internet. How-
ever, the Internet can only play this essential role in healthcare if
the knowledge provided over this powerful media is made access-
ible and delivered to healthcare professionals in the right form to
meets their needs. Healthcare professionals often cannot ﬁnd the
information they need when they need it and if they do the qual-
ity may be uncertain.
National electronic Library of Infection: NeLI http://www.neli.or-
g.uk is providing the best available evidence around investiga-
tion, treatment, management and control of infectious diseases.
NeLI, a specialist library of the National electronic Library of
Health (NeLH), is a digital library providing the best available
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evidence-based knowledge, enhanced with medical quality tags
provided by members of major professional societies and
expert committees in the area of communicable disease in the
UK. The quality tag consists of a bottomline critically summa-
rising the paper, and a checklist, which answers brief questions
about the methodological issues, level of evidence, potential
biases and applicability of the results. The resultant quality tag
and a signature of the particular society are attached to the
document.
The Web log evaluation of NeLI: A web log analysis investigating
data for the period from January 2002 till June 2003 was per-
formed by Gemma Madle (g.c.madle@city.ac.uk). The results
revealed that the number of users has signiﬁcantly increased from
422 in January 2002 to 1154 in June 2003, the number of sessions
increased from 622 in January 2002 to 1609 in June 2003. Over
two-thirds of users (70%) are using IPs registered in the UK or
US. Hospital-based users are spending more time in a session and
are returning to visit the site more often in a month than other
users. The average time spent by hospital-based users in a session
was 8 min and 23 s compared with 4 min 52 s for all users and
hospital-based users visit the NeLI an average of 6.71 times per
month compared with 1.52 times for all users. Top ten topics
pages include: Meningitis (2.82%), HIV (2.72%), Tuberculosis
(2.68%), Tinea (2.55%), Antimicrobial Resistance and Healthcare
Associated Infection (1.93%), Staphylococcus aureus (1.85%), Chla-
mydia (1.83%), Parvovirus (1.73%), Helicobacter (1.69%), Salmon-
ella (91.68%).
P1177 Psychological aspects of needle-stick injury to
health care workers in a teaching hospital
J.W. Sohn, C.S. Han, S.H. Kim, M.J. Kim, H.J. Cheong, W.J. Kim,
S.C. Park, S.I. Kim
Seoul, Ansan-si, Kyunggi-do, KOR
Purpose: Health care workers (HCW) are exposed to daily risk
of injury by needle-sticks or other medical instruments. The sta-
tistics of needle-stick injury are distributed annually and the vic-
tims are medically controlled appropriately. But, the
psychological impacts on the victims of needle-stick injury have
not been studied yet. We tried to evaluate the stress, anxiety
levels, and depressive symptoms of HCW with the history of
needle-stick injury.
Methods: Researchers consisted of psychiatrist, infection specialist
doctor, and infection control nurse. They provided questionnaire
items about needle-stick injury and preventive activities. Psycho-
logical scales applied in this study were Beck depression inven-
tory; BDI, Perceived Stress Scale; PSS, and Hamilton Anxiety
Scale; HAM-A. The responses from 370 HCW were analysed sta-
tistically using SPSS 10.0.
Results: The proportion of male to female was 21.6% (n ¼ 80)
and 78.4% (n ¼ 290). Among the subjects, 23.8% (n ¼ 88) were
doctors, 63.0% (n ¼ 233) were regular nurses, 8.1% (n ¼ 30) were
ward assistants, 4.3% (n ¼ 16) were technicians, and 0.8% (n ¼ 3)
were others. The proportion of HCW with or without needle-stick
injury was 71.1% (n ¼ 263) and 28.9% (n ¼ 107). Total PSS score
was 19.48  3.52, total HAM-A score was 11.39  8.74, and total
BDI score was 30.35  6.99 at ordinary times. In case of women,
the scores of all three measurement levels were higher than that
in men. HAM-A and BDI scores were signiﬁcantly higher among
HCWs with needle-stick injury history (P ¼ 0.00). PSS and BDI
scores of HCW with needle-stick injury experience were higher
after the occurrence of needle-stick injury than that at ordinary
times. The existence of HBs Ab of HCWs with needle-stick injury
history was not signiﬁcant in PSS, HAM-A, and BDI scores
(P > 0.05).
Conclusions: Women who work in general hospital reported
higher level of stress, anxiety, depression compared with men.
Subjects with experiences of needle-stick injury showed signiﬁ-
cantly higher level of anxiety and depression. Among the subjects
with needle-stick injury experiences, higher level of depression
and stress scales were observed.
P1178 Implementation of the ISO 9001:2000 standard in
the Infectious Diseases Surveillance and Control Ofﬁce of the
Department of Public Health, Western Health Board, Ireland
R. Cloughley, D. McKeown, O. McWeeney
Galway, IRL
Objectives: The Infectious Diseases Surveillance and Control
Ofﬁce (IDSCO) is part of the Department of Public Health, in
Merlin Park. The primary functions of the ofﬁce are: (1) surveil-
lance of infectious diseases for the Western Health Board; (2) pro-
duction of the monthly Westﬁle bulletin; (3) management and
control of outbreaks of infectious diseases. The need for health
services to focus on quality was clearly stated in the 2001 Health
Strategy for Ireland. This prompted the IDSCO team to apply the
ISO 9001:2000 standard to the surveillance and control of infec-
tious diseases in the Western Health Board.
Methods: Conforming to the ISO 9001:2000 standard involved
carefully delineating the functions of the ofﬁce and determining
measuring points where performance could be assessed. Some
steps proved problematic and the progress towards registration
will be outlined, along with some of the difﬁculties encountered.
Results: Implementation of the ISO 9001:2000 standard and suc-
cessful registration usually takes a full year. The IDSCO was
registered successfully by the National Standards Authority of Ire-
land (NSAI) after only 10 months. This is all the more remarkable
since it was the ﬁrst time this standard has been applied to the
surveillance and control of infectious diseases in Ireland; and may
also be the ﬁrst such registration in Europe. Implementation of
the ISO 9001:2000 standard has resulted in the following improve-
ments to the surveillance and control of infectious diseases in the
Western Health Board: (1) The monthly surveillance bulletin
‘Westﬁle’ has been improved by the addition of formal customer
feedback measurement. (2) The accuracy of regional infectious dis-
ease ﬁgures reported in the bulletin has been improved by modiﬁ-
cation of the process used to extract the data. (3) The control and
management of outbreaks has been improved by addition of spe-
ciﬁc measuring points that can assess how efﬁciently the process
is controlled at each point. (4) Continuous review, as an integral
part of the ISO 9001:2000 standard; ensures that the system cur-
rently in place will be reviewed on an ongoing basis to ensure it
delivers the best service possible.
Conclusion: The implementation of the ISO 9001:2000 standard in
the IDSCO was a tortuous but ultimately worthwhile process. As
it was a national, and possibly a European ﬁrst, the experience we
have gained from the successful implementation of the ISO
9001:2000 standard may assist others considering registration.
P1179 The User Satisfaction Survey – an instrument to
adjust and improve clinical microbiology services
S. Hartvig Hartzen, H. Colding
Charlottenlund, Copenhagen, DK
Objectives and background: Budget cuts are general conditions of
our public health care system and constitute a daily challenge.
Accordingly laboratory administrators must constantly adjust
laboratory services in a manner as professionally safe as possible.
In connection with a major budget cut we decided to improve our
basis for decision-making and involve our customers by perform-
ing a user satisfaction survey.
Study design – a survey: A questionnaire with 35 questions and 8
sections: requisition, reporting, diagnostic service, staff service,
consultative service, duty/opening hours, improvements and
adjustments, general comments. Participants: The questionnaire
was sent to 211 employees at four different hospitals representing
the following departments: paediatric, internal medicine, ICU,
and surgery. Questions were constructed as postulates with six
response alternatives: strongly agree, agree, both agree and disag-
ree, strongly disagree, disagree, neither agree nor disagree.
Results (selected): Response rate, 65%. Overall, our customers
were satisﬁed with our requisition system and our result report-
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ing. Concerning our diagnostic service 32% thought that result-
processing times were too long, and 20% were dissatisﬁed with
having to phone the lab to get the report quicker. Most were satis-
ﬁed with the personal service of the staff and the telephone ser-
vice in connection with ﬁndings of acute clinical importance. As
regards the consultative service more internal conferences focus-
ing on particular patients and/or subjects were in demand as well
as further training in microbiology and related subjects. 35%
thought that knowledge of test price would limit the number of
samples taken, 46% thought that better training would have a
similar consequence, and 25% wanted to know more about indi-
cations for sampling.
Conclusion: The user satisfaction survey has in our hands been a
proﬁtable instrument to adjust and make our services better. From
now on we will try to improve our economy and the quality of
the specimens by focusing on training in microbiology, on the
indications for taking samples, as well as making our customers
more price-minded.
P1180 Communication methods used for implementing
antibiotic policy: a pilot project in Belgian hospitals
L. Sourdeau, M.J. Struelens, W.E. Peetermans, C. Suetens and the
Hospital Care Working Group of Belgian Antibiotic Policy
Coordination Commitee (BAPCOC)
Objective: In 2002–2003, a pilot project funded the establishment
of antibiotic management teams (AMT) and antibiotic managers
(AM) in Belgian hospitals. First year activity reports were
reviewed to assess the communication methods used for imple-
menting antibiotic policies.
Methods: The pilot hospitals (n ¼ 35) had a median number of
654 (from 154 to 1597) beds; 17 were general hospitals, 10 general
hospitals with teaching beds and 8 teaching hospitals. Communi-
cation methods used for dissemination of antibiotic recommenda-
tions within the institution were categorised; 1, 2 and 3 points
were granted to passive, active and personalised methods,
respectively, and the cumulative sum was used as a score for
ranking hospitals.
Results: Communication actors were identiﬁed as the AM (sen-
der), guidelines (message) and healthcare staff (receiver). In pas-
sive methods, only the sender knows that the message was
emitted. These included: mailing (33), intranet (6), internal news-
letter (9), e-mailing (2) and posters (1). In active methods, the sen-
der knows that the message was emitted and at least received.
These included: information meetings (lectures, courses, staff
meetings) (13) and infection ward rounds (11). In personalised
methods, the sender knows that the message was emitted,
received and understood. These included: individual feedback (6),
face to face meeting with AM (18), audit (2) and computer-assis-
ted prescribing (9). Hospitals used an average of 3.6 communica-
tion methods (1–8). The mean communication score was of 6.5
points (1–15). General hospitals, general hospitals with teaching
structure and teaching hospitals used an average of 3.2, 5 and 3.7
methods with a mean score of 5.8, 6.3 and 8.3, respectively. No
difference was seen by hospital size in the number of methods
used or communication score.
Conclusion: Advertisement type categorisation of communication
methods showed that all hospitals used at least one passive
method, 39% used at least one active method and 55% used at
least one personalised method. The quality of communication was
higher in hospitals with teaching afﬁliation (P ¼ 0.05).
Antibiotic use and surveillance
P1181 Reduction in outpatient antibiotic sales to
pre-school children – interrupted time-series analysis of weekly
antibiotic sales data in Sweden, 1992–2002
L. Ho¨gberg, T. Oke´, P. Geli, C. Sta˚lsby Lundborg, K. Ekdahl,
O. Cars
Solna, S
Objectives: The availability of extensive retrospective data on
drug sales in Sweden provides unique opportunities to detailed
studies of trends in antibiotic use. We analysed the weekly sales
of antibiotics prescribed in outpatient care to children aged
0–6 years between 1992 and 2002, to identify trends in sales
during the period.
Methods: An interrupted time series model controlling for season-
ality was used to examine the datasets for signiﬁcant level and
trend shifts, with correction for autocorrelation. The total sales of
antibiotics (ATC group J01), as well as the individual subgroups
commonly used to treat respiratory tract infections in children
were studied: phenoxymethyl-penicillin (J01CE); extended-
spectrum penicillin (penicillins with extended spectrum and com-
bination of penicillins including beta-lactamase inhibitors: ATC
groups J01CA and J01 CR) and macrolides (ATC group J01FA).
Data were expressed as number of prescriptions/1000 inhabit-
ants/week.
Results: Overall, sales have decreased in all studied groups dur-
ing the period. For the total antibiotic sales, two signiﬁcant trend
breaks in 1996 and 1999 could be identiﬁed. The ﬁrst and the
third period showed a declining trend in the number of dispensed
prescriptions, while the period between 1996 and 1999 in opposite
showed an increasing trend. Trends in extended-spectrum penicil-
lin sales followed the same pattern, with two trend breaks at 1995
and 1998. As in the total antibiotic group, the baseline and the
third segment show decreasing trends, while the trend was
increasing in the middle segment. For phenoxymethyl-penicillin,
no signiﬁcant trend or level shift could be identiﬁed, and the
trend was slowly decreasing during the whole observation period.
In macrolide sales, a steep decrease was seen in the baseline seg-
ment, but after a trend break in 1995 the trend in sales has been
constant.
Conclusions: The weekly data material used for the analysis is
unique with regard to population coverage and data quality. Even
though no causal relationship can be established between trend
breaks and isolated interventions introduced during the study
period, it is obvious that the work for a more prudent outpatient
antibiotic use in children in Sweden has been successful. How-
ever, the reasons behind the increasing trend in broad-spectrum
antibiotics seen in the middle of the decennium needs to be
explained.
P1182 Blood cultures as a surrogate marker of case-mix for
adjustment of hospital antibiotic consumption
F. Lamoth, P. Francioli, G. Zanetti
Lausanne, CH
Objectives: Surveillance of hospital antibiotic consumption is an
important step towards appropriate use. Consumption is gener-
ally adjusted to an indicator of hospital occupancy, e.g. patient-
days. Such indicators are readily available, but they do not allow
adjustment to the case-mix. We investigated whether the number
of blood samplings drawn for culture could be used as a surro-
gate marker of the burden of infection in a hospital ward, and
therefore could serve for adjustment of antibiotic consumption to
case-mix.
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Methods: We ﬁrst determined one set of clinical and laboratory
criteria to deﬁne opportunities for prescription of antibiotics
(OPA), based on retrospective review of adult patients hospital-
ised in one university hospital (derivation sample: 178 patients;
validation sample: 200 patients). The correlation between OPA
and actual antibiotic prescription was good (positive predictive
value (PPV) 81%, negative predictive value (NPV) 95%). Then
correlation between blood cultures and OPA was established for a
medical ward. Finally, we compared antibiotic consumption in
this ward measuring it either in deﬁned daily doses (DDD) per
patients-day, or in DDD per blood culture, for 16 consecutive tri-
mesters.
Results: Blood cultures had a 70% PPV and a 97% NPV of pre-
dicting OPA. Of the 16 consecutive trimesters, 2 were found
showing up high antibiotic consumption (>95% CI for the mean)
as measured in DDD either per patients-day or per blood culture.
For three trimesters antibiotic consumption was high according to
one measurement method only. Analysis of random samples of 50
patients per trimester showed that this discrepancy was not due
to the instability of blood cultures as marker of OPA. It also con-
ﬁrmed that blood cultures were more accurate for adjustment of
consumption since (i) for one trimester with high consumption in
DDD per patients-day only, this result was actually due to higher
incidence of OPA; (ii) two trimesters with high consumption in
DDD per blood culture only had indeed low incidences of OPA,
and therefore a probable problem with antibiotic use that was not
identiﬁed when measured in DDD per patient-day.
Conclusion: Blood cultures are a stable marker of OPA in a med-
ical ward. This allows the identiﬁcation of periods deserving a
detailed investigation given the unexplained high antibiotic con-
sumption.
P1183 Audit of the usage of broad-spectrum antibiotics in
a Belgian university hospital: much room for improvement!
B. Delaere, P.Y. Decleire, M. Bary, J.D. Hecq, Y. Glupczynski
Yvoir, B
Objectives: In order to improve the quality of antimicrobial pre-
scription local written guidelines for empiric and documented
antibiotic therapy were developed and launched in April 2002. A
speciﬁc prescription formulary aiming to evaluate the usage of
broad-spectrum antibiotics was introduced in June 2003.
Methods: From 1 June to 31 August 2003, we assessed the pre-
scription of all broad-spectrum antibiotics. Parameters recorded
and analysed included patient’s data (clinical diagnosis, microbio-
logical data) and antibiotic’s speciﬁc data (choice of indication,
daily dose, mode of administration and duration of therapy. Ade-
quacy of therapy was deﬁned according to our local reference
guidelines.
Results: The patient cohort consisted of 266 patients presenting
301 infectious episodes (210 in patients from various medical units
and 91 from patients in different surgical wards). Four units (hae-
matology, pneumology, cardiovascular and digestive surgery)
accounted for almost 60% of all prescribed antibiotics. Treatments
were considered appropriate in 221 (73.7%) episodes and
non-adequate in 80 other episodes (including 29 indeterminate
therapies due to lack of microbiological/clinical data). Adequate
therapies were recorded in 31/34 epidoses with concomitant bac-
teraemia. The agents most frequently inadequately prescribed
included the ﬂuoroquinolones (FQs) (41 [52%]), the aminoglyco-
sides (16 [18%]) and piperacillin/tazobactam (11 [14%]). For the
FQs, the main reason accounting for inadequate prescription was
the lack of indication (33/41), for aminoglycosides excessive dur-
ation was found in 13/16 episodes. Inadequate therapies were
predominantly observed in empiric therapy (59/80). The types of
infections most frequently concerned in inappropriate therapies
were: urinary tract (UTI) (30%), abdominal (29%) and respiratory
tract infections (22%). The units in which inappropriate prescrip-
tion patterns were most frequently observed included digestive
surgery (38%), gastroenterology (47%) and neurology (25%).
Conclusion: Overall this audit highlighted areas (types of infec-
tions and specialty-speciﬁc) where discordances of prescribing
with the empiric or documented antimicrobial guidelines were
frequently observed. Of most concern was the frequent inappro-
priate usage of FQs as well as the inadequate diagnosis/manage-
ment of UTI. This study further highlights the need for the
establishment of continued educational programs focusing on
appropriate antimicrobial prescribing.
P1184 Development of a paediatric daily deﬁned dose
system for the measurement of antibiotic consumption in
paediatric units
C. Antachopoulos, J. Dotis, V. Pentsioglou, J. Evdoridou,
E. Roilides
Thessaloniki, GR
Background and objectives: Antimicrobial consumption is fre-
quently measured using the daily deﬁned dose (DDD) system
assigned by WHO to every antimicrobial drug. DDD is the pre-
sumptive average maintenance daily dose of a drug used for its
main indication in adults. The fact that the existing DDDs are
derived from adult doses could compromise the validity of this
tool in studies involving paediatric patients. Since drug doses in
children are most frequently based on body weight (BW), the cal-
culation of paediatric DDDs should take into account the mean
BW of children admitted to a paediatric unit. Our objective was to
develop a method for the calculation of paediatric and neonatal
DDDs, for common antimicrobial drugs used in a tertiary hospi-
tal.
Methods: We calculated the mean BW of 229 children consecu-
tively admitted to the paediatric wards of our hospital. We then
calculated the paediatric DDD for a given antimicrobial with the
equation: ped DDD ¼ mean BW (kg)  dose (mg/kg), where dose
(mg/kg) is the average or usual recommended paediatric dose of
the drug, according to approved textbooks or formularies. For
neonatal DDDs, we multiplied the mean BW of 255 infants con-
secutively admitted to the neonatal unit [(birth weight + discharge
weight) / 2] with the average or usual recommended neonatal
dose of the drug. We used ceftriaxone to apply our proposed pae-
diatric and neonatal DDD system.
Results: The mean BW of the paediatric patients was 18.42 kg
(95% CI: 16.48–20.35 kg) and that of the hospitalised neonates
was 2.57 kg (95% CI: 2.48–2.66 kg). Based on our method, with an
average paediatric dose of 75 mg/kg and a neonatal dose of
50 mg/kg of ceftriaxone, the paediatric DDD was found to be
1.4 g and the neonatal DDD 0.13 g. By employing the DDD
assigned to ceftriaxone by WHO (2 g), the consumption of this
drug during 2002 in three different departments of our hospital
(adult, paediatric, neonatal) was 5.11, 2.87 and 1.09 DDDs per 100
bed-days, respectively. By using, however, the adjusted DDD sys-
tem for the paediatric and neonatal wards, the consumption was
found to be 5.11, 4.11 and 16.83 DDDs per 100 bed-days, respect-
ively.
Conclusion: The development of paediatric and neonatal DDDs
with this BW-based approach, using collective data from different
hospital departments and countries, could greatly facilitate antibi-
otic consumption studies involving paediatric or neonatal units.
P1185 The impact of multiresistance in risk factor analyses
of antibiotic exposure among antimicrobial-resistant bacteria
E. Tacconelli, M.A. Cataldo, R. Cauda, E.M.C. D’Agata
Rome, I; Boston, USA
Background: Antibiotic resistant infection is a growing medical
concern. Therefore, accuracy of epidemiological studies is funda-
mental to elaborate the best interventions to reduce the spread of
antibiotic resistance. Previous risk factors analyses have assumed
single-drug resistance in the bacteria under study. Since many
bacteria may be multidrug-resistant, we hypothesise that the
assessment of antibiotic exposure as risk factor for the emergence
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of antibiotic resistance will differ depending on whether
single-drug or multi-drug resistance is analysed.
Methods: A case–case–control study was performed to determine
differences in intravenous antibiotic use in the previous 30 days
among two groups of cases. The ﬁrst group of cases included
patients harbouring Pseudomonas aeruginosa (PA) resistant only to
ciproﬂoxacin (CR-PA) and the second group of cases included
patients harbouring CR-PA, resistant to one or more of the follow-
ing antibiotics (MDR-PA): ceftazidime (CFZ), aminoglycoside
(AMG), imipenem (IMP) or piperacillin-tazobactam (PipT). Con-
trols were selected among patients admitted to same hospital not
harbouring PA. Matching for number of days from admission to
CR-PA or MDR-PA recovery among cases and duration of hospi-
talisation among controls was performed. Potential confounders
were included in a conditional logistic regression analysis.
Results: A total of 384 patients had been enrolled. Forty-two
patients had CR-PA and 151 MDR-PA recovered in two Univer-
sity hospitals were compared with 192 controls. Use of quinolones
was independently associated with CR-PA (OR 2.1, 95% CI 1.3–
3.2, P < 0.01) and MDR-PA (OR 2.2, 95% CI 1.2–3.8, P < 0.01),
while use of 3rd gen. cephalosporins (OR 2.3, 95% CI 1.4–4.1,
P < 0.01), AMG (OR 2, 95% CI 1.1–3.9, P ¼ 0.01), IMP (OR 2.4,
95% CI 1.1–5.3, P ¼ 0.02), and PipT (OR 2.5, 95% CI 1.1–6.6,
P ¼ 0.02) were signiﬁcantly associated to MDR-PA only. There
were no statistically signiﬁcant differences between CR-PA and
MDR-PA with controls for age, comorbidities, intensive care unit
or health-care facility exposure, and duration of therapy within
30 days.
Conclusion: When multidrug resistance is taken into considera-
tion, signiﬁcant differences in antibiotic exposures are identiﬁed
between single-drug resistant vs. multidrug-resistant bacteria.
Future epidemiological studies should consider co- and cross-
resistance to other antibiotics when analysing risk factors for the
emergence of antimicrobial resistant bacteria.
P1186 Large-scale nationwide point prevalence study of
indications for antibiotic use in 54 Swedish hospitals in 2003
G. Skoog, O. Cars, K. Ska¨rlund, S. Elowson, H. Hanberger,
I. Odenholt, M. Prag, J. Struwe, E. Torell, P. Ulleryd, M. Erntell –
The STRAMA-program
Objectives: The objective of the study was to introduce a nation-
wide survey system for frequent assessment of the use of antimi-
crobial agents in relation to diagnose. The STRAMA-groups have
performed the ﬁrst point prevalence study, PPS, using a
web-based reporting system.
Method: A nationwide PPS with one personal visit to each depart-
ment was performed within a 2-week period in November 2003.
The protocol was designed to present demographic data as well
as the amounts and indications for antimicrobial agents against
bacteria and fungi. Treatments were recorded in relation to diag-
noses and prophylactic use, community acquired (CAI) and hospi-
tal acquired infection (HAI). Nineteen pre-deﬁned diagnosis
groups were used.
Results: 54 hospitals participated in the study. 4178 patients trea-
ted with antimicrobial agents were included out of 13 529 admit-
ted to nine university hospitals (1538 treated patients), 20 county
hospitals (1855 patients), and 25 local hospitals (785 patients).
31% of the admitted patients were treated with antimicrobials. A
total of 4395 treatments were recorded. 266 (6.4%) were given to
children (<17 years) and 49.9% to women. The indication for
treatment was CAI in 17%, HAI in 9% and prophylaxis in 6%.
For adults cultures were taken before oral treatment in 60% and
before parenteral treatment in 69%. The most commonly used
antimicrobials for adults, expressed in DDD, in treatment and in
prophylaxis were cephalosporins (23 and 18%), isoxazolyl-pc (13
and 47%), ﬂuoroquinolones (12 and 9%), broadspectrum-pc (10
and 4%). The total amount of antimicrobials used for adults was
40.3 DDD/100 admitted patients. For children the corresponding
results in number of treatments were; cephalosporins (42 and
31%), beta-lactamase sensitive penicillins (8 and 8%), tienamycins
(8 and 1%), glycopeptides (7 and 0%), and co-trimoxazole (6 and
15%). The number of treatments was 39.9/100 admitted children.
Analysis of different diagnoses shows over-use of cephalosporins
in community acquired pneumonia and ﬂuoroquinolones in urin-
ary tract infections.
Conclusions: The PPS method was successfully introduced result-
ing in one of the largest surveys in Europe of antimicrobial hospi-
tal treatment. The study describes suboptimal prescription
patterns for certain diagnoses.
P1187 Antibiotic consumption in ambulatory care in
Germany: a regional NUTS-I level analysis
K. de With, H. Schro¨der, M. Steib-Bauert, K. Nink, W.V. Kern
Freiburg, Bonn, D
Objectives: The MABUSE (Medical AntiBiotic Use Surveillance &
Evaluation) network, a German cooperative group of infectious
disease specialists, WIdO, the SARI programme and hospital
pharmacists, collects antibiotic consumption data in ambulatory
(AC) and hospital care (HC) settings. In the present study we
evaluated geographical aggregation of AC data on the level of
NUTS-I (Nomenclature of Units for EU Territorial Statistics) areas
in order to allow regional analysis of consumption data which
may be more meaningful than presenting national estimates for a
large country with cultural, historical and geographical diversity
and long borders with other EU countries.
Methods: AC data (covering all antibiotic prescriptions within the
compulsory health insurance, i.e. 86% of the total population,
years 2001 and 2002) were calculated using the WHO/ATC DDD
deﬁnitions and expressed as DDD/1000 per year for the 16 Ger-
man NUTS-I areas (corresponding to federal states). In a second
analysis, the four small-size NUTS-I areas Bremen, Hamburg, Ber-
lin and Saarland were included into 12 geographically ﬁtting lar-
ger areas in order to have a more balanced data presentation in
terms of geographical and structural organisation.
Results and conclusions: AC consumption in 2001 ranged between
3322 and 5802 DDD/1000, corresponding to 9.1 and 15.9 DDD per
1000 population and day). There was no major change between
2001 and 2002 values, except that non-small-spectrum beta-lac-
tams slightly increased. NUTS-I areas in the northern and western
parts of the country showed in 2001 much higher consumption
(range, 5286–5802 DDD/1000) than those in the southern part
(range, 4389–4432 DDD/1000) or in the east (range, 3322–4391
DDD/1000). This pattern did not change after our modiﬁed
NUTS-I analysis: northern part, 5286–5734 DDD/1000, western
part, 5006–5601 DDD/1000, southern part, 4389–4432 DDD/1000,
eastern part, 3769–4232, respectively. This regional representation
of German consumption data allowed useful evaluation of pat-
terns of different antibiotic drug class and subgroup consumption
and may also be valuable for interregional comparisons within
the ESAC project.
P1188 SARI – Surveillance of Antibiotic Use and Bacterial
Resistance in German Intensive Care Units
E. Meyer, D. Jonas, F. Schwab, H. Ru¨den, P. Gastmeier,
F. Daschner
Freiburg, Berlin, Hannover, D
Objective: To provide epidemiological data on antibiotic resist-
ance, prophylactic or therapeutic use of antibiotics and on the cor-
relation between antibiotic use and resistance rates in intensive
care units (ICUs) in Germany, which are considered to be high
risk areas for the emergence and spread of multi-resistant bacter-
ial pathogens.
Methods: ICUs collected data on patient days, antibiotic use
(deﬁned daily doses¼ DDD according WHO) and resistance rates
of selected antimicrobial pathogens on all non-duplicate clinical
isolates. Antibiotic use density (AD) is calculated in DDDs/1000
patient days. The data were recorded, analysed centrally and
communicated to the participants every 3 months.
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Results: Project SARI started in February 2000, and includes data
on antibiotic use and resistance rates in 38 medical, surgical and
interdisciplinary ICUs. To date (from February 2000 to June 2003),
a total of 1142 months, 413 065 patient-days and 550 288 deﬁned
daily doses (DDDs in accordance with the WHO) have been cov-
ered, with a mean antibiotic usage density (AD) of 1335 DDDs/
1000 patient-days and resistance data on 37 612 isolates from
ICUs. In all the ICUs, mean antibiotic usage rates are highest for
penicillins with lactamase inhibitor (AD 305.8) and quinolones
(AD 137.1). Cumulative data for ICUs testing in accordance with
DIN (n ¼ 22) show an MRSA rate of 22.7%, and a ciproﬂoxacin
resistant Escherichia coli rate of 11.5%. Comparison of these resist-
ance rates for the time periods July 2000 to June 2001 and July
2002 to June 2003 (Wilcoxon test) shows a signiﬁcant increase in
MRSA and ciproﬂoxacin resistant E. coli. Use of ciproﬂoxacin cor-
relates signiﬁcantly with the rate of methicillin-resistant S. aureus,
as does imipenem use with the rate of imipenem resistant P. aeru-
ginosa.
Conclusion: National and local data on ICUs are necessary for
effective infection control. They offer a basis from which to
improve infection control and antibiotic management in ICUs
(http://www.sari-antibiotika.de).
P1189 Reduction of antibiotic use by a
community-oriented educational programme
B. Chazan, R. Colodner, W. Sakran, N. Guy, R. Raz
Afula, IL
Introduction: Avoiding excessive use of antibiotics is the clue for
combating community acquired antibiotic resistant pathogens.
Objective: to implement and evaluate the efﬁcacy of a community
intervention program of continuous medical education oriented to
primary care clinics with emphasis on appropriate use of antimi-
crobial drugs.
Materials and methods: From October 2000 to April 2003 we con-
ducted a prospective educational study in community primary
care clinic based on ‘guidelines for antimicrobial treatment in pri-
mary care’. The aim was to promote inﬂuenza vaccination and
judicious antibiotics use specially for respiratory infections. Six-
teen community clinics (168 644 patients) were included:
8 ¼ Intervention Group (IG ¼ 86 330 patients) and eight Control
Group (CG ¼ 82 314 patients). Total population in this area
(442 700 patients) was evaluated as Reference Group (RG). Total
volume of antibiotics prescribed to adult patients was evaluated
and measured as DDD/1000 patients. Narrow-spectrum agents
(NSA) and broad-spectrum agents (BSA) were deﬁned. Four con-
secutive winters: from October 1999 to February 2000 as baseline
data, 2000–2001 after guidelines distribution and 2001–2002 to
2002–2003 as intervention period were evaluated.
Results: A decrease in the total use of antibiotics was measured
in all the groups, but more signiﬁcantly in the IG [RG:6.4%,
CG:16.4% IG:20.1% (p < 0.0001 for all)]. Main change was noted
in BSA [RG:8.2%, CG:4.9%, IG:17% DDD/1000 patients
(p < 0.0001 for IG only)].
Conclusions: The present study showed that a community-orien-
ted educational programme signiﬁcantly reduced antibiotic use in
the Interventional Group in general and in the broad-spectrum
antibiotic group in particular. More efforts and ampliﬁcation of
this type of interventions are imperative to stop increasing antimi-
crobial resistance.
P1190 Evaluation of compliance to perioperative antibiotic
prophylaxis guidelines
I. Wybo, H. Vandenbussche, T. De Beer, D. Pie´rard, S. Lauwers
Brussels, B
Objectives: To evaluate surgeons’ adherence to the hospital guide-
lines for perioperatively administered antibiotics in both planned
and urgent interventions.
Methods: (1) Retrospective analysis in all planned surgical inter-
ventions performed between February and June 2002. Hospital
guidelines: a standard prophylactic regimen, varying according to
type of surgery, is printed on the anaesthesiology record via the
hospital information system (HIS). The anaesthesiologist is expec-
ted to follow these recommendations; they can however be over-
ruled by the surgeon. Data analysis: planned and actually
performed intervention and administered antibiotics data were
extracted from the HIS. (2) Prospective analysis of 40 consecutive
urgent interventions performed in April 2003. Hospital guidelines:
no standard regimen can be generated by the HIS in these cases;
instead, a handout listing the regimen for the most frequently per-
formed urgent interventions is available in the operating room
(OR). Data analysis: A junior staff member daily collected OR-tari-
ﬁcation/medication prescription forms and interviewed surgeons.
Results: (1) Only the 1051 cases where there was total agreement
between planned and performed interventions (¼75% of all
planned interventions) were analysed. Overall, antibiotic prophy-
laxis was correct in 73% of interventions. In only 4.8% of cases
where prophylaxis was indicated and given, another molecule
than the one proposed, was administered. Incorrect prophylaxis
was observed in 2.5% of cases where an antibiotic was given
although it was not indicated and in 24.4% of cases where no
antibiotic was given although it was indicated. Many of these
cases were laproscopic interventions for which the surgeons –
having acquired more experience with these techniques – had
asked the anaesthesiologist to diverge from the original guide-
lines. (2) In 30 of 40 (75%) urgent operations antibiotic prophy-
laxis was given if indicated or withheld if not. In only 6 of 14
interventions where antibiotic prophylaxis was indicated the right
molecule was administered (4) or the motivation of divergence
was correctly registered (2). Many surgeons did not know about
the hand-out.
Conclusions: Providing easy access to guidelines improves compli-
ance with adequate prophylaxis: the choice of antibiotic was more
adequate in planned than in urgent interventions. In addition,
guidelines should be adapted regularly and attention should be
given to good communication.
P1191 Use of overnight processing of bacteriology samples
to modify antibiotic prescribing habits in the community
I.M. Gould, F.M. MacKenzie, L. Shepherd
Aberdeen, UK
Objectives: Through the use of accelerated bacteriology laboratory
examination (ABLE) of community specimens, antibiotic prescri-
bing in the Grampian region of Scotland has reduced by 30% in
the last 6 years. Antibiotic use declined signiﬁcantly more in gen-
eral practices that used the system than didn’t and more in Gram-
pian compared with the rest of Scotland. In this study, we present
an audit of antibiotic prescribing in Grampian and of how ABLE
is being used to reduce prescribing.
Methods: Ten general practices were audited in the spring of
2003, including ﬁve high ABLE users and ﬁve low-users. The
low-users of the ABLE service provided prescription lists for all
consecutive patients receiving an antibiotic. The high-users of the
service provided prescription lists only for consecutive patients
entered into the ABLE system. Antibiotic prescription data and
laboratory data were entered into an Excel spreadsheet and
analysed using SPSS.
Results: Grampian is in the N.E. of Scotland with a population of
540 000 and approximately 90 general practices. A total of 699
patients were audited of which 357 were entered into the ABLE
system and 342 were not. A total of 31% were male and 69%
female. 419 specimens (367 ABLE, 62 non-ABLE) were sent for
culture of which 162 were positive (130 ABLE, 32 non-ABLE). A
total of 43.2% were urines, 27.7% throat swabs, 8.8% sputum
samples and 4.5% wound swabs. An antibiotic was prescribed in
472 cases including 130 (36.3%) of the 357 ABLE patients, all of
whom were culture positive. Totally, 27.6% of ABLE patients
returned to the GP surgery for their prescription, 6.7% had the
prescription sent to their community pharmacy and 65.7% had a
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delayed action prescription. In all, 32.3% of patients made a
repeat visit to their GP, largely because of persistent symptoms.
The repeat visit rate was very similar between the two groups
(104/324 low ABLE vs. 111/343 ABLE).
Conclusions: This audit suggests that ABLE is being used cor-
rectly, with only 33% of ABLE patients receiving an antibiotic
prescription at ﬁrst consult. This ﬁgure is very similar to our ori-
ginal study. It can be concluded that ABLE is being used correctly
and that it is likely to be partially responsible for the lower antibi-
otic prescribing rates in Grampian.
P1192 Inﬂuence of an antibiotic facilitator in a surgical
unit
I.M. Gould, E. O’Driscoll, B. Jappy
Aberdeen, UK
Objectives: Improved liaison with the microbiology laboratory
and auditing of prescriptions have been suggested as possible
ways of improving the quality of antibiotic prescribing. These
strategies were investigated in a large teaching hospital where
antibiotic consumption is high.
Methods: A clinical pharmacology MSc student audited prescri-
bing on two general surgical units in our hospital. In one unit (I)
she attended daily morning ward rounds and provided copies of
the latest microbiology reports for discussion.
Results: 209 patients were studied over a 3-month period. Mean
hospital stay was 8 days. In all 127 patients received prophylaxis
(P), 97 received empiric therapy (E) and 15 received both P and E.
Both units had similar rates of antibiotic prescribing; 19.7% in
control (C) vs. 21.3% in I. Combination therapy was used in 55%
of patients, usually metronidazole plus either cefotaxime (CTX),
gentamicin or trimethoprim. Co-amoxiclav was the most common
mono-therapy. Most P was single dose although 14 and 21
patients were given two and three doses of CTX, respectively.
Although not statistically signiﬁcant, the number receiving E (97)
and microbiology tests (151) were both higher in I (54 vs. 46%
and 56 vs. 44%). Negative culture results (57% of I and 37% of
C) led to discontinuation of treatment in only one patient. In light
of positive culture results the proportion of patients where E was
satisfactory was higher in I than C [11 of 21 vs. 3 of 18 (P ¼ 0.06)]
although appropriate streamlining was carried out on all but one
patient. Positive culture results led to initiation of therapy in three
patients.
Conclusions: I used the laboratory more frequently than C and
also used more appropriate E. However, the effects of the inter-
ventions were probably modest as C was quick to streamline ther-
apy on receipt of culture results. An antibiotic facilitator had a
modest but positive impact on prescribing and use of laboratory
services and could be used in a wider role to delay or stop treat-
ment more quickly in minor infections and shorten P.
P1193 Perioperative antibiotic prophylaxis – adherence to
local hospital guidelines
V. Adamson, P. Mitt, H. Vestman, M. Maimets
Tartu, Pa¨rnu, EST
Objectives: The use of antimicrobial prophylaxis (AMP) for selec-
ted surgical procedures is one of the measures used to prevent
the development of surgical site infections (SSIs). In our hospital,
the guidelines for surgical AMP were developed in 2002 accord-
ing to the CDC recommendations for the prevention of SSIs. The
main recommendation was the administration of cefazolin or ce-
foxitin 30 min before skin incision. The aim of the current study
was to evaluate the prescribing patterns of surgeons for AMP
before the implementation of the guidelines and to study adher-
ence to the guidelines after its enforcement.
Methods: Retrospective analysis by reviewing anaesthetic records
within two periods each with the duration of one month: Septem-
ber 2001 (a year prior to the implementation of the above guide-
lines, period I) and September 2003 (a year after the
implementation of the above guidelines, period II). The following
data were recorded: type of procedure, choice of antibiotic, timing
of the ﬁrst dose, dosing interval of antibiotic and whether the
AMP was indicated or not.
Results: There were 1238 and 1404 operations performed within
period I and period II, respectively. AMP was applied in 450
(36%) of cases in period I and 732 (52%) of cases in period II.
Antibiotics used in period I: ceftriaxone 22%; ampicillin combined
with gentamicin 19%; cefuroxime 17%; cefazolin 9%. Antibiotics
used in period II: cefazolin 84%; cefoxitin 7%. Timing of the ﬁrst
dose was appropriate in 32% (period I) and 45% (period II) of
cases. Antibiotic indication, choice, dosing interval were concor-
dant with the hospital guidelines in 80, 89, 96%, respectively, in
period II. Overall percentage of adherence to all studied aspects
of the guideline was 57%.
Conclusions: This study shows that the implementation of the
guidelines inﬂuences the prescribing patterns of surgeons for
AMP. Perioperative use of antibiotics increased within period II.
Timing of the ﬁrst dose of AMP needs to be improved in partic-
ular. Further educational efforts are considered necessary in the
future.
P1194 Increase and change in patterns of hospital
antimicrobial use, Denmark, 1997–2001
M. Muscat, B. Mu¨ller-Pebody, B. Pelle, B.M. Klein, D.L. Monnet
Copenhagen, DK
Objectives: To analyse the changes in antimicrobial use in Danish
public hospitals over the period 1997–2001.
Methods: Data on the number of WHO deﬁned daily doses
(DDD) of antimicrobials were obtained from the Danish Medi-
cines Agency. Data on the number of patient-days were obtained
from the National Board of Health. Psychiatric hospitals, a neuro-
logical centre, a rehabilitation centre, as well as psychiatric, outpa-
tient and day wards were excluded. For each hospital, we
calculated the number of DDD per 100 patient-days for both the
total antibacterials for systemic use, i.e. group J01 of the Anatom-
ical Therapeutic Chemical (ATC) and for selected classes of this
group.
Results: Between 1997 and 2001, antimicrobial use in Danish hos-
pitals increased 18% from 38.7 to 45.7 DDD per 100 patient-days.
Most of the increase (62%) was attributed to commonly used
groups of antimicrobials, mainly penicillins with extended spec-
trum (ATC group J01CA) and the beta-lactamase sensitive (J01CE)
and resistant penicillins (J01CF) (Figure 1). There was also an
increase in newer ‘broad-spectrum’ antimicrobials, i.e. combina-
tions of penicillins with beta-lactamase inhibitor (J01CR), cephalo-
sporins (J01DA), carbapenems (J01DH) and ﬂuoroquinolones
(Figure 1), contributing to 38% of the increase in total use. These
‘broad-spectrum’ antimicrobials represented 19% of total use in
the Danish hospital sector in 2001. Moreover, there were large
variations among hospitals in their use of both the total antimicro-
bials and the speciﬁc classes.
Figure 1. Use of selected antimicrobials in hospitals in Denmark,
1997–2001.
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Conclusions: This increase and change in pattern of antimicrobials
used in Danish hospitals is a cause of concern and necessitates
close monitoring. Possible explanations include (1) a trend
towards earlier discharge resulting in a higher number of admis-
sions (possibly more doses for surgical prophylaxis, (2) longer
hospital stays required mostly by sicker patients who more often
receive antimicrobial treatment, (3) the more frequent prescription
of combination therapy, and (4) intensive marketing of ‘broad-
spectrum’ antimicrobials. As a ﬁrst intervention, we are now
establishing stratiﬁcation criteria and standards for comparisons
of antimicrobial use levels among hospitals with similar character-
istics.
P1195 Restricted antibiotic evaluation and
pharmacoeconomic outcomes
I. Gasco´n, F. Jover, J.M. Cuadrado, M.A. Pardo, T. Aznar,
V. Ortiz de la Tabla, C. Martı´n, M. Martı´nez, M.D. Camacho
Alicante, E
Objectives: Implantation of a program to evaluate the quality of
restricted antimicrobial agents prescription and pharmacoeconom-
ic outcomes of the intervention proposed by the multidisciplinary
antimicrobial management team (AMT).
Methods: AMT is integrated by an infectious disease physician, a
clinical pharmacist and a clinical microbiologist. From 1 October
to 23 November 2003, all hospitalised patients with restricted anti-
biotic prescription were daily reviewed by the AMT. Revision cri-
teria were according to the Infection Disease Committee
Guidelines, based on the Sanford Guide to Antimicrobial Therapy.
Clinical, microbiological and pharmacological data were collected
from each patient. Antibiotic therapy appropriateness, restricted
therapy eligibility, length treatment and economics outcomes were
evaluated, and an alternative antibiotic was considered when
necessary. Economic evaluation included only the medication cost.
Statistical analysis was performed with the SPSS package.
Non-parametric test were used.
Results: 70 patient prescriptions were reviewed. Restricted agents
prescribed were ceftazidime (34.3%), imipenem (25.7%), amikacin
(17.1%), piperacilin-tazobactam (10%), cefepime (7.1%), merope-
nem (2.9%), aztreonam (1.4%) and teicoplanin (1.4%). Most fre-
quent diagnostic was sepsis/febrile syndrome (32.9%), following
by gastrointestinal (20%) and respiratory (17%) pathologies.
Microbiological culture was performed in 64.3% of patients. Anti-
biotic therapy was not recommended in 15.7% cases and the
restricted antibiotherapy were not suitable in 54.3%. The average
of treatment length prescribed was 7 days, which is statistically
different respect to the median 4 days recommended by the AMT
(P < 0.001). These extra days would result in a 9460 cost. The
total restricted antimicrobial cost was 17067 (243 /patient),
where 1675 correspond to not appropriate therapy amount.
Approximately the half amount of right antibiotic prescription
belongs to not eligible restricted therapy (7467 ), that could be
substituted by better alternatives (1950 ). The total AMT interven-
tion saving would have been 7190 (102 /patient).
Conclusion: Restricted antibiotics prescription is not appropriate
in more than half the cases evaluated. There is a low microbiolo-
gical justiﬁcation of prescription and the antibiotic treatment
length is overestimated. The AMT intervention would result in an
important saving.
P1196 Comparison of antimicrobial resistance in hospital-
acquired and community-acquired bacteraemia
R. Reynolds, N. Potz – BSAC Working Party on Bacteraemia
Resistance Surveillance
Objective: To compare prevalence of antimicrobial resistance in
blood-derived isolates from patients hospitalised for more than
48 h (in >48), assumed to represent hospital-acquired infections,
with those from all other patients (in <48).
Methods: Bacteraemia isolates were collected from a total of 29
laboratories in the UK and Ireland in 2001 and 2002, excluding
duplicates within one week. Isolates were centrally tested by
BSAC agar dilution MIC method and categorised by BSAC break-
points. Percentages were compared by exact test.
Results: The table shows percent resistant (intermediate for peni-
cillin, positive for ESBL). Estimates of percentage resistance were
higher in isolates from patients hospitalised >48 h for most anti-
microbials in all six groups reported here. The increase was statis-
tically signiﬁcant for most antimicrobials with S. aureus, reﬂecting
the endemic presence of EMRSA 15 and 16 in our hospitals. It was
also signiﬁcant for many antimicrobials with CNS; penicillin with
S. pneumoniae; piperacillin-tazobactam, cefuroxime and ESBLs with
klebsiella; and cefuroxime and ESBLs with enterobacter. In other
cases, the study lacked power to detect increases from a low base-
line: even 200 isolates per group are too few to detect a change
from 1 to 5%, 5 to 10%, or 20 to 30% reliably at 5% signiﬁcance
level. There was no resistance to linezolid in these Gram-positive
bacteria, or to imipenem in these Enterobacteriaceae.
Conclusion: Antimicrobial resistance was more prevalent in
hospital-acquired infection than in infections acquired elsewhere.
ESBLs were much more prevalent in, but not exclusive to, isolates
from patients hospitalised >48 h.
P1197 The impact of a nationwide antibiotic restriction
policy on antibiotic usage and cost
A. Azap, K.-O. Memikoglu, F. Cokca, E. Tekeli
Ankara, TR
Objective: Antibiotics are the most commonly prescribed drugs in
Turkey. Most of the health expenditure is spent for antibiotics.
The government has released a regulation in February 2003 in
order to decrease antibiotic expenses, and injudicious use of anti-
microbial agents. The aim of the study is to assess the impact of
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n ¼ 167
in<48
n ¼ 111
in>48
n ¼ 241
in<48
n ¼ 324
in>48
n ¼ 96
Oxacillin-R 29.1 50.2 64.9 79.3
Penicillin-I & R 6.2 13.5
Ciproﬂoxacin-R 33.5 48.3 37.8 56.8 24.4 20.8
Erythromycin-R 33.0 48.3 56.8 66.8 17.3 16.7
Tetracycline-R 3.8 2.6 48.6 56.0 4.0 3.1
Gentamicin-R 1.6 9.0 45.0 66.8 100.0 100.0
Imipenem-R 8.2 18.4 10.8 20.3 0.0 0.0
Piperacillin/
tazobactam-R
29.7 49.4 24.3 34.0 6.5 10.4
Linezolid-R 0.0 0.0 0.0 0.0 0.0 0.0
E. coli Klebsiella spp. Enterobacter spp.
in<48
n ¼ 296
in>48
n ¼ 177
in<48
n ¼ 198
in>48
n ¼ 236
in<48
n ¼ 99
in>48
n ¼ 231
Amoxicillin-R 57.8 62.1 98.5 98.7 94.9 95.2
Amoxicillin/
clavulanate-R
23.3 25.4 7.6 11.9 90.9 92.2
Cefuroxime-R 8.1 13.0 14.1 22.0 62.6 73.6
Ciproﬂoxacin-R 7.1 7.9 6.1 8.5 9.1 11.3
Gentamicin-R 11.8 10.7 4.0 8.5 10.1 15.2
Imipenem-R 0.0 0.0 0.0 0.0 0.0 0.0
Piperacillin/
tazobactam-R
3.0 4.5 5.6 11.4 15.2 23.8
ESBL-positive 1.0 2.3 2.5 7.2 2.0 10.0
CNS ¼ coagulase-negative staphylococci. ESBL ¼ extended spectrum beta-
lactamase
R ¼ resistant, I ¼ intermediate. *P < 0.05
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this nationwide antibiotic restriction policy (NARP) at a university
hospital.
Materials and methods: Ibn-i Sina Hospital is a 1200-bed university
hospital in which there was not any restriction on antibiotic pre-
scription before February 2003. The regulation released by govern-
ment in February 2003, divided the antimicrobial agents into four
groups. The ﬁrst group contains the antibiotics that can be pre-
scribed by any physician. Second group antibiotics can be pre-
scribed by any specialist. Third group antibiotics can be
prescribed by specialists for 3-day use but infectious diseases (ID)
specialist approval is necessary for longer treatments. Last group
antibiotics can be prescribed by only ID specialists. All hospital-
ised patients were visited on 18 February (prior to NARP) and on
15 September 2003 (after NARP), by ID specialists. Data were
recorded on individual forms for each patient receiving antimicro-
bial agent. The appropriateness of antimicrobial treatments were
assessed according to published guidelines by two ID specialists
and one ID professor. Chi-square test was performed, a P value of
<0.05 was accepted as signiﬁcant.
Results: Of the 856 hospitalised patients, 178 (20.7%) were
receiving antimicrobial treatment on the 1st prevalence day (18
February). On the 2nd prevalence day (15 September), 179
(20.8%) of 857 hospitalised patients were on antimicrobial treat-
ment. Before and after NARP, 64 and 71.5% of antimicrobial
treatments were judged appropriate, respectively (P ¼ 0.131).
Inappropriate antibiotic usage was higher in prophylactic use
than empiric use (40 vs. 10%, P < 0.01). The main reason for
inappropriateness in prophylactic use was longer duration of
prophylaxis than needed. Consultation requests from medical
departments increased from 8 to 36% (P < 0.01). After NARP
42.4% of the empirical treatments was begun after ID consulta-
tion, while it was 14.2% (P < 0.01) before NARP. The daily cost
of inappropriate use was 2.615 and 2.142 dollars, before and
after NARP, respectively.
Conclusion: NARP had a good but unsatisfactory impact on anti-
biotic usage and cost. We need other interventions for an optimal
outcome.
P1198 The relation between Escherichia coli resistance and
antibiotic consumption in Europe: an EARSS/ESAC study
N. Bruinsma, M. Elseviers, P. Schrijnemakers, E. Tiemersma,
J. Monen, R. Vander Stichele, H. Grundmann, H. Goossens and
EARSS and ESAC participants
Objectives: EARSS (European Antimicrobial Resistance Surveil-
lance System) and ESAC (European Surveillance of Antibiotic
Consumption) explored the linkage of their databases to investi-
gate the relationship between resistance of invasive Escherichia coli
isolates and antibiotic consumption in ambulatory care in Europe.
Methods: Of 18 countries, antibiotic susceptibility testing (AST)
data for aminopenicillins, 3rd generation cephalosporins, amino-
glycosides and ﬂuoroquinolones of primary invasive E. coli iso-
lates were extracted from the EARSS database for 2002. ESAC
provided total antibiotic consumption and consumption of the
antibiotic classes penicillins, cephalosporins, aminoglycosides, and
ﬂuoroquinolones in ambulatory care according to ATC/DDD clas-
siﬁcation for 2001. For statistical analysis a Spearman rank correla-
tion (Rs) test was used.
Results: A signiﬁcant correlation (P < 0.01) was found between
resistance to aminopenicillins (Rs ¼ 0.740), aminoglycosides
(Rs ¼ 0.680), ﬂuoroquinolones (Rs ¼ 0.697) and consumption for
the same antibiotic classes, except for consumption and resistance
to 3rd generation cephalosporins (Rs ¼ 0.401, P > 0.05). Probably
because 3rd generation cephalosporin resistance is mainly a hospi-
tal problem (outbreaks of ESBL positive strains) it is more related
to infection control and not reﬂected by consumption in ambula-
tory care. Aminopenicillin (Rs ¼ 0.740) and aminoglycoside resist-
ance (Rs ¼ 0.562) both correlated (P < 0.05) with consumption of
broad-spectrum penicillins, and may indicate genetic linkage.
Aminopenicillin (Rs ¼ 0.585) and ﬂuoroquinolone resistance
(Rs ¼ 0.534) both correlated with total ambulatory care consump-
tion (P < 0.05).
Conclusions: At this high aggregation level a lot of unknown and
uncontrollable factors can lead to confounding. However, correla-
tions were found between antibiotic resistance in E. coli and anti-
biotic consumption in ambulatory care, especially by antibiotic
class, signalling the presence of effects worthy of further ecologi-
cal investigations.
P1199 Faecal carriage of quinolone-resistant E. coli in
children in the community
J. Shapira, M. Raz, N. Keller, B. Shainberg, N. Yavzori,
E. Derazne, T. Halperin, G. Rahav, E. Rubinstein,
G. Regev-Yochay
Ramat Gan, Rishon Lezion, IL
Objectives: To deﬁne the prevalence and risk factors for faecal
carriage of quinolone resistant E. coli strains in children in the
community and to evaluate the mechanisms of resistance.
Methods: A cross-sectional study of children visiting their paedia-
tricians. E. coli was isolated from the stool of each child, obtained
by rectal swabs. Epidemiological data was gathered from the
patient’s ﬁle and parent questionnaire. Risk factors for carriage of
quinolone-resistant strains were assessed by univariate and multi-
variate analyses. Resistance to nalidixic acid (NA) and oﬂoxacin
(OFL) was established by the disc diffusion assay, and conﬁrmed
by MIC determination, using the agar dilution method. Activity
of efﬂux pumps in the NA-R strains was assessed with reserpine,
an efﬂux pump inhibitor. DNA sequencing identiﬁed mutations
in strains lacking efﬂux pump activity.
Results: 812 rectal swabs were obtained from children aged 0–
40 months. A total of 627 of the cultures (77%) yielded E. coli
strains. 133/627 (21%) of the isolates were NA-R. 32/133 (24%) of
the NA-R strains were also OFL-resistant (OFL-R). The NA-R iso-
lates were signiﬁcantly more resistant to all other antimicrobials.
The only risk factor for carriage of NA-R strains was younger age
(adjusted OR 3.12; 95%CI 1.85–5.28). Efﬂux pump activity was
found in 75 NA-R strains (44%), yet only in three OFL-R strains
(7%). Point mutation analysis of 20 NA-R strains showed that
most of the NA-R/OFL-R strains (n ¼ 8) exhibited three speciﬁc
mutations: gyrA83 – 100%, gyrA87 – 100%, and parC – 75%.
However, NA-R/OFL-S isolates (n ¼ 9) displayed fewer muta-
tions: gyrA83 – 89%, gyrA87 – 78%, and parC – 0%.
Conclusions: Quinolone-resistant E. coli is prevalent in children
despite no previous therapy with quinolones. Apart from young
age, no risk factors were found for faecal carriage of NA-R strains
by children. Efﬂux pump activity was associated with resistance
to NA, but not to OFL. Multiple target mutations were correlated
with higher-level resistance to quinolones.
P1200 Laboratory and hospital reference data for
validation of resistance data collected by the European
Antimicrobial Resistance Surveillance System (EARSS)
E.W. Tiemersma, N. Bruinsma, O. Lyytika¨inen, K.G. Kristinsson,
P. Schrijnemakers, J. Monen, J.E. Degener, H. Grundmann and
EARSS participants
Objectives: The European Antimicrobial Resistance Surveillance
System (EARSS) collects antimicrobial resistance data for ﬁve
invasive indicator pathogen species (Streptococcus pneumoniae, Sta-
phylococcus aureus, Escherichia coli, Enterococcus faecium and E. fae-
calis). Data are collected from almost 800 laboratories in 28
countries from 1999 onwards. A questionnaire was mailed to all
laboratories to assess the representativeness and validity of data
collected by EARSS and to calculate speciﬁc incidence rates.
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Methods: In the spring of 2003, a questionnaire with laboratory-
and hospital-speciﬁc questions was mailed via national distribu-
tors to participating laboratories. Information was collected on
geographic location, blood culture frequency, hospital type, and
degree of specialisation, catchment population, number of beds
and number of patient-days. With this information, we calculated
population coverage and the incidence of the infections monitored
by EARSS.
Results: The questionnaire was sent out in 22 of the 28 countries
participating in EARSS. In these countries, 306 of 379 laboratories
responded (81%). EARSS covered on average 70% of the national
population of these countries, which amounts to almost 94 million
inhabitants. In most countries, laboratories were evenly distri-
buted over the country. The number of blood culture sets per
1000 patient-days varied over Europe, being less than 15 in the
Eastern European countries and over 30 in most Northern Euro-
pean countries, as well as in the United Kingdom, Spain, France
and Israel. Plotting country-speciﬁc MRSA proportions against
incidences showed a high linear correlation (R2, 0.92) for almost
all countries, except for some Eastern European countries (Figure).
This is possibly due to the culturing of serious infections only,
leading to an overestimation of MRSA proportion, but an under-
estimation of MRSA incidence.
Conclusion: Good national coverage indicates that the EARSS data
give a good approximation of the situation of antimicrobial resist-
ance in Europe. EARSS susceptibility proportions correctly reﬂect
resistance incidence in most countries, although resistance might
be overestimated in some Eastern European countries.
Vaccines and immunisation
P1201 Modulation of immune response on ovalbumin
sensitisation in BCG immunised mice
W. Janaszek-Seydlitz, J. Michalkiewicz, B. Bucholc, P. Gorska
Warsaw, PL
Introduction: Epidemiological studies suggest an inverse correla-
tion between infections and development of atopy. The aim of this
study was to test whether a pre-existing Th1-type immune
response elicited by BCG immunisation could suppress allergic
sensitisation in Balb/c mice and whether such immunomodula-
tion is depended on immunogenicity of used BCG substrains.
Methods: Immunisation: Male Balb/c mice, aged 6–8 weeks were
immunised with an attenuated Mycobacterium bovis strains (BCG):
Moreau or Tice commonly used as BCG vaccines in infants.
1  106 CFU/0.1 mL PBS were injected in each mouse intraven-
ously. Control mice received PBS. Sensitisation: Half of immu-
nised mice were sensitised by repeated intraperitoneal injections
of 10 lg chicken ovalbumin (OVA) emulsiﬁed in 1.5 mg Al(OH)3
on days 14, 28 and 35. Control mice were injected with Al(OH)3
alone. Tissue culture of spleen mononuclear cells: Spleens from all
animals were prepared on day 42. Cells (MNCs) were stimulated
for 96 h with Concanavalin A (2.5 lg/mL) or 104 BCG/mL or
20 lg/mL OVA. Measure of lymphocytes proliferation: To some
of the cultures 3[H]-thymidine was added for the last 18 h
(1 lCi/well) and the proliferation rate was calculated. Determin-
ation of cytokines level: IL-4 and IFN-c were measured by ELISA
(OptEIA-kits) in supernatants of MNCs cultures.
Results: (1) Splenic MNCs of BCG (Moreau or Tice) immunised
mice after activation with Con A have shown higher prolifer-
ation rate (SIM ¼ 14.3; SIT ¼ 19.7) than, splenic MNCs of BCG
immunised and after then sensitised OVA mice (SIM ¼ 1.61;
SIT ¼ 2.11) or only OVA sensitised mice (SIM ¼ 5.55). The dif-
ferences were signiﬁcant (P < 0.001). (2) Signiﬁcantly higher level
of IFN-c production was observed in MNCs cultures of mice
immunised BCG (Moreau ¼ 3.4 ng/mL; Tice ¼ 4.4 ng/mL) than
in MNCs cultures of mice OVA sensitised (2.5 ng/mL). (3) The
animals that were immunised BCG and then sensitised OVA
have shown increase of production IFN-c (Moreau ¼ 3.2 ng/mL;
Tice ¼ 3.8 ng/mL). (4) Production of IL-4 was signiﬁcantly
higher in MNCs cultures of animals sensitised OVA (0.4 ng/mL)
than of animals immunised BCG (Moreau ¼ 0.2 ng/mL;
Tice ¼ 0.27 ng/mL) or immunised BCG and then sensitised
OVA (0.25 and 0.29 ng/mL).
Conclusions: BCG vaccine can modulate immune response of mice
on OVA changing it from Th2-type to Th1. Immunogenicity of
used BCG substrain has inﬂuence on intensity of Th2 immune
response inhibition.
P1202 Polyprenyls of plant origin augment speciﬁc
biologic activity of tick-borne encephalitis and rabies vaccines
S.V. Ozherelkov, R.S. Godunov, T.N. Kozhevnikova,
A.N. Narovlyansky, A.V. Pronin, A.V. Sanin
Moscow, RUS
Objectives: This study was aimed to reveal possible potentiating
effect of Phosprenyl compound (PC) upon speciﬁc biologic activ-
ity of tick-born encephalitis (TBEV) and rabies (RV) vaccines. The
main active ingredients of PC are polyprenyls extracted from pine
needles.
Methods: Vaccines effectiveness was estimated using standard
protective murine assay developed at the IPVE. Each group con-
sisted of 15 BALB/c mice, 12–14 g. Concentrated tick-born
encephalitis vaccine (TBEV) series 494 and 552, and rabies vac-
cine (RV) series 429, 430 were used throughout. PC was used as
a 0.4% solution. In the experiments with RV, the PC drug was
injected i.m. at a dose 25 mcg/mouse (10 RV dilutions from 1:5
to 1:10 000 were used). In the experiments with TBEV, PC was
diluted so that any dilution of the vaccine would contain
100 mcg PC, and this admixture was injected s.c. Control mice
were immunised with the vaccines only. RV or TBEV was injec-
ted twice with 1-week interval. Seven days later mice were
infected with either of the two viruses. TBE virus was injected
i.p., at a dose 100 LD50/0.2 mL, and rabies virus s.c., at a dose
600 LD50/0.1 mL). Simultaneously with each of the vaccine,
mice were injected with PC according to two protocols: when
injected with TBEV, to each of the vaccines dilutions 100 mcg of
PC was added and injected in one syringe; when vaccinated
with RV, mice were also injected with PC (i.m. 25 mcg/mouse).
After infection, all mice were supervised for 3–4 weeks and
numbers of ill and dead mice were estimated. Index of mortal-
ity, and 50% minimal immunising dose (MID50) were then cal-
culated.
Results: PC was found to signiﬁcantly increase speciﬁc protective
activity of RV: when injected simultaneously with PC, index of
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RV’s protective activity was increased 1.9-fold compared with
immunisation protocol without PC. Similarly, MID50 of TBEV
injected simultaneously with PC was augmented 8–10-fold in
comparison with the control.
Conclusion: Taken together, our data prove that PC is able to po-
tentiate speciﬁc biologic activity of viral vaccines against tick-born
encephalitis and rabies. The effect of PC was observed following
both i.m. and s.c. injections. Possible mode of the above PC action
may be connected with the earlier revealed ability of PC to acti-
vate mononuclear phagocyte cells at early stages of the immune
response development, and to augment IL-1, IL-4, IL-5, and IL-6
production. Adjuvant effect of PC for RV in dogs was also
revealed in our previous studies.
P1203 The assessment of 3 years of routine vaccination
against Haemophilus inﬂuenzae b in the Czech Republic
V. Lebedova, C. Benes, P. Kriz
Prague, CZ
Objectives: Routine vaccination against Haemophilus inﬂuenzae b
(Hib) of infants using tetravalent DiTePe+Hib vaccine was intro-
duced in the Czech Republic in July 2001. Three years before the
introduction of this mass vaccination the nation-wide active sur-
veillance of invasive diseases caused by Hib was introduced.
These conditions provided an excellent possibility to assess the
impact of routine vaccination against Hib.
Methods: The active surveillance was introduced in January 1999
and case deﬁnition of invasive Hib disease included meningitis,
epiglottitis, bacteraemia and/or sepsis, pneumonia and arthritis.
According to the laboratory results, Hib cases were deﬁned as
conﬁrmed, probable and suspected. After the introduction of rout-
ine Hib vaccination of infants, the surveillance was extended by
the reporting of Hib vaccination failure (three categories according
to the classiﬁcation used in the UK): true vaccine failure, apparent
vaccine failure and possible vaccine failure.
Results: A total incidence of Hib invasive disease ranged between
1.0 and 1.1/100 000 population before the introduction of routine
Hib vaccination (in 1999 and 2000). The highest incidences in both
years were in the age groups 0–11 months (17.1/100 000, and
15.6/100 000, respectively) and 1–4 years (17.4/100 000, and 20.9/
100 000, respectively). The active surveillance data for 2001–2003
indicate the decrease of Hib invasive disease in the target age
group (0–11 months) after the introduction of routine Hib vaccin-
ation, in which the age speciﬁc morbidity was 15.6/100 000 in
2001, 3.3/100 000 in 2002 and 3.3/100 000 in 2003 (preliminary
data for 2003). Data of vaccine failure are as follows: one case of
possible vaccine failure in 2001, no vaccine failure in 2002 and
two true vaccine failures in 2003 (preliminary data for 2003).
Conclusion: Routine Hib vaccination of infants was introduced in
the Czech Republic in July 2001. The results of active surveillance
indicate rapid decrease of Hib invasive disease in the target age
group under the inﬂuence of this mass vaccination. Hib vaccine
failure is very rare.
Acknowledgement: This study was supported by research grant
NI/6803-3 of the Internal Grant Agency of the Ministry of Health
of the Czech Republic.
P1204 Changes in distribution of pneumococcal serotypes
in the Czech Republic between January 1996 and December
2003
J. Motlova
Prague, CZ
Objectives: Any project to develop and/or introduce an appropri-
ate narrow spectrum conjugate pneumococcal vaccine implies col-
lecting serotype data from different countries all over the world.
We have reviewed the capsular serotypes/serogroups of pneumo-
cocci identiﬁed from invasive diseases in the Czech Republic (CR)
between January 1996 and December 2003.
Methods: Pneumococci isolated from patients with invasive dis-
eases were typed using the quellung reaction with antisera from
the Statens Serum Institut, Copenhagen.
Results: A total of 1531 strains from blood, cerebrospinal ﬂuid
(CSF), section material (1022 strains), pleural aspirate, bronchial
aspirate and bronchoalveolar lavage ﬂuid (509 strains) were exam-
ined; 239 out of them were collected from young children (under
5 years), and 1292 from older children and adults (5 years or
more). In descending order of frequency, types 3, 19F, 23F, 1, 14
and 4 were common to all age groups, while types 6B (13%), 19F
(12%), 14 (11%), 1 and 23F (8% each), 3 (7%) and 6A (5%) were
signiﬁcantly associated with young children and types 3 (14%),
19F (8%), 1, 14 and 23F (6% each) and 4 and 8 (5% each) were
prevalent in older children/adults. The coverage of the 7, 9 and
11-valent conjugate vaccines was substantially higher in children
as young as 5 years with 63, 70, and 80%, respectively, compared
with 35, 40, and 59% in the other age group. We investigated
changes in pneumococcal serotypes distribution between the years
1996 and 2003. The proportion of pneumococcal infections caused
by the seven serotypes included in the conjugate vaccine
increased signiﬁcantly from 56 to 72% in young children, and
from 22 to 39% in older children/adults. The proportion of infec-
tions caused by the epidemic serogroups (1–3 and 5) in patients
regardless of age decreased slightly from 20 to 16%. During the
period studied, a progressive increase in the incidence of strains
of serogroup 4 from 2 to 9% was recorded. Strains of serogroup 5
were detected rarely, serogroup 2 was not identiﬁed.
Conclusion: Although a signiﬁcant increase in the incidence of
serotypes/serogroups included in the so far only licensed 7-valent
conjugate pneumococcal vaccine was found in the CR for the per-
iod 1996–2003, the 11-valent conjugate formulation only remains
suitable for use among the Czech population. Serogroups 1 and 3
regularly prevail in clinical specimens of all types collected from
patients with invasive infections of all age groups.
P1205 Efﬁcacy of a vaccine against Salmonella enteritidis
based on Gantrez nanoparticles as adjuvant and delivery system
C. Gamazo, J. Ochoa, J. Irache
Pamplona, E
Objectives: The most commonly used adjuvants for human use
are aluminium salt derivatives. However, they present some
drawbacks including irritation and inﬂammation, undesirable IgE
production (strong Th2 response) and incapacity to elicit effective
Th1 cellular immune response. Other adjuvants, including Fre-
und’s adjuvant, primarily induce a Th1 response but the side
effects are not acceptable for human use. In the current communi-
cation, we introduce nanoparticles of Gantrez as an alternative
adjuvant.
Methods and results: Salmonella enterica serovar Enteritidis
(S. Enteritidis) is a major cause of human food-borne illness. The
development of stable, efﬁcacious, and safe live vaccines to pre-
vent human and poultry salmonellosis is still a major challenge.
Live attenuated vaccines administrated parenterally are protective
and used widely in poultry. However, they cause some inconveni-
ence related with their residual virulence and instability related
with storage. An alternative is the employment of subcellular vac-
cines containing immunodominant components of the bacteria
and the appropriate safe immunoadjuvant. Accordingly, an anti-
genic extracts from S. enteritidis (clinical isolated) was obtained
after a heat treatment in saline of whole bacteria [HE extract, con-
taining ﬂagellin, porins, OmpA, ﬁmbriae (14–22 kDa), among
other proteins, and LPS]. In order to improve the immunogenicity,
HE was loaded in Gantrez nanoparticles of a size close to 200 nm.
Chemical and serological analysis indicated that HE encapsulated
conserved its antigenicity. The protection conferred by immunisa-
tion with free HE or HE-Gantrez nanoparticles against a lethal
dose of S. enteritidis in BALB/c mice was similar (90 vs. 80%,
after 21 days post-challenge). By contrast, empty nanoparticles
conferred only 20% of protection, and all control mice died after
6 days post-challenge. Spleen cells from immunised mice with
HE-nanoparticles elicited a higher level of IFN-gamma with
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respect to free HE (801 vs. 373 pg/mL, respectively, on day 10
post-immunisation); furthermore, the speciﬁc humoral immune
response induced corresponded with an enhanced Th1 response
as well (IgG2a/IgG1, 4.51 vs. 2.98, respectively).
Conclusions: Nanoparticles of Gantrez provide a safe and easily
manufactured vaccine adjuvant and delivery system. Further
studies in new experimental conditions are now in progress in
order to conﬁrm the beneﬁcial properties of this new adjuvant.
P1206 The effects of gene deletions in recombinant
vaccinia virus (rVV) genome on anticancer immunity induced
by rVV based vaccine
J. Mackova´, Sˇ. Nemeckova´, L. Kutinova´, J. Krysˇtofova´, P. Hainz,
P. Ota´hal, V. Sroller, P. Gabriel
Prague, CZ
Objectives: The association between human cervical carcinoma
and infection with high-risk human papillomaviruses (e.g. HPV16,
HPV18) has been proved formerly. A therapeutical vaccine effect-
ively enhancing cell-mediated immune responses against tumour-
associated antigens would offer a great potential for the treatment
of cervical cancer. Our aim was to examine the role of B8R, A44L,
C7L and C23L/B29R rVV genes for immunogenicity of the model
vaccine based on recombinant vaccinia virus expressing modiﬁed
HPV16 E7 tumour antigen.
Methods: Recombinant viruses were derived from strain Praha,
clone 13. Deletion mutants were prepared by homologous recom-
bination with DNA of specially constructed plasmids. HPV16 E7
gene carried three point mutations in Rb-protein binding domain
(rVV-E7ggg). Dendritic cells were derived from C57Bl/6 mice
bone marrow and cultivated in presence of GM-CSF cytokine. The
immune response was detected by IFN-gamma ELISPOT and tetr-
amer assays. Anticancer immunity was shown as tumour growth
protection after challenge with tumorigenic TC-1 cells.
Results: (1) Dendritic cells supported protective effects of rVV-
E7ggg immunisation. (2) In vitro tests of cell-mediated immunity
showed that after i.p. administration, there was no difference
between B8R (encodes soluble IFN-gamma receptor) deleted virus
and virus without deletion. (3) B8R gene deletion increased im-
munogenicity of intraperitoneally administered rVV in in vivo
experiment. (4) Viruses with A44L or C23L/B29R (soluble recep-
tor for CC chemokines) deleted genes induced lower cellular
response. (5) A44L (3-beta hydroxysteroid dehydrogenase) gene
deletion did not inﬂuence the protection after rVV i.p. immunisa-
tion. (6) B8R, A44L and C7L (host-range protein) gene deletions
did not affect immunogenicity of rVV transduced dendritic cells.
Conclusions: Our results showed that products of B8R, A44L or
C7L genes do not affect immunogenicity of dendritic cell-based
vaccines.
Antimicrobial susceptibility in Gram-negative bacteria - II
P1207 Simple method to evaluate the in vitro activity of
several antimicrobial agents against bacterial bioﬁlms
J. Alcala´, I. Garcı´a, L. Martı´nez-Martı´nez, E.J. Perea, A´. Pascual
Seville, E
Objectives: The use of prosthesic materials for temporary or per-
manent implantation has been accompanied by the emergence of
implant-associated infections, which are difﬁcult to eradicate.
Standard in vitro susceptibility tests only evaluate antimicrobial
agent activity against planktonic bacteria and do not evaluate
adherent bacteria. In the present study we have developed a sim-
ple and reproducible method to evaluate in vitro bactericidal
activity of several antimicrobial agents against sessile bacteria.
Moreover, bactericidal activities of these antimicrobial agents
against planktonic and adherent bacteria have been evaluated.
Methods: Escherichia coli (ATCC 25922) and Pseudomonas aeruginosa
(ATCC 27853) were used. Minimal inhibitory concentration (MIC)
and minimal bactericidal concentration (MBC) were determined
by broth microdilution method, according to NCCLS guidelines.
The antimicrobial agents tested were: ampicillin (AMP), cefuroxi-
me (CFX), cefotaxime (CTX), ciproﬂoxacin (CIP), gentamicin
(GNT), trimethoprim/sulfamethoxazole (SXT), imipenem (IMP)
and meropenem (MRP) against E. coli, and piperacillin (PIP), CIP,
GNT, tobramycin (TBM), ceftazidime (CTZ), cefepime (FEP), IMP
and MRP, against P. aeruginosa. MBC of adherent bacteria
(MBCADH) was determined from the 96-well plates used for MIC
and MBC determinations. Plates were washed two times with
cold PBS. At this time, 150 lL of PBS were added to each well,
the plates were sealed and adherent bacteria were detached by so-
nication. Surviving bacteria were determined by plating. All
experiments were performed ﬁve times.
Results: With E. coli the MBCADH values of AMP, CFX and CTX
were 32, 512 and 64 times higher than MBC of suspended bac-
teria, respectively. Carbapenems-MBCADH values were 512 times
higher than MBC. MBCADH values of CIP, GNT and SXT were
32, 64 and 256 times higher than MBC, respectively. With P. aeru-
ginosa, MBCADH values of PIP, CTZ, FEP and both carbapenems
were 256 times higher than MBC. CIP-MBCADH values were also
256 times higher than MBC and aminoglycosides-MBCADH val-
ues were 512 times higher than MBC.
Conclusion: The developed method is simple and reproducible to
evaluate in vitro activities of tested antimicrobial agents against
sessile bacteria. For all antimicrobial agents tested, and with both
strains, the MBC of adherent bacteria was always much higher
than MBC of suspended bacteria.
P1208 Antibiotic resistance markers (ARMS) in the
Bacteroides fragilis group (Bfg): Clindamycin (CL), Cefoxitin
(FOX), and Trovaﬂoxacin (TV) alone and in combination
K. Aldridge, S. Broyles
New Orleans, USA
Objectives: Antimicrobial resistance in Bfg has continued to
increase to several classes of agents, but little is known about
multiresistance among Bfg. This study determined the effect of
selected ARMS as phenotypic predictors of cross-resistance (C–R)
to other antimicrobials.
Methods: A total of 3100 clinical isolates of the Bfg were tested
for susceptibility to CL, FOX, TV, cefotaxime (TX), ceftizoxime
(ZX), cefotetan (TN), piperacillin (PP), ampicillin-sulbactam (AS),
piperacillin-tazobactam (PT), imipenem (IM), meropenem (ME)
and ertapenem (ER). MICs were determined by NCCLS broth
microdilution using the same test medium throughout. MICs were
collated to determine percentage of isolates susceptible (S) or
resistant (R). Statistical comparisons (odds ratios (OR) and adjus-
ted P-values) were established by Pearson’s chi-squared test fol-
lowed by Bonferroni stepdown adjustment.
Results: Overall % Cl and % Fox-R were 22 and 16%, respect-
ively, regardless of C–R to other agents, however, Cl-R was 13%
in the absence of Fox-R and Fox-R was 4% in the absence of Cl-R
(P < 0.05). When CL and FOX MICs were phenotypically linked
(SS to RR) increased C–R (%R) to other agents was noted for ZX
(9–52%; P < 0.01; OR, 2–11); TX (12–76%; P < 0.01; OR, 2–23); TN
(10–93%; P < 0.01; OR, 4–125); PP (6–68%; P < 0.01; OR, 3–35); AS
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(0.3–22%; P < 0.001; OR, 8–103); and TC (0.4–26%; P < 0.01; OR,
5–91). Neither CL nor FOX resistance increased the % R to PT
while both IM and ER but not ME were inﬂuenced by FOX and
CL (P < 0.05) alone and together. TV-R was 6% overall and 4%
without CL-R and FOX-R isolates. C-R was more signiﬁcant when
TV-R was linked to FOX-R. Only two isolates had a CL FOX TV-R
phenotype and were C-R to ZX, TX, TN, PP, AS, TC and ER but S
to PT.
Conclusions: Results demonstrate signiﬁcant associations among
ARMS of three separate classes, which predict C-R to beta-lactams
among Bfg. These analyses of phenotypic antibiotic resistance sug-
gest further investigation of genetic linkage and/or clinical out-
comes.
P1209 In vitro activities of BAL9141 and seven other beta-
lactam antimicrobial agents towards clinical isolates of 12
members of the Enterobacteriaceae family
M. Kresken, M. Heep
Bonn, D; Basle, CH
Objectives: BAL9141 is the ﬁrst of a new class of anti-MRSA ce-
phalosporins, which also possesses broad activities towards most
clinically relevant bacterial pathogens. This study aimed at evalu-
ating the in vitro activity of BAL9141 and seven other beta-lactams
against selected Enterobacteriaceae isolates including extended
spectrum beta-lactamase (ESBL)-producing strains.
Methods: A total of 209 isolates comprising 15 Citrobacter freundii,
20 Enterobacter aerogenes, 30 Enterobacter cloacae, 26 Escherichia coli
(11 of which were known to be ESBL-producers), 16 Klebsiella
oxytoca (ﬁve ESBL-producers), 42 Klebsiella pneumoniae (28 ESBL-
producers), and 10 each of Citrobacter koseri, Morganella morganii,
Providencia rettgeri, Providencia stuartii, Serratia liquefaciens, and Ser-
ratia marcescens were obtained from various culture collections in
Germany. MICs of BAL9141, cefepime, ceftazidime, ceftriaxone,
aztreonam, piperacillin, piperacillin-tazobactam, and imipenem
were determined by broth microdilution according to NCCLS
guidelines.
Results: BAL9141 displayed excellent activity against the majority
of isolates, but low activities towards ESBL-producing E. coli and
Klebsiellae. Activity of BAL9141 against individual species based
on MIC50- and MIC90 values (mg/L) and rates of susceptible
strains at the proposed breakpoint of 4 mg/L were as follows: C.
koseri (0.06/2/90%), C. freundii (0.06/0.5/100%), E. aerogenes
(0.06/0.125/95%), E. cloacae (0.125/2/93%), E. coli [overall: 0.125/
64/65%; known ESBLs: 64/128/18% others: 0.06/0.125/100%], K.
oxytoca (2/>64/56%), K. pneumoniae [overall: 4/64/50%; known
ESBLs: 32/64/25%; others: 0.125/0.5/100%], M. morganii (0.06/
0.06/100%), P. rettgeri (<0.06/<0.06/100%), P. stuartii (<0.06/
<0.06/100%), S. liquefaciens (0.125/1/100%), and S. marcescens
(0.125/0.25/100%). Overall, 80.4% of isolates were inhibited by
BAL9141 at 4 mg/L. This rate was comparable to those of ceftri-
axone (79.4%), ceftazidime (77.5%), and aztreonam (78.9%).
Conclusion: In addition to its anti-MRSA activity, the spectrum of
activity of BAL9141 towards members of the family Enterobacteri-
aceae resembles that of third generation cephalosporins and aztre-
onam.
P1210 Drug resistance patterns of typhoidal and non-
typhoidal Salmonella species in Hamadan, west of Iran
R. Youseﬁ Mashouf
Hamadan, IR
Objectives: The epidemiological studies indicate that the incidence
of salmonellosis is increasing throughout the world. The uncon-
trolled and inappropriate usage of antibiotics has caused multi-
drug resistance in these organisms, in recent years.
Methods: In a cross-sectional descriptive study, 204 strains of
typhoidal salmonella (T.S) and 114 strains of non-typhoidal sal-
monella (N.T.S) were examined to determine drug resistance. The
strains were collected from patients who referred to cilinical cen-
tres in Hamadan during 1999–2001. They were serotyped and
then tested for their antibiotic resistance patterns, using Kirby–Ba-
uer method for eight antibiotics.
Results: The salmonella isolated from patients were as follows: ‘S.
typhi, S. paratyphi A, B, C. S. typhimurium, S. enteritidis, S. cholerasu-
is, S. agona, S. arizona, S. infantis, S. havana, S. lexington and S. vir-
chow’. A proportion of strains (>60%) were resistance to
carbenicillin and ampicillin. Resistance to ciproﬂoxacin and nali-
dixic acid was very low (<15%). S. typhimurim (100%), S. typhi
(95.7%) paratyphi B (89.2%) and enteritidis (60%) showed multi-
drug resistance (MDR).
Conclusions: Our results showed that most of Salmonella spp. iso-
lated from patients in Hamadan city (the west of Iran) was resist-
ant to beta-lactam antibiotics, whereas, most of them were
sensitive to ﬂuoroquinolones antibiotics. We suggest that the use
of some newer antibiotics such as new ﬂuoroquinolones, ceftazi-
dime and aztreonam as effective therapy against salmonella spe-
cies in this region.
P1211 Efﬁcacy of crude extracts of Thai medicinal plants
on antibiotic-resistant Helicobacter pylori strains isolated from
peptic ulcers
S.P. Voravuthikunchai, S. Brusentsev, J. O’Rourke, H. Mitchell
Hatyai, Songkla, TH; Sydney, AUS
Objectives: Helicobacter pylori resistant rates to both metronidazole
and clarithromycin are now increasingly reported. The aim of our
study was to screen for effective medicinal plants widely used in
Thai traditional medicine for the treatment of this organism.
Methods: Twenty-four preparations of aqueous and ethanolic
extracts of 12 kinds of Thai herbs including Andrographis paniculat-
a, Centella asiatica, Curcuma longa, Garcinia mangostana, Peltophorum
pterocarpum, Piper betle, Psidium guajava, Punica granatum, Quercus
infectoria, Uncaria gambir, Walsura robusta, and Zingiber cassumunar
were tested for their antibacterial activity against 17 hospital
strains of antibiotic-resistant H. pylori, H. pylori ATCC 43504, and
H. pylori ATCC 43579. Inhibition of growth was preliminarily tes-
ted by the paper disc agar diffusion method. Antibiotic suscepti-
bility discs were used as control. Minimum inhibitory
concentration (MIC) was determined by the agar dilution method
in petri dishes with millipore ﬁlter.
Results: All clinical isolates tested proved susceptible to six medi-
cinal plants including P. pterocarpum, P. betle, P. granatum, Q. infec-
toria, U. gambir, and W. robusta. The inhibition zones (annular
radius) ranged from 9 to 23 mm. Among these extracts, P. grana-
tum, Q. infectoria, and W. robusta demonstrated the greatest inhibi-
tion zones, ranging from 15 to 23 mm. Both aqueous and
ethanolic extracts of P. granatum and Q. infectoria posessed signiﬁ-
cantly effective antibacterial activity against all strains of H. pylori
with the MIC values of 0.8 and 6.25 mg/mL, respectively.
Conclusions: As both aqueous and ethanolic extracts of P. grana-
tum and Q. infectoria were very effective against all strains of H.
pylori, these two plant species are being investigated in this labor-
atory to provide alternative treatment of H. pylori.
P1212 French multicentre study of antibiotic resistance
among Gram-negative anaerobes. Focus on decreased
susceptibility to metronidazole
L. Dubreuil, L. Calvet, F. Mory, C. Muller, M. Bezian, M. Choma-
rat, H. Jean-Pierre, S. Bland, T. Fosse, F. Golsdtein, H. Drugeon
Lille, Nancy, Paris, Bordeaux, Lyon, Montpellier, Annecy, Nice,
Nantes, F
Objectives: Survey of antibiotic resistance among Gram-negative
anaerobes.
Methods: MICs for amoxicillin, ticarcillin either alone or com-
bined with clavulanic acid, piperacillin–tazobactam, cefoxitin, imi-
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penem, clindamycin and metronidazole were determined using
the agar reference method (NCCLS, Norma M11A5) on 376 strains
collected in nine French hospitals in 2002–2003.
Results: Within the Bacteroides fragilis group, resistance rates
(NCCLS breakpoints) were, respectively: amoxicillin + clavulanic
acid 4.3%, ticarcillin 29.2%, ticarcillin + clavulanic acid and pip-
eracillin + tazobactam 0.2%, cefoxitin 6.3%, imipenem 0.08%,
clindamycin 38.5%. Resistance to metronidazole could not be
detected but 3.5% of the investigated strains demonstrated
decreased susceptibility to metronidazole (MIC ¼ 8 or 16 mg/L).
The same phenomena could be observed for 7/65 strains of Prevo-
tella. b-lactamase production was detected in 55% of Prevotella
strains and 5.4% of Fusobacterium strains. Considering Gram-neg-
ative bacilli other than the B. fragilis group resistance to piperacil-
lin-tazobactam, cefoxitin and imipenem could not be detected. On
the whole Gram-negative anaerobes resistance to clindamycin
reached nearly 30%, meanwhile 4.5% of the investigated strains
had decreased susceptibility to metronidazole.
Conclusion: Resistance rates were similar to those obtained in
2000–2001 but decreased susceptibility to metronidazole appeared
for the ﬁrst time among Prevotella species.
P1213 Rate of capnophilic Gram-negative bacteria isolated
from patients with periodontitis and study of their sensitivity to
selected antibiotics
M.H. Salari, M.H. Shirazi, R. Hafezi, G. Hassanpor
Tehran, IR
Objectives: Microbiological studies identiﬁed more than 200 bac-
terial species in periodontal pockets, only a limited number have
been implicated as periodontal pathogens. The purpose of this
study was to investigate the rate of capnophilic Gram-negative
bacteria in patients with periodontitis and to determine the sensi-
tivity of isolates to selected antibiotics.
Methods: Samples were collected with sterile paper points from
deepest periodontal pockets of 406 patients (161 males, 245
females; aged 18–55 years). The samples were cultured under cap-
nophilic conditions on selective media. Isolates were characterised
to species level by conventional biochemical tests. The sensitivity
of isolates to antibiotics was investigated by Kirby–Beuer method.
Results: The rate of isolates was 186 Actinobacillus actinomycetem-
comitans (45.8%), 152 Capnocytophaga species (37.4%) and 139 Eike-
nella corrodens (34.2%). The rate of samples associated with
monobacteria and polybacteria were 295 (72.7%) and 85 (20.9%),
respectively. Capnophilic Gram negative bacterial growth was not
observed in 32 samples (7.9%). The sensitivity of these bacteria to
ampicillin, was 67.1, 73.3, 44.2%; Chloramphenicol 94.9, 83.4,
90.7%; doxycyclin 90.9, 87.5, 86.4%; erythromycin 50.9, 86.8,
49.7%; tetracycline 94.9, 84.7, 78.6% and penicillin G 64.8, 70.5,
54.1%, respectively. The results of statistical analysis (Chi-square
test) show no signiﬁcant differences between sex (P > 0.60) and
also age groups of patients (P > 0.70).
Conclusion: It is concluded that, in the number of patients, sam-
ples, and the complexity of capnophilic Gram-negative bacteria
and in other samples only one of these bacteria were identiﬁed.
Further studies for identiﬁcation of other agents are suggested.
Meanwhile, the sensitivity of isolates to selected antibiotics was
relatively high.
P1214 In vitro activity of colistin against non-fermentative
Gram-negative bacilli
O¨. Kurt Azap, H. Arslan, F. Ergin, S. Karaman, U¨. Cagir
Ankara, TR
Objectives: Multi-drug resistance of Gram-negative nosocomial
isolates has become a problem in everyday clinical practice in the
intensive care units. Because no fundamentally new anti-infective
drugs are currently available, it appears that we need to re-evalu-
ate the ‘old’ drugs. Colistin, a polymyxin was used from the
1960s to the early 1980s. Because of toxicity considerations its sys-
temic use is completely abandoned. The aim of this study was to
evaluate the in vitro activity of colistin against non-fermentative
Gram-negative bacilli of which are difﬁcult-to-treat nosocomial
pathogens.
Materials and methods: A total of 132 non-fermentative Gram-neg-
ative isolates (55 Pseudomonas aeruginosa, 48 Acinetobacter baumanii,
21 Stenotrophomonas maltophilia, eight Burkholderia cepacia) were tes-
ted. Colistin was obtained from Sigma Chemicals and Co. Min-
imal inhibitory concentrations (MICs) were determined using agar
dilution technique.
Results: The antimicrobial activity of colistin against the Gram-
negative nosocomial isolates are summarised in the Table.
Conclusion: The results of this study are in broad agreement with
other published data and conﬁrmed that colistin has maintained
useful in vitro activity against P. aeruginosa and A. baumanii. Colis-
tin may be a good therapeutic option in the treatment of severe
infections caused by multi-drug resistant P. aeruginosa and A. bau-
manii.
P1215 Susceptibility testing of Stenotrophomonas
maltophilia: effect of temperature and medium on results
A. King
London, UK
Objective: Susceptibility testing of Stenotrophomonas maltophilia is
particularly difﬁcult and is affected by both temperature and
medium. The purpose of this study was to identify suitable test
methods and, if possible, interpretive criteria for appropriate anti-
biotics.
Methods: Seventy isolates of S. maltophilia were tested for suscep-
tibility to co-trimoxazole, minocycline, moxiﬂoxacin, co-amoxiclav
and aztreonam. MICs were determined on IsoSensitest and Mul-
ler–Hinton agars at both 37 and 30C. Disc diffusion zone diame-
ters were measured on IsoSensitest agar at both temperatures. In
addition chloramphenicol, ciproﬂoxacin and doxycycline were tes-
ted by disc diffusion only at 30C.
Results: In general, isolates grew better at 30C and MICs were
higher and zone diameters smaller. MICs of co-trimoxazole were
similar on both media at both temperatures and correlation with
zone diameters was good and microbiological breakpoints easy to
establish. For the tetracyclines correlation between MIC and zone
diameter was good but there were no isolates with high-level
resistance and, as MICs were close to the breakpoint recommen-
ded for other species, it was difﬁcult to establish zone break-
points. For all beta-lactams MIC results were higher on Muller–
Hinton than on Isosensitest agar and there was poor correlation
with zone sizes at both temperatures. Most isolates were clearly
resistant to chloramphenicol and ciproﬂoxacin but moxiﬂoxacin
had some potentially useful activity.
Conclusion: Susceptibility testing of S. maltophilia should be done
at 30C, the optimum temperature for growth. Co-trimoxazole can
be tested on either Muller–Hinton or IsoSensitest agar and micro-
biological breakpoints established with conﬁdence. The tetracy-
clines and moxiﬂoxacin can also be tested on either medium but
breakpoints are tentative because of the lack of isolates with high-
Table. The minimum inhibitory concentrations (MICs) of colistin
against the non fermentative gram-negative bacteria tested
MIC (mg/L)
Species (No. of isolates tested) Range MIC50 MIC90
A. aeruginosa (55) 2–	32 2 4
A. baumanii (48) 
0.5–	32 2 4
S. maltophilia (21) 4–	32 4 	32
B. cepacia (8) 4–	32 	32 	32
335Clinical Microbiology and Infection, Volume 10, Supplement 3, 2004
level resistance and distribution of MICs around the MIC break-
points. Interpretation of results for beta-lactam antibiotics is difﬁ-
cult; MICs are much higher on Muller–Hinton agar than on
IsoSensitest agar and there is little or no correlation between MIC
and zone size and for this reason they should not be tested by
disc diffusion until the clinical relevance has been assessed.
P1216 Bactericidal activity of ﬁve antimicrobial agents
against Campylobacter jejuni tested by time-kill studies
J. Engberg, K. Schønning, M. Voldstedlund, E. Dzajic,
N. Frimodt-Møller
Copenhagen, DK
Objectives: To evaluate the bactericidal activity of two macrolides
(erythromycin (MIC 2 mg/L) and azithromycin (MIC 0.06 mg/L)),
ciproﬂoxacin (MIC 0.25 mg/L), gentamicin (MIC 1 mg/L) and tet-
racycline (MIC 1 mg/L) against Campylobacter jejuni ATCC 33560.
Methods: Time-kill studies were performed in Campylobacter
Enrichment Broth (Bolton formula) incubated in a microaerobic
atmosphere at 42C. Bacteria were inoculated in broth medium to
a ﬁnal concentration of approximately 5  105 CFU/mL. Antibiot-
ics prepared in sterile water were added to ﬁnal concentrations of
0.25, 0.5, 1, 2, 4, 8 or 16  MIC. Samples (0.1 mL) were removed
at periodic intervals at 0.5, 0, 2, 5 and 18 h of incubation. Samples
were serially diluted 10-fold and subsequently spread on 5%
blood agar plates. After 1 or 2 days of incubation in a microaero-
bic atmosphere, the number of colonies was counted.
Results: A viability decrease of >1 log was not observed within
the initial 5 h of incubation regardless of concentration above MIC
of erythromycin and azithromycin. However, this bacteriostatic
phase was followed by a strong dose-independent bactericidal
activity of both agents. In contrast, gentamicin and ciproﬂoxacin
demonstrated rapid, dose-dependent bactericidal activities with
viability reductions after 2 h incubation of >3 log at 16  MIC for
both agents. Tetracycline exhibited bacteriostatic activity.
Conclusion: This study suggests that the activities of erythromycin
and azithromycin, two ﬁrst-line drugs for the treatment of campylo-
bacteriosis are similar. Gentamicin and ciproﬂoxacin exhibited rapid
and signiﬁcant bactericidal effects and support the position of the for-
mer as the drug of choice for systemic Campylobacter infections.
P1217 The effect of subinhibitory concentrations
(sub-MICs) of amikacin and ciproﬂoxacin on adherence of
P-ﬁmbriated Escherichia coli strains to human epithelial cells
D. Wojnicz
Wroclaw, PL
Objectives: The aim of this investigation was to examine the inﬂu-
ence of sub-MICs (1/2, 1/4 and 1/8 MIC) of amikacin (AN) and
ciproﬂoxacin (CIP) on adherence ability to P-ﬁmbriated E. coli
strains to human epithelial cells.
Methods: Two E. coli strains (315 and 5579) isolated from urinary
tract infections were used. The MICs of AN and CIP for each
strain in Mueller–Hinton broth were determined by using micro-
dilution method. Strains were grown in Tryptic Soy Broth to sti-
mulate the expression of pili. Human periurethral epithelial cells
were collected from fresh urine. Equal volumes of epithelial cells
and antibiotics treated bacterial suspension were mixed in tubes.
Following incubation, unattached bacteria were removed from the
suspension by centrifugation. The ﬁnal epithelial cell pellets were
dried on glass slides in air and then were May–Grunwald stained.
The attached bacteria on 40 separate cells were quantiﬁed by
direct light microscopy and adherence was determined as the
mean number of bacteria attached per cell.
Results: The mean number of bacteria attached to epithelial cell
before their exposure to sub-MICs of antibiotics (control) was 47.4
for E. coli 315 and 45.9 for E. coli 5579. After exposure to 1/2 MIC
of CIP the mean number of bacteria per epithelial cell was only
5.5 (E. coli 315) and 8.25 (E. coli 5579). After exposure to 1/4 MIC
of CIP the mean number of bacteria was 25.15 (E. coli 315) and
26.25 (E. coli 5579); after exposure to 1/8 MIC it was 30.7 (E. coli
315) and 30.6 (E. coli 5579). AN affected the bacterial adhesive
capacity less than did CIP. The mean number of bacteria attached
to epithelial cell was 36.8 (E. coli 315) and 40.8 (E. coli 5579) at
concentration 1/2 MIC of AN. After exposure to 1/4 MIC and 1/
8 MIC the mean number of bacteria (E. coli 315) per epithelial cell
was 40.6 and 42.4, respectively. After exposure to 1/4 MIC and
1/8 MIC the mean number of bacteria (E. coli 5579) attached to
one epithelial cell was 45.6 and 45.7, respectively. These values
corresponded to the values observed in control.
Conclusions: Sub-MICs of antibiotics decreased capacity of E. coli
to adhere to epithelial cells. Decrease of the number of bacteria
attached to one epithelial cell was proportional to concentrations
of antibiotics. The adhesive capacity of P-ﬁmbriated E. coli strains
was signiﬁcantly decreased after exposure to sub-MICs of CIP.
P1218 Activity of meropenem against Gram-negative
isolates from a Polish paediatric intensive care unit – part of the
MYSTIC (Meropenem Yearly Susceptibility Test Information
Collection) Programme, 1997–2003
J. Patzer, D. Dzierzanowska, A. Pawin˜ska, P. Turner
Warsaw, PL; Macclesﬁeld, UK
Objectives: The aim of this analysis was to assess the in vitro
activity of meropenem (MEM) and eight other antibiotics against
Gram-negative isolates from a Paediatric Intensive Care Unit
(PICU).
Methods: Between 1997 and 2003, 740 Gram-negative isolates
were recovered from a variety of specimens obtained from chil-
dren hospitalised in the PICU of the Children’s Memorial Health
Institute, Warsaw, Poland. Isolates were identiﬁed using conven-
tional methods. Minimum inhibitory concentrations (MICs) of
MEM, imipenem (IPM), piperacillin + tazobactam (TAZ), cefotaxi-
me (CTX), ceftazidime (CAZ), cefepime (CPE), gentamicin (GM),
tobramycin (TM) and ciproﬂoxacin (CIP) were determined using
the NCCLS agar dilution method.
Results: The collection of Gram-negative isolates included Escheri-
chia coli (n ¼ 107), Enterobacter cloacae (n ¼ 153), Klebsiella oxytoca
(n ¼ 58), Klebsiella pneumoniae (n ¼ 133), Serratia marcescens
(n ¼ 29), Acinetobacter baumanii (n ¼ 59), Pseudomonas aeruginosa
(n ¼ 154) and other species (n ¼ 47). Carbapenems, MEM and
IPM, were active against >90% of isolates, with the exception of
P. aeruginosa. CIP showed similar high activity. However, our
results are from PICU in which CIP is not used except for very
serious infections. The MIC90 (mg/L) of MEM was nearly identi-
cal in 1997 and 2003. It was equal to 0.03–0.125 for Enterobacteria-
ceae, 1.0 for A. baumanii and 8.0 for P. aeruginosa. The MIC90 of
IPM was equal to 0.25–0.5 for Enterobacteriaceae, 1.0 for A. bauma-
nii and 16 for P. aeruginosa. The overall order of activity of beta-
lactams was MEM > IPM > CPE > TAZ > CAZ > CTX. GM and
TM were active against 62.4 and 58.9%, respectively.
Conclusions: MEM and IPM were the most active antibiotics
(>90% susceptibility) against the tested isolates, with no observed
reduction in activity over 7 years. After the carbapenems, CIP was
the most active antibiotic, but CIP is very rarely used in children.
P1219 Stenotrophomonas maltophilia clinical isolates in a
tertiary care hospital: 5-year study
E. Platsouka, A. Kallimani, E. Perivolioti, M. Dimoutsos,
H. Belesiotou, O. Paniara
Athens, GR
Objective: To determine the incidence and the susceptibility to
antimicrobials of clinical isolates of Stenotrophomonas maltophilia in
a tertiary care hospital over a 5-year period.
Methods: During the 5-year period, December 1998 to November
2003, all S. maltophilia strains from clinical specimens were studied.
The isolates were identiﬁed by commercial available Pasco system
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(ID panels). Over the entire study period, susceptibility testing was
performed by the broth microdilution method using the Pasco sys-
tem (MIC panels) and the Etest strips to different antimicrobial
agents according to the recommendations of the NCCLS guidelines.
Pseudomonas aeruginosa ATCC 27853 was used as quality control.
Results: A total of 146 S. maltophilia strains were isolated from clinical
samples. The 46 isolates belonged to ICU patients (31.5%) and 100
were from patients of 22 different wards. The incidence of S. malto-
philia was increased over the time of study. The number of isolates
(n) per year was: n ¼ 3 (1998–1999), n ¼ 32 (1999–2000), n ¼ 24
(2000–2001), n ¼ 36 (2001–2002), n ¼ 51 (2002–2003). The source of
specimens was: sputum (52), bronchial secretions and lavage (37),
pus (18), urine (13), blood (10), body ﬂuids (7), tip of central vein cath-
eters (7), and CSF (2). Regarding the antibiotic susceptibility, 100% of
the strains were susceptible to moxiﬂoxacin, 91% were susceptible to
cotrimoxazole, 89% to levoﬂoxacin, 76% to ceftazidime, 74% to ci-
proﬂoxacin, 72% to piperacillin/tazobactam and 67% to trovaﬂoxa-
cin. All strains were resistant to imipenem and 99% of the strains
were resistant to meropenem. A variety of susceptibility phenotypes
was observed and molecular studies (PCR-PFGE) suggested that
there were no epidemic clusters in the hospital.
Conclusions: S. maltophilia has been an increasing nosocomial
pathogen in our hospital. Moxiﬂoxacin was the most active ﬂuoro-
quinolone between levoﬂoxacin, trovaﬂoxacin, oﬂoxacin and ci-
proﬂoxacin followed by levoﬂoxacin. Cotrimoxazole is still highly
active agent among the other antimicrobials in our clinical isolates.
P1220 Antimicrobial resistance in Campylobacter strains
isolated from humans in Crete, Greece
S. Maraki, E. Nioti, A. Georgiladakis, G. Samonis, Y. Tselentis
Heraklion, GR
Background: Infections with Campylobacter species, particularly Cam-
pylobacter jejuni and Campylobacter coli, are recognised as one of the
most common causes of bacterial diarrhoea in humans worldwide.
Objective: To determine the antimicrobial resistance rates of ther-
mophilic Campylobacter strains isolated from diarrhoeal patients in
Crete, Greece.
Methods: A total of 621 Campylobacter isolates from stool speci-
mens of patients suffering from acute diarrhoeal infections during
January 1992 and November 2003 were included. Identiﬁcation
was done according to standard microbiological methods. Antimi-
crobial susceptibility testing was performed by the disk diffusion
method using Muller–Hinton agar supplemented with 5% sheep
blood; the plates were incubated at 37C for 24 h in a microaero-
philic atmosphere. The following antibiotics were tested: erythro-
mycin, tetracycline, trimethoprim/sulfamethoxazole, gentamicin,
chloramphenicol, and ciproﬂoxacin.
Results: Six hundred and twenty-one strains of Campylobacter
were studied. Of them, 493 (79.4%) were C. jejuni and 128 (20.6%)
C. coli. Most isolates (71.8%) were resistant to trimethoprim/sulfa-
methoxazole. Resistance rates observed to other antibiotics were
as follows: 43.6% to tetracycline, 7.4% to chloramphenicol, and
2.5% to gentamicin. High percentages of resistance to ciproﬂoxa-
cin (39.6%) were found, while resistance to erythromycin was
observed in 16.7% of the isolates.
Conclusion: The increased rates of Campylobacter resistance in our
region emphasise the need for a more restrictive policy on the use
of antibiotics in both humans and farm animals.
P1221 In vitro activities of non-traditional antimicrobials
against multiresistant strains of P. aeruginosa and A. baumanii
isolated from intensive care units
H. Arslan, O. Kurt Azap, F. Ergin, S. Ozbalikci Karaman, E. Oruc¸,
F. Can, M. Demirbilek
Ankara, TR
Objective: To evaluate in vitro activities of azithromycin, doxycy-
cline, rifampin and colistin against multi drug resistant (MDR)
strains of P. aeruginosa and A. baumanii isolated from intensive
care units (ICUs).
Materials and methods: Thirty-ﬁve P. aeruginosa and 25 A. bauma-
nii stains that were found to be multi-drug resistant were inclu-
ded the study. Isolates were collected from the specimens of the
patients in ICUs between 2001 and 2003. All isolates were identi-
ﬁed by standard methods and stored at 20C until use. Antibi-
otic powders of azithromycin (Pﬁzer), doxycycline (Sigma),
rifampin (Sigma) and colistin (Sigma) were obtained from the
manufacturers. MICs were determined by agar dilution method
on Muller–Hinton agar and results were interpreted according to
the recommendations of NCCLS for azithromycin, doxycycline
and rifampin. MIC value for colistin was accepted <4 mg/mL
(Catchpole et al, J Antimicrob Chemother 1997; 39: 255–260). P.
aeruginosa ATCC 27853 and E. coli ATCC 25922 were used as
control strains. MIC50 and MIC90 values are summarised in the
Table.
Results: High MIC values were detected against MDR- P. aerugi-
nosa strains for tested antibiotics. Colistin susceptibility was 89%
for these bacteria but the MIC90 value was high (>32 mg/L). Of
the tested antibiotics doxycycline and colistin seemed to be active
against MDR- A. baumanii strains while azithromycin and rifam-
pin have high MIC values. Hundred per cent of isolates were sus-
ceptible to colistin.
Conclusion: MDR- Pseudomonas and Acinetobacter strains, which
cause nosocomial infections with an increasing ratio in recent
years, have limited treatment options. According to our in vitro
study results non-traditional antibiotics such as doxycycline and
colistin can be an alternative for the infections caused by MDR-
Acinetobacter isolates but not for Pseudomonas.
P1222 Nosocomial infections by P. aeruginosa in Brazil –
MYSTIC Program 2003
C. Mendes, E. Sakagami, C. Oplustil, P. Turner, J. Sampaio,
C. Kiffer – MYSTIC Brazil Group
Objective: To establish the susceptibility pattern of P. aeruginosa
isolated in 20 Brazilian hospitals during the MYSTIC Program
2003.
Methods: Clinically signiﬁcant P. aeruginosa isolates (n ¼ 470)
were collected from hospitalised patients in 20 hospitals in nine
Brazilian cities during 2003. Only one isolate per patient was
included. A central laboratory conﬁrmed the identiﬁcation and
determined the minimal inhibitory concentrations (MICs) of me-
ropenem (MEM), imipenem (IPM), ciproﬂoxacin (CIP), ceftazi-
dime (CAZ), cefepime (CPM), piperacillin/tazobactam (PIP/TAZ),
amikacin (AK), gentamicin (GEM), and tobramycin (TOB) using
the Etest methodology. Interpretative criteria used were those des-
cribed by NCCLS document M100-S13.
Results: Fifty-seven per cent were isolated from intensive care
units, 27% from general wards and 11% from neutropenic patient
units. Blood cultures represented 11.4% of all clinical samples.
Susceptibility patterns (%) are shown in the table below:
Table MIC50 and MIC90 values of tested antibiotics for multi-
drug resistant P. aeruginosa and A. baumanii strains
Bacteria (n) Antibiotics MIC50 MIC90 Range
P. aeruginosa (35) Azithromycin >16 >16 8–>16
Doxycycline 8 8 <1–64
Colistin 2 >32 2–>32
Rifampin 8 8 <1–>128
A. baumanii (25) Azithromycin 4 >16 <1–>128
Doxycycline <1 <1 <1–64
Colistin 2 2 1–4
Rifampin 2 >128 <1–>128
337Clinical Microbiology and Infection, Volume 10, Supplement 3, 2004
Conclusions: Susceptibility was highest for PIP/TAZ, AK and
MEM, although no drug presented high activity. The pattern
observed suggests speciﬁc resistance mechanisms in the region,
possibly with metallo-beta-lactamase presence. Also, previous
editions of the program in Brazil have shown signiﬁcant clonal-
ity of carbapenem resistant P. aeruginosa inter- and intra-centres
contributing to elevated resistance rates. The use of combination
therapy to treat P. aeruginosa infections in Brazil may be justi-
ﬁed.
P1223 Antimicrobial susceptibility of Bordetella
bronchiseptica strains
E. Rosales, G. Molina, G. Garza-Malacara, A. Fernandez-Ramirez,
G. Barcenas-Morales, J. Montaraz-Crespo
Cuautitlan Izcalli, MEX
Background: Bordetella bronchiseptica has been considered upper
respiratory tract pathogen of many mammalian species (dogs,
cats, rabbits, etc.) and some immunosupressed individuals. There
are few studies about antibiotic pharmacodynamics against this
microorganism; however empiric prescription is very common. So
the aim of this work was to determine the antibiotic proﬁle (sus-
ceptibility-resistance, MIC, and PAE) of B. bronchiseptica strains
isolated from different mammal species.
Methodology: B. bronchiseptica strains from pharyngeal swabs of
some domestic species (dogs, cats, donkeys, horses, rabbits,
pigs) and individuals were isolated and identiﬁed by biochemi-
cal, serological and PCR (using DAL1 and DAL3 primers)
assays. We employed 10 antibiotics in order to determine sus-
ceptibility-resistance (by agar diffusion method), minimal inhibi-
tory concentration (MIC) (by double dilutions of the antibiotics
in microplaques and cultured on agar) and post-antibiotic effect
(PAE) by method described by Craig and Gudmundsson
(1996).
Results: Forty isolates of B. bronchiseptica (18 from cat, 10 from
dog, six from human, two from pig and donkey, and one from
rabbit and horse) were identiﬁed by PCR amplifying 1200 pb
band in agarose gel; biochemical test as urease, catalase, and
oxidase positive and carbohydrates no-fermentation. Hundred
per cent isolated strains were sensitive to amikacin and kanamy-
cin, 87.5% to tetracycline, 82.5% to rifampicin, 72.5% to ampicil-
lin, 55% to erythromycin, 12.5% to penicillin and nitrofurantoin;
7.5% to vancomycin and 0% to bacitracin. The results of MIC
showed heterogeneous values (the amounts varied from: amika-
cin 0.25–100 mg/mL, ampicillin 16–112 mg/mL, tetracycline
0.05–150 mg/mL, penicillin 50–25 000 IU, kanamycin 0.125–
32 mg/mL). Also the results of PAE showed different values
among strains isolated from the same specie; e.g. strains isolated
from cat show values from 1 h to 5 h 40 min, while strains from
dog show values from 1 h 20 min to 6 h 50 min; and human
strains show values from 16 h. In general, isolated strains from
human > dog > cat > donkey showed resistance for more antibi-
otics.
Conclusions: Many factors inﬂuence of development resistance
against antibiotics, such as sub-optimal concentration exposition,
in order to avoid this problematic and agree with the results of
the present work suggests determinate proﬁle antibiotic for each
individual independently of species and give it appropriated dos-
ing regimens.
P1224 Postantibiotic effect of antimicrobial combinations
on multiresistant Pseudomonas aeruginosa
E.J. Giamarellos-Bourboulis, N. Kentebozidis, Z. Chryssouli,
I. Galani, H. Giamarellou
Athens, GR
Objectives: Management of nosocomial infections caused by
multidrug-resistant (MDR) isolates relies on antimicrobial combi-
nations. Their application would be promising only if they pos-
sess an extended postantibiotic effect (PAE). The present study
focused on the determination of the PAE of these combinations
on P. aeruginosa.
Methods: A 6 log 10 inoculum of 15 isolates resistant to ceftazi-
dime (CZ), imipenem (IM), meropenem, aztreonam, ciproﬂoxacin
(CIP) and amikacin (AM) were in vitro exposed for 24 h to CZ, IM
and CIP and to their interaction with AM in tubes of Mueller–
Hinton broth. All beta-lactams and AM were applied at a concen-
tration of 16 mg/L and CIP at 2 mg/L; these concentrations are
equal to the mean serum levels of the applied antimicrobials. PAE
was estimated only for isolates with synergy documented after
24 h of growth. At 24 h, tubes were centrifuged and the bacterial
pellet was re-suspended in broth; bacterial growth was then esti-
mated at regular time intervals. PAE was assessed as the time
period requested for bacterial growth to increase more than
1 log 10. The effect of antimicrobial combinations was calculated
after subtracting the PAE of the most potent single agent.
Results: Synergy at 24 h was found in nine (60%), seven (46.7%)
and three (20%) isolates by the interaction of CZ and AM, of IM
and AM and of CIP and AM, respectively. Mean  SE PAE of
these interactions was 7.11  3.2, 14.93  3.29 and 16.17  7.83 h,
respectively.
Conclusions: In vitro synergism between beta-lactams and AM or
between CIP and AM is accompanied by an extended PAE provi-
ding pharmacodynamic evidence for the need of the application
of these combinations for the management of infections by MDR
P. aeruginosa.
P1225 Achromobacter (Alcaligenes) bacteraemia: a 14-year
retrospective analysis at a comprehensive cancer centre in the
United States
G. Aisenberg, A. Safdar
Houston, USA
Objective: Alcaligenes species may occasionally lead to serious
infections in patients with an underlying malignancy. We sought
to determine treatment options in cancer patients with Alcaligenes
bloodstream infection.
Methods: Retrospective analysis of Alcaligenes species isolated
between 26 December 1989 and 27 July 2003 was performed at
M.D. Anderson Cancer Center, Houston, USA.
Results: Among 387 patients, Alcaligenes species was isolated from
699 culture samples. Forty-six patients (12%) were bacteraemic;
1.8 positive blood culture per patient (82 positive cultures). In 28
patients (61%) single blood culture sample grew Alcaligenes spe-
cies; 18 (39%) had multiple positive blood cultures (11 had two
(+) cultures, ﬁve patients had equal to or greater than three (+)
cultures and in one patient bacteraemia remained persistent at
equal to or greater than seven (+) blood cultures). Most blood-
stream isolates (n ¼ 76; 42 patients, 91%) were A. xylosoxidans;
A. denitriﬁcans and A. faecalis were other identiﬁable species. In 34
patients (74%) Alcaligenes bacteraemia was monomicrobial,
whereas in nine individuals (20%) two organisms were identiﬁed,
and in 6% (n ¼ 3), three or more microorganisms-associated con-
comitant bacteraemia–fungaemia was noted. In vitro susceptibility
was performed in 43 patient isolates, 28 antimicrobial agents were
tested. The MIC90 for all Alcaligenes species was within suscept-
ible range for carbapenems, piperacillin–tazobactam, ticarcillin–
clavulanic acid, and trimethoprime–sulfamethoxazole. MIC50 was
in non-susceptible range against ﬂuoroquinolones (ciproﬂoxacin,
levoﬂoxacin), aminoglycosides, aztreonam, ampicillin–sulbactam.
PIP/TAZ AK MEM CAZ CPM IPM TOB GEM CIP
Susceptible 62.8 62.5 61.1 56.9 56.1 55.8 51.7 50.6 47.5
Intermediate – 4.2 3.9 8.3 16.9 6.4 7.8 2.8 4.2
Resistant 37.2 33.3 35.0 34.7 26.9 37.8 40.6 46.7 48.3
MIC50 32.0 4.0 1.5 4.0 8.0 3.0 1.5 4.0 2.0
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Following are the yearly distribution of blood culture Alcaligenes
isolates: [year, total isolates, blood isolates n (%)] 1989, 1, 0 (0%);
1990, 9, 2 (22%); 1991, 23, 6 (26%); 1992, 19, 1 (5%); 1993, 20, 2
(10%); 1994, 30, 3 (10%); 1995, 21, 3 (14%); 1996, 18, 3 (17%);
1997, 20, 4 (20%); 1998, 30, 4 (13%); 1999, 49, 4 (8%); 2000, 60, 4
(7%); 2001, 53, 6 (11%); 2002, 53, 5 (9%), and in 2003, 34 total Al-
caligenes clinical isolates, 1 (3%) was isolated from blood culture
specimen.
Conclusions: Since 1990, we observed no increase in Alcaligenes
bloodstream infections in patients receiving cancer treatment at
our institution. The susceptibility data indicates that empiric anti-
microbial regimens consisting of ﬂuoroquinolones, aminoglyco-
sides, or monobactams may be unsuitable for cancer patients with
systemic Alcaligenes infection.
P1226 In vitro susceptibility of antibiotic resistant
Escherichia coli from urine samples to ertapenem and twelve
other antibiotics
A. Alhambra Mosquera, J. Cuadros, J. Cacho, J.-L. Go´mez-Garce´s,
J.-I. Alo´s
Madrid, E
Objectives: The purpose of this study was to examine the in vitro
susceptibility to ertapenem and 12 other antibiotics of antibiotic
resistant E. coli strains isolated from recent urine samples sent to
the microbiology laboratory.
Methods: A total of 315 strains from three microbiology laborator-
ies of the Community of Madrid (Spain), were collected during
the year 2003. The strains were selected based on their resistance
to ciproﬂoxacin and/or gentamicin and/or cefotaxime and/or
their production of extended-spectrum beta-lactamases (ESBL).
The minimum inhibitory concentration (MIC) for each antibiotic
was determined using the agar dilution method following the rec-
ommendations of NCCLS. The detection of ESBL production was
based on the agar diffusion technique using E-test strips of cefo-
taxime/cefotaxime clavulanate and ceftazidime/ceftazidime cla-
vulanate, and cefoxitin discs.
Results: See table below:
On comparing antibiotic resistance among ESBL-producing
strains (n ¼ 35) and non-ESBL-producing strains (n ¼ 280), statis-
tically signiﬁcant differences were obtained in the ﬁrst group for
resistance to ciproﬂoxacin (P ¼ 0.002) and to gentamicin
(P ¼ 0.011).
Conclusions: (1) All the strains were susceptible to ertapenem, im-
ipenem and amikacin. Ertapenem was the most active of all drugs
tested (MIC90 ¼ 0.06 mg/L). (2) The ESBL-producing strains were
signiﬁcantly more resistant to ciproﬂoxacin and to gentamicin
than those that do not produce ESBL. (3) In view of its antimicro-
bial power and, in addition, its favourable pharmacokinetic char-
acteristics, ertapenem may constitute a good therapeutic
alternative for urinary infections caused by antibiotic resistant
E. coli.
P1227 Susceptibility to ertapenem and other antibiotics of
Amp-C producing enterobacteria isolated from urine samples
A. Alhambra Mosquera, J. Cuadros, J. Cacho, J.-L. Go´mez-Garce´s,
J.-I. Alo´s
Madrid, E
Objectives: The purpose of this work was to study the in vitro
activity of ertapenem and 12 other antibiotics against recent Amp-
C producing enterobacteria isolated from urine samples sent to
the laboratory for the diagnosis of urinary infection.
Methods: A total of 98 strains from three microbiology laborator-
ies of the Community of Madrid (Spain), were collected during
the year 2003. The type and number of microorganims was as fol-
lows: Morganella morganii (39), Enterobacter cloacae (30), Enterobacter
aerogenes (9), Enterobacter asburiae (2), Citrobacter freundii (5), Serra-
tia liquefaciens (1), Serratia marcencens (6), Providencia stuartii (6).
The minimum inhibitory concentration (MIC) for each antibiotic
was determined using the agar dilution method following the rec-
ommendations of NCCLS.
Results: See table below: Ertapenem always showed a MIC
equal to or less than that of imipenem, with the exception of four
strains of Enterobacter cloacae. None of the bacteria studied showed
resistance to the tested carbapenems, and only nine strains of
M. morganii showed intermediate susceptibility (MIC ¼ 4 mg/L)
to imipenem.
Conclusions: Ertapenem is a powerful agent against betalactamase
Amp-C producing enterobacteria. These bacteria showed a MIC90
of 0.5 mg/L to ertapenem, and all the strains studied were sus-
ceptible to this antibiotic. Ertapenem was the most active of all
drugs tested. Ertapenem and amikacin may constitute a good
alternative for urinay infections caused by these pathogens, as
well as piperacillin/tazobactam, imipenem and gentamicin that
were active against more our 90% of the strains.
Antibiotic Range MIC90 (mg/L) %S %R
Ampicillin 
2–>16 >16 7 92.4
Cefazollin 	1–>16 >16 64.4 26.6
Cefuroxime 
1–>16 >16 70.8 23.5
Cefotaxime 
0.06–>16 >16 84.1 14.6
Amoxicillin/
clavulanate

2/1–>32/16 32/16 57.1 16.2
Piperacillin/
tazobactam

1/4–>64/4 16/4 95 2
Imipenem 
0.06–1 0.5 100 0
Ertapenem 0.008–4 0.06 100 0
Gentamicin 
0.5–>8 >8 70.2 27
Amikacin 
1–16 4 100 0
Fosfomycin 
1–>128 8 97.2 2.2
Ciproﬂoxacin 
0.12–>4 >4 10 89.6
CO-trimoxazole 
0.5/9.5–>4/76 >4/76 25.7 74.3
Antibiotic Range MIC90 (mg/L) %S %R
Ampicillin >16 >16 0 100
Cefazollin >16 >16 0 100
Cefuroxime 2–>16 >16 28.5 65.3
Cefotaxime 
0.06–>16 >16 87.7 12.3
Amoxicillin/
clavulanate
16/8–32/16 >32/16 0 99
Piperacillin/
tazobactam

1/4–>64/4 16/4 92.8 4.1
Imipenem 0.12–4 2 90.8 0
Ertapenem 0.008–4 0.5 100 0
Gentamicin 
0.5–>8 2 90.8 6.2
Amikacin 
1–8 4 100 0
Fosfomycin 
1–>128 >128 47 41.8
Ciproﬂoxacin 
0.12–>4 >4 79.6 16.4
CO-trimoxazole 
0.5/9.5–>4/76 >4/76 79.6 20.4
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P1228 Evaluation of measles-speciﬁc immunity
in a high-risk group
E.K. Bukin, A.V. Atrasheuskaya, S.N. Kameneva, N.L. Maksimov,
A.P. Agafonov, G.M. Ignatyev
Koltsovo-Novosibirsk, RUS
Objectives: The main task of our research was deﬁnition of speci-
ﬁc parameters of humoral and cellular immunity of the medical
staff having contacts with measles virus (MV) patients.
Methods: With this purpose the anamnesis data of 19 medical
workers have been analysed. Saliva and serum specimens were
collected from every subject. For extraction of human peripheral
blood mononuclear cells (PBMC) the whole donors’ blood was
used. For evaluation measles-speciﬁc humoral immunity serum
immunoglobulins G were measured using commercial test-system
‘Enzygnost(R) Anti-Measles Virus/IgG’ (Dade Behring Marburg
GmbH, Germany). The virus-neutralising activity of serum sam-
ples was determined by plaque reduction neutralisation test (PRN)
and haemagglutination inhibition test (HAIT). Moreover, we detec-
ted the ability of serum antibodies to bind with native MV proteins
as well as recombinant haemagglutinin (NH) by Western-blot
assay. The levels of speciﬁc IgA and IgG in saliva were deﬁned by
enzyme-linked immunosorbent assay (ELISA). We used inacti-
vated MV and recombinant NH protein as antigens for ELISA.
Measles-speciﬁc T-cell response was measured by proliferation of
PBMC incubated with different measles antigens compared with
control cells which were incubated with nonspeciﬁc antigen. An
ELISpot assay was used to detect IFN-gamma producing cells after
stimulation with measles antigen. The stimulation index was the
ratio of mean spots in speciﬁc and nonspeciﬁc activated cell wells.
Results: High level of speciﬁc IgG was detected in all examined
serum samples. These data had a strong correlation with virus-
neutralising activity of sera. Research of saliva specimens revealed
high production of speciﬁc IgA. Interestingly, that detection of
speciﬁc antibodies to NH protein was observed with high virus-
neutralising activity of serum in the same time. The level of mea-
sles-speciﬁc T-cell response was signiﬁcantly higher after stimula-
tion with the native virus than recombinant NH protein.
Similarly, mean number of mononuclear cells producing IFN-
gamma was higher in the presence of the native virus.
Conclusion: The study of anamnesis data revealed no cases of MV
disease inside of examined group with high risk of the infection.
The fact allows to assume that protective anti-measles immunity
is due to presence of the speciﬁc IgA in saliva, high virus-neutral-
ising activity of serum antibodies in combination with high level
of cellular immunity.
P1229 Evaluation of oral ﬂuid IgM, RT-PCR and
genotyping for early diagnosis and characterisation of cases in
Swiss measles outbreaks
D. Burki, J.-L. Richard, M. Omeyer, K. Bir, C. Noppen,
C. Schaefer, S. Santibanez, L. Matter
Basle, Berne, CH; Berlin, D
Introduction: In measles surveillance, the use of oral samples
rather than blood may improve patient early diagnosis and epide-
miological studies because of better acceptance of non-invasive
samples by patients and physicians.
Objectives: To assess suitability of oral ﬂuid as sample and of sal-
ivary IgM and PCR as methods for rapid diagnosis of measles
infection in an epidemiological study.
Materials and methods: In response to clinical and/or laboratory
notiﬁcation of measles cases to the Swiss Federal Ofﬁce of Public
Health, physicians were invited to provide oral ﬂuid samples
using sponge swabs along with dates of sampling and onset of
symptoms. IgM EIA adapted for oral ﬂuid (Microimmune, UK-
Brentford) and, following overnight transport of samples, nested
RT-PCR (Robert Koch-Institute, Berlin) were performed. Reactive
samples were genotyped using the variable part of the N gene. A
novel LightCycler PCR (Viollier) was performed on samples fro-
zen at 80C immediately after receipt.
Results: 91 samples were collected 2–70 days after the onset of symp-
toms. Nineteen were IgM and nested RT-PCR negative, 55 IgM posit-
ive and nested RT-PCR positive, four IgM negative and nested RT-
PCR positive, 17 IgM positive and nested RT-PCR negative. Retesting
of these 17 samples by LightCycler PCR revealed 13 positive (all col-
lected within the ﬁrst week after onset of symptoms) and four negat-
ive results (two collected >2 weeks and two borderline IgM).
Genotyping revealed 26 D5, 6 D7, and 12 D8 measles virus infections.
Conclusions: Oral ﬂuid is suitable for early diagnosis of measles
infection. In the ﬁrst week after the onset of symptoms PCR may be
superior to IgM detection. It also allows for genotyping. The detec-
tion of D5 and D8 genotypes, which are prevalent in Asia but not in
Europe, suggests that genotyping may be useful for epidemiological
studies. Discrepancies between nested RT-PCR and LightCycler
PCR will require further analyses because of different preanalytical
conditions. Oral ﬂuid IgM may be useful in PCR-negative samples
collected >2 weeks after onset of symptoms.
P1230 A measles outbreak in an ultra-orthodox partially
immunised community
C. Stein-Zamir, Z. Zentner
Jerusalem, IL
Objectives: Although measles is a vaccine preventable disease,
outbreaks continue to occur, particularly in unimmunised or parti-
ally immunised populations. Lately, an outbreak occurred in an
ultra-orthodox community in Jerusalem. An epidemiologic investi-
gation and a vaccination campaign were conducted.
Patients and methods: The ﬁrst cases of measles were reported in the
middle of March 2003. All patients were from the ultra-orthodox
community. The index case was a 2-year-old child who arrived as a
visitor to Israel while in the incubation phase of measles. The disease
spread rapidly throughout the community during the holiday’s sea-
son. Many patients and families had had minimal contact with health
authorities, and were wary of any such association. Contact with the
community leaders and involvement of an ultra-orthodox-managed
voluntary organisation facilitated access to the population.
Results: Within 4 months 102 cases of measles were recorded, of
whom 90 (88%) were unimmunised. The mean age was 8.3 years
(range: 4 months to 43 years). No serious complications of the dis-
ease were observed. A large scale immunisation campaign was
initiated and in the ﬁrst 3 days, over 2000 infants were immu-
nised, followed by over 6000 children who were immunised
within ultra-orthodox educational institutions. Fifty per cent of
those children had no previous contact with preventive health ser-
vices. The last case was observed in August 2003.
Conclusions: The population and timing of the outbreak created
unique problems necessitating a coordinated effort in order to
interrupt measles transmission. In spite of high immunisation cov-
erage country-wide, close surveillance of susceptible populations
is essential. The social derivatives will hopefully assist the use of
public health measures in the future.
P1231 Serological screening for CMV antibodies during
pregnancy: possibilities to select a high-risk group for
congenital infection
A. Naessens, A. Casteels, L. Decatte, S. Lauwers, W. Foulon
Brussel, B
Objective: Screening programs for congenital CMV infection
(CCMV) are difﬁcult to implement since this implicates routine
viral culture of urine from all neonates. In this study we evalu-
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ated the feasibility of a serological screening program for detect-
ing neonates at risk for a CCMV infection.
Methods: 7140 unselected mother-infant pairs were included. In
the mother a serological screening consisted of the detection of
CMV-antibodies (IgG and IgM) at the ﬁrst prenatal visit and at
delivery (on cord blood). In the neonate CMV urine culture was
performed to diagnose congenital infection.
Results: Serological screening showed evidence of past infection in
3850 women (53.9%); 3098 (43.4%) women had no antibodies in
their ﬁrst serum sample, and 192 (2.7%) women had both IgG and
IgM antibodies when ﬁrst tested during pregnancy. Seroconversion
during pregnancy was detected in 44 of the seronegative women
(1.4%). Forty-four CCMV infections were diagnosed (0.64%): eight
in the group of past infections; 22 out of the 44 women who sero-
converted during pregnancy; 14 in the group of women with a pos-
itive IgM in their ﬁrst serum sample. IgM positivity on cord blood
was found in 44% of the congenital infected neonates.
Conclusion: Screening at the ﬁrst prenatal visit and on cord blood,
deﬁnes two major risk groups for CCMV: women with seroconver-
sion during pregnancy and women with IgM antibodies in their
ﬁrst prenatal serum sample (0.6 and 2.7%, respectively, of the preg-
nant population). In these selected groups, CMV culture should be
performed in the neonate. This type of screening allows the detec-
tion of 82% of all CCMV cases. IgM detection on cord blood increa-
ses the detection rate to 91% of all congenital CMV infections.
P1232 Frequency of human papillomavirus infection
among patients with chronic tonsillitis
D. Velyvyte, A. Laiskonis, V. Uloza, A. Gozdzicka-Jozeﬁak
Kaunas, LIT; Poznan, PL
Objectives: Our aim was to establish the frequency of human pap-
illomavirus (HPV) infection in the upper respiratory tract of
patients with chronic tonsillitis, to identify detected viral types
and to evaluate inﬂuence of some risk factors on HPV persistence
in the upper respiratory tract.
Methods: The group of random selected 50 patients (31 female and
19 male, mean age, 13.64 years; range, 2–54) with chronic tonsillitis
treated in the Department of Otolaryngology, Kaunas University of
Medicine, was examined. Epidemiological characteristics and objec-
tive data were analysed; routine laryngological examination was
performed. The biopsies of tonsils were taken during tonsillectomy
and analysed for the presence of HPV DNA using the polymerase
chain reaction (PCR). Viral typing using PCR was performed as des-
cribed by Tucker et al.
Results: HPV DNA was detected in 30% (15/50) of patients. HPV 6
and 11 types were predominant (14/50, 28% of patients). High on-
cogenic risk HPVs (only type 18) were detected in two (1/50)
patients. None were positive for HPV 16. There were no signiﬁcant
differences in frequency of HPV infection in the upper respiratory
tract according to age and sex (P > 0.05). Investigated risk factors
(low resistance of immunity, the inclination to diseases of respirat-
ory system, enlargement of submandibular lymph nodes, dental
caries, and smoking) were statistically signiﬁcant detected in HPV
positive patients (P < 0.001).
Conclusions: The frequency of HPV infection in the upper respir-
atory tract of patients with chronic tonsillitis is high; HPV 6 and
11 types are predominated. Some investigated risk factors have
statistically signiﬁcant inﬂuence on persistence of HPVs in the
upper respiratory tract of patients with chronic tonsillitis.
P1233 Detection of human papillomaviruses using PCR
and sequence analysis in routine cervical cancer screening –
correlation of HPV type and cytology
S. Ko¨sel, S. Burggraf, W. Engelhardt, B. Olgemo¨ller
Munich, D
Objectives: Persistent infection with human papillomaviruses
(HPV) is the main cause of cervical carcinoma. Individual HPV
types are associated with different risks for the development of
cervical dysplasia and carcinoma. In this study we correlated cy-
tologic ﬁndings with the results of a highly sensitive and type
speciﬁc HPV assay routinely performed in our laboratory.
Methods: HPV tests and examination of Pap smears of 1875 cervi-
cal specimens were performed in parallel or with an interval of
few weeks. HPV types were determined using PCR ampliﬁcation
(L1 consensus primers MY09, MY11 and GP5+, GP6+ nested
primers) followed by sequence analysis. HPV16 viral loads were
quantiﬁed against the beta-globin gene using a HPV16 speciﬁc
LightCycler PCR protocol.
Results: 932 cervical samples (49.7%) were HPV positive. Thirty-
seven different HPV types were found. Women with severe cervi-
cal dysplasia most frequently carried HPV16 (62%). HPV18,
HPV31, HPV33, HPV35, HPV45, HPV51, HPV52, HPV53, HPV58
HPV62, HPV66, HPV73, HPV82 and HPV11 were found with
lower frequencies in these patients. In mild to moderate cervical
dysplasia, in addition to HPV16 (36%) numerous HPV types were
detected which so far are not classiﬁed as high risk HPV (HPV54,
HPV67, HPV70, HPV83, HPV84, HPV90, CP8304). These HPV
types are dot detected by the HPV test most frequently used in
routine HPV testing (Hybrid-Capture 2 assay). The HPV16 viral
load was signiﬁcantly higher in patients with cervical dysplasia
compared with patients with normal cytology.
Conclusion: Our results show that HPV types which are not detec-
ted by the most frequently used commercial hybridisation assay
(HPV53, HPV62, HPV66, HPV73, HPV82) can cause severe cervi-
cal dysplasia and possibly cervical cancer. The HPV16 viral load
may predict the further progression or regression of dysplastic
lesions. Cytology in combination with a type speciﬁc HPV test,
which detects all HPV types and allows the classiﬁcation of indi-
vidual risks, will produce a more reliable and effective screening
for cervical cancer.
P1234 Coxsackie viral infection in patients during
1993–2002
A. Petrovicova, S. Bopegamage, L. Barak
Bratislava, SK
Objectives: The infection with coxsackieviruses is associated with
different acute clinical syndromes, but recent data refer about its
important role in some chronic disorders, such as juvenile diabe-
tes mellitus, cardiomyopathies, etc. The aim of presented study
was to obtain information about incidence and trends of cox-
sackieviral infection in the young Slovak population. This was
acquired using comparison of the markers of actual and recent
infection in 655 patients with different diagnoses up to 20 years of
age in a 10-year interval.
Methods: Actual coxsackieviral infection was ascertained on the
basis of at least fourfold increase of virus-neutralising antibodies
in paired serum samples and/or detection of virus-speciﬁc IgM
antibodies in virus-neutralising tests. The presence of antibodies
against individual serotypes was considered as the marker of
overcome infection. The results were compared according to the
groups of diagnoses (A – newly diagnosed juvenile diabetes melli-
tus, B – myocarditis and other cardiology diagnoses, C – other
diagnoses, mainly meningitis, febrile status, exanthematous dis-
ease, etc.).
Results: Actual coxsackievirus infection was conﬁrmed in 218
(33.3%) patients (A – 34.5%, B – 36.7%, C – 22.9%). In all
diagnoses the most frequent was infection with coxsackievirus
B4 (CV B4 – 38.5%) followed by CV B2 (16.1%) and CV B3
(13.6%). The most prevalent serotype in 1993–1997, 1999 and
2002 was CV B4, in 1998 CV B2, in 2000 CV B5 and in 2001
CV B3. In the individual sera the antibodies were detected
against 1.71–5.0 serotypes (mean); the number was lowest in A
group and highest in C group. This ﬁnding seems to support
the so called ‘hygiene hypothesis’, which stresses the role of
immune experience with coxsackieviral infection in early child-
hood in the pathogenesis of juvenile diabetes mellitus. In all
groups a decrease in mean number of viral exposures during
the followed interval was observed.
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Conclusions: The circulation of coxsackieviruses in our population
is relatively frequent. The role of coxsackieviruses, as proved in
the pathogenesis of many clinical syndromes, accentuates the
need for regular monitoring of the prevalence of coxsackieviral
infection in the young population.
P1235 Human enteroviruses (HEV) in the treated
wastewater of the Slovak Republic: a 4-year monitoring
(1999–2003)
Z. Sobotova, S. Blahova, S. Bopegamage
Bratislava, SK
Background: Human enteric viruses enter the water environment
through the discharge of waters contaminated with sewage. The
assessment of these circulating enteroviruses gives an indication
of the human exposure to the enteric viruses. They are shed in
the faeces of infected individuals (clinically overt or asympto-
matic).
Objective: To investigate the presence of the non-polio human en-
teroviruses in wastewater in different districts of the Slovak
republic.
Methods: During the years 2000, 2001, 2002, 2003 samples were
collected from the wastewater treatment plants from 42 localities
in the Slovak republic four to ﬁve times per year and processed
by the standard methods recommended by the WHO Regional
Reference Laboratory (RRL) in Helsinki. Samples in volumes of
1 L were concentrated using a two-phase method of separation:
polyethylene-glycol (PEG) and dextran. Two eluates were collec-
ted – from the bottom and the interphase – and both were sepa-
rately treated with chloroform. The processed samples were
inoculated in three cell lines: RD (rhabdomyosarcoma), Hep-2
(epidermoid carcinoma), L20B, a mouse cell line expressing the
human poliovirus receptor (PVR: CD155). Two blind passages
were made. When a cytopathic effect was observed the isolates
were identiﬁed by the virus neutralisation test using typing
pools of horse serum for typing according to Lim Benyesh-Mel-
nick of enteroviruses. The typing pools were obtained from
the National Institute of Public Health and the Environment,
Bilthoven (RIVM).
Results: Year 1999: ECHO 6 was isolated in October mainly from
the different districts of the Banska Bystrica region. Year 2000:
Coxsackievirus B5 was isolated in October from different districts
of Trnava region. Year 2001: mainly Coxsackievirus B5 and ECHO
30 were isolated from the districts of Banska Bystrica, Presov and
Trnava regions. Year 2002: Coxsackievirus B3 was isolated from
in the months of September and October and the districts of Brati-
slava, Trnava and Kosice regions. Year 2003: ECHO 6, ECHO 12,
CVB 3, CVB 4 and CVB 5 were isolated in the months of June,
July and August from the districts of Bratislava, Trnava, Kosice
and Nitra regions.
Conclusions: Our results show the presence of different enterovi-
ruses in treated wastewater indicating that these viruses are circu-
lating in the population living in those areas. The study
demonstrates the value of wastewater analysis for sentinel of gas-
trointestinal viruses in the population.
P1236 The therapeutic effects of milrinone in treatment of
enterovirus 71-induced pulmonary oedema
C.-C. Liu, S.-M. Wang, H.-Y. Lei, M.-C. Huang, J.-M. Wu,
C.-T. Chen
Tainan City, TW
Objectives: To evaluate the potential therapeutic effect of milri-
none, a phosphodieasterase (PDE) inhibitor, in treatment of
patients with enterovirus 71 (EV71)-induced pulmonary oedema.
Methods: Twenty-four children with severe EV71-induced pul-
monary oedema were enrolled, from April 1998 through June
2003, in southern Taiwan. They were divided into groups treated
before and after the introduction of milrinone therapy. Aetiologi-
cal diagnosis was made by viral cultures and identiﬁed by speciﬁc
immunoﬂuorescence and neutralisation tests.
Results: All 24 patients were below 5 years of age. The mortality
was lower in milrinone-treated than in milrinone-untreated group
(36.4 vs. 92.3%, P ¼ 0.005). Sympathetic tachycardia was
decreased in patients treated with milrinone compared with con-
trols (205.7  25.8 vs. 143.5  17.1/min, P ¼ 0.004). A marked
decrease in IL-13 (76.6  8.8 vs. 162.1  87.5 pg/mL, P ¼ 0.001)
was observed in milrinone-treated patients compared with con-
trols. There was a signiﬁcant reduction in WBC (10 800  500 vs.
19 500  800/cmm, P ¼ 0.009) and platelet counts
(256 600  44 700 vs. 400 100  86 500/cmm, P ¼ 0.001) in milri-
none-treated patients compared with controls.
Conclusions: The administration of milrinone was associated with
a lower mortality in patients with EV71-induced pulmonary
oedema and cardiopulmonary failure. The results appear to be
related to improvement in sympathetic regulation and decrease in
IL-13 production. Milrinone therapy may provide a valuable
therapeutic approach for this highly lethal disorder.
P1237 Detection of the aetiological predominance of
norovirus in the hospital (nosocomial) gastroenteritis outbreaks
in Hungary
G. Reuter, K. Krisztalovics, B. van der Veer, E. de Bruin,
H. Vennema, M. Koopmans, G. Szuˆcs
Pe´cs, Budapest, HUN; Bilthoven, NL
Objectives: Outbreaks of acute gastroenteritis associated with
norovirus (Caliciviridae) cause serious health problems in hospi-
tals. In order to identify the magnitude of the norovirus outbreaks
in hospitals, including their epidemiological and clinical character-
istics and the genetic variability of the detected calicivirus strains,
hospital outbreaks of gastroenteritis were investigated in Hun-
gary.
Methods: Between 1 November 1998 and 1 May 2003, 447 stool
samples from reported non-bacterial and non-rotaviral hospital
gastroenteritis outbreaks were tested for norovirus by reverse-
transcription polymerase chain reaction (RT-PCR) followed by
sequencing and enzyme immunoassay (EIA).
Results: Eighty-six (54%) of the reported 160 (data from K. Bo¨r-
o¨cz, NCE, Budapest) hospital gastroenteritis outbreaks were
investigated for norovirus and 85 (99%) epidemics were positive
by RT-PCR (n ¼ 74) or EIA (n ¼ 11). In sixty-eight (92%) of the
74 RT-PCR-positive outbreaks norovirus were conﬁrmed by
sequencing. Outbreaks occurred mainly in wards for internal dis-
ease patients (43%) and involved more than two wards (16%).
Personal contact was the most common mode of transmission.
Average attack rate was 20% but it was 32% (0–80%) for the
hospital staff. Outbreaks lasted for 14 days (3–53 days) on aver-
age. The main symptoms were diarrhoea (87%) and vomiting
(51%). Genotyping revealed that diversity and frequency of the
genotypes changed over time, although the genogroup II strains
predominated (97%). Outbreak strains grouped in clades Lords-
dale (n ¼ 55; 78% including new-variant Lordsdale virus,
n ¼ 30), Hawaii (n ¼ 5; 7%), Wortley (n ¼ 3; 4%), Birmingham
(n ¼ 2; 3%). Moreover a recently emerged group of recombinant
strains (n ¼ 6; 8%) with four different capsid types were also
detected (GGIIb/Hilversum polymerase). Both epidemic clusters
caused by genetically identical strains and mixed infections with
genetically different strains at the same wards were observed. A
distinct peak of the norovirus outbreaks (n ¼ 43; 52%) was seen
in the winter period of 2002/2003, associated with a new-variant
Lordsdale virus.
Conclusions: In Hungary, this is the ﬁrst countrywide surveillance
of norovirus gastroenteritis outbreaks in hospitals. The study con-
ﬁrmed that noroviruses are the most frequent etiological agents
preceding other enteric bacterial and viral pathogens in the hospi-
tal. These nosocomial outbreaks cause signiﬁcant ﬁnancial and
public health problems in the country’s health-care providing sys-
tem.
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P1238 Molecular epidemiology of astrovirus infection in
Italian children with gastroenteritis
S. De Grazia, G.M. Giammanco, C. Colomba, L. Bonina, A. Cascio,
S. Arista
Palermo, Messina, I
Objectives: A 1-year study involving children suffering from acute
diarrhoea was conducted from August 1999 to July 2000 in
Palermo, Italy. Our goals were: to deﬁne the epidemiological role
of human astrovirus (HAstV) as a cause of gastroenteritis in Ital-
ian children; to compare these illnesses with those caused by
other enteric viruses; to analyse genetic correlation between our
HAstV isolates and prototype strains from other geographical
areas.
Methods: Stool specimens were collected from 439 children, hos-
pitalised at the ‘G. Di Cristina Children’s Hospital’, presenting
three watery stools in a period of 24 h with a sudden onset. Rout-
ine diagnostic tests for rotavirus and bacterial pathogens were car-
ried out on all specimens. One hundred and ﬁfty-seven rotavirus
and bacteria-negative specimens were tested for the presence of
HAstV, adenovirus, and norovirus by EIA tests (Cambridge, Bio-
science, Worcester, MA; Dako Diagnostics, Cambridgeshire, UK).
All specimens positive for HAstV were conﬁrmed by reverse tran-
scription (RT)-PCR ampliﬁcation and isolation on PLC/PRF/5
human hepatoma cell line. HAstV ampliﬁed ORF2 region was se-
quenced for genetic typing.
Results: Rotavirus was detected in 179 cases (40.7%). HAstVs
were found in ﬁve cases (3.1%), adenoviruses type 40/41 in eight
(5%), non-enteric adenoviruses in ﬁve (3.1%), and norovirus in
nine (5.7%) (Table 1). Concurrent infection was detected in two
samples. All of HAstV infected children were less than 2 years of
age (median age: 13.4 months). HAstV infections occurred
between March and May. The disease induced by HAstV was
mild and comparable to those caused by norovirus and adenovi-
rus type 40/41. The BLAST analysis of the ORF-2 sequences
referred the single 1999 isolate and three of the four 2000 isolates
to serotype 1, while the fourth was of serotype 3. The phylogenet-
ic tree including all published HAstV sequences clustered the
three 2000 type 1 isolates together (Figure 1). Analysis of the nuc-
leotide and amino acid sequences of the capsid region determin-
ing the serotype showed high conservation within our serotype 1
isolates. Amino acid similarity was lower between our type 3 iso-
late and reference strains.
Conclusions: This is the ﬁrst report of molecular characterisation
of HAstV isolates in Italy; our results provide additional informa-
tion about HAstV strains causing enteritis in children. For ade-
quate prevention strategies further epidemiological studies on
astroviral enteritis are needed.
P1239 Incidence of Norwalk like viruses in stool samples
of patients with gastroenteritis in the Tyrol, Austria 2002/2003
F. Jax, B. Falkensammer, D. Orth, M. Dierich, H. Stoiber
Innsbruck, A
Objectives: Viral gastroenteritis is a common illness in humans
with high morbidity reported worldwide. In recent years, Nor-
walk like Viruses (NLVs) have emerged as an important cause of
viral gastroenteritis in people of all age groups and showed to be
the main cause of outbreaks of gastroenteritis in institutions such
as nursing homes and hospitals. Norovirus infection usually pre-
sents as acute-onset vomiting, diarrhoea and abdominal cramps.
The aim of this study was to elucidate the incidence of NLVs in
stool samples of patients with the clinical diagnosis gastroenteritis
in the Tyrol.
Methods: From August 2002 until March 2003, 91 stool samples of
patients (of all age groups) from the Austrian province Tyrol with
the clinical diagnosis gastroenteritis were collected. Beside the
routine diagnostic of enteropathogenic bacteria these faecal speci-
mens were analysed for NLVs. The virus was detected by using a
reverse transcription (RT)-PCR.
Results: NLVs were detected in 23 (25.27%) of 91 faecal speci-
mens tested. Five of these NLV positive specimens were associ-
ated with an outbreak in a hotel. There was one patient with dual
infection of NLVs and Salmonella and two patients with NLVs
and Campylobacter. Salmonella were found in only 11 (12.09%) of
the analysed stool samples. Other pathogens such as Campylobac-
ter, EHEC (enterohemorrhagic E. coli), Yersinia, Shigella, Rotavirus
and Clostridium difﬁcile were found to a lesser percentage.
Conclusions: NLVs are very frequent agents of diarrhoea. Efforts
should be made to establish a laboratory based rapid detection
system for food-borne viruses because early diagnosis and imme-
diate hygiene measures are the best way to avoid epidemic
spread.
P1240 The investigation of parvovirus B19 infection in
patients with haematologic disorders and chronic anaemia by
using PCR and ELISA
T. Us, L. Ozunel, Y. Akgun, Z. Gulbas
Eskisehir, TR
Objectives: Human parvovirus B19 (B19) causes a variety of dis-
ease syndromes determined by the age and haematological status
of the host. In immunologically healthy hosts, B19 may cause ery-
thema infectiosum in children, acute polyarthritis in adults, tran-
sient aplastic crisis in patients with haemolytic anaemia and has
been associated with fetal death. Parvovirus B19 has a marked
tropism for erythroid progenitor cells and this may lead to chro-
nic anaemia in predisposed individuals. It was the purpose of the
present study to investigate prospectively the frequency of parvo-
virus B19 infections with a diagnosis of haematologic disorders
and chronic anaemia.
Methods: In order to determine the diagnostic use of different
markers of parvovirus B19 infection, serum specimens obtained
from 105 patients (85 adults, 20 children) with haematologic disor-
der (acute and chronic leukaemia, malignant lymphoma, haemo-
lytic anaemia, myelodysplastic sydrome, aplastic anaemia, etc.)
were tested for speciﬁc antibodies and viral DNA through the use
of PCR and ELISA techniques. All patients in the study met
standard criteria for chronic anaemia.
Results: Evidence of parvovirus B19 infection was found in 33/
105 (31.4%) patients by demonstrating viral DNA and/or speci-
ﬁc IgM antibody. Parvovirus B19 infections was established in
three of 11 patients with chronic myeloid leukaemia, in three of
11 patients with acute myeloid leukaemia, in two of six patients
with autoimmune haemolytic anaemia, in two of ﬁve patients
with aplastic anaemia, in two of 11 patients with multiple myel-
oma, in three of eight patients with hodgking lenfoma, in ﬁve
of 10 patients with non-hodgking lenfoma, in one of six patients
with myelodysplastic syndrome, in three of patients with Tha-
Table 1 Demographic and clinical ﬁndings associated with single viral infections in children hospitalized
with acute gastroenteritis in Palemo, 1999–2000.
Characteristic
Type of infection
Rotavirus Adenovirus Adenovirus
40/41
Non-enteric
adenovirus
Norovirus
No tested 439 157 157 157 157
No. (%) of children
infected
179 (40.7) 5 (3.1) 8 (5) 5 (3.1) 9 (5.7)
No. sex male 99 (55.3) 4 (80) 3 (37.5) 2 (40) 4 (44.4)
Age (mo.) 14.7 (7.9–23.2) 13.4 (3–13.6) 6.7 (2.8–18.2) 12.2 (2–17.3) 12.2 (7.5–22.9)
Days of diarrhea 5 (3–6.5) 4 (4–4) 4 (3–5.5) 6 (3.5–7.5) 4.5 (4–6.5)
Maximum number
of stools/day
6 (4–10) 6 (3–8) 5.5 (3–6) 8.5 (6–11.5) 7 (5.5–9)
Vomiting (%) 153 (8.5) 3 (60) 6 (75) 3 (60) 3 (33.3)
Days of vomiting 1.5 (1–2) 1 (0–1) 1.5 (0.5–2.5) 2.5 (1–3.5) 1 (1.5–1.5)
Fever (%) 135 (75.4) 2 (40) 3 (37.5) 3 (60) 6 (66.6)
Maximum fever (C) 38.5 (38–39) 38.5 (38–39) 38.2 (37–39.2) 39 (38.5–39) 39.1 (37.7–39.3)
No. (%) of
dehydrated children
71 (40) 2 (40) 1 (12.5) 2 (40) 1 (11.1)
Days of hospitalization 4 (4–6) 5 (4.5–5.5) 4 (3.5–4.5) 5.5 (4.5–6.5) 3.5 (3–5.5)
Mean seventy score (SD) 9 (8–11) 8 (3–9) 7 (6–9) 11 8 (6–9)
If not otherwise speciﬁed data are median and (lower and upper quartiles).
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lassaemia, in four of 11 chronic lenfositic leukaemia, in six of 19
acute lenfositic leukaemia. In four of the 33 positive patients
only parvovirus B19 DNA could de detected, while nine
patients tested positive for both parvovirus B19 DNA and speci-
ﬁc IgM. In the remaining 20 positive patients only speciﬁc IgM
could be detected.
Conclusion: Since no predictive paraclinical or clinical features
were observed, we recommend that all cases of haematologic dis-
orders with chronic anaemia be tested for the presence of parvovi-
rus B19 infection. Due to the discrepancies between DNA and
IgM results, the diagnostic procedures should include a search for
speciﬁc DNA by PCR methods if speciﬁc IgM has been found to
be negative.
P1241 The relationship between arthritis and parvovirus
B19 infection
B. Kocazeybek, R. Caliskan, S. Masatlioglu, M. Aslan, S. Altun,
S. Saribas, S. Ergin, E. Uckan, V. Ko¨ksal, K. Altas, I. Fresko
Istanbul, TR
Objectives: It has been claimed that parvovirus B19 infection may
play a role in autoimmune diseases like rheumatoid arthritis (RA)
and systemic lupus erythematosus (SLE). In order to evaluate the
role of parvovirus B19 in aetiopathogenecity of these diseases,
synovial ﬂuids and serum samples were investigated for parvovi-
rus B19.
Methods: Synovial ﬂuids and serum samples were collected from
20 patients with early synovitis and 31 patients with RA at 1-
month intervals. Serum samples were also collected also from 25
patients with SLE, 25 patients with osteoarthritis as diseased con-
trol group and 50 people were used as healthy control group in
this study. The detection of parvovirus B19 IgM and parvovirus
B19 IgG in serum samples were performed using ELISA and the
detection of parvovirus B19 DNA in synovial ﬂuid samples was
performed with polymerase chain reaction (PCR).
Results: Our PCR study demonstrated that parvovirus B19 IgM,
B19 IgG and B19 were present in three patients of early synovitis
group. Two of these three patients were later diagnosed with RA
and one was diagnosed with SLE. Parvovirus B19 DNA was
detected in synovial ﬂuids of eight patients in the RA group and
parvovirus B19 IgM and parvovirus B19 IgG were found positive
in four of these patients and only B19 IgG was found positive in
the other four patients with RA. Both of the control groups did
not exhibit parvovirus B19 IgM positivity.
Conclusions: Our results support the other studies suggesting the
possible role of parvovirus B19 in aetiopathogenesis of RA at case
level.
P1242 Immunodetection of parvovirus B19 virus in human
plasma: appraisal of a novel ﬂuorometric immunoassay and
comparison with an enzyme immunoassay
F. Loftus, S. O’Keeffe, S. Doyle, D. O’Leary, G. Elliott, S. Kerr
Dublin, Kildare, IRL
Objective: Human parvovirus B19 is the causative agent for ery-
thema infectiosum or ‘ﬁfth disease’ of children. Symptoms are
usually mild in healthy individuals; however, symptoms can be
very severe in pregnant women and in the immunocompromised.
The aim of the present work is to investigate the performance
characteristics of two new viral detection systems, an antigen-cap-
ture enzyme immunoassay (EIA) method to detect parvovirus B19
in human plasma and an alternative ﬂuorescence labelling tech-
nique (FIA) for enhanced assay sensitivity.
Method: Recombinant parvovirus B19 capsid protein was used
to immunise rabbits and sheep. The antibodies produced were
employed in an antigen-capture enzyme immunoassay (EIA)
and a ﬂuoroimmunoassay (FIA). The EIA utilised a conven-
tional peroxidase-labelled conjugate, while the FIA utilised a B-
phycoerythrin (ﬂuorophore) labelled conjugate. The sensitivity
of the assays were evaluated using both puriﬁed recombinant
parvovirus B19 particles and plasma samples of known parvovi-
rus viraemic load as determined using a validated PCR
method.
Results: Here we show that the sensitivity of the peroxidase
labelled EIA is of the order of 5  107 parvovirus B19 genome
equivalents per millilitre. The EIA was able to detect virus in
the presence of IgG and IgM antibodies and no false-positive
results were obtained. Also we show that the EIA and FIA
methods are similar in terms of sensitivity when directed toward
the detection of puriﬁed recombinant parvovirus capsid protein
(VP2).
Conclusion: EIA and FIA methods as presented are broadly equiv-
alent in terms of speciﬁcity towards the parvovirus B19 antigen
VP2 capsid protein. Both systems show potential utility in the
screening of blood products for the presence of parvovirus B19
antigen.
P1243 Crimean Congo haemorrhagic fever (CCHF), the
main aetiological cause of viral haemorrhagic fevers in the last
4 years (2000–2003) in Iran
S. Chinikar, A. Fayaz, R. Mirahmadi, V. Mazaheri, F. Ahmadne-
jad, M. Gooya, B. Hooshmand, P. Nabeth, M.F. Saron
Tehran, IR; Dakar, SN
Objectives: CCHF virus is from Bunyaviridae family and Nairovi-
rus genus and causes severe haemorrhagic symptoms in man. As
this disease has been observed in many parts of Iran and epidemi-
ological studies are useful for its control, in this study with colla-
boration of the Pasteur Institute of Dakar (WHO reference centre),
the situation and the incidence rate of the disease in the country
in recent years have been analysed.
Methods: Serum samples from 597 CCHF suspected patients have
been collected from different provinces of Iran and transferred to
the laboratory of Arboviruses of the Pasteur Institute of Iran. Sam-
ples have been analysed by speciﬁc ELISA method for IgM and
IgG detection against CCHF, Yellow Fever, Rift Valley Fever, Den-
gue 2 and also by RT-PCR technique for detection of the CCHF
virus genome.
Results: By using the ELISA method, 227 patients had IgM
against CCHF virus (conﬁrmed cases) and 215 had IgG. By the
RT-PCR method, 34 patients were positive. Most cases of the dis-
ease were from the south-east of Iran (the Sistan-Baluchestan
province). The number of suspected, conﬁrmed and death cases
according to year are as follows: 2000 (54, 20, 4), 2001 (167, 61, 7),
2002 (247, 100, 8) and January to 4 October 2003 (132, 46, 5). All
conﬁrmed cases had fever, haemorrhage and thrombocytopenia.
About 79.3% were male and 20.7% female. Farmers and butchers
formed 32.7% of the positive cases. About 40.1% of the conﬁrmed
cases were between 16 and 30 years. Between the conﬁrmed cases,
43.2% had previous contact with domestic animals and 3.9% had
contact with ticks. The serum samples were negative for the other
VHFs.
Conclusion: CCHF is the most important haemorrhagic fever in
Iran. This disease occurs more frequently in the south-east part of
the country and this fact emphasises the entrance of the disease
from this region. From the obtained results, RT-PCR technique
together with ELISA method is the best way of detection of the
disease. RT-PCR positive results are less numerous because the
viraemia period is short in humans. In the ﬁrst years of the sur-
vey, positive cases of the disease showed an increasing rate and
this demonstrates a greater incidence of the disease, a progression
in the methods of the diagnosis and a development of the skills of
the laboratory staff. The decrease in the rate of the disease this
year can be due to a development of the knowledge for the pro-
phylaxis of the disease or a decrease in the proliferation and activ-
ity of the ticks.
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P1244 Crimean-Congo haemorrhagic fever in Sistan and
Baluchestan province of Iran, a case–control study
S. Izadi, K. Holakouie Naieni, S.R. Madjdzadeh, A. Nadim
Zahedan, Tehran, IR
Objectives: Since summer 1999 several cases of Crimean-Congo
hemorrhagic fever have been reported from different parts of Iran.
The main objectives of this research were determination of the
most important ways and patterns of transmission, and epidemio-
logic characteristics of this disease.
Design: In this population based case–control study, 24 patients
from Zabol and Zahedan Districts in the Sistan and Baluchestan
province, reported to the Center for Disease Control of Iran, have
been compared with 300 controls. The controls were sampled
through ‘probability proportional to size cluster sampling’ method
from the general population of the same districts. The following
variables were checked: age, sex, living environment (rural vs.
urban), education years, job, past history of tick bite, contact his-
tory with livestock, history of livestock slaughtering, presence of
an animal place at home, history of keeping of livestock in house.
Results: Variables, which increased the chance of disease, include:
history of slaughtering (OR ¼ 7.57, CI: 2.21–25.91), high-risk occu-
pations (OR ¼ 4.97, CI: 0.97–25.43), history of tick bite
(OR ¼ 105.89, CI: 9.32–1202.44), above 40 years of age (OR ¼ 7.32,
CI: 1.06–50.26).
Conclusion: The results of this study conﬁrm that the scheme of
risk factors and risk groups of Crimean-Congo hemorrhagic fever
in Iran do not differ substantially from the other parts of the
world. Even taking care of livestock for a short period at home
can increase the chance for CCHF.
P1245 Detection of IgG and IgM antibodies vs.
West Nile virus
E. Anastasakou, P. Duramani, C. Kapotis, S. Mavrea
Athens, GR
Introduction: West Nile virus (WNV) is an arbovirus. Arboviruses
are zoonotic and transmitted through arthropods like mosquitoes.
In recent years, in the temperate regions of Europe and North
America, WNV is a threat to public health. Twenty per cent of the
infected people will proceed to develop West Nile fever which
portrays mild symptoms of fever, muscle aches, head aches and
occasionally the appearance of a skin rash on the trunk of the
body. There may also be a swelling of the lymph glands. These
particular symptoms last a few days. From the individuals who
develop a severe disease <1% will develop encephalitis or menin-
gitis. The aim of this study was the detection of IgG and IgM anti-
bodies vs. WNV in the serum of patients with
meningoencephalitis and in the serum of outpatients with no
symptoms of CNS.
Material and methods: 55 patients with meningoencephalitis who
were hospitalised in various hospitals of Attica comprised group
A (ages ranging from 18 to 67 years). A total of 133 outpatients
from our hospital comprised group B (ages ranging from 16 to
78 years). The ELISA method was used to detect the presence of
antibodies in the serum.
Results: No patient of group A had positive IgG or IgM antibod-
ies but two patients of group B, one male and one female with
respective ages of 42 and 53 years, showed the presence of IgG
positive antibodies and IgM negative antibodies. Both individuals
reported having ﬂu-like symptoms consisting of a low fever, mus-
cle pains and headaches 3 and 4 months before the detection of
antibodies.
Conclusions: We emphasise that only IgG antibodies were detec-
ted in the group B (patients with no symptoms of CNS).We con-
clude that arboviruses exist in the Greek vicinity but we have no
evidence from the groups we tested that these arboviruses devel-
oped meningoencephalitis.
P1246 Comparison of tick-borne encephalitis incidence in
the Czech Republic under extreme weather conditions in 2001–
2003
V. Danielova, M. Daniel, B. Kriz, C. Benes, K. Zitek
Prague, CZ
Objectives: Tick-borne encephalitis (TBE) is very sensitive to cli-
matic conditions. The aim of our analyses is to demonstrate the
direct effect of different extreme weather conditions prevailing in
three following years on the incidence of TBE human cases. These
data are compared also with the activity of Ixodes ricinus.
Methods: TBE data incidence is taken out from EPIDAT database
(National Institute of Public Health, Prague); TBE is the notiﬁable
disease in the Czech Republic since 1951. Weather conditions in
the period under study are based on database of Czech Hydrome-
teorological Institute (Prague) and are evaluated by standard
methods of state meteorological service. Activity of I. ricinus was
monitored by all seasonal weekly ﬂagging of ticks on experimen-
tal plots (measuring 600 m2).
Results: TBE incidence sharply arose in the beginning of 1990 and
the high values are observed (with some ﬂuctuation) till now due
to the climate modiﬁcation, as it was demonstrated in previous
communications. The situation was similar in spring/summer sea-
sons in the years under study (as for TBE incidence, weather con-
ditions and tick activity). All three summer/autumn seasons were
quite different. Oversized precipitations in 2001 caused high tick
activity and thus second peak of TBE incidence approaching
nearly spring/summer value. Heavy long-lasting rains in August
2002 (resulting in catastrophic ﬂoods) brought extremely wet wea-
ther conditions but inﬂuenced TBE morbidity negatively thanks
mainly to decreased human outdoor activities. Very warm and
dry weather (from August to November) in 2003 depressed the
TBE incidence to minimal values. The changes in TBE vector I. ric-
inus activity were very similar, thus explaining the way of the
weather inﬂuences on TBE incidence.
Conclusions: The presented comparison contributes to the prob-
lem of climate change inﬂuence on vector-borne diseases which is
intensively studied in the WHO/EC Project Climate Change and
Adaptation Strategies for Human Health in Europe. Moreover the
results could be used for the prediction of TBE risk assessment
according to weather conditions.
P1247 Tick-borne encephalitis risk forecast based on
climate and microclimate factors affecting the activity of vector
Ixodes ricinus tick
M. Daniel, K. Zitek, V. Danielova, B. Kriz, J. Valter, I. Kott
Prague, CZ
Objectives: The aim is to solve the following problems: (1) Whe-
ther the relationship between the weather and tick behaviour is
solid enough to be used for the prediction of tick activity, and
thus for the prediction of risks of TBE infection. (2) Whether
macrometeorological data provided by standard meteorological
networks can be used to estimate tick activity. The study includes
an examination of the tightness of relationships between the so-
called macro-scale weather, as presented by standard meteorologi-
cal stations, and authentic microclimate of typical forest ecosys-
tems containing ticks and TBE virus.
Methods: Observations were realised in the south-eastern periph-
ery of Prague, which is the site of Czech Hydrometeorological
Institute Observatory (Prague-Libus), and where the experimental
plots for monitoring were established in relevant type of forest
growth (Querceto-carpinetum). I. ricinus activity was investigated
by the ﬂagging method on three plots (200 m2 each) in weekly
intervals. The instruments for micrometeorological observations
were installed between the experimental plots. Meteorological ele-
ments were measured (every 30 min) in continuous 24-h measure-
ments during 10 selected days according to different synoptic
situation. Macrometeorological data were used from the CHMI
meteorological observatory. Simple and multiple linear regression
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and quadratic regression were used to test the relation between
the weather and I. ricinus activity.
Results: Eight models of the relationships were tested, of which
four were single-parametric and four were double-parametric.
Double quadratic regression provided far better results. The rela-
tionship between daily I. ricinus activity and weather is character-
ised by distinct determinability and can be described using two-
to three-parameter models.
Conclusions: A very high concordance in the trends of daily pat-
terns of meteorological elements obtained from a standard wea-
ther station and of the microclimate of the forest containing ticks
and TBE virus suggests that a warning system can be created
actually evaluating and predicting the risk of I. ricinus tick attack
and thus TBE infection based on the use of macrometeorological
data as a predictor.
P1248 A qualitative detection of tick-borne encephalitis in
clinical samples by real-time PCR
E. Zamapchova, V. Cihlarova
Ceske Budejovice, CZ
Diagnosis of tick-borne encephalitis (TBE) in patients is based on
clinical ﬁndings, cerebrospinal ﬂuid (CSF) analysis and ﬁndings of
speciﬁc IgM and IgG antibodies in serum. In 15–20% of patients,
diagnosis is possible only from second sample of serum 7–14 days
after the onset of the second phase of the disease. Therefore, there
is a need of fast, sensitive and accurate method for routine diag-
nostic of TBE in human samples. We have adapted our existing
TBEV reverse transcription PCR (RT-PCR) detection system to the
one-step qualitative real-time RT-PCR. The method is based on
the detection of a nuclear acid ampliﬁcation during exponential
phase of PCR when the reaction reaches its optimal course. In our
study we have worked with the LighCycler instrument (Roche
Diagnostic, UK). As a detection format, DNA binding dye SYBR
Green I have been used. Speciﬁcity and sensitivity of ampliﬁca-
tion reactions were enhanced by combining ampliﬁcation with a
melting curve analysis. The system was established and validated
using viral RNA extracted from brain tissue of suckling mice
(BALB/c) infected with TBEV (strain Hypr). In order to evaluate
real-time RT-PCR for routine diagnostic purposes, we have
applied the assay to CSF or serum samples from patients with
early diagnosis of TBE (onset of fever, headache and neurological
symptoms less than 3 days before admission to hospital and lum-
bal punction). Diagnosis of TBE was based on typical clinical pic-
ture and serological ﬁndings in serum sample (IgM over
150 WIEU, IgG over 150 WIEU). Of the 70 clinical samples investi-
gated for TBEV RNA, none was tested positive. To avoid false
negative results we have elaborated a positive control. We have
spiked a negative patient CSF sample with 10-fold dilutions of
viral RNA extracted from brain tissue of infected suckling mouse.
Although the method was sensitive to detect 1 PFU in a reaction
volume of microlitre of artiﬁcially infected CSFs, it fails to detect
viral RNA in samples from patients with serologically proven
TBE. The result indicates that virus load decreases with the onset
of serum antibodies and cannot be regularly detected in CSF by
RT-PCR. The method is not suitable for routine diagnosis of TBEV
in patients with detectable antibodies and the suitability for detec-
tion in patients without serum antibodies should be evaluated.
P1249 Changes in diagnostics and treatment of tick-borne
encephalitis
V. Struncova, D. Sedlacek, M. Svecova, P. Pazdiora
Pilsen, CZ
Objectives: The aim of our retrospective study is to evaluate chan-
ges in anamnestic data, diagnostic schedule, treatment and out-
comes of tick-borne encephalitis (TBE) that occurred in the region
of West Bohemia in the last 10 years.
Methods: We compared two sets of patients who suffered from
TBE in 1994, and in 2003, respectively. Set A consists of 67
patients median age 37 years, range 1.5–77). Set B consists of 63
patients (median age 40, range 6–74). Analysis of anamnestic data,
clinical features, results of laboratory investigation and serological
methods – complement ﬁxation reaction (CFR), HIT, VNT-IgM
were used in 1994, and ELISA IgM and IgG were used in 2003.
Results: In the history of the illness, we noticed tick bite in 72 and
42% (P < 0.05), and a two-phase course in 83 and 94%, respec-
tively. The patients of both sets were clinically presented with
signs of meningitis 7.5 and 9.5%, meningoencephalitis 19.4 and
47.7% (P < 0.05), encephalitis 68.6 and 41.2% (P < 0.05) and ence-
phalomyelitis 4.5 and 1.6%. Investigation of cerebrospinal ﬂuid
(CSF) was done in 82 and 71% (P < 0.05). Diagnoses were con-
ﬁrmed serologically in blood by CFR in set A. The results were
received in 8–43 days. The blood and CSF were serologically
investigated by the ELISA test; results were available in 1–5 days
in set B. The treatment was supportive; corticosteroids were indi-
cated in 66 and 63%, antibiotics in 48 and 4.8%(P < 0.05). The
lengths of stay in hospital were 12.8 and 8.6 days (P < 0.05). Two
patients died (fatality rate 3%) and six (9%) were left with seque-
lae in 1994. Twenty-one patients (23%) were left with sequelae in
2003. The incidence of TBE is the same in the two sets, the diag-
nosis is conﬁrmed earlier (3 days in the average), the number of
CSF investigations decreased, the length of stay is shorter, and
treatment with antibiotics was used 10 times less frequently.
Conclusion: The timely conﬁrmation of diagnosis by the ELISA sero-
logical test inﬂuenced subsequent investigation and treatment, and
has limited the use of antibiotics. No speciﬁc treatment for TBE has
been available until now. Be vaccinated, do not become ill!
P1250 Severe courses of tick-borne encephalitis in Ostrava,
1999–2003
A. Zjevikova, I. Orsagova, L. Roznovsky, J. Januska
Ostrava, CZ
Objectives: We investigated occurrence of severe as far as fatal
courses of tick-borne encephalitis in patients hospitalised at the
Department of Infectious Diseases, University Hospital in Ostrava,
during the last 5 years.
Methods: Tick-borne encephalitis in 96 hospitalised patients at the
age of 4–71 years was proved in 1999–2003. The aim of our inves-
tigation was to determine the rate of severe or fatal courses of the
disease.
Results: Serious course of tick-borne encephalitis with necessity of
intensive care was observed in 27 from 96 patients (28%). Five of
them (5%) with bulbar form of encephalitis required assisted ven-
tilation. One patient cured without sequelae, the other one pro-
gressed to the persistent paresis of the right upper extremity.
Three patients (3%) with long-term artiﬁcial ventilation died. A
62-year-old male and a 71-year-old female died of complicated
mycotic sepsis and a 30-year-old male died because of acute me-
diastinitis following iatrogenic damage during puncture tracheos-
tomy.
Conclusion: Severe courses of tick-borne encephalitis represent
almost one-third of cases in our group of 96 patients. However,
fatal courses are not often, they were proved in three patients
with bulbar form and necessity of long-term artiﬁcial ventilation.
Profylactic vaccination is widely recommended, especially in
adults from endemic regions.
P1251 Puriﬁcation and analysis of the structure of prion
aggregates from yeast Saccharomyces cerevisiae
D. Kryndushkin, I. Alexandrov, V. Kushnirov, M. Ter-Avanesyan
Moscow, RUS
Objectives: Prions cause several incurable infectious diseases in
mammals. They represent a novel type of infectious agent – mis-
folded homogeneous protein aggregates, which are able to cata-
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lyse conformational changes of normal type protein. To investi-
gate prion phenomenon we use yeast Saccharomyces cerevisiae,
which contain several proteins with prion properties. The best
studied of them is Sup35 prion protein. In vitro, puriﬁed Sup35
can form amyloid-like ﬁbres, which was shown to be infectious
after introducing into yeast cells. Moreover, in the prion state
Sup35 is found in aggregated form in yeast cells, but the structure
of these aggregates is unknown. Here, we present a novel method
for puriﬁcation of prion aggregates from yeast cells. Using it, we
investigate structural and biochemical properties of yeast prions.
Methods: The method developed is based on our ﬁnding of condi-
tions that can distinguish prions from other cellular aggregates.
The key point of purifying strategy is the stability of Sup35 prion
polymers in sodium dodecyl sulphate (SDS), in contrast to other
protein complexes of yeast lysates. After strong SDS treatment we
used ultracentrifugation or electrophoretic approach to obtain
high-puriﬁed prion material. Furthermore, we used high-resolu-
tion electron microscopy to reveal the detailed structure of puri-
ﬁed prion polymers.
Results: This approach allowed us to show that the Sup35 prion
aggregates in vivo represent agglomerations of relatively small pri-
on polymers with amyloid-like properties. We determined the size
of polymers; this size is characteristic of a given prion variant and
differs between the variants. We showed that puriﬁed prion poly-
mers are able to convert non-prion Sup35 molecules into SDS-
resistant prion aggregates in yeast lysates, which means that these
polymers are infectious. We studied the effects of some prion-cur-
ing factors (such as chaperones and other chemicals) on the size
of prion polymers. Finally, using electron microscopy, we
obtained high-resolution pictures of prion polymers and con-
ﬁrmed amyloid-like structure of these polymers.
Conclusion: This work represents the ﬁrst attempt to purify prion
aggregates from yeast cells and to analyse their structure. The
method developed may have wider application for the analysis of
other prion and amyloid phenomena both in lower and in higher
eukaryotic organisms.
Diagnostic methods - II
P1252 Evaluation of the VCAT3 neisseria selective
medium
T. Tirczka, M. Gacs, M. Fu¨zi
Budapest, HUN
Aim: To evaluate the sensitivity and speciﬁcity of the VCAT3 neis-
seria selective medium manufactured by BioMerieux, France.
Materials and methods: A total of 1161 randomly selected samples
taken by swab from the throat of patients with upper respiratory
infections were plated on both VCAT3 medium and home-made
chocolate agar plates supplemented with 25 mg/L vancomycin. In
another experiment a 103 CFU/mL suspension of Neisseria menin-
gitidis control strain/ATCC 122004/ was added to 50 throat sam-
ples/swabs soaked in 2 mL of physiological saline/respectively at
a 1:1 ratio and plated (mikrol) on the same media. All the inocula-
ted media were incubated at 35C for 48 h in 5% CO2 atmo-
sphere. The plates were read twice: after 24 and 48 h of
incubation. Isolated Neisseria strains were identiﬁed by the API
NH test (BioMerieux).
Results: Growth on the VCAT3 media could be properly evaluated
after 48 h of incubation; there was no growth or only pin-point
colonies of Neisseria were seen after 24 h of incubation. Of the
1161 throat samples, ﬁve yielded N. meningitidis on VCTA3 agar
and three on the home-made chocolate agar plates. The N. menin-
gitidis control strain could be recovered from all the 50 samples
on VCTA3 agar. VCTA3 proved highly selective: 47 of the 50 sam-
ples grew exclusively N. meningitidis and on only three of the
plates grew some colonies of additional bacteria. The sensitivity
of the VCTA3 agar was also tested: N. meningitides (ATCC 122004)
was suspended in physiological saline and 10 ll of a
5  100 CFU/mL suspension was plated on the media. All the
VCTA3 agar plates yielded three to 20 colonies of Neisseria. Colon-
ies of N. meningitidis were characteristic and easy to recognise on
VCTA3 agar.
Conclusions: The selectivity of VCTA3 agar proved excellent; the
medium is well-suited for the isolation of N. meningitidis from
specimens containing large numbers of various bacteria. The sen-
sitivity of the medium is also appropriate. Furthermore, since col-
onies of N. meningitidis are typical on VCTA3 agar plates the use
of the medium can be recommended for clinical bacteriology
laboratories.
P1253 A rapid antigenic test combined with a sore throat
score vs. culture in group A Streptococcal pharyngitis
C.S. Stingu, T. Turcu
Iasi, RO
Objective: To establish the sensitivity and speciﬁcity of three diag-
nostic approaches in Group A Streptococcal pharyngitis: a rapid
antigen test, a sore throat score and a combination of these two
vs. culture.
Methods: This study included 91 patients hospitalised between 15
May and 1 December 2003 in Infectious Disease Hospital from
Lasi, Romania. Two pharyngeal swabs were collected from each
patient, one for rapid antigen test (One Step Strep A Test Cassette
– AccuBioTech – a two side sandwich immunoassay) and the
other for culture. All beta haemolytic streptococci were identiﬁed
as group A with a latex-agglutination kit (Slidex Strepto A – Bio-
Merieux). The sore throat score had ﬁve criteria: age, fever,
absence of cough, tender anterior cervical nodes, tonsillar swelling
or exudates. The score range is 1 to 5. In this study we included
only patients with no antibiotic therapy prior to examination and
with no other infectious diseases.
Results: Of the 91 patients, 30 (32.97%) had a positive result for
group A streptococci (culture plus latex agglutination – consid-
ered gold standard). Rapid antigen test had two false positive and
one false negative results. This test had a sensitivity of 96.67%
(95%CI: 82.78–99.92%) and a speciﬁcity of 96.72% (95% CI:
88.65–99.6%). Score higher or equal to 3 had a sensitivity of
51.61% (95% CI: 33.06–69.85%) and a speciﬁcity of 60% (95%CI:
46.54–72.44%). All 10 patients with score 0 had negative results
for rapid strep and culture. If we add results from rapid antigen
testing to all patients with score higher or equal to 3 we will not
miss any positive result (95%CI: 69.15–100%) and will have a
good speciﬁcity: 93.33%(95%CI: 68.05–99.83%).
Conclusions: The rapid antigen test we used had very good sensi-
tivity and speciﬁcity. The patients with score 0 should be exclu-
ded from further testing. The rapid strep test performed on all
patients with score higher than 0 will increase sensitivity and spe-
ciﬁcity of the score. Even if we cannot exclude culture, this diag-
nosis approach may give good results on a ﬁrst visit of a patient
for sore throat.
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P1254 Comparison of ﬁve media for detection of group B
Streptococci in vaginal/rectal swabs from pregnant women
L. Stoakes, S. Burn, M. Myers, M. John, Z. Hussain
London - Ontario, CAN
Objectives: Routine screening of pregnant women for group B
Streptococci (GBS) rather than risk-based approach is now recom-
mended. We evaluated ﬁve media for the detection of GBS in
pregnant women 35–367 weeks gestation.
Methods: Vaginal/rectal swabs transported in Amies media (Star-
plex Scientiﬁc, Canada. In the laboratory, the swabs were trans-
ferred to tubes containing 0.8 mL sterile saline and vortexed. One
hundred microlitres of the bacterial suspension was used to
inoculate each of the following media, CNA agar with 5% sheep
blood (Oxoid Canada), selective Todd Hewitt broth with 5%
sheep blood (THB, Oxoid Canada), LEN GBS agar (GBSA, North-
eastern Laboratory Services, Winslow, ME), NEL GBS broth
(GBSB), and Instant Granada broth (IGB, Biomedics, Madrid,
Spain). CNA, GBSB, GBSA, and IGB were examined after 24 and
48 h of incubation. Development of orange to red colouration in
GBSA, GBSB, and IGB was considered to be an indication of GBS
growth. GBSB, IGB if negative and THB were subcultured onto
CNA after 24 h incubation.
Results: Specimens from 405 women were processed, 97 (24%) of
these were found to be positive for GBS. Seven (7.2%) of 97 GBS
were non-haemolytic and non-pigment producing and were not
detected in GBSB, GBSA, and IGB. Detection of GBS after 24 and
48 h incubation was achieved in 79 (81.4%) and 80 (82.6%) speci-
mens, respectively, by CAN, 84 (86.6%) and 86 (88.7%) specimens
by GBSA, 82 (84.5%) and 86 (88.7%) specimens by GBSB and 86
(88.7%) and 88 (90.7%) specimens by IGB. Ninety-one (93.8%)
GBS were isolated from IGB subcultures and 90 from GBSB and
IGB subcultures.
Conclusions: All media, except CNA performed well. THB subcul-
tures had the least overgrowth with commensal organisms. Broth
media performed better than plate media. For most strains, results
from GBSA, GBSB, IGB were available earlier than those of THB.
However, more GBS were identiﬁed on subcultures from GBSB
and IGB than could be identiﬁed in these media after 48 h incuba-
tion. Consequently turn-around time for broth media was the
same.
P1255 Usefulness of fatty acid analysis for identiﬁcation of
nutritionally variant streptococci
E. Durnova´, I. Porazilova´, J. Jancova´, G. Novotna´
Ostrava, Prague, CZ
Objectives: Nutritionally variant streptococci (NVS) were described
as a major causative agent of septicaemia in neutropenic cancer
patients and accounted for serious cases of infective endocarditis.
In clinical laboratories, the identiﬁcation of NVS is often depend-
ent upon their phenotypic characterisation. An overlap in physio-
logic characteristics between NVS and other Gram-positive
catalase-negative cocci is known.
Methods: Our study examined, if it is possible to conﬁrm prelim-
inary phenotypical identiﬁcation as NVS by fatty acid analysis
based on whole cell fatty acid methyl esters (MIS Sherlock, MIDI,
Inc., USA). Two years of study on Gram-positive catalase-negative
cocci recovered from blood cultures yielded nine isolates of NVS.
According to the analysis of partial 16S rRNA gene sequence,
NVS-isolates were identiﬁed as Granulicatella adiacens (7) and Abi-
otrophia defectiva (2). To conﬁrm correct interpretation of fatty acid
results, NVS reference strains and ‘viridans streptococci’ isolates,
which were identiﬁed as Streptococcus spp. and phenotypically
resembled NVS, were also included in the study. The obtained
fatty acid compositions of our isolates were also compared with
the phenotypically similar Gemella morbillorum.
Results: All Streptococcus spp. signiﬁcantly differed from other
strains tested by lower amount of both C16: 1w9c and C18: 1w9c.
In comparison with other NVS, only G. elegans showed unique
fatty acid composition, the amount of C18: 2w6,9c was almost
three times higher and C16: 1w9c was not detected at all. For fur-
ther differentiation of A. defectiva, G. adiacens and G. morbillorum,
three fatty acids were chosen – C16: 0, C18: 1w9c and C18:
2w6,9c. Unlike G. adiacens and G. morbillorum, the amount of C16:
0 lower than 30% and simultaneously the amount of C18: 1w9c
higher than 20% were detected in A. defectiva. G. adiacens differed
from G. morbillorum by the amount of C18: 2w6,9c being lower
than 3%.
Conclusions: (1) The fatty acid composition of phenotypically sim-
ilar Streptococcus spp. differs signiﬁcantly from all tested NVS. (2)
Fatty acid analysis could be an useful tool for the discrimination of
G. elegans from G. adiacens and A. defectiva. (3) In case of failure of
satelitism behaviour, the found differences in fatty acid composi-
tion could help to distinguish G. morbillorum from NVS.
Acknowledgement: Our work was supported by the Ministry of
Health of the Czech Republic, Id.code: MZO/ZA/00538.
P1256 Evaluation of the SM ID 2 medium: comparison to
the SM ID, BBL CHROMagar Salmonella and Hektoe¨n media
J-Y. Dusseau, P. Ge´roˆme, J. Bougere, S. Orenga, D. Robichon,
C. Roger-Dalbert
Lyon, La Balme les Grottes, F
Objective: The aim of this study was to evaluate the performance
of a new formula of SM ID (bioMe´rieux) medium, SM ID 2, par-
ticularly in terms of the speciﬁcity and sensitivity to detect var-
ious Salmonella choleraesuis species serotypes. The performance of
the SM ID 2 medium was compared with three other media: SM
ID, BBL CHROMagar Salmonella (Becton Dickinson) and Hektoe¨n
(bioMe´rieux).
Methods: The study consisted of testing 260 samples: 15 diarrhoea
stool specimen, 171 stool specimen for bacteriological and parasi-
tological standard examinations, 45 rectal swabs, and 29 artiﬁci-
ally contaminated non-diarrhoea stool specimen.
Results: Seventeen non-artiﬁcially contaminated samples contained
one Salmonella strain. With respect to sensitivity, the SM ID 2
medium is signiﬁcantly more sensitive in detecting Salmonella spe-
cies than the BBL CHROMagar Salmonella medium at 24 and 48 h.
This medium is also more sensitive than the SMID medium at 24
and 48 h. The sensitivity of the SM ID 2 and Hektoe¨n media are
identical. The speciﬁcity of the SM ID 2 medium is consistently
greater than 95%. Statistically, the SM ID 2 medium shows specif-
icity signiﬁcantly higher at 24 h than both the SM ID and Hektoe¨n
media. This difference is not present at 48 h. The speciﬁcity of the
SM ID 2 medium is lower than that of the BBL CHROMagar Sal-
monella medium at 24 h but equivalent at 48 h. The difference is
not statistically signiﬁcant. In terms of legibility, the data are in
accordance with the way the laboratory technicians are able to
easily distinguish the Salmonella colonies on the SM ID 2 medium
from the annex ﬂora present.
Conclusion: The SM ID 2 medium is a chromogenic medium effect-
ively adapted for routine laboratory use for the detection of Salmon-
ella in stools and rectal samples. This study demonstrates better
legibility performance compared with SM ID, as well as fewer false
positives, which results in saving of both time and costs.
P1257 Shewanella species: infections in Denmark and
phenotypic characterisation
H.M. Holt, B. Gahrn-Hansen, B. Bruun
Odense, Hillerød, DK
Objectives: Human infections with Shewanella species are rare,
especially in countries with a temperate climate. We present seven
case reports of typical Shewanella infections from Denmark and
results of conventional phenotypic characterisation and antibiotic
susceptibility testing on 179 Danish isolates.
Methods: Clinical records from ﬁve patients with Shewanella algae
and two patients with Shewanella putrefaciens infections were
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obtained. Phenotypic characterisation was made by standard
methods and susceptibility testing by direct agar diffusion with
Rosco Neo-Sensitabs (R).
Results: Two cases of bacteraemia, one wound abscess and two ear
infections with S. algae are presented; in four of these cases S. algae
was found in pure culture. All patients were treated with antibiotics
speciﬁc for S. algae. S. putrefaciens was found in mixed culture in a
drainage ﬂuid and in a foot ulcer, and was not treated speciﬁcally.
S. algae was able to grow at 42C and in 6% NaCl, to reduce nitrite
and was resistant to colistin (150 lg) in contrast to S. putrefaciens.
Conclusion: Differentiation between S. algae and S. putrefaciens is
possible using conventional phenotypic tests. This differentiation
is important because the two species have different pathogenic
potentials in humans.
P1258 Simple sample preparation methods to detect
Shiga-toxin-producing E. coli from human stools by Duopath
Verotoxin
C. Park, H. Schmidt, A. Ditzen, D. Murphy, A. Bubert
Falls Church, USA; Dresden, D; Brisbane, AUS; Darmstadt, D
Background: Haemorrhagic colitis and haemolytic uraemic syn-
drome can be caused by Shiga toxin-producing Escherichia coli
(STEC) O157 and non-O157 STEC. Since the latter serotypes fer-
ment sorbitol and lack other phenotypic markers, they cannot be
recognised on agar plates. The Duopath Verotoxin (DV, Merck
KGaA) is a new easy-to-use immunochromatographic (lateral
ﬂow) test for detecting both Stx1 and Stx2 individually on the
same device. Its performance has been described recently (Park,
et al., 2003; J. Clin. Microbiol. 41:2650–53). In this study, stool
samples were streaked on SMAC agar and incubated overnight
after which a colony sweep was harvested from the plates. The
swab was suspended in distilled water containing polymixin B
and after short incubation, the mixture was delivered to the sam-
ple port of DV. Both DV and Premier EHEC (Meridian Bioscience)
detected all 12 fresh positive STEC (6 O157:H7 and 6 non-O157)
and agreed 100% with 248 negative specimens.
Objectives: The application of DV directly from stools and over-
night broth performed poorly. This study evaluated a two-step
broth enrichment (24–26 h) method before applying to DV device.
Methods: As a preliminary study, 19 STEC stool samples were tes-
ted by inoculating into EHEC Diretmedium (Heipha, Germany)
and/or EC broth. Overnight incubation was followed by a short
post-enrichment step (4 h) in a new modiﬁed CAYE broth
(Merck,KGaA). This broth was supplemented with Carbadox,
which is an inducer for Stx production.
Results: All samples enriched by this method were positive when
compared with the commercial ELISA test. With samples of high
optical density readings, the DV correlated well yielding strong
lines of signal. In most cases, the Carbadax was found to enhance
the appearance of stronger signal on DV.
Conclusions: We introduced two sample preparation methods for
Duopath Verotoxin, which are simple to perform and easy to
interpret. However, an extended study is in order to conﬁrm the
efﬁcacy of two-step broth sample preparation method. The DV is
capable of providing a turnaround time of 24–26 h and has a
great potential for clinical applications.
P1259 The biological characterisation of new phage types
of Salmonella enterica serovar Enteritidis
V. Majta´n, L. Majta´nova´
Bratislava, SK
Objectives: Salmonella enterica serovar Enteritidis is an important
cause of food-borne infections in many countries around the
world. The object of this study was to characterise the chosen
virulence factors (surface hydrophobicity, motility, bioﬁlm forma-
tion) of 52 S. enteritidis isolates representing three new phage
types identiﬁed in the Slovak Republic during the 2003.
Methods: The phage types were identiﬁed according to Ward et al.
(1987). The hydrophobicity was determined on the basis of bacter-
ial adherence to hydrocarbon-xylene (BATH) and salt aggregation
test with ammonium sulphate. The assay of motility was per-
formed on the semisolid agar medium (0.35%). The bioﬁlm-form-
ing abilities of strains were examined in the tube test after
cultivation in a starvation medium.
Results: Fifteen strains belonged to the phage type (PT) 9a (28.8%),
26 to the PT 13a (50.0%) and 11 strains were PT 25. The results of
adhesion of strains to xylene revealed a higher adhesion of strains of
both PTs 9a and 25 in comparison with PT 13a. Adhesion was found
to be high in 12 strains of PT 9a (80.0%) and in nine strains of PT 25
(81.9%). Motility of strains of all PTs was high. The bioﬁlm forma-
tion after cultivation of strains in a starvation medium refer to their
high virulent potential. The bioﬁlm was formed by all strains except
for two strains of both PTs 13a and 25 and one strain of PT 9a.
Conclusions: The identiﬁcation of new phage types can include the
differences in their reservoirs and in the distribution of contamin-
ated food as well as in their virulence properties. The presented
ﬁndings refer to the pathogenic potential of new phage types of S.
enteritidis strains.
P1260 Phage typing of Salmonella enterica serovar
Typhimurium isolated from humans in the Slovak Republic,
2000-2003
L. Majta´nova´, V. Majta´n
Bratislava, SK
Objectives: Salmonella enterica serovar Typhimurium is a common
cause of salmonellosis among humans and animals in many coun-
tries. In contrast to countries of West Europe, the participation of
this serovar in aetiology of salmonellosis in the Slovak Republic
(SR) is low and epidemiologically of little signiﬁcance. In our
human population, serovar Enteritidis still predominates. The con-
trol of outbreaks and management of cases is greatly facilitated by
the rapid isolation and identiﬁcation of the responsible microor-
ganism. Phage typing has become the reference method for the
primary subdivision of strains of serovar Typhimurium for epide-
miological investigations.
Methods: Two hundred and ﬁfty-eight strains of human origin
that occurred as the sporadic cases during the years 2000–2003 in
the SR were examined. The strains were phage typed according to
the method of Anderson et al. (1977). All strains were also tested
for susceptibility to 10 antibiotics by a disc diffusion method.
Results: Seventeen phage types (PTs) were detected among the 258
isolates. The most common PT was found to be DT104 (22.9%), fol-
lowed by PTs DT41, DT68, DT193, DT20a, DT6, DT12a, DT67,
DT36, DT37, DT14, DT99, DT120, DT125. Ten strains were classiﬁed
as react-but-do-not-conform strains (RDNC) and 97 strains were
not typeable. Of DT104 isolate, 32 strains (54.2%) with characteristic
resistance to ampicillin (A), chloramphenicol (C), streptomycin (S),
sulphisoxazole (Su) and tetracycline (T) were found. The strains of
other PTs were also resistant to antibiotics in different range.
Conclusions: The results of this study demonstrate that the multi-
drug-resistant DT104 strains have wide distribution in humans in
the SR. With regard to this, it is important to pay attention to
detection and further examination of multidrug-resistant strains of
serovar Typhimurium of various phage types.
P1261 Comparison of culture methods for isolation and
enumeration of Legionella species from cooling tower water
samples
P.G.H. Peerbooms, J.D. Schalekamp, A.A. Bartels
Amsterdam, Rotterdam, NL
Background and objectives: Cooling towers have been repeatedly
implicated as source of Legionella infections in humans. The water
in these cooling towers contains high numbers of contaminating
bacteria. Culture of Legionella species from cooling tower water is
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therefore difﬁcult, and widely different results are found using dif-
ferent culture methods, both with regard to the number of positive
samples and the number of colony forming units in positive sam-
ples. Setting standards for the acceptable number of Legionella in
cooling tower water is hampered by these difﬁculties. The objective
of this study was to investigate which protocol would result in the
highest recovery of Legionella from cooling tower water with the
lowest investment of manpower and culture media.
Methods: We compared several culture methods including the
method described by the ISO and a method used by a Dutch ref-
erence laboratory with the procedure as prescribed by the Dutch
standardisation institute (NEN). Thirty cooling towers were sam-
pled in the summer in both cities.
Results: Seventy percent of the cooling towers were contaminated
with Legionella species in numbers ranging from 200 to >106 CFU/
L. Failure to isolate Legionella was mostly caused by overgrowth of
the inoculated media by other non- Legionella bacteria.
Conclusion: Methods using ﬁltration, heat decontamination and
the use of highly selective culture media with glycin containing
antibiotic supplements resulted in the highest recovery rates of
Legionella from these water samples. The method as described by
the ISO was among the best methods and required relatively little
materials and labour. Our results conﬁrm that setting a standard
for this type of water may be difﬁcult.
P1262 Clinical study of a new chromogenic medium for
the isolation and the direct identiﬁcation of Staphylococcus
aureus
M-E. Reverdy, C. Roger-Dalbert, D. Robichon, J. Etienne
Lyon, La Balme les Grottes, F
Objective: The current using of chromogenic medium in laborator-
ies, allows visualising and rapidly identifying various microbial
species, especially in polymicrobial samples. The aim of the study
was to evaluate the biological performances of a new chromogenic
medium S. aureus ID bioMerieux (SA ID) for easy identiﬁcation of
S. aureus colonies by a green colouration.
Methods: The study was carried out to test this new medium in
parallel with the CHROMagar S. aureus medium (CM SA) on
which S. aureus colonies are pink. Columbia blood agar was used
as reference method. In total, 515 clinical samples were inoculated
directly on the three media either with a swab or with a 10 lL
loop (100 blood cultures, 108 nasal swabs, 102 suppurations
(swabs or liquid pus), 73 ear, nose, throat and bronchial samples,
29 urines, 54 faeces, 49 genital samples). The three media were
incubated for 24 h in aerobic conditions at 35C. The colonies
were identiﬁed by the catalase test, the Slidex staph plus kit and
the coagulase test. In case of discordant results, additional identi-
ﬁcation tests were performed.
Results: 129 S. aureus were isolated: 112 S. aureus were recovered
on both chromogenic media, there were two false negatives on SA
ID, and 15 on CM SA. There were 18 false positives on SAID
(nine of them are catalase negative and easily differentiated from
S. aureus with regard to the thin aspect of the colonies). There
were four false positives on CM SA. For SAID medium the sensi-
tivity was 98.4%, the positive predictive value (PPV) was 87.6%
(93% by eliminating the nine Gram-positive cocci obviously not S.
aureus), the speciﬁcity was 95.3%, and the negative predictive
value (NPV) was 99.5%. For CM SA medium, the sensitivity was
88.4%, the VPP was 96.6%, the speciﬁcity was 98.9%, and the
VPN was 96.2%.
Conclusion: The results clearly indicate that chromogenic media
enable a simple and rapid method of recovering speciﬁc bacterial
species even in polymicrobial samples or when the pathogenic
bacterial species are present in small quantities among abundant
commensal ﬂora. The sensitivity of the SA ID medium is greater
than that obtained with CM SA, but on the other hand, because of
this good growth capacity, the speciﬁcity and PPV for CM SA are
slightly better. In addition SA ID inhibits most non-staphylococci
Gram-positive bacteria as well as most Gram-negative bacteria
with, only a few multi-resistant Gram-negative bacilli recovered.
P1263 Detection of Helicobacter pylori: evaluation of
staining methods
T. Babic, H. Basic, B. Miljkovic Selimovic, B. Kocic
Nis, CS
Objectives: To compare the sensitivity of traditional detection
methods (haematoxylin and eosin (HE) stain, modiﬁed Giemsa
stain) and immunohistochemistry using a commercially available
anti- Helicobacter pylori antibody (Dako, Denmark) in diagnosis of
H. pylori infection in gastric biopsy and resection specimens.
Methods: Thirty gastric antral biopsies showing chronic gastritis
together with tissue blocks from gastrectomy specimens for duo-
denal ulcer were reviewed histologically. The parafﬁn sections
were stained with HE and modiﬁed Giemsa and immunoenzy-
matically treated by alcaline phosphatase anti-alkaline phospha-
tase (APAAP) method for the identiﬁcation of H. pylori.
Results: The presence of chronic gastritis was conﬁrmed in the 30
gastric biopsy specimens. A diagnosis of duodenal ulcer was con-
ﬁrmed in the mucosa from the gastrectomy specimens. The HE,
modiﬁed Giemsa and immunoenzymatic treated sections were
carefully examined for the presence of H. pylori. HE-stained H. py-
lori appeared as slightly basophilic, spiral-shaped organisms
attached to the apical surface of the surface mucous cells. How-
ever, curved bacteria were only detected when found in great
numbers. Using a modiﬁed Giemsa stain, the spiral-shaped bac-
teria of H. pylori stained blue, were attached to the brush border
of the gastric foveolar epithelial cells and inside gastric pits. In
some cases masked bacteria hidden within mucous were obvious
only in immunostained preparations (red deposits). Similarly, in
modiﬁed Giemsa treated sections, coccoid forms, which were par-
ticularly seen in sections from resection specimens, caused some
uncertainty. These coccoid H. pylori were obvious in immuno-
stained preparations. H. pylori was identiﬁed in 34.4% sections
stained with HE, but it could be identiﬁed with greater frequency
in sections stained with modiﬁed Giemsa (71.8%). It could be
detected at a still greater frequency in sections stained with APA-
AP (90.6%). In all cases the bacteria were more prominent and
easier to detect in the immunostained sections than in sections
stained tinctorially.
Conclusion: Immunoenzymatic staining of tissue sections by the
APAAP procedure is a highly sensitive and speciﬁc method. At
the same time, it is a reliable and easy to perform tool for detect-
ing this organism in gastric biopsy and resection specimens.
P1264 Antibiotic-associated colitis: value of colonic
ultrasound in diagnosis and follow-up
L. Tarantino, A Giorgio, G. Stefano de, V. Scala, A. Di Sarno,
G.Liorre, P. Sorrentino, A. Sullo
Naples, I
Background: Thickening of bowel wall at Ultrasound (US) is an
aspeciﬁc sign in infectious-inﬂammatory bowel diseases. We eval-
uated US of colon as a tool for diagnosis and follow-up of antibi-
otic associated colitis (AAC).
Patients and methods: We retrospectively studied clinical and ima-
ging records of 32 patients (18 males; age: 27–80 years) with the
diagnosis of AAC. All diagnosis were based on patients’history of
massive antibiotic intake preceding clinical signs (diarrhoea,
abdominal pain, fever). Causes of antibiotic intake were: porto-
systemic encephalopathy in 13 cirrhotis patients, recent surgery in
eight patients, respiratory tract infections in nine, liver abscess in
two. Cultures of blood and faeces were performed in all
patients. In 10 cases, stools were tested for toxin of Chlostridium
difﬁcile by enzyme-linked immunosorbent assay (ELISA). All
patients underwent colonic US within 24 h from admission at our
institution and every 3 days during the following 15 days. Thir-
teen patients also underwent colonoscopy. All patients were trea-
ted with Metronidazole (125 mg  4/day) and Vancomycin
(500 mg  4/day) for 10 days.
Results: ELISA test for Chlostridium difﬁcile toxins was positive in
4/10 (40%) patients. All blood cultures were sterile. In 4/13
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patients (31%) colonoscopy showed mucosal pseudomembranes,
pathognomonic pattern for the diagnosis of Pseudomembranous
colitis while in nine patients it showed an aspeciﬁc pattern of
acute colitis. US showed normal (
4 mm) colonic wall thickness
in seven patients and colonic wall thickening (ranging from 8 to
33 mm) in 25/32 patients (78%). Nineteen of 32 (59%) patients
had colonic wall thickness <15 mm while in 13/25 (41%) patients
it was >15 mm.
Follow-up: Remission of symptoms occurred in all patients within
2–11 days (mean: 3.6 days). Persistence of symptoms was signiﬁ-
cantly longer in patients with colonic wall thickness >15 mm
(mean: 5.1 days) than in patients with <15 mm (mean 2.5 days) at
US. Four cirrhotic patients relapsed 7–14 days after completion of
therapy. Three of them (75%) still showed persistence of colonic
wall thickening after the 10 days of metronidazole-vancomycin
therapy. Normalisation of colonic wall thickness (
4 mm) at US
occurred in 29 patients within 3–9 days. None of these patients
relapsed after completion of treatment.
Conclusions: Although aspeciﬁc, thickening of colonic wall at US
seems to be a very sensitive tool for diagnosis and follow-up of
AAC.
P1265 Can the use of a microbiological screen of dental
implants predict implant failure?
C. Smith, E. Nyako, A. Preston, C. Watson, J. Dave
Leeds, UK
Objectives: To determine whether measuring the bacterial load of
dental implants or detecting the presence of selected microorgan-
isms can predict implant failure.
Methods: The presence of selected ‘target’ organisms (S. aureus,
beta-heamolytic streptococci, coliforms, anaerobes, and Candida
species) was detected from paper point samples taken from 19
patients in areas around failing (FI) and healthy implants (HI).
Each paper point was placed into 1 ml of sterile nutrient broth
and quantitatively cultured using the following media: blood
agar, heated blood agar (enumeration), aerobic Mannitol salt agar,
aerobic MacConkey agar, anaerobic neomycin agar, Fastidious
anaerobe agar with a 5 ug metronidazole disc and Sabourauds
agar. Anaerobic bacteria were identiﬁed to the level of Gram mor-
phology and pigmentation; all other isolates were identiﬁed to
species or genus level.
Results: Nine patients had >10 CFU/mL of one target organism
present in either implant sample; ﬁve patients had >10 CFU/mL
of more than one target organisms present and ﬁve patients were
found to have no target organisms present. Of the 14 patients
who had one or more than one target organisms present, the
association with implants was as follows, 14% patients had the
target organism present in the HI only, 43% had the target organ-
isms present in the FI only and 43% had the target organisms
present in both implants. Implant bacterial loads were as follows:
53% patients had a higher bacterial load around the FI; 11% had
a higher bacterial load around the HI; 11% had the same bacterial
load in both implants and in 26% details of the bacterial load
were not recorded.
Conclusion: Measuring the bacterial load of dental implants may
be a more predictive measure of implant failure than screening
for the presence of speciﬁc microorganisms.
P1266 Acute primary diagnosis of malaria on medical
wards in a non-endemic country using the Binax Pf/Pv (R) rapid
antigen detection test
L. Wiese, A. Friis-Møller, H. Fjeldsøe-Nielsen, J.Hansen,
T. Hornstrup, B. Bruun, O. Heltberg, T. Højbjerg, G. Gomme,
J. Kurtzhals
Copenhagen, Hvidovre, Hillerød, Odense, Næstved, Aalborg, DK
Microscopy for malarial parasites may be unreliable in non-ende-
mic countries. We assessed the Binax Pf/Pv (R) rapid antigen test
for routine clinical use where training and routine of alternating
staff and other factors may affect the promising outcome in con-
trolled studies. The test was consecutively performed on patients
with suspected malaria admitted to nine Danish hospitals both at
bedside and in the laboratory. Results were compared with expert
microscopy of Giemsa-stained smears. Samples from 83 patients
were examined by at least one rapid test. All 11 Plasmodium falci-
parum and two of three P. vivax infections were detected. There
were three false negative (one P. malariae, one P. vivax, and one P.
ovale), but no false positive tests. Some found it difﬁcult to per-
form the test. In particular, the presence of three bands, which
may be interpreted as either P. falciparum or a mixture of P. falci-
parum with another species, was confusing. In addition, quantiﬁ-
cation and staging of the parasites was not possible. Rapid testing
for malaria may be used for preliminary diagnosis of P. falcipa-
rum, but microscopy should always be performed as soon as poss-
ible, irrespective of the antigen test result. The study continues
and updated results will be presented.
P1267 Differentiation of Candida albicans from other yeast
species using a new, simple and non-hazardous biochemical
test kit
A. Brown, B. De Caux, P. Druggan, S. Hall, P. Stephens
Basingstoke, UK
Objectives: Owing to differences in antifungal susceptibility, it is
important to rapidly distinguish Candida albicans from other yeast
species in order to initiate effective therapy. The germ-tube test
(GT) remains an important physiological test for the differentiation
of C. albicans from other Candida spp. by its ability to produce pseu-
dohyphae in serum at 37C. However, this method requires incuba-
tion for 2–4 h followed by microscopic examination. Oxoid
Biochemical Identiﬁcation System (OBIS) albicans is intended as a
simple and rapid replacement for GT, incubation time being
reduced to 1 h without the need for subjective microscopic exam-
ination. It is a non-carcinogenic, two-stage biochemical test that
does not use ﬂuorogenic substrates, thereby, eliminating the need
for UV detection, providing both safety and ease of use.
Methods: The test kit detects two enzymes, beta-D-galactosamini-
dase and L-proline aminopeptidase using chromogenic substrates.
Both these enzymes are produced by C. albicans whereas one or
both enzymes are absent in other yeast species. OBIS albicans was
tested with 310 clinical yeast isolates. One hundred and seventy-
two were tested using OBIS albicans and GT and 138 were tested
using OBIS albicans and a chromogenic detection medium
(CHROMagar Candida) (CHROM).
Results: In the ﬁrst part of the study, for the differentiation of C.
albicans (n ¼ 132), OBIS albicans had a sensitivity and speciﬁcity
of 100 and 95%, respectively, and GT 100 and 92.5%. In the sec-
ond part of the study, for the differentiation of C. albicans
(n ¼ 76), OBIS albicans had a sensitivity and speciﬁcity of 100%
and CHROM 100% and 98.7%.
Conclusion: OBIS albicans is recommended as a less subjective,
more rapid and user-friendly alternative to the germ-tube test,
being easier to use than other commercially available rapid bio-
chemical tests for the presumptive identiﬁcation of C. albicans
from pure culture clinical isolates.
P1268 Identiﬁcation of chlamydial antigens by means of
the phage surface display technique
C. Hermann, M. Mu¨ller, S. Michelfelder, T. Hartung
Constance, D
Chlamydophila pneumoniae is an emerging pathogen with high
serological prevalence. To date, serological tests use whole ele-
mentary bodies as antigen, which are less standardised and sub-
jective with regard to interpretation. The use of pure recombinant
and thus well-characterised antigens could contribute to the
improvement of the diagnostic speciﬁcity and sensitivity, which
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are not satisfactory at the moment. A random phage surface dis-
played genomic library of C. pneumoniae TW 183 with a complex-
ity of 7.2  105 independent clones was generated and afﬁnity
selected for IgG-speciﬁc clones, using two different highly sero-
positve serum pools. Pool 1 was composed of eight sera from
atherosclerosis patients and pool 2 of 20 sera from healthy sero-
positive donors. Restriction analysis and sequencing of afﬁnity
enriched clones revealed that the sequence for the polymorphic
membrane protein family A (pmp 19) was present in 70% of the
clones enriched using both serum pools. Open reading frames
encoding porphobilinogen deaminase and serin/threonin protein
kinase were present in 11 and 5% of the enriched clones, respect-
ively. Seven other proteins were found at lower frequency. No
clones were enriched when sera from C. pneumoniae-negative
donors were used for selection. Reverse transcription-PCR analy-
sis showed that all enriched sequences are indeed transcribed
during infection of HEp-2 cells. The three predominant proteins
(pmp 19, porphobilinogen deaminase, serin/threonin protein kin-
ase) might represent promising antigen candidates for the devel-
opment of general diagnostic reagents for the detection of
C. pneumoniae infections.
P1269 Detection of Chlamydophila pneumoniae in acute
exacerbation of COPD patients by real-time PCR and MIF test
Y. Uyar, M. Gu¨naydin, C. Eroglu, A. Karadag, A. Karayunus,
L. Erkan,S. Canbaz
Samsun, TR
Objective: Chlamydophila pneumoniae is a common respiratory tract
pathogen known to be associated with pneumonia, bronchitis, phar-
yngitis and asthma. We aimed to study the role of C. pneumoniae
infections in patients with acute exacerbation of chronic obstructive
pulmonary disease (AECOPD) using Micro-Immunoﬂourescence
(MIF) test and Real-Time polymerase chain reaction (PCR) method.
Methods: Real-Time PCR was used to determine C. pneumoniae
from throat swab (n ¼ 69) and sputum (n ¼ 61) samples from 69
patients with AECOPD and throat swab (n ¼ 64) samples from 64
healthy individuals. C. pneumoniae antibodies was performed by
MIF test in both groups to determine acute infection.
Results: C. pneumoniae infection was detected in 15 (21.7%)
patients by MIF test and/or real-time PCR. Twelve (17.4%)
patients of AECOPD group were positive for C. pneumoniae by
real-time PCR. Serological evidences of acute infection were found
in ﬁve (7.2%) patients by MIF test. Two patients were positive for
C. pneumoniae infection with both PCR and MIF methods. On the
other hand, acute infection was not detected in control group by
MIF test. Five (7.8%) persons of control group were positive for
C. pneumoniae by PCR. The presence of acute C. pneumoniae infec-
tion in between two groups was statistically signiﬁcant (P < 0.05).
However, no statistically signiﬁcant differences were found
between sputum and throat swab samples by using PCR
(P > 0.05). C. pneumoniae IgG seropositivity was 82.6% in AE-
COPD patients and 62.5% in control group (P < 0.05). Chronic
persistent C. pneumoniae infection was detected in 43.5% of AE-
COPD patients and 23.4% of control (P < 0.05).
Conclusion: In conclusion, our ﬁndings suggested that C. pneumo-
niae might have a role in the pathogenesis of AECOPD. In addi-
tion, real-time PCR may be a useful method in the diagnosis of C.
pneumoniae infection and could be utilised for both of sputum and
throat swab samples.
P1270 Isolation and characterisation of oral Actinomyces
species from patients with periodontal diseases
S. Eshraghi, M.H. Shirazi, S. Yaghmaei
Tehran, IR
The present study was carried out on 100 patients with periodon-
tal diseases referred to the Faculty of Dentistry, Tehran University
of Medical Sciences. The main purpose of the study was the isola-
tion and characterisation of the oral Actinomyces species, which
are residents in dental plaque. The samples were selected based
on the following criteria: periodontal plaque with deep pocket
(>3 mm), no antibiotic therapy for a period of at least 2 weeks,
and lack of systemic diseases. In this study 100 specimens were
collected during a period of 6 months and the following results
were obtained. One species of Actinomyces viscosus and two spe-
cies of Actinomyces naeslundii were isolated from the patients with
gingivitis and periodontitis. Of the 100 patients with gingivitis
and periodontitis, aged between 18 and 57 years, 46 were males
(46%) and 54 were females (54%). The peak incidence of the dis-
eases (35%) was in the third age grouping (31–40) and the low
incidence (10%) was in the ﬁrst age grouping (<20). Forty patients
(40%) complained of gum disease and bleeding with incidence of
(42.5%) in female and (57.5%) in male. The results of this study
suggest that: Actinomyces species may contribute to the aetiology
of periodontal diseases and further work is required.
P1271 Evaluation of a new Oxoid ELISA for the detection
of enteric adenoviruses
J. Cloke, D. Hirst, A. Hole, A. Parker
Basingstoke, Bristol, UK
Objectives: The Oxoid Adenovirus ELISA is a new rapid method
designed to detect adenoviruses in faecal samples using speciﬁc
antibodies raised towards the hexon protein. Sensitivity, speciﬁci-
ty, positive and negative predictive values (PPV and NPV) of the
assay were determined using faecal samples submitted for routine
investigation of adenovirus infection.
Methods: One hundred and four archived faecal samples that were
analysed had previously been conﬁrmed as adenovirus positive by
electron microscopy (EM). Fifty-four adenovirus negative faecal
samples were also analysed. These either naturally contained or
were spiked with non-adenoviral intestinal viruses, bacteria, fungi
and protozoa. Faecal samples were thoroughly mixed with dilution
buffer in a sample tube. A total of 50 ll of the sample and conjugate
were added to each well of the microtitre plate and the plate incu-
bated at room temperature for 30 min without shaking. The plate
was washed ﬁve times with wash buffer before adding the substrate
reagent and developing at room temperature for 15 min. Stop rea-
gent was then added and the plate read at 450 nm with the plate
reader blanked on air. Each assay run was validated by ensuring
that positive and negative (diluent) control absorbances were
greater than 1.000 and less than 0.150, respectively. Individual sam-
ple results were determined using the following equation: Cut-
off ¼ Diluent Control absorbance + 0.1. Samples were determined
as positive if absorbance values were at least 10% greater than the
cut-off value, negative if at least 10% less than the cut-off value and
equivocal if within 10% of the cut-off value.
Results: Sensitivity and speciﬁcity of the Oxoid Adenovirus ELISA
were 94.2 and 98.1%, respectively, in comparison to EM. Six samples
that had previously been conﬁrmed as positive by EM produced neg-
ative results with the Oxoid assay. On re-examination by EM adeno-
virus particles were absent from these samples. PPV and NPV for
this assay were calculated to be 99.0 and 89.8%, respectively.
Conclusion: The Oxoid Adenovirus ELISA is a simple, rapid method
for the diagnosis of adenovirus infection in stool samples. Incubation
steps are at room temperature and do not require shaking. Results
are available within 3 h with a permanent copy of results for laborat-
ory records. The assay will be particularly useful for laboratories that
process large numbers of samples but lack access to EM.
P1272 Evaluation of a new Oxoid ELISA for the detection
of rotavirus
J. Cloke, D. Hirst, A. Hole, A. Parker
Basingstoke, Bristol, UK
Objectives: The Oxoid Rotavirus ELISA is new rapid method
designed to detect rotavirus in faecal samples using speciﬁc anti-
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bodies raised towards the major capsid protein (VP6). The sensi-
tivity, speciﬁcity, positive and negative predictive values (PPV
and NPV) of the assay were determined using faecal samples
which had been submitted for routine investigation of rotaviral
infection.
Methods: One hundred and one archived faecal samples that had
previously been conﬁrmed as rotavirus positive by routine labor-
atory analysis were analysed. Fifty-eight rotavirus negative faecal
samples were also analysed. These either naturally contained or
were spiked with non-rotaviral intestinal viruses, bacteria, fungi
and protozoa. Faecal samples were thoroughly mixed with dilu-
tion buffer in a sample tube. A total of 50 ll of the sample and
conjugate were added to each well of the microtitre plate and the
plate incubated at room temperature for 30 min without shaking.
The plate was washed ﬁve times with wash buffer before adding
the substrate reagent and developing at room temperature for
15 min. Stop reagent was then added and the plate read at
450 nm with the plate reader blanked on air. Each assay run was
validated by ensuring that positive and negative (diluent) control
absorbances were greater than 1.000 and less than 0.150, respect-
ively. Individual sample results were determined using the fol-
lowing equation: Cut-off ¼ Diluent control absorbance + 0.2.
Samples were determined as positive if absorbance values were at
least 10% greater than the cut-off value, negative if at least 10%
less than the cut-off value and equivocal if within 10% of the
cut-off value.
Results: The Oxoid Rotavirus ELISA demonstrated good sensitiv-
ity (97.1%) and speciﬁcity (96.3%). Three samples (2.8%) positive
for rotavirus on receipt in the laboratory produced negative
results with the Oxoid ELISA. On examination by electron micros-
copy, rotavirus particles were absent from these samples. PPV
and NPV for this kit were calculated to be 95.3 and 94.5%,
respectively.
Conclusion: The Oxoid Rotavirus ELISA is a simple, rapid method
for the diagnosis of rotavirus infection in stool samples. Incuba-
tion steps are at room temperature and do not require shaking.
The assay is easy to perform enabling results to be obtained
within 3 h with a permanent record of the results.
Mycobacterial disease: pathogenesis and therapy
P1273 Reaction to cheese during tuberculosis treatment
A. Carvalho, M. Manfrin, R. Poni Gore, S. Capone, S. Caligaris,
A.Armellini, T. Giovine, A. Matteelli, G. Carosi
Brescia, I
We present a case of tyramine syndrome or ‘cheese reaction’ after
ingestion of parmesan cheese by a patient assuming isoniazid for
breast tuberculosis (TB). A 26-year-old nurse had a microbiological
diagnosis of breast tuberculosis (TB) and was started on standard
four-drug antituberculosis therapy. Seven weeks later she developed
episodes of facial ﬂushing, respiratory distress (‘constriction on
throat’), headache and asthenia. The episodes were noticed while din-
ing and lasted 30 min. Other than the symptoms associated to facial
ﬂushing, the patient reported mood alteration since the beginning of
TB treatment, alternating periods of euphoria and depression, insom-
nia and somnolence. The patient was informed about the possibility
that her symptoms were associated with cheese and black wine
intake in association with isoniazid use. She conﬁrmed the regular
consumption of different kinds of cheese, especially parmesan cheese.
The patient was encouraged to avoid the consumption of cheese and
TB therapy was maintained. The patient by her own initiative deci-
ded to test the association of her symptoms with the ingestion of
cheese. Few days later she ate a large amount of parmesan cheese:
after 10–15 min she presented the typical reaction, that in this occa-
sion lasted 1 h. Since that episode, the patient avoided eating ripened
cheese and remained free of symptoms. She successfully completed
her TB treatment course with no further adverse events. The most fre-
quent symptoms/signs associated with tyramine syndrome are skin
ﬂushing, palpitation and elevated blood pressure, usually beginning
some minutes after ingestion of food rich in tyramine. Tyramine syn-
drome is a reaction secondary to the inhibitory effect of isoniazid on
monamino oxidase (MAO) activity, causing high concentration of tyr-
amine at the nervous system level. In the case presented here the con-
trol of symptoms was achieved by restricting cheese from the
patient’s diet. Physicians should be aware of the syndrome to avoid
unnecessary interruption of TB treatment.
P1274 The predictive value of serum procalcitonin levels
in patients with pulmonary tuberculosis
O. Baylan, A. Balkan, A.S. Inal, O. Kisa, A. Albay, L. Doganci
Ankara, TR
Objectives: The aim of our prospective study was to evaluate the
predictive value of serum procalcitonin (PCT) levels in diagnosis
of pulmonary tuberculosis (PTB).
Methods: We measured serum PCT levels on admission and
6 months after antituberculous therapy (ATT) in 75 male adult
patients aged 19–80 years (mean age 23.1 years), who had bacteri-
ologically diagnosed (smear and culture positivity) active PTB
(study group). Also, 75 male adult healthy individuals aged 18–
56 years (mean age 23.3 years) with no physiological complaints
were enrolled (control group).
Results: The measured serum PCT levels were within normal
range both in healthy individuals (mean 0.15, range 0.02–0.47 ng/
mL) and in patients after 6 months of ATT (mean 0.15, range
0.03–0.43 ng/mL). Serum PCT levels had been slightly high on
admission in patients with PTB, before the implementation of
ATT (mean 0.47, range 0.02–1.09 ng/mL) (P < 0.05) in comparison
with controls and patients who had ATT.
Conclusion: We thought that the serum PCT level on admission
was not a reliable indicator in the diagnosis of PTB even if statisti-
cally meaningful results are obtained. Serum PCT assay may be
helpful to differentiate PTB from bacterial community acquired
pneumonia. Elevated admission serum PCT levels (>1 ng/mL)
could help clinicians to limit the number of tuberculosis cultures
to be processed and to decrease the number of empiric ATT.
P1275 Determination of IL-4, IL-6, IL-8 interleukins and
TNF-a in patients with tuberculosis during treatment
C. Kapotis, M. Dimadi, S. Mavrea, I. Tsiaras, D. Alepopoulou,
E.Kosmaoglou, E. Aanastasakou
Athens, GR
Aim: The aim of the study was the determination of interleukins
IL-4, IL-6, IL-8 and TNF-a in patients with tuberculosis.
Patients and methods: Determinations were performed in sera of 12
patients (ﬁve women, seven men, age 15–87) successively as fol-
lows: ﬁrst, before the beginning of treatment; second 5–7 days
after beginning; third 10–15 days after beginning; fourth 60 days
after beginning and ﬁfth 180 days after beginning of treatment.
All determinations were performed by ELISA.
Results: The results were as follows. For IL-4, mean values were
20.9 (min 3, max 45), 40.3 (min 12, max 73), 67.5 (min 28, max
146), 25 (min 2, max 58), 2.7 (min 0, max 6) successively. For IL-6,
mean values were 83.3 (min 22, max 180), 103 (min 34, max 200),
209 (min 135, max 347), 132 (min 56, max 190), 4.2 (min 2, max 7)
successively. For IL-8, mean values were 39.7 (min 8, max 88),
45.8 (min 2, max 77), 47.2 (min 12, max 90), 44 (min 14, max 76),
42 (min 18, max 88) successively. For TNF-a, mean values were
27.9 (min 2, max 125), 41.9 (min 3, max 154), 100 (min 23, max
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242), 45 (min 5, max 140), 10 (min 0, max 134) successively.
Results were statistically evaluated with SPSS system and Fried-
mann’s test was used. For IL-4, chi square was 40.5 (Asymp. Sig:
0.001); for IL-6, chi square was 42.3 (Asymp. Sig: 0.00); for IL-8,
chi square was 3.3 (Asymp. Sig: 0.5), for TNF-a chi square was 29
(Asymp. Sig: 0.006).
Conclusions: Results show that there are signiﬁcant differences
between successive measurements of IL-4, IL-6 and TNF-a in sera
of patients with tuberculosis during treatment, while differences
in successive measurements of IL-8 are not statistically signiﬁcant.
Values were signiﬁcantly raised in the third measurement of all
markers with the exception of IL-8.
P1276 Intracellular growth of clinical isolates of
M. tuberculosis with different ability of dissemination
L. Folgueira, A. Boluda, F. Chaves, E. Palenque, J.R. Otero
Madrid, E
Objectives: There is scarce information about the virulence mecha-
nisms used by M. tuberculosis to evade host inmune defences.
Restriction fragment length polymorphism (RFLP) typing is a use-
ful tool for differentiating isolates and identifying speciﬁc strains
as responsible for tuberculosis outbreaks. Assessment of the viru-
lence of these isolates by measuring their ability to grow in
human macrophages may be useful to explain the extent of
spread of a particular strain in the community.
Methods: We selected four clinical isolates from patients with pul-
monary tuberculosis based on RFLP typing; isolate 1072 was the
most prevalent strain cultured in our laboratory and it has been
responsible for several outbreaks; strain 4590 was isolated in a
small cluster, and strains 7506 and 3625 are unique strains that
cause disease in only one patient. We have used virulent M. tuber-
culosis strain H37Rv as control.
Method: Macrophages were prepared from peripheral blood
mononuclear cells (PBMC) from healthy donors, and 5  105
adherent cells/well were plated in 24-well plates in RPMI with
10% fetal bovine serum and 10% of human serum and cultured
for 7 days to mature into macrophages. Cells were infected with
suspensions of the different strains of M. tuberculosis studied
using a ratio of 1 bacillus/20 cells. At time points 1, 3, 7 and
20 days, infected macrophages were lysed and the intracellular
mycobacterial growth was analysed by a quantitative real-time
PCR assay that ampliﬁed a region of the 85 kDa antigen.
Results: All the clinical strains tested presented an intracellular
growth higher than the control strain H37Rv; after 20 days of cul-
ture strain 1072, responsible for several clusters, and the unique
strain 7506, grew signiﬁcantly (P < 0.001) more than strain H37Rv.
Conclusions: The ability of M. tuberculosis strains to grow in
human macrophages is an individual characteristic of each strain
and our data indicated that it is not always correlated with the
dissemination between population.
P1277 Sigma factors and hspX expression could be
markers of stress adaptation and reactivation of growth of
Mycobacterium tuberculosis in acidiﬁed cultures
S. Gordillo, J. Dı´az, I. Amat, E. Guirado, S. Molinos,
C. Vilaplana,V. Ausina, P.J. Cardona
Badalona, E
Objectives: M. tuberculosis is the paradigm of intracellular bacteria
and the explanation of its behaviour inside the phagosome may
be crucial to deeply know its pathogenesis. Too many efforts have
been done to elucidate these mechanisms, but few studies have
been performed related to the acidiﬁcation of phagosome. An in
vitro model was made to resemble these acidic conditions inside
macrophages. We studied the survival of M. tuberculosis and the
genetic expression within a range of pHs from 4.5 to 6.5 for
15 days.
Methods: M. tuberculosis strain H37Rv was grown in 7H9 medium
to mid-log phase and frozen in aliquots. Following, one frozen ali-
quot was grown in non-acidiﬁed 7H9 medium until exponential
and steady-state phase. Starting from the same culture, inocula-
tion in previous acidiﬁed medium (to ﬁnal pHs of 4.5–5–5.5–6 and
6.5 at 25C) was performed by triplicate at the point of exponen-
tial and steady-state phase. We determined the CFUs from acidi-
ﬁed cultures and the mRNA expression by real-time PCR of 64
genes related to heat shock proteins, metabolism and sigma fac-
tors for 15 days.
Results: Related to CFUs from the exponential phase derived cul-
tures of pH 4.5–5 and 5.5, no survival was detected (<10 UFCs)
after 7 days. Noteworthy, a progressive drop of hspX, acr, rpoA
and recA was obtained until day 7 that was undetectable. Interest-
ingly, sigE, sigF, sigG and sigH expressions increased in cultures
of pH 4.5 from day 7. Survival of the steady-state phase derived
cultures of pH 4.5–5 was very low (<100 UFCs) after 7 days too,
but curiously CFUs from pH 5.5 cultures were maintained con-
stant from the beginning and started to grow from day 7. Again,
CFUs of pH 6 and 6.5 were able to grow normally, reaching
superior numbers than the same pH cultures from exponential
phase. The same proﬁle of sigma factors was obtained as in expo-
nential phase. On the contrary, hspX showed superior levels from
day 7 in pH 5.5.
Conclusion: A well-deﬁned proﬁle of sigma factors could provide
M. tuberculosis an ability to survive in low pHs conditions.
Increase of hspX expression might be a marker of the adaptation
of bacilli to stressing conditions and growth reactivation. In
regard to survival, we also conﬁrm that cultures submitted to
stress conditions, like the steady-state derived cultures, are able to
best adapt their metabolism to acidiﬁcation.
Acknowledgement: Research support: Fondo de Investigaciones
Sanitarias. Grant no. 01/0644.
P1278 The effects of azathioprine and prednisolone on
cytokine expression in the skin and blood of severe leprosy
type 1 reaction patients
S.N.S. Marlowe, S. Khanolkar-Young, R. Manandhar, N. Shrestha,
P.W. Roche, M. Macdonald, P.G. Nicholls, D.N.J. Lockwood on
behalf of Follereau Luxembourg, LEPRA
Objectives: To compare the cytokine production in skin lesions
and blood of severe leprosy type 1 reaction (T1R) Nepali patients
taking azathioprine and or prednisolone. To relate these ﬁndings
to the clinical state of the patients and the drug treatment admin-
istered.
Method: Forty patients were randomly assigned to a 12-week
treatment with either AP (12 weeks azathioprine at 3 mg/kg/day
plus 8-week reducing course prednisolone starting at 40 mg/day)
or P (12-week reducing course prednisolone starting at 40 mg/
day). Levels of leprosy antigen-induced tumour necrosis factor
(TNF-a), interleukin-10 (IL-10) and gamma-interferon (IFN-c) in
whole blood was assessed by ELISA before, during and after
treatment. The effects of treatment on the cellularity and cytokine
(TNF-a, IL-10, IL-2) expression in the skin lesions of patients were
studied using immunohistochemistry. Two skin biopsies were
taken from each patient to cover the period before, during and
after treatment.
Results: No difference was found between the two treatment
groups with respect to cytokine expression in the skin or blood.
For both groups, median levels of whole blood TNF-a and IFN-c
fell during treatment, but as the dose of prednisolone decreased,
the level of cytokine expression increased. Neither treatment had
any signiﬁcant effect on median whole blood IL-10 or skin TNF-a
expression. In both groups, median levels of IL-10 and IL-2 in the
skin decreased during and after treatment. No correlation was
found between cytokine expression in the skin and blood and
clinical outcome.
Conclusion: We conclude that the combination of azathioprine and
short-course prednisolone produces no difference in cytokine
expression in the skin and blood of T1R patients compared with a
longer course of prednisolone. This study agrees with previous
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work that prednisolone is associated with a dose-dependent
reduction in TNF-a and IFN-c in the blood, but this does not cor-
relate to TNF-a expression in skin lesions of T1R patients. Our
data also shows a reduction in both Th1 and Th2 cytokine expres-
sion in skin lesions with treatment. This indicates that improve-
ment in T1Rs may not only be due to the down regulation of Th1
cytokines and the up regulation of Th2 cytokines. We found no
correlation with level of pro-inﬂammatory and anti-inﬂammatory
cytokines and clinical outcome in T1R patients giving no indica-
tion of possible immunological markers for those patients with
recurrent or relapsing T1Rs.
P1279 Serum total adenosine deaminase level in active
pulmonary tuberculosis in comparison to other infectious
diseases in Iran
S. Amini Afshar, L. Gachkar, Ma. Keshtkar Jahromi, B. Haghighat,
Mi. Keshtkar Jahromi
Tehran, Shiraz, IR
Objective: In order to have an acceptable rapid test helping the cli-
nicians in the diagnosis of active pulmonary tuberculosis, we eval-
uated the importance of elevated serum adenosine deaminase in
active pulmonary tuberculosis vs. other infectious diseases.
Methods: We measured serum total adenosine deaminase level in
three groups: (1) cases of active pulmonary tuberculosis who were
conﬁrmed by positive sputum smears for acid-fast bacilli in
association with compatible clinical and radiological ﬁndings, (2)
cases of other infectious diseases including Brucellosis, Endocardi-
tis, Salmonellosis, meningitis conﬁrmed by clinical ﬁndings and
related laboratory tests and (3) healthy controls. Serum adenosine
deaminase levels were measured before treatment was started.
Data analysis was performed by chi-square; ANOVA and LSD.
The signiﬁcance level was evaluated for P value of less than 0.05.
Results: We evaluated 51 (21 females and 30 males aged
47.7  19 years) cases of active pulmonary tuberculosis, 11 (six
females and ﬁve males aged 44.7  21 years) cases of other infec-
tious diseases and 50 (14 females and 36 males aged
48.4  11 years) cases of healthy individuals. Mean serum total
adenosine deaminase level in pulmonary tuberculosis
(42.4  21.5 IU/mL) and other infectious diseases
(38.3  23.4 IU/mL) was meaningfully more than controls
(26.6  8.2 IU/mL), (P < 0.0001 and P < 0.03 respectively), but the
difference in pulmonary tuberculosis and other infectious diseases
was not statistically signiﬁcant. There was no signiﬁcant differ-
ence in age and gender between the above groups.
Conclusion: We conclude that serum total adenosine deaminase
increases in infectious diseases but it cannot differentiate pulmon-
ary tuberculosis from other infectious diseases.
P1280 Paradoxical response in inﬂiximab-treated patients
with disseminated tuberculosis
C. Garcia Vidal, S. Rodrı´guez Ferna´ndez, J. Martı´nez Lacasa,
M.Salavert, R. Vidal, M. Rodrı´guez Carballeira, J. Garau
Terrassa, Valencia, Barcelona, E
Objective: Inﬂiximab is a tumour necrosis factor antagonist that
has been approved for the treatment of certain autoimmune dis-
eases. A number of opportunistic infections have been reported in
patients treated with this drug. The most frequent is tuberculosis,
usually extrapulmonary and disseminated. The aim of our study
is to describe the clinical features of the disease and response to
antituberculous therapy in patients with disseminated tuberculo-
sis who have been treated with inﬂiximab.
Design: Retrospective cohort study.
Methods: Between 1999 and 2002, we reviewed all patients that
had been treated with inﬂiximab and had developed active tuber-
culosis infection in three acute referral centres from different geo-
graphic locations, in Spain.
Results: In the cohort of 284 patients that had been exposed to this
drug, six patients (2.1%) developed disseminated tuberculosis,
and four (67%) presented a paradoxical response while on antitu-
berculous treatment. Two were women and mean age was 43.5
(SD13.3) years. Indications for inﬂiximab therapy included rheu-
matoid arthritis (2), ankylosing spondylitis (1) and Crohn’s dis-
ease (1). The most frequent clinical presentation was swelling of
pre-existing adenopathic mass. The median number of months
with inﬂiximab treatment before tuberculosis diagnose was two
(range1–24). The mean time interval between initiation of antitu-
berculous treatment and the development of paradoxical reaction,
was 9 weeks. Two cases were treated with anti-inﬂammatory
agents (steroids and NSAIDS) with progressive improvement. In
the other two cases local excisional surgery was required.
Conclusions: Our experience suggests that patients with TB after
inﬂiximab exposure have a high probability of having a paradox-
ical reaction and that this may be due to immunologic mecha-
nisms. Reinitiation of inﬂiximab once active TB is controlled
should be contemplated. Physicians should be aware of this
increased risk and when paradoxical reaction is suspected, consi-
der the use of corticosteroids.
P1281 Long-term efﬁcacy of a 6-month treatment regimen
(6HR2Z) for HIV-negative tuberculous meningitis
J.F. Garcı´a Rodrı´guez, R. la Fuente-Ferna´ndez de,
M.V. LorenzoGarcı´a, A. Ferna´ndez Rial, A. Marin˜o Callejo,
P. Sesma Sa´nchez
Ferrol, E
Objective: To investigate the long-term efﬁcacy of a 6-month
treatment regimen (6HR2Z) for tuberculous meningitis in the
HIV-negative population.
Methods: All HIV-negative patients with tuberculous meningitis
attended in our Centre entered a 6-month treatment protocol
(6HR2Z) and were prospectively followed in our Tuberculous
Unit for a period of 70.1  55.5 months (only one case was lost to
follow-up 3 months after entering the study). The diagnosis of
tuberculous meningitis was based on cerebrospinal ﬂuid (CSF)
examination, cultures and/or pathology of specimens. Demo-
graphics as well as a complete set of tests (including BCG, Man-
toux test, chest X-ray, and brain CT scan) were collected in each
case. Daily doses employed in the 6HR2Z protocol were: isoniazid
(H), 5 mg/kg; rifampin (R), 10 mg/kg; and pyrazinamide (Z), 30–
35 mg/kg.
Results: We recruited 19 patients with HIV-negative tuberculous
meningitis. There were seven females and 12 males (mean age,
40  22.5 years; range, 11–74 years). All patients had CSF ﬁndings
compatible with tuberculous meningitis. Four patients (21%) had
also pulmonary tuberculosis. In 10 cases (53%), the ﬁnal diagnosis
was established by the demonstration of M. tuberculosis in CSF
culture; in two additional cases, M. tuberculosis was recovered
from culture of expectorated sputum specimens (not from CSF).
Distribution of clinical stage was as follows: stage I (eight cases;
42%), stage II (eight cases; 42%), and stage III (three cases; 16%).
All patients were initially treated according to the 6-month
6HR2Z protocol. In addition, nine patients received adjunctive
therapy with corticosteroids. As to the outcome, 14/18 (78%)
patients were cured, two (11%) died of tuberculosis during the
ﬁrst days of treatment, and two (11%) died of unrelated causes 2
and 41 months after starting treatment, respectively. Three
patients developed complications during the treatment, two devel-
oped brain tuberculomas (treatment was prolonged for 3 more
months in one case), and one developed a tuberculous brain
abscess, which was removed surgically (treatment was prolonged
for 6 more months). Thirteen of the 19 patients who entered the
study (68%) completed the treatment as initially planned (i.e.
6-month therapy); only four of them had some late sequelae (an-
osmia, one case; paraparesis, one case; headache, two cases).
Conclusion: Our results suggest that a 6-month treatment regimen
(6HR2Z) is optimal for tuberculous meningitis in the HIV-negative
population.
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P1282 Mycobacterium tuberculosis complex sigma factor H
gene expression during pulmonary tuberculosis treatment
S. Dworniczak, J. Pendzich, W. Mazur, U. Mazurek, G. Niepsuj,
J.Kieda-Szurkowska, D. Ziora, J. Kozielski
Zabrze, Sosnowiec, PL
Objectives: The objective of our study was to evaluate the speciﬁc
transcriptional activity of mycobacteria contained in the sputum
expectorated by patients with pulmonary tuberculosis during
their treatment.
Methods: This was done by measuring the mRNA level for Myco-
bacterium tuberculosis extracytoplasmic sigma factor H with the aid
of the real-time Q-RT-PCR performed on ABI PRISMTM 7700.
The study group consisted of 52 patients (mean age 44  11,
M ¼ 39, F ¼ 13) with pulmonary tuberculosis conﬁrmed by AFB
(+) and culture (+). The sputum samples were taken for the analy-
sis before anti-tuberculous treatment and after 4 weeks of treat-
ment (standard set: RFP+INH+PZA+SM).
Results: In the beginning of the therapy the proportion between
sigma H (sigH) mRNA positive and negative sample was equal.
After 1 month of poly-therapy 70% of samples were sigH tran-
script positive and culture was still positive in 94%. The mean
copy number of sigH transcript per 1 lg of total RNA was twice
higher during treatment than at the beginning of the therapy (4342
(1659) vs. 8034 (2007), respectively; mean (SEM)).
Conclusion: The increasing level of sigH factor transcript during
treatment could reﬂect the probable role of this co-factor of tran-
scription in stating defence reactions of Mycobacteria to anti-myco-
bacterial action of immune system and speciﬁc drug therapy.
Discovering the mechanisms of interaction between this pathogen
and the host in the context of introduced therapy could help in bet-
ter management of tuberculosis and ﬁnding new way of treatment.
Mycobacterial disease: multiresistant tuberculosis
P1283 Diagnosis of multiresistant tuberculosis by
detection of mutations in rpoB and inhA by real-time PCR
L. Brum, T. Ramos, L. Barreiro, E. Pereira
Lisbon, P
Objective: The emergence of multidrug-resistant tuberculosis
(MDR), characterised by the resistance to at least rifampin (RIF)
and isoniazid (INH), made the application of molecular methods
to early detection of resistant M. tuberculosis strains a priority.
More than 96% of RIF-resistant strains have speciﬁc mutations
within an 81-bp region of the rpoB gene, encoding for the aˆ subunit
of the RNA polymerase. In contrast, molecular characterisation of
INH resistance is complex, and has been associated with mutations
in at least four different genes: katG, inhA, kasA and ahpC. The aim
of this study was to detect in a single tube RIF and INH resistance-
associated mutations in rpoB and inhA genes by real-time PCR
using Light-Cycler (Roche).
Methods: rpoB, inhA and katG and genes of 30 MDR strains were
sequenced on an ABI-Pris (Applied Byosistems). We found that
most of our isolates had no mutations in katG but mutations
occurred frequently in inhA gene. Primers and hybridisation
probes were designed for these more frequently found mutations
in rpoB and inhA genes and 30 resistant strains were analysed,
comparing to control sensitive strains, in a Light Cycler.
Results: Melting curves, by presenting changes in Tm, allowed the
detection of the mutation in the rpoB gene in 100% of the strains,
being 90% at the codon 531 and 10% at the codon 516. Among the
inhA gene we found the searched mutation in 63.3% of the strains.
Conclusions: The method provided a rapid and accurate way to
detect RIF-resistance among M. tuberculosis strains, and to predict
the presence of MDR, most RIF-resistant strains are MDR. As to
INH resistance, we found that in this study inhA gene is the pre-
dominant target of mutation.
P1284 Can phenotypic susceptibility testing for
M. tuberculosis be performed before identiﬁcation?
O´. Pe´rez-Olaso, M.J. Ruiz-Serrano, N. Garcı´a-Escribano,
M. Marı´n-Arriaza, D. Garcı´a Viedma de, E. Bouza
Madrid, E
Objectives: Given the increase in multidrug-resistant M. tuberculo-
sis (MDRTB) throughout the world, new tests seem necessary to
promptly detect resistant strains. Thus, we prospectively evalu-
ated a modiﬁed MGIT-SIRE(R) method (Mycobacterial growth
indicator tube-streptomycin, isoniazid, rifampin, ethambutol)
based on DIRECT decontaminated specimen susceptibility to
isoniazid (INH) and rifampin (RIF) in patients infected with
M. tuberculosis (MTB). We compared the results obtained, concern-
ing time gain and accuracy, to the reference MGIT-SIRE method
performed once the MTB was isolated and identiﬁed (here, as
INDIRECT susceptibility test).
Methods: Starting from January 2003, we selected all strongly Acid
Fast Bacilli (AFB)-positive smears (stronger than 50 AFB/ﬁeld).
Samples were decontaminated and cultured according to stand-
ardised procedures and DIRECT specimen susceptibility testing to
INH and RIF was performed in MGIT using the protocol
approved by the FDA for MTB susceptibility testing. Brieﬂy,
500 lL of specimen was DIRECTLY inoculated into MGIT, using
0.1 lg/mL INH and 1.0 lg/mL RIF as critical concentrations. We
used a 1  102 sample dilution as growth control. MTB isolates
were identiﬁed by AccuProbe(R) (GEN-PROBE(R)) and their sus-
ceptibility tests (INDIRECT susceptibility tests) were performed
using the MGIT-SIRE procedure (BD(TM)).
Results: We processed 26 samples in parallel with both the direct
and indirect procedure. Compared results were as follows: 23 of
26 samples (88.5%) were susceptible to INH, whereas 25 (96.1%)
were susceptible to RIF. The results of both procedures agreed
100%, giving our new DIRECT method an accuracy of 100%. The
mean time to detection was 10.8 days using the DIRECT proce-
dure, and 19.0 with the INDIRECT one.
Conclusions: The DIRECT specimen susceptibility test MGIT-SIRE
is a new, rapid and accurate method to measure susceptibility to
INH and RIF. This procedure provides results earlier than INDI-
RECT MGIT-SIRE, with a mean time gain of 8.2 (P < 0.0001). The
DIRECT susceptibility test enables us to rule out MDRTB. These
results could be very useful for the prompt recognition of MDRTB,
especially in an area of high prevalence for resistant MTB.
P1285 Antimicrobial susceptibilities of Mycobacterium
tuberculosis strains isolated from clinical specimens in Crete,
Greece
Z. Gitti, S. Maraki, F. Kontos, I. Kyriakakis, Y. Tselentis
Heraklion, GR
Objective: To evaluate the activities of ﬁrst-line antituberculosis
drugs on 100 strains of Mycobacterium tuberculosis isolated from
clinical specimens.
Methods: One hundred Mycobacterium tuberculosis strains were tes-
ted, which were isolated from different clinical specimens between
2001 and 2003. For the drug sensitivity study, the standard method
of Canneti-Grosset was performed. The drugs tested were: isoniaz-
id (INH), rifampicin (RF), ethambutol (ETB), streptomycin (SM),
para-4-aminosalicylic acid (PAS), and pyrazinamid (PYZ).
Results: Resistance to one drug was observed in 14% of the iso-
lates. SM, INH, ETH, and PYZ resistance rates were 6, 3, 2 and
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3%, respectively. Resistance to two or more drugs (MDRTb) was
observed in 5% of the isolates. One percent of the isolates was
resistant to SM + IZH, 1% to SM + PYZ, 1% to SM + IZH + RF,
1% to SM + ETH + RF and 1% to SM + IZH + PAS.
Conclusion: Continuous surveillance on the susceptibility pattern
to the antituberculosis drugs on local level is necessary for deter-
mining therapeutic regimens, important precondition for avoiding
the appearance of MDR strains.
P1286 Malnutrition in multidrug resistant tuberculosis
patients in the Philippines
V. Antonios, I. Sia, J. St. Sauver, R. Orillaza, M. Quelapio,
T. Tupasi
Rochester, USA; Makati City, Manilla, PH
Objectives: Little is known about the nutritional status of patients
with multidrug resistant tuberculosis (MDR TB), and whether
nutritional status impacts treatment outcomes. Therefore, the pur-
pose of our study was to describe baseline nutritional status of
patients with MDR TB in the Philippines, and to determine whe-
ther baseline nutritional status was associated with time to spu-
tum smear and culture conversions.
Methods: Records of MDR TB patients currently receiving treat-
ment at the Makati Medical Center DOTS-Plus Pilot Project in
Makati City, the Philippines were reviewed. Data collected inclu-
ded age, gender, occupation, weight, height, body mass index
(BMI), drug regimen, and monthly sputum acid-fast bacillus (AFB)
smear and culture results for the ﬁrst 6 months of treatment. Time
to smear or culture conversion was deﬁned as the month at which
the ﬁrst of two negative smears or cultures was observed. Data
were summarised using means and standard deviations or num-
bers and percentages. Log rank tests were used to compare time to
sputum smear and culture conversion among those who were and
those who were not malnourished. All data were analysed using
the JMP statistical software package (SAS Institute, 2003).
Results: Among 43 patients, there were 23 (53.5%) males and 20
(46.5%) females; the mean age was 39.3 ± 13.6 years. At baseline,
MDR TB patients had a mean BMI of 19.2 ± 4. Half of these
patients were malnourished (BMI < 18.5), and 14 (33.3%) had
moderate–severe malnutrition (BMI < 17). Four (9.3%) patients
had positive smears after 6 months of treatment. Malnutrition was
signiﬁcantly associated with a longer time to sputum smear con-
version (P ¼ 0.02). Malnutrition was not associated with time to
culture conversion (P ¼ 0.98).
Conclusion: Malnutrition is common in Filipino MDR TB patients.
Prevalence of malnutrition in these patients far exceeds national
prevalence rates of 13.2% and 4.4% for malnutrition and moder-
ate–severe malnutrition, respectively, in adult Filipinos. There was
a signiﬁcant association between malnutrition and slower sputum
AFB smear conversion; correlation with culture conversion was
not demonstrated, possibly due to the small number of patients
studied. Further data on this population are currently being col-
lected to better understand the relationship between nutritional
status and MDR TB treatment outcomes.
P1287 Resistance problem in Mycobacterium tuberculosis:
evaluation of the resistance of 166 M. tuberculosis strains
against four major drugs
S. Saribas, Y. Bagdatli, N. Yildiz, O¨. Yigit
Istanbul, TR
Objectives: In our study, we aimed to detect the presence ofM. tuber-
culosis with BACTEC MGIT (Mycobacteria Growth Indicator Tubes)
(Becton-Dickenson) 960 system and reference method Lo¨wenstein–
Jensen (L–J) in clinical samples having suspect of pulmonary and
extrapulmonary tuberculosis and also to determine the resistance of
the isolated M. tuberculosis strains against four major antimicrobial
drugs and to evaluate the primary and secondary resistance of the
cases. The study period was between 2001 and 2003.
Methods: BACTEC MGIT 960 system uses a ﬂuorescent compound
that is sensitive to oxygen. The recovery of mycobacteria is faster
in this method from the solid media (L–J). Antimicrobial suscepti-
bility tests were performed with BACTEC MGIT 960 SIRE kit and
L–J. We followed the test procedure in the MGIT kit and we used
proportion method in L–J to detect susceptibility to streptomycin,
isoniazid, rifampin and ethambutole.
Results: One hundred and sixty-six strains were identiﬁed as M.
tuberculosis with conventional biochemical tests (niacin and cat-
alase production). In 166 cases consisting of 141 newly and 25
previously diagnosed patients; drug resistance were seen in 23
(13.8%), which were 10 (7.09%) as primary and 13 (52%) secon-
dary resistance. In one drug resistance, both primary and secon-
dary resistances were detected, two drug resistance was seen only
in primary resistance (one case), four drug resistance was seen
only in secondary resistance (four cases) and three drug resistance
was seen only in secondary resistance (one case). The highest
cumulative drug resistance was found against streptomycin in pri-
mary and against rifampicin in secondary resistance.
Conclusions: Our results emphasises that high ratio of secondary
resistance in public may be related to insufﬁciency of therapy and
this may cause a serious increase of primary tuberculosis with
new contaminations.
P1288 Recovery rate and drug resistance of mycobacterial
strains by the BACTEC 460TB system during 2001–2003 in
Kocaeli, Turkey
S. Gu¨nde, E. Karaali, A. Willke
Kocaeli, TR
Objectives: To investigate the rate of isolation and in vitro activity
of antituberculous agents against M. tuberculosis isolated from
human clinical samples.
Methods: From 2001 to 2003, 2576 samples have been processed
for tuberculosis in Kocaeli University Hospital. All samples were
cultured on Lo¨wenstein–Jensen medium and in Middlebrook
7H12 broth medium after decontamination and concentration
steps. Drug susceptibility tests to isoniazid (INH), streptomycin
(S), ethambutol (E), and rifampin (R) were performed by using
the radiometric BACTEC 460TB system.
Results: Out of the 2576 samples, 1690 were from the respiratory
tract (sputum, pulmonary biopsy, bronchoalveolar lavage, bron-
choalveolar brush specimen), 528 were urine, 283 were from body
ﬂuids (153 pleural, 51 peritoneal, 45 intraarticular, 34 CSF), 73
were from skin and tissue biopsies, two were gastric aspirate, and
faeces. M. tuberculosis were isolated in 81 (3.1%) cases including
redundant samples: 45% were from the respiratory tract, 25%
were urine, 18%were body ﬂuids, 12% were tissue biopsies. Six
of the samples were MOTT identiﬁed from respiratory tract speci-
mens (3), urine (2) and knee effusion material (1). Our results of
susceptibility testing are summarised in Table 1.
Table 1. Susceptibility testing results of M. tuberculosis, during
2001–2003, in Kocaeli University, Turkey
Total testing number 91
Susceptible to all four drugs 64(79%)
Any streptomycin (S) resistance –
Any isoniasid (INH) rersistance 8(9.8%)
Any rifampin (R) resistance 2(2.4%)
Any ethambutol (E) resistance 7(8.6%)
S monoresistance –
INH monoresistance 6(7.4%)
R monoresistance –
E monoresistance 6(6.1%)
Total monodrug resistance 11(13.5%)
Total INH + R resistance(MDR) –
Total INH + E resistance 2(2.1%)
Total R+E resistance 1(1.2%)
Total polyresistance other than MDR 3(3.7%)
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Conclusions: These data showed that, among ﬁrst-line drugs, drug
resistance is not yet a problem in therapy of tuberculosis for Ko-
caeli. INH resistance can be a big problem in future, while strep-
tomycin is still active against all the isolates.
P1289 Drug resistance rates of M. tuberculosis strains from
civilian and prison patients in Samara region, Russia
Y. Balabanova, M. Ruddy, S. Kuznetsov, I. Fedorin, A. Melentyev,
S. Zakharova, N. Malomanova, E. Elizarova, V. Nikolayevskyy,
J. Hubb, F. Drobniewski
London, UK; Samara, RUS; Odessa, UKR
Background: The true extent of drug resistant tuberculosis (TB)
globally is unknown. We have initiated a study to determine the
extent of resistance and the molecular epidemiology of drug
resistance in Samara, one of 89 regions within Russia.
Design: Cross-sectional study of prison and civil TB patients in
Samara. Phenotypic Rifampicin and Isoniazid resistance was
determined in Samara and at MRU, London using the resistance
ratio and absolute concentration methods. All cultures were ana-
lysed by spoligotyping.
Objectives: To determine true rates of primary and acquired drug
resistance to ﬁrst-line TB drugs and rates of multiple-drug resist-
ance (MDR); to determine the epidemiology of M. tuberculosis
strains in civilian and penitentiary sectors in Samara.
Results: A total of 3408 individuals with TB were enrolled. Isolates
from 600 patients attending all TB institutions in Samara Region
including 295 prisoners were tested. The prevalence of drug resist-
ance (all chronic and new patients) across the Region was 61.2%
(367/600), 50.3% (302/600), 46.9% (282/601), 26.8% (161/600) and
8.9% (23/260) to Inh, Rif, S, E and Z, respectively. The prevalence
of MDR in all TB cases was 47.2% (283/600). Primary resistance
among civilians was 33.7% (32/95), 22.9% (22/96), 28.1% (27/96),
11.5% (11/96) and 6.1% (3/49) to the above mentioned ﬁrst-line
drugs, respectively, and 20.0% (19/95) MDR. The primary resist-
ance analysis demonstrated statistically signiﬁcant difference
between prisoners and civilians. Inh resistance was by 29.0% higher
in the prisoners (95%CI 14–44), Rif resistance was by 15.0% higher
(95%CI 1–29), S resistance by 43.3% (95%CI 27–60), E resistance by
21.9% (95%CI 6–37) and MDR by 17.9% (95%CI 4–32). However,
no signiﬁcant difference was identiﬁed between rates of acquired
resistance among civilian and prison patients. Molecular epidemio-
logical analysis demonstrated the dominance of Beijing strains
– 65.4% (619/946). The prevalence of mono-resistance and MDR
was signiﬁcantly higher among Beijing isolates compared to non-
Beijing strains: the difference was 33.4% (95%CI 25–41), 34.3%
(95%CI 26–42), 26.9% (95%CI 19–35), 19.3% (95%CI 12–26) and
25.8% (95%CI 28–44), respectively, to Inh, Rif, S, E and MDR. The
incidence of primary resistance is signiﬁcantly higher among pris-
oners than civilian patients. The Beijing strain family predominates
and is associated with higher rates of drug resistance.
P1290 Multicentre study on Mycobacterium tuberculosis
susceptibility testing using BacT/ALERT automatic system
A. Ortega Calderon, M.A. Lezcano, A. Alberte, J. Garcia
Madrid, Zaragoza, Valladolid, E
Introduction: In our environment, tuberculose endemia is reducing
by 12% annually but the effect of tuberculosis still remains high,
above all, due to the immigrant population coming from Latin
American, Asian and Eastern European countries, with the possi-
bility of a greater rate of resistance to anti-tuberculosis drugs.
Objectives: The aim of this study is to verify the reproducibility of
the antibiogram results in the system BacT/ALERT through a
cooperative study undertaken by four laboratories belonging to
the following Centres: H. La Paz (Madrid), H. Miguel Servet (Zar-
agoza), H. Rio Hortega (Valladolid) and H. Carlos III (Madrid).
Methods: The Central laboratory sent 20 strains with different
degrees of sensibility to four indicated laboratories. These strains
have been tested previously by the conventional method for the pro-
portions in solid medium. The method used for the antibiogram was
according to the manufacturer’s recommendations. The ﬁnal drug
concentrations used were: 0.1 mcg/mL for isoniazid, 1 mcg/mL for
streptomycin and Rifampicin and 5 mcg/mL for ethambutol.
Results: The following results were obtained from the 80 antibio-
grams performed by the four laboratories. (1) Complete agree-
ment: out of the 80 antibiograms carried out, 78 were concordant
(97.50%) and two were discordant (2.5%). (2) Agreement was
100% for Isoniazid and Rifampicin. (3) For Streptomycin and Eth-
ambutol, agreement reached 95% (one false result resistant to Eth-
ambutol and one false result resistant to Streptomycin). (4) The
results were obtained within an average of 9 days.
Conclusions: According to the results obtained, the sensibility test
carried out with the BacT/Alert 3D system is as accurate as the
conventional procedure using the proportions in solid medium.
P1291 Detection of mutations at embB codons 306 and 497
and iniA codon 501 by PCR-RFLP for rapidly determining
resistance to ethambutol in ethambutol-resistant clinical
Mycobacterium tuberculosis isolates
S. Ahmad, E. Mokaddas, A.-A. Jaber
Safat, KWT
Objectives: Mutations at embB gene codons 306 and 497 and iniA
gene codon 501 occur frequently in ethambutol-resistant Mycobac-
terium tuberculosis isolates. The aim of this study was to improve
or develop PCR–restriction fragment length polymorphism (RFLP)
methods for rapid screening of ethambutol-resistant clinical M.
tuberculosis isolates carrying substitutions at these codon positions.
Methods: The M. tuberculosis H37Rv was used as the susceptible
strain while well-characterised clinical isolates of M. tuberculosis
with speciﬁc substitutions at embB codons 306 and 497 and iniA
codon 501 were used as reference strains. The presence of muta-
tions was detected by PCR ampliﬁcation of the DNA region
around the respective codon position followed by digestion with
appropriate restriction enzymes to generate RFLPs.
Results: The PCR–RFLP performed with Nla III with the suscept-
ible strain carrying ATG and the mutant strains with GTG, ATT
and CTG at embB codon 306 yielded DNA fragments of expected
sizes. The restriction digestion performed with Hae III differenti-
ated the strains with mutation at the ﬁrst codon position (GTG
and CTG) and those with mutations at the third codon position
(ATT). The PCR–RFLP performed with AlwN I and Hpy99 I with
the susceptible and mutant strains for embB codon 497 and iniA
codon 501, respectively, also yielded expected DNA fragment pat-
terns. In a preliminary application to clinical isolates, the estab-
lished methods correctly identiﬁed mutations at embB codons 306
and 497 and iniA codon 501 in ethambutol-resistant M. tuberculosis
strains and the results were conﬁrmed by direct DNA sequencing.
Conclusions: We have developed PCR–RFLP based methods for
rapidly determining the substitutions at embB codons 306 and 497
and iniA codon 501. Since substitutions at these codon positions
occur frequently in ethambutol-resistant clinical M. tuberculosis iso-
lates, application of simple PCR–RFLP-based methods will result
in rapid identiﬁcation of resistant strains carrying these mutations.
Acknowledgement: Supported by Kuwait University Research
Administration grant MI 06/02.
P1292 Molecular characterisation of isoniazid-resistant
Mycobacterium tuberculosis strains from the Free State and
Northern Cape provinces, South Africa
A. van der Spoel van Dijk, M.N. Janse van Rensburg,
S.Z. Mokhethi, A.G.M. van der Zanden
Bloemfontein, ZA; Apeldoorn, NL
Objectives: In South Africa the true extent of isoniazid (INH) and
multidrug resistant tuberculosis (MDRTB) is unknown. A national
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survey has reported an overall INH resistance of 6.3 and 1.6%
MDR for new cases in the Free State (FS) province. However,
INH resistance rates of 14.5–20% have been reported in localised,
high incidence areas. MDR transmission and gene mutation data
are limited. The aim of this study was to determine the strain
diversity of and gene mutations in INH resistant strains isolated
from the FS and Northern Cape (NC) provinces.
Methods: Genotyping was performed on 29 strains using DNA ﬁn-
gerprinting of the IS6110 insertion sequences and spoligotyping
was done on seven (<5 bands) strains. Cycle sequencing of the
katG and rpoB genes was performed on nine strains.
Results: DNA ﬁngerprinting proﬁles showed seven strains with
ﬁve or less insertions. From these, two strains in a cluster were
conﬁrmed by spoligotyping while another cluster was proved to
consist of different strains. The remaining 22 strains contained
nine to 18 copies of the IS6110 insertion sequences. Fingerprinting
patterns were very diverse with 20 different proﬁles in 22 strains.
One cluster (two patients) was evident in each province. At a
65% similarity index, patterns were still too diverse to suggest
recent transmission. KatG mutation analysis of nine strains
revealed three strains with a missense mutation at codon 315
changing AGC to ACC and two mutations were found at codon
463 (CGG to CTG; CGG to CCG). Two of the strains harbouring
the 315 mutation were in the same cluster and investigations sug-
gested interfamily transmission. RpoB gene analysis performed on
7/9 MDR strains revealed three strains with a missense mutation
at codons 531, 526 and 516. Two strains had an addition at codon
514 and one at codon 522. These additions still have to be con-
ﬁrmed. One strain had no changes within the 81-bp region regar-
ded as the core region for rpoB gene mutations. All strains were
in different clusters.
Conclusion: The presence of no large clonal groups agrees with
published data suggesting non-compliance as the major cause of
resistance development. The cluster caused by interfamily trans-
mission indicates an urgent need for active case ﬁnding in close
contacts of infected patients. This study suggests that the DOTS
program in the Free State and Northern Cape is successful, but
continued surveillance of strain transmission and drug resistance
in the general community remains imperative.
P1293 rpoB mutations in rifampin-resistant clinical
Mycobacterium tuberculosis isolates from Turkey
Z.C. Karahan, F. Atalay, M. Uzun, Z. Erturan, M. Atasever,
N. Akar
Ankara, Istanbul, TR
Objectives: Drug-resistant tuberculosis is a serious problem
throughout the world. Resistance to Rifampicin (RIF) is mainly
caused by the mutations in the hot-spot region of the rpoB gene
coding the beta subunit of RNA polymerase. In this study, we
aimed to detect the distribution of rpoB gene mutations in 81 RIF-
resistant clinical Mycobacterium tuberculosis (MTB) isolates from
TURKEY.
Methods: The hot-spot region of the rpoB gene of MTB was ampli-
ﬁed by PCR using the primers BC35 (5¢-ATCAACATCCG-
GCCGGTGGT-3¢) and BC41R (5¢-TACACCGACAGCGAGCCGAT-
3¢) as described previously. Mutations leading to RIF-resistance
were determined by automated sequence analysis.
Results: Seventy-three isolates (90.1%) were found to carry muta-
tions in the ampliﬁed region, while eight isolates (9.9%) carried
no mutations. Overall, 25 different missense mutations affecting
15 codons, and two deletion mutants were identiﬁed. Ten new
mutations – six in the hot-spot region and four outside this region
– were found. The codon numbers of the most frequently encoun-
tered mutations were 531 (45.7%), 526 (16%), 516 (12.3%) and 513
(11.1%). As a result, nearly 90% of the RIF-resistant MTB isolates
were found to carry a mutation in the rpoB gene, Ser531Leu being
the most frequent one.
Conclusions: Although molecular methods identify mutations lead-
ing to RIF-resistance very quickly; for the patients carrying no
mutations in this region, results of the antimycobacterial suscepti-
bility tests must be taken into consideration.
P1294 Use of PCR–SSCP for rapid detection of rifampin
and isoniazid resistance-associated mutations in Mycobacterium
tuberculosis, isolated in Suez Canal region, Egypt
M. El-Sweify, A. Heiba, F. Ibrahim, S. Abbadi, K. Ibrahim,
N. Gomaa, R. Cooksey
Ismailiya, EGY; Atlanta, USA
Objectives: Recently emerged multidrug-resistant MTB (MDR-TB)
is a health problem that created a national concern. Most Egyptian
hospitals do not perform susceptibility testing for MTB isolates.
Empirical treatment with antituberculosis drugs prolongs the per-
iod of illness and infectivity due to emerging MDR-TB during
therapy. PCR–single strand conformational polymorphism
(PCR–SSCP) is evaluated in this work, as a rapid and non-expen-
sive method for detection of MDR-TB.
Methods: Forty MTB strains were isolated from 75 patients with
pulmonary TB (new and retreated cases) attending four main hos-
pitals in the Suez Canal region of Egypt. MTB strains were identi-
ﬁed by growth on LJ medium, biochemical activities, and
ampliﬁcation of IS6110 and IS1245 in a multiplex PCR. They were
tested for susceptibility to rifampin (Rif), isoniazid (Inh), strepto-
mycin (Sm) and ethambutol (Etb) by the standard agar proportion
(AP) method. Isolates were assayed for Rif and Inh mutation-asso-
ciated resistance by two separate PCR–SSCP assays. Mutations
were detected in the 81-bp region of rpoB gene (for Rif) and
321-bp sequence of katG gene for Inh resistance.
Results: Rates of resistance to each drug by AP method were: 47.5,
45, 37.5, and 25%, for Sm, Inh, Rif, and Etb, respectively. Com-
bined resistance to Rif and Inh (MDR-TB) was 35%, while resist-
ance to four drugs was 17.5%. MDR-TB strains were isolated 74%
of retreated cases and none from new cases. Resistance rates to
each drug were higher in retreated cases. These correlations were
statistically signiﬁcant ( P < 0.05). PCR–SSCP was successful in
detecting rpoB gene mutants in 12 out of 15 Rif-resistant isolates;
with sensitivity, speciﬁcity and overall predictivity of 80, 100, and
92.5%, respectively. It could also detect katG mutations in 13/18
Inh-resistant strains, with sensitivity, speciﬁcity and overall
predictivity of 72.2, 100, and 87.5%.
Conclusions: PCR–SSCP might not be the most reliable assay to
detect Rif-resistant MTB; but deﬁnitely it is not recommended for
detection of Inh-resistant MTB. Combination with other molecular
method – such as DNA sequencing – will enhance the sensitivity
and predictivity of PCR–SSCP.
P1295 Tuberculosis caused by multiresistant strains of
Mycobacterium tuberculosis in the Czech Republic.
Microbiological, epidemiological and DNA analysis
M. Havelkova´, L. Charvatova, V. Prı´kazsky´
Prague, CZ
Objectives: Multidrug-resistant tuberculosis (MDR-TB), deﬁned as
a disease caused by Mycobacterium tuberculosis strains resistant to
more antituberculous drugs (at least to isoniazid and rifampicin),
gains in importance in the Czech Republic (CR). These TB cases
refractive to causal therapy are associated with increased risk of
spreading of the infectious agent among population.
Methods: The National Reference Laboratory for Mycobacteria col-
lected, in total, 2813 M. tuberculosis strains isolated in Czech myco-
bacteriological laboratories in the period from 1999 to 2001. All
strains were tested for susceptibility to ﬁrst-line antituberculous
drugs and the multidrug-resistant (MDR) group was also tested
for susceptibility to second-line antituberculous drugs. The MDR
strains were further analysed by DNA ﬁngerprinting (Restriction
Fragment Length Polymorphism – RFLP).
Results and Conclusion: In total, there were 39 MDR-TB cases. A
total of 56 M. tuberculosis strains were isolated from these patients
during the investigated period. On average, MDR-TB accounted
for 1.96% of all TB cases in the CR. The most frequent type of the
MDR-M. tuberculosis isolates was resistant to four ﬁrst-line drugs
(isoniazid, rifampicin, streptomycin, ethambutol) and was found
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in 48.2% of all MDR-M. tuberculosis strains. Isepamicin, clofazi-
min, capreomycin and amikacin are considered to be the most
promising second-line drugs according to the shown data. Based
on RFLP proﬁles, 61.5% of strains were assigned to eight clusters
while the other strains remained unclustered. There were no sig-
niﬁcant differences between the excretors of clustered and unclus-
tered strains concerning geographical distribution and population
structure. Comparison of RFLP proﬁles with the international
database suggests uniqueness of Czech MDR-M. tuberculosis
strains, showing the proﬁles not found elsewhere to date.
Miscellaneous issues
P1296 Chlorination of bacterial surfaces by
N-chlorotaurine
M. Nagl, W. Gottardi
Innsbruck, A
Objectives: N-chlorotaurine (NCT), an endogenous active chlorine
compound, has broad-spectrum activity against microorganisms
and seems to be of advantage in topical therapy of infections of
e.g. the eye, the ear, and the skin. Although at least 20–30 min of
incubation time are necessary for killing of bacteria by NCT, their
virulence is already attenuated within 1 min as demonstrated in
an in vivo model. Rapid chlorination of bacterial surface (‘chlorine
cover’) has been assumed for explanation and been investigated
in this study.
Methods: Washed bacteria were treated for 1–3 min with NCT.
Subsequently the oxidant was removed by centrifugation or ﬁltra-
tion, and the chlorination measured spectrophotometrically after
addition of 5,5¢-dithiobis (2-nitrobenzoic acid).
Results: NCT produced a chlorine cover of about 3 · 10)16 mol
Cl+/CFU on S. aureus. This cover did not kill the microorganisms.
It was inﬂuenced by pH and coating time as well as by the kind
of test strain. Chlorine covers were surprisingly stable, e.g. for
hours at 0C in saline, even without a remarkable reduction of
viability. Regarding the consequences, chlorine-covered S. aureus
was phagocytosed by human granulocytes at a slightly higher rate
than a mock treated one. Moreover, chlorine covered E. coli lost
viability after transfer into active human serum in contrast to
mock treated ones.
Conclusion: Chlorination of bacterial surfaces by the mild oxidant
NCT may explain the rapid loss of virulence before killing takes
place. Chlorine-covered microorganisms seem to be more suscept-
ible to the human defence system, which may be important for
both the clinical application of NCT and its role in innate immu-
nity as a product of leukocytes.
P1297 Amelioration of the prokinetic effect of
erythromycin on oesophageal motility by atropine
A.Z. Helaly, M.A. Shaat, S.E. Rewini
Alexandria, EGY
Background: Erythromycin and its analogues are a group of antibi-
otics, which may be indicated in the clinical use. Side effect of this
group of drugs is mainly concentrated in the ﬁeld of gastroenter-
ology. They are known to have a prokinetic effect. This undesir-
able effect may limit the use of this drug.
Aim of work: The aim of this work was to determine the block
effect of atropine on the receptors with the drug intake in order to
ameliorate the undesirable side effect of the drug when we give
erythromycin in combination with atropine.
Methods: This work was done on three groups of healthy volun-
teers, each group consisted of 10 coherent healthy volunteers. In
group one, erythromycin was taken and oesophageal motility was
assessed. In group two, atropine was taken with erythromycin. In
group three, placebos were taken with erythromycin. Oesophageal
motility was assessed by solid state catheter on a fasting state and
the upper oesophageal sphincter (UES) function was assessed by
pressure of UES and pharyngeal pressure and all the standard
parameters. The body of the oesophagus pressure and the stand-
ard parameters were measured and the lower oesophageal (LES)
pressure and relaxation were measured in all the groups. Statisti-
cal data were analysed according to standard student t test and
signiﬁcant difference was evaluated. The dose of erythromycin
was 500 mg orally once daily for 5 days. Atropine dose was
15 mg/kg orally daily for the same period. The motility studies
were performed at the end of the study.
Results: At 5% level of signiﬁcance the data showed that signiﬁ-
cant changes were found after atropine intake. The increased
motility test produced by erythromycin in group one was signiﬁ-
cantly reduced in group two (P < 0.05), while in group three,
there was no signiﬁcant changes than in group one (P > 0.05).
Conclusion: Erythromycin is one of the macrolide antibiotics that
stimulate activity by binding at receptor on the intestinal mus-
cle cell. This stimulating motility effect is considered in the
evaluation of the side effect of this antibiotic. In this work this
effect is showed to be ameliorated by the antagonistic action
atropine on the receptor. From this work we can conclude that
atropine should be given with erythromycin if you want to
abolish the undesirable effect unless there is contraindication to
atropine.
P1298 Impact of prolonged treatment with
trimethoprim-sulfomethoxazole on the human gut ﬂora
D. Kofteridis, S. Maraki, D. Alegakis, N. Tsagarakis,
E. Barbounakis, G. Samonis
Heraklion, GR
Introduction: Trimethoprim-sulfamethoxazole (TMP-SMX) is a
broad-spectrum antibiotic active against a wide variety of bacteria,
Pneumocystis carinii, and some protozoa, but non-active against an-
aerobes. There are limited data on the effect of this drug on the
gut ﬂora after very prolonged treatment.
Objectives: To describe the impact of TMP/SMX on the gut
ﬂora of a patient who was mistakenly treated with TMP-SMX
(800/160 mg bid) for 2 years.
Case report: A 43-year-old, mentally ill, man presented with a
3-day history of fever (39C) and dysuria. The patient had urine
incontinence, due to a traumatic lumbar spinal fracture, had an
indwelling urinary catheter and was receiving TMP-SMX for urin-
ary tract infection prophylaxis (one loading dose before and one
after any catheter change). However, by mistake, he was continu-
ously taking the drug daily for 2 years. Urinalysis showed
increased protein with numerous leucocytes and bacteria. Urine
culture yielded an extended-spectrum b-lactamase (ESBL) produ-
cing strain of Escherichia coli. Blood cultures were negative. Quan-
titative stool cultures for bacteria and yeasts yielded Candida
albicans 2 · 105 CFU/g, Bacillus licheniformis 9 · 109 CFU/g, En-
terococcus faecalis 1.1 · 1010 CFU/g, Enterococcus faecium
2 · 1011 CFU/g, Bacteroides ovatus 2.5 · 1010 CFU/g, Bacteroides
uniformis >1012 CFU/g, and Clostridium acetobbytulicum
1.2 · 1010 CFU/g.
Conclusions: This unique case conﬁrms the preservation of the
anaerobic gut ﬂora during TMP-SMX treatment and suggests that
this agent is a reasonable treatment option when gut colonisation
resistance is required. The emergence of an ESBL producing strain
of E. coli was apparently the result of the suppression of Gram-
negative aerobic ﬂora. Enterococcus spp. was not affected.
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P1299 Ecological effects of pivmecillinam on the normal
vaginal microﬂora
A˚. Sullivan, M. Karlsson, M. Stro¨m, L. Ydenius,
A. Fianu-Jonasson, B.-M. Landgren, C.E. Nord
Stockholm, S
Objectives: It has been shown that mecillinam affects the normal
oropharyngeal, intestinal and skin microﬂora to a minor extent.
The effect on the vaginal microﬂora is not known. The objective
of this project was to study the ecological impact of pivmecillinam
on the normal vaginal microﬂora.
Methods: Eighteen healthy women, 24–40 years old, with one
sexual partner and not being infected with sexually transmitted
pathogens were included in the study. The day of ovulation was
determined during three subsequent menstrual cycles. Microbiolo-
gical and clinical examinations were performed on the day of
ovulation and on day 3 in all cycles and also on day 7 in cycles 1
and 2. The clinical examinations included observation of vaginal
and cervical epithelium, photographing of cervix, pH- measure-
ments and inspection of any discharge. Vaginal specimens were
collected with sterile swabs at each visit. The specimens were
diluted in pre-reduced medium, diluted 10-fold and inoculated on
selective and non-selective agar plates. All different colony types
were counted and identiﬁed to genus level. Pivmecillinam was
administered 200 mg t.i.d. for 7 days starting on the day of ovula-
tion in cycle 2.
Results: Anaerobic and facultative Gram-positive rods, mainly
species of lactobacilli and actinomyces, dominated the vaginal
microﬂora. Lactobacilli were only isolated sporadically in ﬁve of
the women, all of whom were also colonised with Gardnerella vagi-
nalis. G. vaginalis was further isolated from seven subjects. The
aerobic microﬂora was dominated by species of corynebacteria.
Seven women were colonised with Escherichia coli in low numbers
in one to three samples. Four women were colonised in cycle one
only, one in cycle one and on day 1 in cycle 2, and two women
were colonised on day 3 and on day 7 in cycle 2, respectively.
Candida albicans was isolated from four women and C. dublinensis
from two. Five of these women had a microﬂora with a high per-
centage peroxidase-producing lactobacilli (>80%) while one sub-
ject had no H2O2-producing strains. Four of the women were
colonised in all or in seven of eight samples, one was colonised
on days 3 and 7 in cycle 2 and one women in cycle 3 only. There
were variations in numbers of microorganisms between the men-
strual cycles but not related to the administration of pivmecilli-
nam.
Conclusion: Administration of pivmecillinam did not have any
major ecological impact on the normal vaginal microﬂora.
P1300 Risk of adverse birth and neonatal outcomes for
pregnant users of pivmecillinam – a population-based cohort
study
M.V. Skriver, M. Nørgaard, L.N. Pedersen, H.C. Schønheyder,
H.T. Sørensen
Aarhus, Aalborg, DK
Objectives: Pivmecillinam is widely used by pregnant women in
the Nordic countries for treatment of urinary tract infections.
Long-term treatment with pivmecillinam can lead to carnitine
deﬁciency. Carnitine is an essential cofactor in mitochondrial
metabolism and carnitine deﬁciency may cause metabolic distur-
bances in the newborn. The existing epidemiological data on use
of pivmecillinam during pregnancy are limited to a single cohort
study of 414 pregnant women, based on data from our dataset.
Unexpectedly, in this analysis, we found an increased risk of low
Apgar score in the offspring of women who had redeemed a pre-
scription for pivmecillinam during the third trimester, odds ratio
2.32 (95% conﬁdence interval (95% CI) 0.30–18.16). All other risk
estimates in the study were close to one. The relatively wide 95%
CI for low Apgar score and the fact that sample size is a critical
parameter in the study of drug-induced birth defects, made us
perform a larger observational study in order to achieve greater
statistical power and to add additional neonatal outcomes. We,
therefore, extended the dataset used in the former study in order
to examine the risk of adverse birth and neonatal outcomes
among offspring of Danish women, who had redeemed prescrip-
tions for pivmecillinam during pregnancy.
Methods: In a population-based cohort study based on data from
the North Jutland Prescription Database, the Birth Registry, and
North Jutland County’s Hospital Discharge Registry, Denmark,
we examined the risk of congenital malformations, preterm deliv-
ery, low birth weight, stillbirth, low Apgar score, hypoglycaemia
and respiratory distress syndrome among pregnant users of piv-
mecillinam. The cohort included 2031 women who had taken up
prescriptions for pivmecillinam during pregnancy, and 61 628
women with a livebirth or a stillbirth after the 28th week of gesta-
tion, who did not use pivmecillinam during pregnancy.
Results: The adjusted odds ratios for outcomes associated with use
of pivmecillinam were: congenital malformations 0.83 (95% CI
0.53–1.32), preterm delivery 0.96 (95% CI 0.79–1.18), low birth
weight 0.79 (95% CI 0.52–1.20), stillbirth 1.19 (95% CI 0.30–4.80),
low Apgar score 1.17 (95% CI 0.37–3.66), hypoglycaemia 1.02
(95% CI 0.52–1.98) and respiratory distress syndrome 0.86 (95%
CI 0.43–1.74).
Conclusion: In conclusion, use of pivmecillinam during pregnancy
did not seem to increase the risk of adverse birth and neonatal
outcomes.
P1301 Inﬂuence of ertapenem on cell activation and
co-stimulatory molecule expressions
I. Korzh, V. Nemtsova, I. Fedotova
Kharkov, UKR
Objectives: The inﬂuence of a novel parenteral carbapenem, er-
tapenem, on co-stimulatory molecule expression was examined in
vitro and in vivo.
Methods: Spleen cells obtained from BALB/c mice 10 days after
immunisation with 8.0 lg of haemocyanin absorbed to 4.0 mg of
aluminium hydroxide were cultured in the presence of 100.0
lg/mL of haemocyanin and various concentrations of ertapenem.
We examined the inﬂuence of ertapenem on cell activation by
examining the proliferative response of cells and cytokine produc-
tion. We also examined the inﬂuence of ertapenem on co-stimula-
tory molecule (CD40, CD80 and CD86) expressions on cultured
splenic B-lymphocytes induced by in vitro antigenic stimulation
using ﬂow cytometry. Splenic B lymphocytes were obtained from
these mice 24 h after antigenic challenge, and co-stimulatory
molecule expressions were examined by ﬂow cytometer.
Results: Cell activation induced by in vitro antigenic stimulation
was suppressed by ertapenem when cells were cultured in the
presence of more than 1.0 lg/mL of the agent. Addition of ertape-
nem at a concentration of 0.5 lg/ml into cell cultures also sup-
pressed co-stimulatory molecule (CD40, CD80 and CD86)
expressions on splenic B lymphocytes, which was enhanced by
antigenic stimulation in vitro. Ertapenem administration for
4 weeks clearly suppressed the enhancement of CD40 and CD86
(but not CD80) expressions on splenic B lymphocytes induced by
antigenic stimulation in vivo. This suppressive activity of ertape-
nem on co-stimulatory molecule (CD40 and CD86) expressions
was further strengthened by the treatment of mice for 8 weeks.
Long-term treatment with ertapenem also suppressed CD80
expressions, which was not suppressed by 4-week treatment.
Conclusion: The present results suggest that ertapenem exerts its
immunomodulating effects through suppression of both cell acti-
vation and co-stimulatory molecule expressions induced by anti-
genic stimulation. These suppressive activities of ertapenem might
contribute, in part, to the therapeutic mode of action of ertapenem
on inﬂammatory diseases.
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P1302 Risk factors for candidiasis in the neonatal unit: a
matched case–control study
C. Antachopoulos, K. Patel, B. Sprague, B. Short,
J. Campos, N. Singh,
Washington, USA
Background and objectives: Certain aspects of modern neonatal
intensive care, such as antibiotic administration or central catheter
use, have been associated with Candida infection. There is a lack
of information regarding the role of particular antimicrobial
agents in the development of neonatal candidiasis, while the
association of central catheter use and other risk factors with Can-
dida infection has not been consistently conﬁrmed in multivariate
analysis models. The aim of this study was to improve our know-
ledge of risk factors associated with neonatal candidiasis, with
emphasis on those related to medical care.
Methods: A 1:2 matched case–control study was performed. Cases
were infants admitted to our neonatal unit (NICU) from 1998 to
2002 with Candida spp. isolated from blood, cerebrospinal ﬂuid or
suprapubic urine aspirate. Controls were matched to cases on
birth weight, age on admission and date of admission to the
NICU. Exposure to risk factors, including various antimicrobial
agents, placement of different types of central venous or umbilical
catheters, duration of parenteral nutrition and mechanical ventila-
tion, length of stay in the unit (LOS) and history of necrotising
enterocolitis, were analysed using the NICU database. We also
assessed whether neonates colonised with antimicrobial (ceftazi-
dime)-nonsusceptible Enterobacteriaceae (ANE), including exten-
ded spectrum beta-lactamase producing strains, are at increased
risk of Candida infection. Information regarding colonisation with
ANE was obtained from surveillance rectal cultures.
Results: Sixty infants with Candida infection were matched (among
which 31 had C. albicans and 21 had C. parapsilosis). Multivariate
analysis revealed mechanical ventilation and parenteral nutrition
as independent risk factors for candidiasis. Ampicillin and vanco-
mycin administration was associated with C. albicans infection.
Use of central catheters, LOS, colonisation with ANE and history
of necrotising enterocolitis were not independent risk factors for
candidiasis in the multivariate model.
Conclusion: Parenteral nutrition and mechanical ventilation should
be judiciously used in preterm infants. Changes in antibiotic pol-
icy in the NICU, including restriction of ampicillin and vancomy-
cin use, may prove beneﬁcial for the prevention of candidiasis
and should be further investigated.
P1303 Secular trends in aetiology of neonatal sepsis (1991–
2001)
K. Bindayna, A. Jamsheer, E. Farid, G. Botta
Manama, BH
Objective: To investigate the spectrum of organisms causing neo-
natal sepsis in Bahrain and to assess the sensitivity to antibiotics.
Methods: The medical records of all infants who had positive
blood culture from 1991 to 2001 in neonatal intensive care unit
(NICU) in both Salmaniya Medical Complex (SMC) and Bahrain
Defence Force Hospital (BDF), Bahrain have been reviewed.
Results: A total of 335 (4.1%) children had culture proven
bacteraemia. The main agents isolated were coagulase negative
Staphylococcus (CoNS) in 138 cases (40%) followed by E. coli in
35 cases (10%), S. aureus in 28 cases (8%) and Group B Strepto-
coccus (GBS) in 26 cases (0.2% per thousand live birth), and K.
pneumoniae 24 (7.2%). An increasing, high percentage (5.7%) of
Candida albicans isolation was also noted as a cause for special
concern. During 1999–2001 there was an increase in resistance
to more than three antibiotics in CoNS. All GBS were sensitive
to Penicillin G, Erythromycin and Clindamycin. Klebsiella and
Enterobacter spp. showed resistance to many of the antibiotics
tested, posing difﬁcult therapeutic choices.
Conclusion: Our results differ appreciably from other studies in
developed countries regarding GBS. The role played by GBS in
our setting is modest. Therefore, universal prenatal screening to
detect vaginal and rectal GBS colonisations is unwarranted. It can
be considered in the presence of additional risk factors (premature
delivery, premature rupture of fetal membrane or fever during
delivery). Speciﬁcally tailored polices must be deﬁned according
to the local epidemiology. The threat of fungal infection must be
carefully tackled.
P1304 Investigation of Streptococcus pyogenes strains
isolated from children with fatal STSS
L. Zachariadou, A. Charissiadou, H. Barbaressou, A. Tanna,
A. Efstratiou, A. Hatzis, A. Pangalis
Athens, GR; London, UK
The late 1980s Streptococcus pyogenes (GAS) was presented with
severe infections associated with shock, bacteraemia, acute respir-
atory distress syndrome and death in a signiﬁcant rate. The most
serious infection, streptococcal toxic shock syndrome (STSS) has
attracted special attention because of its lethality. The aim of our
study was to investigate the M-serotypes as well as the sensitivity
to antibiotics and the presence of pyrogenic exotoxin genes (spe
genes) of STSS strains. GAS isolates from three children fulﬁlling
the criteria for STSS were tested. The age and sex of the little
patients were a girl 5, a boy 2.5 and a girl 3.5 years old. All three
cases were fatal. The ﬁrst girl was immunocompromised, having
acute lymphoblastic leukaemia (ALL), the boy had asthmatic
bronchitis treated by bronchodilators and the second girl was phe-
notypically healthy. Two of the isolates originated in blood and
the remaining one in pharynx. One of the blood stains was also
isolated from pleural ﬂuid. The work out of these GAS strains
included Lanceﬁeld serogrouping (TRANSLAB UK kit), serum
opacity factor, T-serotyping (anti-T sera from SERVA Ltd,Prague),
sensitivity to antibiotics (penicillin, vancomycin, chloramphenicol,
rifampicin, erythromycin, clindamycin) by disk diffusion method,
double disk test (Becton Dickinson’s disks) and MIC (Etest,AB
Biodisk). M-serotyping and spe genes were tested by conventional
and molecular techniques (RSIL,HPA,London). STSS isolates
belonged to M12, M28 and M84 serotypes. No strain was resistant
to penicillin, vancomycin, chloramphenicol and rifampicin. Resist-
ance to macrolides of iMLS phenotype attributed to the M84
strain isolated from the girl with ALL. The strains were speB and
speC positive but speA negative. Serotypes M12 and M28 are
among the 10 most frequent ones connected to STSS worldwide,
but they are not as common as M1 and M3.M1 serotype was not
found, as it was expected from the literature and its predomin-
ance in invasive GAS infections encountered in our hospital.
P1305 Beneﬁcial effects of immediate treatment of group A
beta-haemolytic streptococcal pharyngitis with antibiotics
N. Salman, M.A. Talay, A. Somer, I. Yalcin
Istanbul, TR
Objectives: A beneﬁcial effect of antibiotic therapy on the clinical
course of group A beta-haemolytic streptococcal (GABHS) phar-
yngitis has been demonstrated in the past several years. As GAB-
HS pharyngitis is a frequently encountered problem, we thought
the question of treatment impact on symptomatic response and
on recurrent infection should be investigated.
Methods: Sixty children aged 1–12 years (24 girls, 36 boys) with cul-
ture positive for GABHS pharyngitis were enrolled in a random-
ised prospective study comparing the consequences of immediate
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vs. delayed treatment (after 48–56 h) with penicillin. There were 30
patients (18 M, 12 F) in both immediate (I) and delayed (D) treat-
ment groups. Patients who were previously treated with antibiotics
and carriers were excluded. All patients were assessed for the
existence of clinical symptoms (fever, dysphagia, loss of appetite)
and clinical ﬁndings (cryptic/exudative tonsillitis and anterior cer-
vical lymphadenopathy). ASO titres (>250 IU/mL) were assessed
for streptococcal antibody response. All patients underwent ther-
apy with penicillin (50 000 IU/kg/day). Symptoms were assessed
after 2 days. Throat cultures were also repeated. Complications
and recurrences were recorded after 1 and 3 months.
Results: In both groups fever was encountered in all the patients
enrolled in the study. After 48–56 h, seven (23%) in I group
and nine (30%) in D group had fever. Dysphagia was observed
in 76% in I group and 9% of D group patients at the begin-
ning. Clinical ﬁndings and improvement in these ﬁndings were
similar in both groups. After 48–56 h, six (20%) in the I group
and 24 (80%) in the D group were still culture-positive for
GABHS. This result was signiﬁcant (P < 0.05). Although it has
been reported that penicillin treatment seemed to prevent devel-
opment of type speciﬁc immunity to GABHS, ASO titres was
not depressed in the I group after therapy. In the month fol-
lowing documented evaluation of GABHS, no recurrence or
complication occurred in both groups. Similar results were
obtained after 3 months.
Conclusions: We suggest that early initiation of antibiotics for
GABHS will reduce acute symptoms and secondary spread. The
risk of recurrence rate related to diminished streptococcal immu-
nity in the early treated children was not observed in our group.
P1306 An evaluation of once daily cefdinir 25 mg/kg oral
suspension in children with acute otitis media at risk of
persistent or recurrent otitis media
E. Leibovitz, R. Dagan, A. Arguedas, A. Hoberman, M. Pichichero,
T. Busman, M. Paris, S. Bukofzer – The Cefdinir M01-352 Study
Group
Objective: This phase 2/3, open-label, noncomparative, multi-cen-
tre study, assessed the efﬁcacy of once daily CEF in the treatment
of children with AOM at risk of PROM.
Methods: Children aged 6 months to 4 years with signs/symptoms
of AOM at risk of PROM (characterised by ‡2 of the following:
antibiotics in previous 3 months, age £2 years, day-care attend-
ance or siblings/household contacts age £8 years), diagnosed by
pneumatic otoscopy and tympanocentesis, received once daily
CEF for 10 days. Children were evaluated pretreatment (Day 1),
on therapy (Days 4–6), end of therapy (Days 12–14) and follow-up
(Days 25–28). Repeat tympanocentesis on Days 4–6 was used to
assess bacteriologic response.
Results: A total of 447 children were enrolled in the US, Israel
and Latin America. Fifty-seven percent were male, 64% were
£2 years of age. For the 227 children clinically and bacteriologi-
cally evaluable, 58% were male and 74% were £2 years of age;
13% had received pneumococcal conjugated vaccine. Forty-two
percent of these children had ‡3 AOM infections within the
past 12 months (including present infection) and 56% had
received treatment for AOM within previous 3 months. Fifteen
percent had multiple pathogens isolated pretreatment. Forty-
seven percent of S. pneumoniae isolates were penicillin non-sus-
ceptible (PNSP). Bacteriologic eradication on Days 4-6 was
achieved in 159/226 (70%) children and 188/262 (72%) of all
pathogens were eradicated. Bacteriologic response in children
with a single pathogen was 148/193 (77%). Eradication of peni-
cillin susceptible, intermediate and resistant S. pneumoniae was
84% (46/55), 65% (17/26) and 39% (9/23), respectively; eradi-
cation of H. inﬂuenzae was 84/123 (68%). Overall clinical
response for clinically and bacteriologically evaluable children
on Days 12–14 was 82% and for S. pneumoniae and H. inﬂuenzae
it was 75 and 82%, respectively. Clinical response on Days 25–
28 was 142/167 (85%). Clinical response for children with
pretreatment negative and positive cultures was 97 and 82%,
respectively. CEF was discontinued due to an adverse event in
only 3% of children. The most common adverse events were
diarrhoea (13%) and vomiting (7%), most of mild severity.
Conclusions: This study speciﬁcally evaluated children with
AOM at risk for PROM. In this high-risk population, CEF
demonstrated good activity against penicillin susceptible
S. pneumoniae, but decreased activity against PNSP, and a mod-
erate effect against other pathogens. Further studies are needed
to evaluate modiﬁed dosing or formulations of CEF in this
high-risk population.
P1307 Epidemiology of Streptococcus pneumoniae causing
acute otitis media in young children in the Czech Republic
R. Prymula, P. Kriz, J. Motlova, V. Chrobok
Hradec Kralove, Prague, Pardubice, CZ
The increasing prevalence of multiple antibiotic resistances makes
prevention by vaccination a logical approach. Capsular based
pneumococcal vaccines are unsuitable for use in children under
2 years. Preliminary epidemiological data are required before
studying the efﬁcacy of a candidate pneumococcal multi-valent
conjugate vaccines against acute otitis media (AOM) in the Czech
Republic. Serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F are
covered in various candidate vaccines.
Objective: To evaluate the prevalence of Streptococcus pneumoniae
serotypes and their antibiotic resistance in <2 years old children
suffering from AOM.
Method: Between October 1999 and November 2000, samples of
middle ear ﬂuid (MEF) were collected by tympanocenthesis from
310 children <2 years old, originating from 12 areas and diag-
nosed with AOM. MEF were analysed for bacterial identiﬁcation
in culture. Out of 143 AOM cases diagnosed with S. pneumoniae,
141 were typed. Capsular typing of pneumococcal strains was
performed by quellung reaction using serotype-speciﬁc antisera.
MIC method was used for resistance testing.
Results: S. pneumoniae was isolated from MEF specimens as caus-
ing pathogen of AOM in 46%. Serotypes 3, 19F, 14 and 23 repre-
sented 48% of pneumococcal otitis observed during the survey.
All isolates were sensitive to amoxicillin/clavulanic acid. Resistant
strains were found in 1% to penicillin, clindamycin and erythro-
mycin, in 9% to chloramphenicol, 11% to doxycycline and trim-
ethoprim/sulfamethoxazol.
Conclusion: In spite of very low resistance in S. pneumoniae, sero-
types causing AOM in the Czech Republic pneumococcal conju-
gate vaccine is promising approach to control AOM. Eleven-
valent vaccine may protect up to 75% of pneumococcal serotypes
causing AOM, assuming an ideal efﬁcacy, what represents 34% of
all AOM diagnosed in children <2 years old.
P1308 Invasive serotypes of Streptococcus pneumoniae in
nasopharynx of healthy children
I. Korona-Glowniak, A. Malm
Lublin, PL
Objectives: Pneumococcal nasopharyngeal carriage is important
because of its relation both to development of the disease and to
spread of the pathogen. The most common nasopharyngeal
carriage serotypes are the same as the invasive isolates, although
the rank order of speciﬁc seroptypes may be different. Moreover,
the serotype distribution of nasopharyngeal isolates is usually pre-
dictive of invasive isolates in a given population. We examined
prevalence and antimicrobial resistance of invasive serotypes of
S. pneumoniae in nasopharyngeal carriage among healthy children
attending day-care centres (DCCs).
Methods: Throat and nose swabs obtained from 241 children of
aged 3–5, attending four DCCs were plated onto selective sheep
blood agar with 5 mg/L gentamicin. Pneumococci were identiﬁed
by colony morphology, susceptibility to optochin, bile solubility
and slide agglutination test (Slidex PneumoKit, BioMerieux), and
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serotyped using antisera from Statens Serum Institute. Drug sus-
ceptibility of isolates was determined by disk diffusion method
according to NCCLS or by the E-test (AB Biodisk).
Results: Nasopharyngeal carriage of S. pneumoniae was found in
51% of the children. The paediatric serogroups (6, 9, 14, 19, 23)
constituted 77.2% of all 123 isolates. A total of 36.6% (45/123) of
the S. pneumoniae strains were relatively resistant to penicillin
(RRSP) and 8.1% (10/123) – highly resistant to penicillin (HRSP).
All 45 RRSP strains belonged to serotypes 6B, 9V, 14 and 19F
whilst nine HRSP had serotype 14 and 1 HRSP – 15B. The tested
pneumococci were resistant to co-trimoxazole (52%), tetracycline
(35%), erythromicin (25%), clindamicin (25%) and chlorampheni-
col (27.6%). Resistance to at least three antibiotic classes (MDR
– multidrug resistance) was found in 42 isolates (34.1%) and all
of them belonged to the paediatric serogroups. Among MDR
strains, 61.9% were non-susceptible to penicillin.
Conclusion: Children in DCCs may constitute an important reser-
voir of resistant strains and may contribute to its spread in the
community. It is important for communities to obtain the accurate
and current knowledge of local antibiotic resistance patterns to
determine appropriate empirical approach to pneumococcal infec-
tions in an era of rapidly increasing resistance of S. pneumoniae to
currently available agents.
P1309 Resistance proﬁle of S. pneumoniae and beta-
lactamase production in H. inﬂuenzae and M. catarrhalis
isolated from 258 children with upper respiratory tract infection
in Southern Brazil – 2002
C. Mendes, C. Zoccoli, F. Rossi, G. Duboc, P. Garbes,
L. Pedneault, J. Sampaio, C. Kiffer
Sao Paulo, Florianopolis, Rio de Janeiro, BR; Brussels, B
Objective: Establish the susceptibility proﬁle of S. pneumoniae and
the beta-lactamase production of H. inﬂuenzae and M. catarrhalis
from children with upper respiratory tract infection (URTI) in Bra-
zil.
Methods: Samples (one per patient) were selected from patients
less than 5 years old during the 2002 period. All subjects had clin-
ical diagnosis of URTI and a positive culture result for at least
one of the selected pathogens (S. pneumoniae, H. inﬂuenzae and M.
catarrhalis). Clinical data related to age, gender, diagnosis and
samples are described. S. pneumoniae isolates were tested against
penicillin, amoxacillin, amoxacillin/clavulanic acid, cefuroxime
axetil, cefaclor and azithromycin. Minimal inhibitory concentra-
tions (MIC) were determined by Etest methodology. Interpretative
criteria used were those described by NCCLS documents M100-
S13. H. inﬂuenzae and M. catarrhalis isolates were tested for
beta-lactamase production by chromogenic cephalosporin method
[Ceﬁnase (R)].
Results: There were 290 isolates from 258 children less than
5 years old. Most samples were from middle ear ﬂuid (59.9%),
followed by nasopharyngeal swab (23.7%) and oropharyngeal
swab (12.9%). Age group of >2 £ 5 years old represented 51.6%.
Most were outpatients (93.4%) with diagnosis of acute otitis
(45.9%), followed by acute sinusitis (8.9%) and recurrent otitis
(7.4%). Among 139 isolates of H. inﬂuenzae and 35 isolates of M.
catarrhalis, 13.7% and 94.3% were beta-lactamase producers,
respectively. Among S. pneumoniae (n ¼ 116), 100% were suscept-
ible (S) to amoxicillin (MIC90 ¼ 0.094 lg/mL), 13.0% were inter-
mediate (I) and 1.7% resistant (R) to penicillin
(MIC90 ¼ 0.125 lg/mL), 17.2% I and 6.9% R to azithromycin
(MIC90 ¼ 1.0 lg/mL), and 0.9% I and 6.9% R to cefaclor
(MIC90 ¼ 0.75 lg/mL).
Conclusions: Signiﬁcant rate of beta-lactamase production in H.
inﬂuenzae was detected, while an expected rate was observed
in M. catarrhalis. In S. pneumoniae, penicillin full resistance was
still rare, although intermediate susceptibility was common.
Azithromycin resistant/intermediate S. pneumoniae was more
common than the latter in this population. Empiric therapy
with penicillins alone or in low dose should be avoided in this
population.
P1310 Streptococcus agalactiae: vaginal and rectal carriage
in females in childbirth, incidence of early-onset disease,
distribution of serotypes, susceptibility to antimicrobials
J. Motlova, L. Strakova, P. Urbaskova, M. Hanzl, P. Sak,
M. Balejova, T.Sever, M. Bartova
Prague, Ceske Budejovice, CZ
Objectives: To screen females in childbirth for vaginal and rectal
Streptococcus agalactiae (group B strains – GBS) carriage and to
establish the incidence of early-onset disease (EOD) due to GBS,
distribution of serotypes and GBS susceptibility to antimicrobials
in the Czech Republic (CR).
Methods: Females in childbirth were screened for vaginal and ano-
rectal carriage of GBS based on the CDC recommended criteria.
Invasive strains isolated from newborns were collected from 30
microbiological and clinical centres all over the CR within pros-
pective active surveillance for EOD. In parallel, the EOD incidence
was monitored in a perinatology centre in Ceske Budejovice in
passive retrospective and prospective studies. Serotypes were
identiﬁed by a precipitation reaction with home-made rabbit sera
and antigenic extracts prepared according to Lanceﬁeld’s modiﬁ-
cation. The minimum inhibitory concentrations of penicilllin, amp-
icillin, cefotaxime, tetracycline, erythromycin and clindamycin
were evaluated according to the NCCLS guidelines.
Results: Altogether 586 females in childbirth were investigated to
show an overall colonisation rate of 29.3% (172/586) in the vagina
and/or in the rectum. During a 3-year active surveillance, 141
invasive GBS isolates from newborns were collected in the refer-
ence laboratory; the incidence was calculated to be 0.96 per 1000
live births. Based on passive surveillance, the following incidence
rates were documented: 1.2 per 1000 live births and 0.5 per 1000
live births prior to and after implementation of the EOD preven-
tion project. Serotype III prevailed, followed by types Ia, II and V
identically among women and neonates. All our isolates were sus-
ceptible to beta-lactam antibiotics. Resistance to erythromycin
(and clindamycin) was found in 4.4% isolates from pregnant
women, i.e. with an almost double frequency as compared with
invasive strains isolated from neonates (8.5%). Resistance to tetra-
cycline was found in 84.3% of the isolates from females and in
91.5% of the strains from neonates. The majority of isolates of
GBS resistant to erythomycin (65.5%) belong to type V.
Conclusion: Compared with the EOD incidence, GBS carriage in
pregnant woman is rather high in the CR as compared with the
literature data. Our ﬁndings conﬁrm uniform susceptibility of
GBS to penicillin and other beta-lactam antibiotics tested. The
study showed signiﬁcance of type V strains in perinatology.
P1311 Sorbitol non-fermenting (SNF) E. coli strains in
children with acute diarrhoea
X. Agathocleous, A. Makri, I. Varzakakos, G. Kanellopoulou,
M. Varvery, H. Papavasileiou
Athens, GR
Introduction: Shiga toxin-producing E. coli strains (STEC) have
been recognised as important aetiologic agents of diarrhoea and
rarely serious outbreaks and sporadic cases of life-threatening
haemorrhagic colitis and haemolytic uraemic syndrome (HUS)
worldwide. E. coli O157:H7 is the most frequently identiﬁed sero-
type. A characteristic phenotypic feature of this pathogen is the
inability to ferment sorbitol after overnight incubation. Sorbitol–
MacConkey agar (SMAC) is used for routine screening.
Objective: We wanted to determine the frequency and characteris-
tics of SNF E. coli strains in children with acute diarrhoea attend-
ing a general paediatric hospital in Athens, Greece, in two
predetermined chronological periods.
Materials and methods: Between 1/1988 and 1/1989 as also between
1/2000 and 1/2002, 850 and 3805, respectively, faecal samples
from children (3–14 years of age) with acute diarrhoea were
screened in SMAC (Biomerieux). The SNF strains were identiﬁed
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using API20, serotyped with poly/mono speciﬁc serum and
immune chromatography. For the detection of shiga-toxin, the
Shiga Toxin Micro plate Assay (ProSpecT) was used. Susceptibil-
ity tests to antibiotics were performed by disk-diffusion method
according to NCCLS recommendations.
Results: Out of 4655 stool specimens 44 (0.9%) were SNF (21
strains the earlier period and 23 the latter). No O157:H7 was isola-
ted and no shiga toxin was detected. Of these 44 strains, 7
(15.9%) matched with EPEC serotypes, O127:B8 (n4), O111:B4
(n : 2) and O55:B5 (n : 1). The SNF strains showed signiﬁcant
resistance to Ampicillin (36.4%), Trim/sulfa (20%) and Cephalo-
thin (20%).
Conclusion: Our study demonstrates that O157:H7 E. coli strains
are not detected in Greek children. In contrast EPEC were fre-
quent among the SNF E. coli over a decade. We recommend cul-
ture in SMAC, antiserum serotyping and shiga toxin detection
with EIA in children with acute diarrhoea.
P1312 Rickettsia typhii infection in children in Cyprus
C. Georgiou, M. Koliou, A. Hadjipanayis, N. Persianis, P. Zarvos,
C. Hadjichristodoulou, M. Theodoridou, C. Kattamis – Paediatric
Surveillance Unit Cyprus-Greece
Objectives: Ricketsia typhii is an obligate intracellular parasite,
which causes the zoonotic infection of murine typhus. This study
aims at identifying clinical cases of murine typhus in children in
Cyprus and study the epidemiological and clinical characteristics
of the disease.
Methods: Prospective study of all cases of murine typhus occur-
ring over a period of 2 years (October 2001 to September 2003) in
children in Cyprus diagnosed and managed by primary care pae-
diatricians or admitted in hospitals. The presence of antibodies
against R. typhii with titres of IgG‡:960 or IgM‡:400 and/or a
fourfold rise of the IgG titre between two assays were considered
as a strong indication of acute infection. The minimal presumptive
clinical criteria for the diagnosis were the presence of fever
and/or headache and/or skin rash.
Results: During this time 15 patients fulﬁlled the serological and
clinical criteria of the disease. Ages ranged from 4 to 14 years
with mean age 8.5 years. Most cases occurred in summer and
early autumn, while greatest incidence was noticed in agricultural
areas. Most common clinical manifestations were fever (100%),
chills (90%) and rash (55%). Lymphadenopathy was also frequent
(57%) but not splenomegaly (25%). Mean duration of fever from
onset until diagnosis was 7.6 days. Laboratory abnormalities
included moderately elevated ESR, raised transaminase levels
(72%), leukopenia (25%) and thrombocytopenia (17%). Most
patients required hospitalisation mainly because of persistent
fever. One of these cases was complicated with meningoencepha-
litis (6.6%). However, the outcome after appropriate treatment
was good in all patients.
Conclusions: R. typhii in children in Cyprus is not a rare disease. It
mainly attacks school age children who usually present with per-
sistent fever, rash and lymphadenopathy. It usually runs a benign
course and responds favourably to appropriate antibiotic treatment.
P1313 Genomovar status and antibiotic resistance of
Burkholderia cepacia complex isolates in cystic ﬁbrosis centre in
Kosice, Slovakia
Y. Navesnakova, P. Drevinek, O. Cinek, L. Tkacikova
Kosice, SK; Prague, CZ
Objectives: The aims of the study were: (i) to evaluate the preval-
ence of Burkholderia cepacia complex (Bcc) isolates in patients with
cystic ﬁbrosis (CF) (ii) to determine their genomovar status (iii) to
determine antibiotic susceptibility of each Bcc isolate and (iv) to
determine the most appropriate bactericidal antibiotic combination.
Methods: From August 2000 to November 2003, we collected 506
sputum samples from 42 patients with cystic ﬁbrosis attending
The Regional CF Centre in Kosice, Slovakia. All sputum samples
were examined by standard laboratory culture techniques inclu-
ding plating on the Burkholderia Cepacia Selective Agar (BCSA).
All putative Bcc isolates were further subjected to recA-based nes-
ted PCR to conﬁrm the correct assignment to the genus Bcc and
to determine the genomovar status. Antibiotic susceptibility test-
ing for the Bcc isolates was evaluated by standard laboratory tech-
niques using disk-diffusion method. Multiple combination
bactericidal antibiotic testing for multiresistant isolates of the Bcc
was done in microtitre plates using a modiﬁed time vs. kill curve
method.
Results: The prevalence of Bcc isolates is 26.1% (11 patients). Six
out of 42 CF patients (14.3%) have been infecting with multiresist-
ant strains of genomovar III, recA subgroup IIIA. One patient har-
bours genomovar III, recA subgroup IIIB, and the remaining three
positive patients have the infection with genomovar IV. The most
effective single antibiotic against multiresistant strains of genom-
ovar IIIA are meropenem and ceftazidim. The most effective tri-
ple-antibiotic combinations contain high-dose tobramycin,
meropenem and the third additional antibiotic (ceftazidim, ciproﬂ-
oxacin, amikacin)
Conclusion: Burkholderia cenocepacia (genomovar III) is a multire-
sistant opportunistic pathogen with the most pronounced negative
effect in morbidity and mortality of CF patients. The accurate
identiﬁcation of Bcc completed with molecular genetic tools is
very important from epidemiological point of view in order to
control and minimise cross-infection in CF patients.
P1314 Late clearance of viraemia in four perinatally
HCV-infected children: should the concept of HCV infection
chronicity be revised in paediatrics patients?
G. Bossi, E. Minola, C. Lazzaroni, B. Salati, A. Maccabruni
Pavia, Bergamo, I
Background: Current deﬁnition of HCV infection in a perinatally
exposed baby still relies on two positive HCV-RNA test (one dur-
ing the ﬁrst year of life) and/or anti-HCV positivity beyond the
18th month. The long-term outcomes of HCV infection vertically
acquired are unknown and unpredictable. In paediatric setting,
the progression to chronicity of HCV-related liver damage seems
to be very frequent but the true liver disease is generally milder
than in adults. Because of the young age of the patients, an anti-
retroviral treatment should be advisable, but the experience with
the available drugs have been dissatisfactory. In particular, we
still lack ﬁrm criteria for treating HCV infected children, and also
when to start therapy still remains debated.
Patients: Based on the above criteria, between 1992 and 2003, 27
HCV vertically infected children were identiﬁed at our centres.
Starting from birth, anti-HCV, HCV-RNA and ALT assessment
were performed every 4 months during the ﬁrst year of life and
then every 4–6 months (mean follow-up 58 months, range 4–128).
Results: All the 27 babies proved to be HCV-RNA positive by the
sixth month and thereafter till the ﬁrst negative result. A sus-
tained clearance of HCV-RNA could be documented in 4/27 cases
(15%). In two cases (genotypes 2a/2c and 3a, respectively) the
ﬁrst HCV-RNA negative was observed at 18 months of age and
then conﬁrmed by three subsequent negative results obtained at
3 months intervals. In one case (genotype 2a), HCV-RNA became
undetectable at 60 months of age; 4 years later the PCR test is still
negative. In the last child HCV-RNA tested positive from birth to
48 months (genotype 1b); the viraemia proved to be negative by
the age of 5 years and then had been steadily negative for more
than 5 years. All the four children are steadily anti-HCV negative
with normal ALT values.
Conclusion: Our data suggest that in children at risk for HCV
infection vertically acquired, the diagnostic criteria of infection
and chronicity should be reconsidered on the basis of test PCR
results evaluated during a more extended period of follow-up. In
case with no evidence of severe liver damage, the antiretroviral
therapy should not be taken into consideration for children under
5 years of age or in any case without an adequate follow-up.
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